Provisional Patent Application Serial No. 60/434, 962, filed December 20, 2002, which is incorporated by reference herein in its entirety.

BACKGROUND OF THE INVENTION (1) Field of the Invention : [0002] The present invention relates to certain cyclic and heterocyclic compounds which inhibit mitogen-activated protein kinase-activated protein kinase-2 (MAPKAP kinase-2, or MK-2), and also to methods of using such compounds to inhibit MK-2 and for the prevention and treatment of TNFa mediated diseases or disorders in subjects that are in need of such prevention and/or treatment.

(2) Description of the Related Art: [0003] Mitogen-activated protein kinases (MAPKs) are members of conserved signal transduction pathways that activate transcription factors, translation factors and other target molecules in response to a variety of extracellular signals. MAPKs are activated by phosphorylation at a dual phosphorylation motif with the sequence Thr-X-Tyr by mitogen-activated protein kinase kinases (MAPKKs). In higher eukaryotes, the physiological role of MAPK signaling has been correlated with cellular events such as proliferation, oncogenesis, development and differentiation. Accordingly, the ability to regulate signal transduction via these pathways could lead to the development of treatments and preventive therapies for human diseases associated with MAPK signaling, such as inflammatory diseases, autoimmune diseases and cancer.

[0004] In mammalian cells, three parallel MAPK pathways have been described. The best characterized pathway leads to the activation of the extracellular-signal-regulated kinase (ERK). Less well understood are the

signal transduction pathways leading to the activation of the cJun N- terminal kinase (JNK) and the p38 MAPK. See, e. g., Davis, Trends Biochem. Sci. 19 : 470-473 (1994); Cano, et al, Trends Biochem. Sci.

20: 117-122 (1995).

[0005] The p38 MAPK pathway is potentially activated by a wide variety of stresses and cellular insults. These stresses and cellular insults include heat shock, UV irradiation, inflammatory cytokines (such as TNF and IL-1), tunicamycin, chemotherapeutic drugs (i. e., cisplatinum), anisomycin, sorbitol/hyperosmolarity, gamma irradiation, sodium arsenite, and ischaemia. See, Ono, K., et al, Cellular Signalling 12, 1-13 (2000).

Activation of the p38 pathway is involved in (1) production of proinflammatory cytokines, such as TNF-a ; (2) induction of enzymes, such as Cox-2; (3) expression of an intracellular enzyme, such as iNOS, which plays an important role in the regulation of oxidation; (4) induction of adherent proteins, such as VCAM-1 and many other inflammatory-related molecules. Furthermore, the p38 pathway functions as a regulator in the proliferation and differentiation of cells of the immune system. See, Ono, K. , et al., Id. at 7.

[0006] The p38 kinase is an upstream kinase of mitogen-activated protein kinase-activated protein kinase-2 (MAPKAP kinase-2 or MK-2).

(See, Freshney, N. W., et al., J. Cell, 78 : 1039-1049 (1994) ). MK-2 is a protein that appears to be predominantly regulated by p38 in cells.

Indeed, MK-2 was the first substrate of p38a to be identified. For example, in vitro phosphorylation of MK-2 by p38a activates MK-2. The substrates that MK-2 acts upon, in turn, include heat shock protein 27, lymphocyte-specific protein 1 (LAP1), cAMP response element-binding protein (CREB), ATF1, serum response factor (SRF), and tyrosine hydroxylase. The substrate of MK-2 that has been best characterized is small heat shock protein 27 (hsp27).

[0007] The role of the p38 pathway in inflammatory-related diseases has been studied in several animal models. The pyridinyl imidazole compound SB203580 has been shown to be a specific inhibitor of p38 in

vivo, and also has been shown to inhibit activation of MK-2, (See, Rouse, J. , et al, Cell, 78 : 1027-1037 (1994); Cuenda, A., et al, Biochem. J. , 333 : 11-15 (1998)), as well as a MAP kinase homologue termed reactivating kinase (RK). (See, Cuenda, A., et al., FEBS Lett, 364 (2) : 229- 233 (1995)). Inhibition of p38 by SB203580 can reduce mortality in a murine model of endotoxin-induced shock and inhibit the development of mouse collagen-induced arthritis and rat adjuvant arthritis. See, e. g., Badger, A. M., et al., J. Pharmacol Exp. Ther., 279 : 1453-1461 (1996).

Another p38 inhibitor that has been utilized in an animal model that is believed to be more potent than SB203580 in its inhibitory effect on p38 is SB 220025. A recent animal study has demonstrated that SB 220025 caused a significant dose-dependent decrease in vascular density of granulomas in laboratory rats. (See, Jackson, J. R., et al, J. Pharmacol.

Exp. Ther., 284: 687-692 (1998) ). The results of these animal studies indicated that p38, or the components of the p38 pathway, can be useful therapeutic targets for the prevention or treatment of inflammatory disease.

[0008] Due to its integral role in the p38 signaling pathway, MK-2 has been used as a monitor for measuring the level of activation in the pathway. Because of its downstream location in the pathway, relative to p38, MK-2 has been measured as a more convenient, albeit indirect, method of assessing p38 activation. However, so far, research efforts exploring therapeutic strategies associated with the modulation of this pathway have focused mainly on the inhibition of p38 kinase.

[0009] Several compounds that inhibit the activity of p38 kinase have been described in U. S. Patent Nos. 6,046, 208,6, 251,914, and 6,335, 340.

These compounds have been suggested to be useful for the treatment of CSBP/RK/p38 kinase mediated disease. Commercial efforts to apply p38 inhibitors have centered around two p38 inhibitors, the pyridinylimidazole inhibitor SKF 86002, and the 2,4, 5 triaryl imidazole inhibitor SB203580.

See, Lee, J. C., et al, Immunopharmacology 47, 185-192 (2000).

Compounds possessing a similar structure have also been investigated as

potential p38 inhibitors. Indeed, p38 MSP kinase's role in various disease states has been elucidated through the use of inhibitors.

[00010] Kotlyarov, A. et al, in Nat. Cell Biol., 1 (2) : 94-97 (1999) introduced a targeted mutation into a mouse MK-2 gene, resulting in MK- 2-deficient mice. It was shown that mice lacking MK-2 possessed increased stress resistance and survived LPS-induced endotoxic shock better than MK-2+ mice. The authors concluded that MK-2 was an essential component in the inflammatory response that regulates biosynthesis of TNFa at a post-transcriptional level. More recently, Lehner, M. D., et al, in J. Immunol., 168 (9) : 4667-4673 (2002), reported that MK-2-deficient mice showed increased susceptibility to Listeria monocytogenes infection, and concluded that MK-2 had an essential role in host defense against intracellular bacteria, probably via regulation of TNF and IFN-gamma production required for activation of antibacterial effector mechanisms.

[00011] The location of MK-2 in the p38 signaling pathway at a point that is downstream of p38 offers the potential that MK-2 could act as a focal point for modulating the pathway without affecting as many substrates as would the regulation of an enzyme further upstream in the signaling cascade--such as p38 MAP kinase.

[00012] Accordingly, it would be useful to provide compounds and methods that could serve to modulate the activity of MK-2--in particular, to act as inhibitors of MK-2 activity. Such compounds and methods would be useful for the provision of benefits similar to p38 MAP kinase inhibitors, which benefits include the prevention and treatment of diseases and disorders that are mediated by TNFa. It would be even more useful to provide MK-2 inhibitors having improved potency and reduced undesirable side effects, relative to p38 inhibitors.

SUMMARY OF THE INVENTION [00013] Briefly therefore, the present invention is directed to a novel compound having the structure of formula I : Formula l :

wherein : Z2 and Z3 are nitrogen, Z1, Z4 and Z5 are carbon, and join with Z2 and Z3 to form a pyrazol ring, or optionally, Z4 and Z5 are nitrogen, Z1, Z2 and Z3 are carbon and join with Z4 and Z5 to form a pyrazol ring; Ra is selected from: 1)

where dashed lines indicate optional single or double bonds; when Ra is ring M and ring M is aromatic, M1 is carbon and is substituted with (L) nR1, M5 is carbon, and each of M2, M3, M4 and M6 is independently selected from carbon and nitrogen and is unsubstituted or substituted with (L) nR1 ; when ring Mis partially saturated, M1 is carbon and is mono-or di- substituted with (L) nR\ M is carbon, and each of M2, M3, M4 and M6 is independently selected from carbon, nitrogen, oxygen and sulfur, and when M2, M3, M4, or M6 is oxygen or sulfur, it is unsubstituted, and when M2, M3, M4 or M6 is carbon or nitrogen, it is optionally unsubstituted; or mono-or di-substituted with (L) nR ; when Ra is ring Q and ring Q is aromatic, Q1 is selected from carbon and nitrogen, and when Q1 is carbon, it is substituted with (L)nR1, and when Q1 is nitrogen, it is unsubstituted, Q4 is selected from nitrogen and carbon, and each of Q2, Q3 and Q5 is independently selected from nitrogen and carbon, and if carbon, it is substituted with (L)nR1 ; optionally when ring Q is aromatic, Q1 is carbon and is substituted with (L) nR\ Q is carbon, and one of Q2, Q3 and Q5 is optionally oxygen or sulfur, and the remainder of Q2, Q3 and Q5 are independently selected from nitrogen and carbon, and if carbon, are substituted with (L) nR' ; when ring Q is partially saturated, Q1 is selected from carbon and nitrogen, and if carbon, it is mono-or di-substituted with (L) nR1, and if nitrogen, it is unsubstituted or substituted with (L)nR1, Q4 is selected from carbon and nitrogen, but only one of Q1 and Q4 can be nitrogen, each of Q2, Q3 and Q5 is independently selected from carbon, nitrogen, oxygen and sulfur, and if oxygen or sulfur, it is unsubstituted, and if carbon, it is mono-or di-substituted with (L) nR1, and if nitrogen, it is unsubstituted or substituted with (L)nR1 ; when Ra is structure 3, it is fully conjugated, X2 is selected from oxygen or nitrogen substituted with (L)nR1, X1 is carbon and is substituted with (L) nR', and each of X5 and X6 is independently selected from nitrogen and carbon, and if carbon, it is substituted with (L) Rl ;

R'is selected from-H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1- C6 alkyl-R11, C2-C6 alkenyl-R11, C2-C6 alkynyl-R11, C1-C6 alkyl-(R11) 2, C2-C6 alkenyl-(R11)2, CSR11, amino, CONHR11, NHR7, NR8R9, N (R7)-N(R8)(R9), C (R1l) =N-N (R8) (R9), N=N (R7), N (R7)-N=C(R8), C (R1l) =N-O (R10), ON=C (R11), C1-C6 alkyl-NHR7, C1-C6 alkyl-NR8R9, (C1-C4) alkyl-N (R7)- N (R8) (R9), (Ci-C4) alkylC (R11) =N-N (R8) (R9), (C1-C4) alkyl-N=N(R7), (C1- C4) alkyl-N(R7)-N=C(R8), nitro, cyano, CO2R11, O-R10, C1-C4 alkyl-OR10, COR, SR, SSR10, SOR", SO2R11, C1-C6 alkyl-COR", Ci-C6 alkyl-SR10, Ci-Ce alkyl-SOR11, C1-C6 alkyl-SO2R11, halo, Si(R11) 3, halo C1-C4 alkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and Ci-Cio mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-C10 mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R12 ; R7, R8 and R9 are each independently selected from-H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C4 alkyl-R11, C1-C6 alkyl-NHR13, C1-C6 alkyl-NR13R14, O-R15, C1-C4 alkyl-OR15, CO2R15, C (S) OR15, C (O) Sur', C (O) R, C (S) R17, CONHR16, C (S) NHR16 CON (R16) 2, C (S) N (R16) 2, SR15, SOR17, SO2R17, C1-C6 alkyl-CO2R15, C1-C6 alkyl-C (S) OR15, C1-C6 alkyl- C (O) SR, C1-C6 alkyl-COR, C1-C6 alkyl-C (S) R, C1-C6 aikyl-CONHR Ci-Ce alkyl-C (S) NHR16, C1-C6 alkyl-CON (R16) 2, C1-C6 alkyl-C (S) N (R16) 2, C1-C6 alkyl-SR15, C1-C6 alkyl-SOR17, C1-C6 alkyl-SO2R17, halo C1-C4 alkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and Ci-Cio mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-C10 mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by Ria ; R10 is selected from-H, Cl-calo alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkyl-NHR13, C1-C6 alkyl-NR13R14, C1-C4 alkyl-OR15, CSR11, CO2R15, C (S) OR15, C(O)SR15, COR17, C (S) R17, CONHR16, C1-C4 alkyl-R11, C1-C4

alkyl-NH2R13, C (S) NHR16, O-R15, CON (R16) 2, C (S) N (R16) 2, SoRl7, SO2R17, C1-C6 alkyl-CO2R15, C1-C6 alkyl-C (S) OR15, C1-C6 alkyl-C(O)SR15, C1-C6 alkyl-COR17, C1-C6 alkyl-C (S) R17, C1-C6 alkyl-CONHR16, C1-C6 alkyl- C(S)NHR16, C1-C6 alkyl-CON(R16)2, Si(R13)2R17, C1-C6 alkyl-C (S) N (R16) 2, C1-C6 alkyl-SR15, C1-C6 alkyl-SOR17, C1-C6 alkyl-SO2R17, halo C1-C4 alkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-Cio mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-Cio mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by Ris ; R11 is selected from-H, Ci-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2- C6 alkynyl, amino, NHR13, NR13R14, N=NR13, C1-C6 alkyl-NHR13, C1-C6 alkyl-NR13R14, O-R15, C1-C4 alkyl-OR15, SR15, COR13, CO2R17, C1-C6 alkyl- CO2R15, C1-C6 alkyl-C(S)OR15, C1-C6 alkyl-C(O)SR15, C1-C6 alkyl-COR17, C1-C6 alkyl-C (S) R17, C1-C6 alkyl-CONHR16, C1-C6 alkyl-C (S) NHR16, Ci-C6 alkyl-CON (R16) 2, C1-C6 alkyl-C (S) N (R16) 2, C1-C6 alkyl-SR15, C1-C6 alkyl- SOR17, C1-C6 alkyl-SO2R17, halo, halo C1-C4 alkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-Cio mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and Ci-Cio mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R18; R12 is selected from-H, OH, oxo, C1-C10 alkyl, C2-Cio alkenyl, C2- do alkynyl, C1-C10 alkyl-R11, C2-Cio alkenyl-R11, C2-C10 alkynyl-R11, C1-C10 alkyl-(R11) 2, C2-C1o alkenyl-(R11) 2, CSR", hydroxyl C1-C6 alkyl-R11, amino C1-C4 alkyl-R7, amino, NHR7, NR8R9, N (R7)-N(R8)(R9), C (R1l) =N- N (R8) (R9), N=N (R7), N (R7)-N=C (R8), C (R1l) =N-O (R10), ON=C (R11), C1-C10 alkyl-NHR7, C1-C10 alkyl-NR8R9, (C1-C10)alkyl-N(R7)-N(R8)(R9), (C1- C10) alkylC (R11) =N-N (R8) (R9), (C1-C10) alkyl-N=N (R7), (C1-C10)alkyl-N(R7)- N=C (R8), SCN, NCS, C1-C10 alkyl SCN, C1-C10 alkyl NCS, nitro, cyano, O-

Rio Ci-Cio alkyl-OR10, COR11, CO2R11, SR10, SSR10, SOR11, SO2R11, C1- C1o alkyl-COR", C1-C10 alkyl-SR10, Cl-calo alkyl-SOR11, Ci-Cio alkyl- SO2R11, halo, Si(R11)3, halo C1-C10 alkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and Ci-Cio mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, alkyfheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-Cio mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by Rl8 ; R13 and R14 are each independently selected from-H, oxo, C1-C6 <BR> <BR> <BR> alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C4 alkyl-R23, C1-C6 alkyl-NHR19, C1- C6 alkyl-NRi9R, O-R, C1-C4 alkyl-OR, CO2R, COR, C (S) OR C (O) SR21, C (O) R23, C (S) R23, CONHR22, C (S) NHR22 CON (R) 2, C (S) N (R22) 2, SR21, SOR23, SO2R23, C1-C6 alkyl-CO2R21, C1-C6 alkyl- C (S) OR21, Ci-Ce alkyl-C(O)SR21, C1-C6 alkyl-COR23, C1-C6 alkyl-C(S)R23, Ci-Ce alkyl-CONHR22, Cl-C6 alkyl-C (S) NHR22, Ci-C6 alkyl-CON (R22) 2, C1- C6 alkyl-C (S) N (R22) 2, C1-C6 alkyl-SR21, C1-C6 alkyl-SOR23, Ci-C6 alkyl- SO2R23, halo C1-C4 alkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-Cio mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and Ci-Cio mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R24 ; R15 and R16 are independently selected from-H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkyl-NHR19, C1-C6 alkyl-NR19R20, C1-C4 alkyl-OR21, CSR11, CO2R22, COR23, CONHR22, CON(R22)2, SOR23, SO2R23, C1-C6 alkyl-CO2R22, C1-C6 alkyl-COR23, C1-C6 alkyl-CONHR22, C1- C6 alkyl-CON(R22) 2, C1-C6 alkyl-SR21, C1-C6 alkyl-SOR23, C1-C6 alkyl- SO2R23, halo C1-C4 alkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-Cio mono-and bicyclic cycloalkyl, wherein aryl,

heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and Ci-Cio mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R24 ; R17 is selected from-H, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkenyl- R19, C1-C6 alkyl-R19, C2-C6 alkynyl, amino, NHR19, NR19R20, C1-C6 alkyl- NHR19, C1-C6 alkyl-NR19R20, O-R21, C1-C4 alkyl-OR21, SR21, C1-C6 alkyl- CO2R21, Ci-Ce alkyl-C (S) OR21, C1-C6 alkyl-C (O) SR, Ci-C6 alkyl-COR23, C1-C6 alkyl-C (S) R23, C1-C6 alkyl-CONHR22, C1-C6 alkyl-C (S) NHR22, Cl-C6 alkyl-CON(R22) 2, C1-C6 alkyl-C (S) N (R22) 2, C1-C6 alkyl-SR21, C1-C6 alkyl- SOR23, C1-C6 alkyl-SO2R23, halo C1-C4 alkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-C1o mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and Ci-Cio mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R24; R18 is selected from-H, oxo, OH, Ci-Cio alkyl, C2-C10 alkenyl, C2- <BR> <BR> Clo alkynyl, C1-C1o alkyl-R23, C2-C1o alkenyl-R23, C2-C1o alkynyl-R23, Ci-C10 alkyl-(R23)2, C2-C10 alkenyl-(R23)2, CSR23, amino, NHR19, NR20R20, N(R19)- N(R20)(R20), C(R23)=N-N(R20)(R20), N=N(R19), N(R19)-N=C(R20), C(R23)=N- O (R21), ON=C(R23), C1-C10 alkyl-NHR19, C1-C10 alkyl-NR20R20, (C1- C10) alkyl-N (Ri9)-N (R20)(R20), (C1-C10)alkylC(R23) =N-N (R20)(R20), (C1- Ciao) alkyl-N=N(R19), (C1-C10)alkyl-N(R19)-N=C(R20), SCN, NCS, Ci-Cio alkyl SCN, C1-C10 alkyl NCS, nitro, cyano, O-R21, C1-Cl0 alkyl-OR21, COR23, CO2R23, SR21, SSR21, SOR23, SO2R23, C1-C10 alkyl-COR23, C1-C10 alkyl-SR21, C1-C1o alkyl-SOR23, C1-C1o alkyl-S02R23, halo, Si (R23) 3, halo Cl-calo alkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-Cio mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl,

heterocyclylalkyl, and Ci-Cio mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R24 ; R19 and R20 are each independently selected from-H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C4 alkyl-R29, C1-C6 alkyl-NHR25, C1-C6 alkyl-NR25R26, O-R27, C1-C4 alkyl-OR27, CO2R27, C(S)OR27, C(O)SR27, C (O) R29, C (S) R29, CON28, C (S) NHR28, CON (R28) 2, C (S) N (R23) 2, SR27, SOR29, SO2R29, C1-C6 alkyl-CO2R27, C1-C6 alkyl-C (S) OR27, Ci-C6 alkyl- C (O) SR, C1-C6 alkyl-COR29, C1-C6 alkyl-C (S) R29, C1-C6 alkyl-CONHR28, Ci-C6 alkyl-C (S) NHR28, C1-C6 alkyl-CON(R28)2, C1-C6 alkyl-C (S) N (R23) 2, C1-C6 alkyl-SR27, C1-C6 alkyl-SOR29, C1-C6 alkyl-SO2R29, halo C1-C4 alkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-Cio mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-Cio mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R30 ; R21 and R22are independently selected from-H, C1-C10 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkyl-NHR25, C1-C6 alkyl-NR25R26, C1-C4 alkyl-OR, CSR11, CO2R28, COR29, CONHR, CON (R23) 2, SOR29, SO2R29, C1-C6 alkyl-CO2R28, C1-C6 alkyl-COR29, C1-C6 alkyl-CONHR28, C1- C6 alkyl-CON(R28)2, C1-C6 alkyl-SR27, C1-C6 alkyl-SOR29, C1-C6 alkyl- SO2R29, halo C1-C4 alkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and Ci-calo mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-Cio mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R30 ; R23 is selected from-H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkenyl- R25, C1-C6 alkyl-R25, C2-C6 alkynyl, amino, NHR25, NR25R26, C1-C6 alkyl- NHR25, C1-C6 alkyl-NR25R26, O-R27, C1-C4 alkyl-OR27, SR27, C1-C6 alkyl- CO2R27, C1-C6 alkyl-C (S) OR27, C1-C6 alkyl-C(O)SR27, C1-C6 alkyl-COR29,

Ci-C6 alkyl-C (S) R29, Cl-C6 alkyl-CONHR23, C1-C6 alkyl-C (S) NHR28, C1-C6 alkyl-CON (R23) 2, Ci-C6 alkyl-C (S) N (R23) 2, C1-C6 alkyl-SR27, C1-C6 alkyl- SOR29, C1-C6 alkyl-SO2R29, halo C1-C4 alkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and Ci-Cio mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and Ci-Cio mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R 30 ; R24 is selected from-H, OH, C1-C10 alkyl, C2-Cio alkenyl, C2-C10 alkynyl, C1-C10 alkyl-R29, C2-Cio alkenyl-R29, C2-Cio alkynyl-R29, Ci-Clo alkyl-(R29)2, C2-C10 alkenyl-(R29)2, CSR29, amino, NHR25, NR26R26, N(R25)- N(R26)(R26), C(R29)=N-N(R26)R26), N=N(R25), N(R25)-N=C(R26), C(R29)=N- O (R 27), ON=C (R29), C1-C10 alkyl-NHR25, C1-C10 alkyl-NR26R26, (C1- Cio) alkyl-N (R25)-N(R26)(R26), (C1-C10)alkylC(R29) =N-N (R26)(R26), (C1- C10) alkyl-N=N(R25), (C1-C10)alkyl-N(R25)-N=C(R26), SCN, NCS, C1-C10 alkyl SCN, C1-C10 alkyl NCS, nitro, cyano, O-R27, C1-C10 alkyl-OR27, CO2R29, COR29, SR27, SSR27, SOR29, SO2R29, C1-C10 alkyl-COR29, C1-C10 alkyl-SR27, C1-C10 alkyl-SOR29, C1-C10 alkyl-SO2R29, halo, Si (R29) 3, halo C1-Cio alkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocylclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-Cio mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-Cio mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R30 ; R25 and R26 are each independently selected from-H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C4 alkyl-R35, C1-C6 alkyl-NHR31, C1-C6 alkyl-NR31R32, O-R33, C1-C4 alkyl-OR33, CO2R33, C (S) OR33, C (O) SR33, C (O) R, C (S) R35, CONHR, C (S) NHR34, CON (R34) 2, C (S) N (R34) 2, SR33, SOR35, S02R35, C1-C6 alkyl-CO2R33, Ci-C6 alkyl-C (S) OR33, Ci-C6 alkyl- C (O) SR33, C1-C6 alkyl-COR35, C1-C6 alkyl-C (S) R35, C1-C6 alkyl-CONHR34, C1-C6 alkyl-C (S) NHR34, C1-C6 alkyl-CON(R34) 2, Ci-C6 alkyl-C (S) N (R34) 2,

C1-C6 alkyl-SR33, C1-C6 alkyl-SOR35, C1-C6 alkyl-SO2R35, halo C1-C4 alkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and Cl-C10 mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-Cio mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R36 ; R27 and R23 are independently selected from-H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkyl-NHR31, C1-C6 alkyl-NR3rR32, C1-C4 alkyl-OR33, CSR11, CO2R34, COR35, CONHR34, CON (R) 2, SOR35, S02R35, C1-C6 alkyl-CO2R34, C1-C6 alkyl-COR35, C1-C6 alkyl-CONHR34, C1- C6 alkyl-CON(R34),2 C1-C6 alkyl-SR33, C1-C6 alkyl-SOR35, C1-C6 alkyl- S02R35, halo C1-C4 alkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-Cio mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-Cio mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R36 ; R29 is selected from-H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkenyl- R31, C1-C6 alkyl-R31, C2-C6 alkynyl, amino, NHR31, NR31R32, C1-C6 alkyl- NHR31, C1-C6 alkyl-NR31R32, O-R33, C1-C4 alkyl-OR33, SR33, Ci-C6 alkyl- CO2R33, C1-C6 alkyl-C (S) OR33, C1-C6 alkyl-C(O)SR33, C1-C6 alkyl-COR35, C1-C6 alkyl-C (S) R35, C1-C6 alkyl-CONHR34, C1-C6 alkyl-C (S) NHR34, C1-C6 alkyl-CON (R34 2, C1-C6 alkyl-C (S) N (R34) 2, C1-C6 alkyl-SR33, C1-C6 alkyl- <BR> <BR> <BR> SOR35, C1-C6 alkyl-SO@R35, halo C1-C4 alkyl, aryl, heteroaryl, heterocylclyl, alkylaryl, alkylheterocylclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and Ci-Cio mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and d-do mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R36 ;

R30 is selected from-H, OH, Ci-Cio alkyl, C2-C1o alkenyl, C2-C10 alkynyl, C1-C10 alkyl-R35, C2-C10 alkenyl-R35, C2-C10 alkynyl-R35, C1-C10 alkyl-(R35) 2, C2-C10 alkenyl-(R35)2, CSR35, amino, NHR31, NR32R32, N (R31)- N C(R35)=N-N(R32)R32), N=N(R31), N(R31)-N=C(R32), C(R35)=N- <BR> <BR> <BR> O (R33), ON=C (R°5), Ci-Cio alkyl-NHR31, C1-C10 alkyl-NR32R32, (C1-<BR> <BR> <BR> <BR> <BR> C10)alkyl-N(R31)-N(R32)(R32), (C1-C10)alkylC(R35) =N-N (R32) (R32) (Ci-<BR> C10)alkyl-N=N(R31), (C1-C10)alkyl-N(R31)-N=C(R32), SCN, NCS, C1-C10 alkyl SCN, C1-C10 alkyl NCS, nitro, cyano, O-R33, Ci-Clo alkyl-OR33, COR35, SR33, SSR33, SOR35, SO2R35, C1-C10 alkyl-COR35, C1-Cio alkyl- SR33, C1-C10 alkyl-SOR35, C1-C10 alkyl-SO2R35, halo, Si (R35) 3, halo C1-C10 alkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and Ci-Cio mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and Ci-Cio mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R36 ; R31, R32, R33 and R34 are each independently selected from-H, alkyl, alkenyl, alkynyl, aminoalkyl, hydroxyalkyl, alkylamino alkyl, dialkylaminoalkyl, alkoxyalkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and Ci-Cio mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and Ci-Cio mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R36 ; R35 is selected from-H, alkyl, alkenyl, alkynyl, aminoalkyl, OH, alkoxy, amino, alkylamino, dialkylamino, hydroxyalkyl, alkylamino alkyl, dialkylaminoalkyl, alkoxyalkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and Ci-Cio mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and Cl-Clo mono-and bicyclic

cycloalkyl are optionally substituted with one or more of the groups defined by R36 ; R36 is selected from-H, alkyl, alkenyl, alkynyl, aminoalkyl, OH, alkoxy, amino, nitro, cyano, halo, alkylamino, dialkylamino, hydroxyalkyl, alkylamino alkyl, dialkylaminoalkyl, alkoxyalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heterocyclylalkyl, and heteroarylalkyl ; R2, R3, R4, R5, F137 and R38 are each independently absent, or selected from an R1 group ; n is 0; and R3 and R4 optionally join to form a ring of 5,6, 7, or 8 atoms, where the atoms in the ring are independently selected from Z3, Z4, O, S, C=O, C=S, S=O, S02, C that is mono or di-substituted with an Ri group, and N that is unsubstituted or substituted with an R'group.

[00014] The present invention is also directed to a novel compound having the structure of formula it : Formula II. wherein : Z2 and Z3 are nitrogen, Z1, Z4 and Z5 are carbon, and join with Z2 and Z3 to form a pyrazol ring, or optionally, Z4 and Z5 are nitrogen, z1, Z2 and Z3 are carbon and join with Z4 and Z5 to form a pyrazol ring; Ra is selected from:

where dashed lines indicate optional single or double bonds; when Ra is ring M and ring M is aromatic, M1 is carbon and is substituted with (L) nR1, M5 is carbon, and each of M2, M3, M4 and M6 is independently selected from carbon and nitrogen and is unsubstituted or substituted with (L) nR1 ; when ring M is partially saturated, M1 is carbon and is mono-or di- substituted with (L)nR1, M5 is carbon, and each of M2, M3, M4 and M6 is independently selected from carbon, nitrogen, oxygen and sulfur, and when M2, M3, M4, or M6 is oxygen or sulfur, it is unsubstituted, and when M2, M3, M4 or M6 is carbon or nitrogen, it is optionally unsubstituted; or mono-or di-substituted with (L) nR1 ;

when Ra is ring Q and ring Q is aromatic, Q1 is selected from carbon and nitrogen, and when Q1 is carbon, it is substituted with (L)nR1, and when Q1 is nitrogen, it is unsubstituted, Q4 is selected from nitrogen and carbon, and each of Q2, Q3 and Q5 is independently selected from nitrogen and carbon, and if carbon, it is substituted with (L)nR1 ; optionally when ring Q is aromatic, Qu ils carbon and is substituted with (L)nR1, Q4 is carbon, and one of Q2, Q3 and Q5 is optionally oxygen or sulfur, and the remainder of Q2, Q3 and Q5 are independently selected from nitrogen and carbon, and if carbon, are substituted with (L)nR1 ; when ring Q is partially saturated, Q1 is selected from carbon and nitrogen, and if carbon, it is mono-or di-substituted with (L) nR1, and if nitrogen, it is unsubstituted or substituted with (L) nR1sQ4is selected from carbon and nitrogen, but only one of Q1 and Q4 can be nitrogen, each of Q2, Q3 and Q5 is independently selected from carbon, nitrogen, oxygen and sulfur, and if oxygen or sulfur, it is unsubstituted, and if carbon, it is mono-or di-substituted with (L) nR1, and if nitrogen, it is unsubstituted or substituted with (L)nR1 ; when Ra is structure 3, it is fully conjugated, X2 is selected from oxygen or nitrogen substituted with (L) nR\ X is carbon and is substituted with (L)nR1, and each of X5 and X6 is independently selected from nitrogen and carbon, and if carbon, it is substituted with (L)nR1 ; R1 is selected from-H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, hydroxyl, C1-C6 alkoxy, C2-C6 alkenyl-R11, C1-C6 alkoxy-R11, COR17, CO2R7, CONHR7, N (R8) 2, amino C1-C4 alkyl, hydroxy C1-C4 alkyl, amino, amino C1-C4 alkyl-R7, halo C1-C4 alkyl, C1-C6 alkyl-NHR7, carbonitrile, SR10, halo, NHR7, NR8R9, NHR7-C1-C6 alkyl, NR8R9-C1-C6 alkyl, nitro, cyano, O-R10, Ci-C4 alkyl-OR10, C1-C6 alkyl-COR'1, halo C1-C4 alkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, or Cl-Clo mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R 12 ;

R7 and R8 are each independently selected from-H, C1-C6 alkyl, C1- C4 alkyl-R11, C1-C6 alkyl-N (R13) 2, CO2R16, COR, aryl, and arylalkyl, wherein aryl and arylalkyl, are optionally substituted with one or more of the groups defined by R18; R9 and R10 are each independently selected from-H, hydroxyl, C1- C6 alkyl, C1-C6 alkyl-R17, C1-C6 alkyl-NH2R13, CO2R16, COR17, C1-C6 alkyl- CO2R16, Ci-Ce alkyl-CONH-R16, C1-C6 alkyl-CON(R16) 2, hydroxy C1-C4 alkyl, halo C1-C4 alkoxy, halo C1-C4 alkyl, Si(R13)2R17, aryl heteroaryl, heterocyclyl, arylalkyl, and C1-Cio mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, and arylalkyl, are optionally substituted with one or more of the groups defined by Ri8 ; R11 is selected from-H, C1-C6 alkyl, C1-C6 alkoxy, hydroxyl, halo, amino, NHR, N (R13) 2, COR13, CO2R17, halo C1-C4 alkyl, aryl, heteroaryl, heterocyclyl, heteroarylalkyl, and heterocyclylalkyl, wherein heterocyclyl, heteroarylalkyl, and heterocyclylalkyl, are optionally substituted with one or more of the groups defined by Ris ; R12 is selected from-H, hydroxyl, oxo, C1-C6 alkyl, hydroxyl C1-C6 alkyl-R11, C1-C10 alkoxy, amino, amino C1-C4 alkyl-R7, NHR7, N (R7) 2, C1- C6 alkyl-NHR7, C1-C6 alkyl-NHR8R9, C1-C6 alkyl-N(R8)2, C1-C6 alkyl-R11, Ci-Ce alkyl-CO2R7R11, C1-C6 alkoxy-R11, nitro, O-R, C=O, COR", CO2R11, SR, SOR, SO2R11, NHSO2R11, C1-C6 alkyl-SR10, halo, halo C1- C4 alkyl, halo C1-C4 alkoxy, hydroxy Ci-C4 alkyl, hydroxy Ci-C4 alkoxy, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-C10 mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and heterocyclylalkyl, and Ci-Cio mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R'8 ; R13 and R14 are each independently selected from-H, oxo, C1-C6 alkyl, COR23, and aryl ; R15 and R16 are each independently selected from-H, aryl, arylalkyl, wherein aryl, arylalkyl, are optionally substituted with one or more of the groups defined by R24 ;

R17 is selected from-H, Ci-Ce alkyl, C1-C6 alkyl-R19, NHR19, aryl, heteroarylalkyl, and heterocyclylalkyl, wherein aryl is optionally substituted with one or more of the groups defined by R24 ; R'8 is selected from-H, oxo, hydroxyl, Ci-Cio alkyl, Ci-Cio alkoxy, amino, amino C1-C6 alkyl, N (R19) 2, C1-C6 alkyl-N (R19) 2, CO2R23, SR21, halo, halo C1-C4 alkyl, aryl, heteroaryl, and heterocyclyi, wherein aryl, heteroaryl, and heterocyclyl, are optionally substituted with one or more of the groups defined by R24 ; R19 and R20 are each independently selected from-H, C1-C6 alkyl, heteroaryl, heterocyclyl, wherein aryl, heteroaryl, and heterocyclyl, are optionally substituted with one or more of the groups defined by R30 ; R21 and R22 are each independently selected from-H and Ci-Ce alkyl ; R23 is selected from-H and C1-C6 alkyl ; R24 is selected from-H, C1-C6 alkyl, C1-C6 alkoxy, CO2R29, halo, and halo C1-C4 alkyl ; R29 is selected from-H, and C1-C6 alkyl ; R30 is selected from-H, aryl, heteroaryl, heterocyclyl, alkylaryl, arylalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, and arylalkyl, are optionally substituted with one or more of the groups defined by R36 ; R36 is selected from-H and halo ; R2, R3, R4, R37 and R38 are each independently selected from an group; n is 0; and R3 and R4 optionally join to form a ring of 5,6, 7, or 8 atoms, where the atoms in the ring are independently selected from Z3, Z4, O, S, C=O, C=S, S=O, SO2, C that is mono or di-substituted with an R1 group, and N that is unsubstituted or substituted with an R1 group.

[00015] The present invention is also directed to a novel MK-2 inhibiting compound that is listed in Table I or Table II, below.

[00016] The present invention is also directed to a novel method of inhibiting MK-2, the method comprising contacting MK-2 with at least one compound that is described in Table I or Table II, below.

[00017] The present invention is also directed to a novel method of preventing or treating a TNFa mediated disease or disorder in a subject, the method comprising administering to the subject an effective amount of an MK-2 inhibiting compound having the structure described in formula 1.

[00018] The present invention is also directed to a novel method of preventing or treating a TNFa mediated disease or disorder in a subject, the method comprising administering to the subject at least one MK-2 inhibiting compound that is described in Table I or Table II, below.

[00019] The present invention is also directed to a novel therapeutic composition comprising a compound having the structure described in formula 1.

[00020] The present invention is also directed to a novel therapeutic composition comprising at least one MK-2 inhibitory compound that is described in Table I or Table II.

[00021] The present invention is also directed to a novel pharmaceutical composition comprising a pharmaceutically acceptable carrier. and at least one MK-2 inhibitory compound having the structure described in formula 1.

[00022] The present invention is also directed to a novel comprising a dosage form that includes a therapeutical effective amount of at least one MK-2 inhibitory compound having a structure described in formula 1.

[00023] Among the several advantages found to be achieved by the present invention, therefore, may be noted the provision of a method that could serve to modulate the activity of MK-2--in particular, to inhibit MK-2 activity--and the provision of a method for the prevention and treatment of diseases and disorders that are mediated by TNFa.

BRIEF DESCRIPTION OF THE DRAWINGS [00024] Figure 1 is a graph showing paw thickness as a function of time from day 0 to day 7 for MK2 (+/+) and MK2 (-/-) mice, which have received serum injection; and

[00025] Figure 2 is a bar chart showing paw thickness at seven days after injection for normal mice, MK2 (+/+) mice receiving serum, MK2 (-/-) mice receiving serum, and MK2 (+/+) mice receiving serum and anti-TNF antibody; DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS [00026] In accordance with the present invention, it has been discovered that certain compounds can inhibit the activity of MAPKAP kinase-2. Many of these compounds exhibit their inhibitory effect at low concentrations--having in vitro MK-2 inhibition IC50 values of under 1.0 , uM, and with some having IC50 values of under about 0.1 I1M, and even as low as about 0. 021lM. Accordingly, these compounds can be potent and effective drugs for use in the inhibition of MK-2, and of special value in subjects where such inhibition would be useful. In particular, these compounds would be useful in methods to prevent or treat diseases and disorders that are mediated by TNFa. For example, they can be used for the prevention or treatment of arthritis.

[00027] Compounds that have a high degree of MK-2 inhibiting activity offer advantages in therapeutic uses, because therapeutic benefits can be obtained by the administration of lower amounts of the present compounds than with less active compounds. Such highly active compounds also result in fewer side effects, and in some embodiments, demonstrate a selectivity for MK-2 inhibition over the inhibition of other related kinases.

[00028] The present MK-2 inhibitory compounds inhibit the activity of the MK-2 enzyme. When it is said that a subject compound inhibits MK-2, it is meant that the MK-2 enzymatic activity is lower in the presence of the compound than it is under the same conditions in the absence of such compound. One method of expressing the potency of a compound as an MK-2 inhibitor is to measure the"IC5o"value of the compound. The IC50 value of an MK-2 inhibitor is the concentration of the compound that is required to decrease the MK-2 enzymatic activity by one-half.

Accordingly, a compound having a lower Iso value is considered to be a more potent inhibitor than a compound having a higher IC50 value. As

used herein, compounds that inhibit MK-2 can be referred to as MK-2 inhibitors, or MK-2 inhibiting compounds or MK-2 inhibiting agents.

[00029] In practice, the selectivity of an MK-2 inhibitor varies depending upon the condition under which the test is performed and on the inhibitors being tested. However, for the purposes of this specification, the selectivity of an MK-2 inhibitor can be measured as a ratio of the in vitro or in vivo IC50 value for inhibition of MK-3, divided by the IC50 value for inhibition of MK-2 (IC50 MK jIC50 MK-2). As used herein, the term"IC50" refers to the concentration of a compound that is required to produce 50% inhibition of MK-2 or MK-3 activity. An MK-2 selective inhibitor is any inhibitor for which the ratio of IC50 MK-s to IC50 MK-2 is greater than 1. In preferred embodiments, this ratio is greater than 2, more preferably greater than 5, yet more preferably greater than 10, still more preferably greater than 50, and more preferably stili, is greater than 100. Such preferred selectivity may indicate an ability to reduce the incidence of side effects incident to the administration of an MK-2 inhibitor to a subject.

[00030] Compounds that are useful in the present method include those having the structure shown in formula I : Formula l : wherein: Z2 and Z3 are nitrogen, Z', Z4 and Z5 are carbon, and join with Z2 and Z3 to form a pyrazol ring, or optionally, Z4 and Z5 are nitrogen, z1, Z2 and Z3 are carbon and join with Z4 and Z5 to form a pyrazol ring; Ra is selected from: 1)

2) where dashed lines indicate optional single or double bonds; when Ra is ring M and ring M is aromatic, M1 is carbon and is substituted with (L) nR1, M5 is carbon, and each of M2, M3, M4 and M6 is independently selected from carbon and nitrogen and is unsubstituted or substituted with (L) nR1 ; when ring M is partially saturated, M1 is carbon and is mono-or di- substituted with (L) nR1, M5 is carbon, and each of M2, M3, M4 and M6 is independently selected from carbon, nitrogen, oxygen and sulfur, and when M2, M3, M4, or M6 is oxygen or sulfur, it is unsubstituted, and when M2, M3, M4 or M6 is carbon or nitrogen, it is optionally unsubstituted; or mono-or di-substituted with (L)nR1 ;

when Ra is ring Q and ring Q is aromatic, Q1 is selected from carbon and nitrogen, and when Q1 is carbon, it is substituted with (L)nR1, and when Q1 is nitrogen, it is unsubstituted, Q4 is selected from nitrogen and carbon, and each of Q2, Q3 and Q5 is independently selected from nitrogen and carbon, and if carbon, it is substituted with (L) nR1 ; optionally when ring Q is aromatic, Q1 is carbon and is substituted with (L)nR1, Q4 is carbon, and one of Q2, Q3 and Q5 is optionally oxygen or sulfur, and the remainder of Q2, Q3 and Q5 are independently selected from nitrogen and carbon, and if carbon, are substituted with (L)nR1 ; when ring Q is partially saturated, Q1 is selected from carbon and nitrogen, and if carbon, it is mono-or di-substituted with (L) nR1, and if nitrogen, it is unsubstituted or substituted with (L) RR, Q4 is selected from carbon and nitrogen, but only one of Q1 and Q4 can be nitrogen, each of Q2, Q3 and Q5 is independently selected from carbon, nitrogen, oxygen and sulfur, and if oxygen or sulfur, it is unsubstituted, and if carbon, it is mono-or di-substituted with (L) nR1, and if nitrogen, it is unsubstituted or substituted with (L) nR1 ; when Ra is structure 3, it is fully conjugated, X2 is selected from oxygen or nitrogen substituted with (L)nR1, X1 is carbon and is substituted with (L) nR1, and each of X5 and X6 is independently selected from nitrogen and carbon, and if carbon, it is substituted with (L)"R1 ; R1 is selected from-H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Cl- C6 alkyl-R11, C2-C6 alkenyl-R11, C2-C6 alkynyl-R11, C1-C6 alkyl-(R11) 2, C2-C6 alkenyl- (R'1) 2, CSR11, amino, CON", NHR7, NR8R9, N (R7)-N(R8)R9), C (R11) =N-N (R8) (R9), N=N (R7), N (R7)-N=C (R8), C (R11) =N-O (Rio), ON=C (R11), C1-C6 alkyl-NHR7, C1-C6 alkyl-NR8R9, (C1-C4)alkyl-N(R7)- N (R8) (R9), (C1-C4) alkylC (Rll) =N-N (R8) (R9), (C1-C4) alkyl-N=N (R7), (C1- C4) alkyl-N (R7)-N=C(R8), nitro, cyano, CO2R11, O-R10, C1-C4 alkyl-OR10, COR, SR, SSR10, SOR11, SO2R11, C1-C6 alkyl-COR11, C1-C6 alkyl-SR10 C1-C6 alkyl-SOR11, C1-C6 alkyl-SO2R11, halo, Si(R11) 3, halo C1-C4 alkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-C10 mono-and bicyclic

cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocylclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-C10 mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R12 ; R7, R5 and R9 are each independently selected from-H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C4 alkyl-R11, C1-C6 alkyl-NHR13, C1-C6 alkyl-NR13R14, O-R15, Ci-C4 alkyl-OR15, CO2R15, C (S) OR15, C (O) SR15, C (O) R, C (S) R17, CONHR, C (S) NHR16 CON (R15) 2, C (S) N (R16) SR15 SOR17, SO2R17, Ci-C6 alkyl-CO2R15, Ci-C6 alkyl-C (S) OR15, C1-C6 alkyl- C (O) SR15, C1-C6 alkyl-COR17, C1-C6 alkyl-C (S) R, C1-C6 alkyl-CONHR16, C1-C6 alkyl-C (S) NHR16, C1-C6 alkyl-CON (R16) 2, C1-C6 alkyl-C (S) N (R16) 2, C1-C6 alkyl-SR15, C1-C6 alkyl-SOR17, C1-C6 alkyl-SO2R17, halo C1-C4 alkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and d-do mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and d-do mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R18 ; Rlo is selected from-H, C1-C10 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkyl-NHR13, C1-C6 alkyl-NR13R14, C1-C4 alkyl-OR15, CSR11, CO2R15, C (S) OR15, C (O) SR15, COR17, C (S) R17, CONHR16, C1-C4 alkyl-R11, C1-C4 alkyl-NH2R13, C(S)NHR16, O-R15, CON(R16)2, C9S)N(R16)2, SOR17, SO2R17, C1-C6 alkyl-CO2R15, C1-C6 alkyl-C(S)OR15, C1-C6 alkyl-C(O)SR15, C1-C6 alkyl-COR17, C1-C6 alkyl-C (S) R17, C1-C6 alkyl-CONHR16, C1-C6 alkyl- C (S) NHR16, C1-C6 alkyl-CON(R16) 2, Si (R13) 2R17, C1-C6 alkyl-C (S) N (R16) 2, C1-C6 alkyl-SR15, C1-C6 alkyl-SOR17, C1-C6 alkyl-SO2R17, halo C1-C4 alkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and d-do mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and Ci-do mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R18 ;

R'1 is selected from-H, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2- C6 alkynyl, amino, NHR13, NR13R14, N=NR13, C1-C6 alkyl-NHR13, Ci-C6 alkyl-NR13R14, O-R15, C1-C4 alkyl-OR15, SR15, COR13, CO2R17, C1-C6 alkyl- CO2R15, Cl-C6 alkyl-C (S) OR15, C1-C6 alkyl-C (O) SR, C1-C6 alkyl-COR, Cl-C6 alkyl-C (S) R17, C1-C6 alkyl-CONHR16, C1-C6 alkyl-C (S) NHRl6, Cl-C6 alkyl-CON (R16) 2, C1-C6 alkyl-C (S) N (R16), 2, C1-C6 alkyl-SR15, C1-C6 alkyl- SOR17, C1-C6 alkyl-SO2R17, halo, halo C1-C4 alkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-Cio mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and Ci-Cio mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R18, ; R12 is selected from-H, OH, oxo, C1-C10 alkyl, C2-C10 alkenyl, C2- Cio alkynyl, C1-C10 alkyl-R11, C2-C10 alkenyl-R11, C2-C10 alkynyl-R11, C1-C10 alkyl-(R11) 2, C2-C10 alkenyl-(R11) 2, CSR11, hydroxyl C1-C6 alkyl-R11, amino C1-C4 alkyl-R7, amino, NHR NR8R9, N (R7)-N(R8)(R9), C (R11) =N- N (R8)(R9), N=N (R7), N (R7)-N=C(R8), C (R11) =N-O (R10), ON=C (R11), Ci-Cio alkyl-NHR7, C1-C10 alkyl-NR8R9, (C1-C10)alkyl-N(R7)-N(R8)(R9), (C1- Clo) alkylC(R11) =N-N (R3) (R9), (C1-C10) alkyl-N=N (R7), (C1-C10)alkyl-N(R7)- N=C (R8), SCN, NCS, Ci-Cio alkyl SCN, C1-C10 alkyl NCS, nitro, cyano, O- R10, Ci-Cio alkyl-OR10, COR11, CO2R11, SR10, SSR10, SOR11, SO2R11, C1- Cio alkyl-COR11, C1-C10 alkyl-SR10, C1-C10 alkyl-SOR11, C1-C10 alkyl- SO2R1r, halo, Si (R11) 3, halo C1-C10 alkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-Cio mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and Ci-Cio mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by Rie ; R13 and R14 are each independently selected from-H, oxo, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C4 alkyl-R23, C1-C6 alkyl-NHR19, C1-

C6 alkyl-NR19R20, O-R21, C1-C4 alkyl-OR, CO2R21, COR21, C (S) OR21, C (O)SR21, C (O) R23, C (S) R23, CONHR22, C (S) NHR22, CON9R22)2, C (S) N (R22) 2, SR21, SOR23, SO2R23, C1-C6 alkyl-CO2R21, C1-C6 alkyl- C C(S)OR21, C1-C6 alkyl-C(O)SR21, C1-C6 alkyl-COR23, C1-C6 alkyl-C (S) R23, C1-C6 alkyl-CONHR22, Ci-C6 alkyl-C (S) NHR22, C1-C6 alkyl-CON(R22) 2, C1- C6 alkyl-C (S) N (R22) 2, C1-C6 alkyl-SR21, C1-Cs alkyl-SOR23, Ci-C6 alkyl- SO2R23, halo C1-C4 alkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and Ci-Cio mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-Cio mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R 24 ; R15 and R16 are independently selected from-H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkyl-NHR19, C1-C6 alkyl-NR19R20, C1-C4 alkyl-OR, CSRll, CO2R22, COR23, CONHR22, CON (R22) 2, SOR23, SO2R23, C1-C6 alkyl-CO2R22, C1-C6 alkyl-COR23, C1-C6 alkyl-CONHR22, C1- C6 alkyl-CON (R22) 2, C1-C6 alkyl-SR21, C1-C6 alkyl-SOR23, C1-C6 alkyl- SO2R23, halo C1-C4 alkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and d-do mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-Cio mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R24 ; R17 is selected from-H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkenyl- Roi9, C1-C6 alkyl-R19, C2-C6 alkynyl, amino, NHR19, NR19R20, C1-C6 alkyl- NHR19, C1-C6 alkyl-NR19R20, O-R21, C1-C4 alkyl-OR21, SR21, C1-C6 alkyl- CO2R21, C1-C6 alkyl-C (S) OR21, Cl-C6 alkyl-C(O)SR21, C1-C6 alkyl-COR23, C1-C6 alkyl-C (S) R23, Cl-C6 alkyl-CONHR22, C1-C6 alkyl-C (S) NHR22, C1-C6 alkyl-CON(R22) 2, C1-C6 alkyl-C (S) N (R22) 2, C1-C6 alkyl-SR21, C1-C6 alkyl- SOR23, C1-C6 alkyl-SO2R23, halo C1-C4 alkyl, aryl, heteroaryl, heterocyclyl,

alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-C1o mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-C10 mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R24; R18 is selected from-H, oxo, OH, C1-C10 alkyl, C2-C10 alkenyl, C2- C1o alkynyl, C1-C10 alkyl-R23, C2-C10 alkenyl-R23, C2-C10 alkynyl-R23, -C1-C10 alkyl-(R23)2, C2-C10 alkenyl-(R23)2, CSR23, amino, NHR19, NR20R20, N(R19)- N(R20)(R20), C(R23)=N-N(R20)(R20), N=N(R19), N(R19)-N=C(R20), C(R23)=N- O (R21), ON=C(R23), C1-C10 alkyl-NHR19, C1-C10 alkyl-NR20R20, (C1- C10)alkyl-N(R19)-N(R20)(R20), (C1-C10)alkylC(R23)=N-N(R20)(R20), (C1- C10) alkyl-N=N(R19), (C1-C10)alkyl-N(R19)-N=C(R20), SCN, NCS, C1-C10 alkyl SCN, C1-C10 alkyl NCS, nitro, cyano, O-R21, C1-C10 alkyl-OR21, COR23, CO2R23, SR21, SSR21, SOR23, SO2R23, C1-C10 alkyl-COR23, C1-C10 alkyl-SR21, C1-C10 alkyl-SOR23, C1-C10 alkyl-SO2R23, halo, Si(R23) 3, halo C1-C10 alkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-C10 mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-C10 mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R24 ; R19 and R20 are each independently selected from-H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C4 alkyl-R29, C1-C6 alkyl-NHR25, C1-C6 alkyl-NR25R26, O-R27, C1-C4 alkyl-OR27, CO2R27, C (S) OR27, C (O) SR, C (O) R29, C (S) R29, CONHR28, C (S) NHR28, CON (R28) 2, C (S) N (R28) 2, SR SOR29, SO2R29, C1-C6 alkyl-CO2R27, C1-C6 alkyl-C (S) OR27, C1-C6 alkyl- C (O) SR, C1-C6 alkyl-COR29, C1-C6 alkyl-C (S) R29, C1-C6 alkyl-CONHR28, C1-C6 alkyl-C (S) NHR28, Cl-C6 alkyl-CON (R28) 2, C1-C6 alkyl-C (S) N (R28) 2, C1-C6 alkyl-SR27, C1-C6 alkyl-SOR29, C1-C6 alkyl-SO2R29, halo C1-C4 alkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and d-do mono-and bicyclic

cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and Ci-Cio mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R30 ; R21 and R22are independently selected from-H, Ci-Cio alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkyl-NHR25, C1-C6 alkyl-NR25R26, Ci-C4 alkyl-OR27, CSR11, CO2R28, COR29, CONHR28, CON (R8) 2, SOR29, SO2R29, C1-C6 alkyl-CO2R28, C1-6 alkyl-COR29, C1-C6 alkyl-CONHR28, C1- C6 alkyl-CON (R2a) 2, C1-C6 alkyl-SR27, C1-C6 alkyl-SOR29, C1-C6 alkyl- SO2R29, halo C1-C4 alkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-Cio mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-Cio mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R 30 ; R23 is selected from-H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkenyl- <BR> <BR> R25, C1-C6 alkyl-R25, C2-C6 alkynyl, amino, NHR25, NR25R26, Ci-C6 alkyl- NHR25, C1-C6 alkyl-NR25R26, O-R27, C1-C4 alkyl-OR27, SR27, C1-C6 alkyl- CO2R27, Ci-Ce alkyl-C (S) OR27, Cl-C6 alkyl-C (O) SR2', C1-C6 alkyl-COR29, Ci-C6 alkyl-C (S) R29, C1-C6 alkyl-CONHR28, C1-C6 alkyl-C (S) NHR28, C1-C6 alkyl-CON (R28) 2, C1-C6 alkyl-C (S) N (R28) 2, C1-C6 alkyl-SR27, C1-C6 alkyl- <BR> <BR> SOR29, C1-C6 alkyl-SO2R29, halo C1-C4 alkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and Ci-Cio mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyf, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-Cio mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R 30 ; R24 is selected from-H, OH, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, Cl-calo alkyl-R29, C2-Cio alkenyl-R29, C2-Cio alkynyl-R29, C1-C10 alkyl- (R29) 2, C2-C10 alkenyl-(R29) 2, CSR29, amino, NHR25, NR26R26, N (R25)-

N (R26) (R26) C (R29) =N-N (R26)(R26), N=N(R25), N(R25)-N=C(R26), C (R29)=N- O (R 27), ON=C (R29), C1-C0 alkyl-NHR25, C1-C10 alkyl-NR26R26, (C1- <BR> <BR> <BR> C10) alkyl-N(R25)-N(R26)(R26), (C1-C10)alkylC(R29) =N-N (R26)(R26), (C1-<BR> C10)alkyl-N=N(R25), (C1-C10)alkyl-N(R25)-N=C(R26), SCN, NCS, C1-C10 alkyl SCN, Ci-Cio alkyl NCS, nitro, cyano, O-R27, C1-C10 alkyl-OR27, <BR> <BR> <BR> CO2R29, COR29, SR27, SSR27, SOR29, SO2R29, C1-Cio alkyl-COR29, C1-Clo alkyl-SR27, C1-C10 alkyl-SOR29, C1-C10 alkyl-SO2R29, halo, Si(R29) 3, halo Ci-Cio alkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and Ci-Cio mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and Ci-Cio mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R30 ; R25 and R26 are each independently selected from-H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Ci-C4 alkyl-R35, C1-C6 alkyl-NHR31, C1-C6 alkyl-NR31R32, O-R33, C1-C4 alkyl-OR33, CO2R33, C (S) OR33, C (O) SR33, C (O) R, C (S) R35, CONHR, C (S) NHR34, CON (R) 2, C (S) N (R34) 2, SR33, SOR35, SO2R35, C1-C6 alkyl-CO2R33, C1-C6 alkyl-C (S) OR33, C1-C6 alkyl- C (O)SR33, C1-C6 alkyl-COR35, C1-C6 alkyl-C (S) R35, C1-C6 alkyl-CONHR34, C1-C6 alkyl-C (S) NHR34, C1-C6 alkyl-CON(R34) 2, C1-C6 alkyl-C (S) N (R34)2, C1-C6 alkyl-SR33, C1-C6 alkyl-SOR35, C1-C6 alkyl-SO2R35, halo C1-C4 alkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-Cio mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and Ci-Cio mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R36 ; R27 and R23 are independently selected from-H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkyl-NHR31, C1-C6 alkyl-NR31R32, C1-C4 alkyl-OR33, CSR11, CO2R34, COR35, CONHR34, CON (R) 2, SOR35, SO2R35, C1-C6 alkyl-CO2R34, C1-C6 alkyl-COR35, C1-C6 alkyl-CONHR34, C1- C6 alkyl-CON (R34)2, C1-C6 alkyl-SR33, C1-C6 alkyl-SOR35, C1-C6 alkyl-

S02R35, halo Ci-C4 alkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-C10 mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and Ci-Cio mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R36 ; R29 is selected from-H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkenyl- R31, Ci-C6 alkyl-R31, C2-C6 alkynyl, amino, NHR31, NR31R32, C1-C6 alkyl- NHR31, C1-C6 alkyl-NR31R32, O-R33, C1-C4 alkyl-OR33, SR33, C1-C6 alkyl- COsR, C1-C6 alkyl-C (S) OR33, C1-C6 alkyl-C(O)SR33, C1-C6 alkyl-COR35, C1-C6 alkyl-C (S) R35, C1-C6 alkyl-CONHR34, C1-C6 alkyl-C (S) NHR34, C1-C6 alkyl-CON (R34) 2, C1-C6 alkyl-C (S) N (R34) 2, C2-C6 alkyl-SR33, C1-C6 alkyl- SOR35, C1-C6 alkyl-SO2R35, halo C1-C4 alkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and d-do mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and d-do mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R36 ; R30 is selected from-H, OH, d-do alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C1-C10 alkyl-R35, C2-C10 alkenyl-R35, C2-C10 alkynyl-R35, C1-C10 alkyl-(R35)2, C2-C10 alkenyl-(R35) 2, CSR35, amino, NHR31, NR32R32, N(R31)- N (R) (R) C (R35) =N-N (R32)(R32), N=N(R31), N(R31)-N=C(R32), C (R35)=N- O (R33), ON=C(R35), C1-C10 alkyl-NHR31, C1-C10 alkyl-NR32R32, (C1- Clo) alkyl-N (R31)-N(R32)(R32), (C1-C10)alkylC(R35)=N-N(R32)(R32), (C1- do) alkyl-N=N(R31), (C1-C10)alkyl-N(R31)-N=C(R32), SCN, NCS, C1-C10 alkyl SCN, d-do alkyl NCS, nitro, cyano, O-R33, Ci-do alkyl-OR33, COR35, SR33, SSR33, SOR35, SO2R35, C1-C10 alkyl-COR35, C1-Cio alkyl- SR33, C1-C10 alkyl-SOR35, C1-C10 alkyl-SO2R35, halo, Si (R35) 3, halo d-do alkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and Ci-Cio

mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and Ci-Cio mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R36 ; R31, R32, R33 and R34 and each independently selected from-H, alkyl, alkenyl, alkynyl, aminoalkyl, hydroxyalkyl, alkylamino alkyl, dialkylaminoalkyl, alkoxyalkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and Ci-Cio mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and Ci-Cio mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R36 ; R35 is selected from-H, alkyl, alkenyl, alkynyl, aminoalkyl, OH, alkoxy, amino, alkylamino, dialkylamino, hydroxyalkyl, alkylamino alkyl, dialkylaminoalkyl, alkoxyalkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-C1o mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and Ci-Cio mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R36 ; R36 is selected from-H, alkyl, alkenyl, alkynyl, aminoalkyl, OH, alkoxy, amino, nitro, cyano, halo, alkylamino, dialkylamino, hydroxyalkyl, alkylamino alkyl, dialkylaminoalkyl, alkoxyalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heterocyclylalkyl, and heteroarylalkyl ; R2, R3, R4, R5, R37 and R38 are each independently absent, or selected from an R'group ; n is 0; and R3 and R4 optionally join to form a ring of 5,6, 7, or 8 atoms, where the atoms in the ring are independently selected from Z3, Z4, O, S, C=O,

C=S, S=O, SO2, C that is mono or di-substituted with an R1 group, and N that is unsubstituted or substituted with an Ri group.

[00031] The"M"ring and the"Q"ring of the structure of formula I can have any number of Ri-Ln-substituent groups, ranging from zero to one or more per ring atom, and such substituent groups can be located on any atom of the ring having a valence suitable for the addition of a substituent group (s). Each such substituent group can have any number of R'groups per L group, ranging from zero to 5. A preferred structure is the presence of either 0 or 1 R1~Ln~ substituent groups on the ring. It is also preferred that the R1-Ln-substituent group is attached to the ring at the M1 or the Q location, respectively.

[00032] The meaning of any substituent at any one occurrence in Formula I, or any other general chemical formula herein, is independent of its meaning, or any other substituent's meaning, at any other occurrence, unless specified otherwise.

[00033] The term"alkyl"is used, either alone or within other terms such as"haloalkyl"and"alkylsulfonyl" ; it embraces linear or branched radicals having one to about twenty carbon atoms or, preferably, one to about twelve carbon atoms. More preferred alkyl radicals are"lower alkyl" radicals having one to about ten carbon atoms. Most preferred are lower alkyl radicals having one to about five carbon atoms. The number of carbon atoms can also be expressed as"C1-C5", for example. Examples of such radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isoamyl, hexyl, octyl and the, like. The term "alkenyl"refers to an unsaturated, acyclic hydrocarbon radical, linear or branched, in so much as it contains at least one double bond. Unless otherwise noted, such radicals preferably contain from 2 to about 6 carbon atoms, preferably from 2 to about 4 carbon atoms, more preferably from 2 to about 3 carbon atoms. The alkenyl radicals may be optionally substituted with groups as defined below. Examples of suitable alkenyl radicals include propenyl, 2-chloropropylenyl, buten-lyl, isobutenyl, penten-1yl, 2-methylbuten-1-yl, 3-methylbuten-1-yl, hexen-1-yl, 3-

hydroxyhexen-1-yl, hepten-1-yl, octen-1-yl, and the like. The term "alkynyl"refers to an unsaturated, acyclic hydrocarbon radical, linear or branched, in so much as it contains one or more triple bonds, such radicals preferably containing 2 to about 6 carbon atoms, more preferably from 2 to about 3 carbon atoms. The alkynyl radicals may be optionally substituted with groups as described below. Examples of suitable alkynyl radicals include ethynyl, proynyl, hydroxypropynyl, butyn-1-yl, butyn-2-yl, pentyn-1-yl, pentyn-2-yl, 4-methoxypentyn-2-yl, 3-methylbutyn-1-yl, hexyl- 1-yl, hexyn-2-yl, hexyn-3-yl, 3, 3-dimethylbutyn-1-yl radicals, and the like.

The term"oxo"means a single double-bonded oxygen. The terms "hydrido","-H", or"hydrogen", denote a single hydrogen atom (H). This hydrido radical may be attached, for example, to an oxygen atom to form a hydroxyl radical, or two hydrido radicals may be attached to a carbon atom to form a methylene (-CH2-) radical. The term"halo"means halogens such as fluorine, chlorine, and bromine or iodine atoms. The term "haloalkyl"embraces radicals wherein any one or more of the alkyl carbon atoms is substituted with halo as defined above. Specifically embraced are monohaloalkyl, dihaloalkyl, and polyhaloalkyl radicals. A monohaloalkyl radical, for one example, may have a bromo, chloro, or a fluoro atom within the radical. Dihalo radicals may have two or more of the same halo atoms or a combination of different halo radicals and polyhaloalkyl radicals may have more than two of the same halo atoms or a combination of different halo radicals. Likewise, the term"halo", when it is appended to alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heteroaryl, and the like, includes radicals having mono-, di-, or tri-, halo substitution on one or more of the atoms of the radical. The term "hydroxyalkyl"embraces linear or branched alkyl radicals having one to about ten carbon atoms any one of which may be substituted with one or more hydroxyl radicals. The terms"alkoxy"and"alkoxyalkyl"embrace linear or branched oxy-containing radicals each having alkyl portions of one to about ten carbon atoms, such as methoxy radical. The term "alkoxyalkyl"also embraces alkyl radicals having two or more alkoxy

radicals attached to the alkyl radical, that is, to form monoalkoxyalkyl and diaikoxyalkyl radicals. The"alkoxy"or"alkoxyalkyl"radicals may be further substituted with one or more halo atoms, such as fluoro, chloro, or bromo, to provide"haloalkoxy"or"haloalkoxyalkyl"radicals. Examples of "alkoxy"radicals include methoxy, butoxy, and trifluoromethoxy. Terms such as"alkoxy (halo) alkyl", indicate a molecule having a terminal alkoxy that is bound to an alkyl, which is bonded to the parent molecule, while the alkyl also has a substituent halo group in a non-terminal location. In other words, both the alkoxy and the halo group are substituents of the alkyl chain. The term"aryl", alone or in combination, means a carbocyclic aromatic system containing one, two, or three rings wherein such rings may be attached together in a pendent manner or may be fused. The term "aryl"embraces aromatic radicals such as phenyl, naphthyl, tetrahydronapthyl, indane, and biphenyl. The term"heterocyclyl"means a saturated or unsaturated mono-or multi-ring carbocycle wherein one or more carbon atoms is replaced by N, S, P, or O. This includes, for example, structures such as: where Z, z1, Z2, or Z3 is C, S, P, O, or N, with the proviso that one of Z, Z1, Z2, or Z3 is other than carbon, but is not O or S when attached to another Z atom by a double bond or when attached to another O or S atom. Furthermore, the optional substituents are understood to be attached to Z, z1, Z2, or Z3 only when each is C. The term"heterocycle" also includes fully saturated ring structures, such as piperazinyl, dioxanyl, tetrahydrofuranyl, oxiranyl, aziridinyl, morpholinyl, pyrrolidinyl, piperidinyl, thiazolidinyl, and others. The term"heteroaryl"embraces unsaturated heterocyclic radicals. Examples of unsaturated heterocyclic radicals, also

termed"heteroaryl"radicals include thienyl, pyrryl, furyl, pyridyl, pyrimidyl, pyrazinyl, pyrazolyl, oxazolyl, isoxazolyl, imidazolyl, thiazolyl, pyranyl, and tetrazolyl. The term also embraces radicals where heterocyclic radicals are fused with aryl radicals. Examples of such fused bicyclic radicals include benzofuran, benzothiophene, and the like. The terms aryl or heteroaryl, as appropriate, include the following structures: where: when n=1, m=1 and Ai-As are each Cru or N, Ag and Aio are carbon; when n=0, or 1, and m=0, or 1, one of A2-A4 and/or A5-A7 is optionally S, O, or NRX, and other ring members are Cruor N, with the proviso that oxygen cannot be adjacent to sulfur in a ring. Ag and Aio are carbon; when n is greater than or equal to 0, and m is greater than or equal to 0,1 or more sets of 2 or more adjacent atoms Ai-Aio are sp3 O, S, NRX, CRXRY, or C= (O or S), with the proviso that oxygen and sulfur cannot be adjacent. The remaining Ai-Ag are CRX or N, and Ag and Aio are carbon; when n is greater than or equal to 0, and m greater than or equal to 0, atoms separated by 2 atoms (i. e., A1 and A4) are Sp3 O, S, NRX, CRXRY, and remaining A1-A8 are independently Cru or N, and Ag and A1o are carbon.

[00034] The term"sulfonyl", whether used alone or linked to other terms such as alkylsulfonyl, denotes respectively divalent radicals-S02-.

"Alkylsulfonyl", embraces alkyl radicals attached to a sulfonyl radical,

where alkyl is defined as above. The term"arylsulfonyl"embraces sulfonyl radicals substituted with an aryl radical. The terms"sulfamyl"or "sulfonamidyl", whether alone or used with terms such as"N- alkylsulfamyl","N-arylsulfamyl","N, N-dialkylsulfamyl"and"N-alkyl-N- arylsulfamyl", denotes a sulfonyl radical substituted with an amine radical, forming a sulfonamide (-S02-NH2), which may also be termed an "aminosulfonyl". The terms"N-alkylsulfamyl"and"N, N-dialkylsulfamyl" denote sulfamyl radicals substituted, respectively, with one alkyl radical, a cycloalkyl ring, or two alkyl radicals. The terms"N-arylsulfamyl"and"N- alkyl-N-arylsulfamyl"denote sulfamyl radicals substituted, respectively, with one aryl radical, and one alkyl and one aryl radical. The terms "carboxy"or"carboxyl", whether used alone or with other terms, such as "carboxyalkyl", denotes-C02-H. The term"carboxyalkyl"embraces radicals having a carboxyradical as defined above, attached to an alkyl radical. The term"carbonyl", whether used alone or with other terms, such as"alkylcarbonyl", denotes- (C=O)-. The term"alkylcarbonyl"embraces radicals having a carbonyl radical substituted with an alkyl radical. An example of an"alkylcarbonyl"radical is CH3- (CO) -. The term "alkylcarbonylalkyl" denotes an alkyl radical substituted with an "alkylcarbonyl"radical. The term"alkoxycarbonyl"means a radical containing an alkoxy radical, as defined above, attached via an oxygen atom to a carbonyl (C=O) radical. Examples of such"alkoxycarbonyl" radicals include (CH3) 3-C-O-C=O)-and- (O=) C-OCH3. The term "alkoxycarbonylafkyl"embraces radicals having"alkoxycarbonyl", as defined above substituted to an alkyl radical. Examples of such "alkoxycarbonylalkyl"radicals include (CH3) 3C-OC (=O)- (CH2) 2-and- (CH2) 2 (-O) COCH3. The terms"amido", or"carbamyl", when used alone or with other terms such as"amidoalkyl","N-monoalkylamido","N- monoarylamido","N, N-dialkylamido","N-alkyl-N-arylamido","N-alkyl-N- hydroxyamido"and"N-alkyl-N-hydroxyamidoalkyl", embraces a carbonyl radical substituted with an amino radical. The terms"N-alkylamido"and "N, N-dialkylamido" denote amido groups which have been substituted with

one alkylradical and with two alkyl radicals, respectively. The terms"N- monoarylamido"and"N-alkyl-N-arylamido"denote amido radicals substituted, respectively, with one aryl radical, and one alkyl and one aryl radical. The term"N-alkyl-N-hydroxyamido"embraces amido radicals substituted with a hydroxyl radical and with an alkyl radical. The term"N- alkyl-N-hydroxyamidoalkyl"embraces alkylradicals substituted with an N- alkyl-N-hydroxyamido radical. The term"amidoalkyl"embraces alkyl radicals substituted with amido radicals. The term"aminoalkyl"embraces alkyl radicals substituted with amino radicals. The term"alkylaminoalkyl" embraces aminoalkyl radicals having the nitrogen atom substituted with an alkyl radical. The term"amidino"denotes an-C (-NH)-NH2 radical. The term"cyanoamidin"denotes an-C (-N-CN)-NH2 radical. The term "heterocycloalkyl"embraces heterocyclic-substituted alkyl radicals such as pyridylmethyl and thienylmethyl. The terms"aralkyl", or"arylalkyl" embrace aryl-substituted alkyl radicals such as benzyl, diphenylmethyl, triphenylmethyl, phenethyl, and diphenethyl. The terms benzyl and phenylmethyl are interchangeable. The term"cycloalkyl"embraces radicals having three to ten carbon atoms, such as cyclopropyl cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl. The term"cycloalkenyl" embraces unsaturated radicals having three to ten carbon atoms, such as cylopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, and cycloheptenyl. The term"alkylthio"embraces radicals containing a linear or branched alkyl radical, of one to ten carbon atoms, attached to a divalent sulfur atom. An example of"alkylthio"is methylthio, (CH3-S-).

The term"alkylsulfinyl"embraces radicals containing a linear or branched alkyl radical, of one to ten carbon atoms, attached to a divalent-S (-O)- atom. The terms"N-alkylamino"and"N, N-dialkylamino"denote amino groups which have been substituted with one alkyl radical and with two alkyl radicals, respectively. The term"acyl", whether used alone, or within a term such as"acylamino", denotes a radical provided by the residue after removal of hydroxyl from an organic acid. The term"acylamino"

embraces an amino radical substituted with an acyl group. An examples of an"acylamino"radical is acetylamino (CH3-C (=O)-NH-).

[00035] In the naming of substituent groups for general chemical structures, the naming of the chemical components of the group is typically from the terminal group-toward the parent compound unless otherwise noted, as discussed below. In other words, the outermost chemical structure is named first, followed by the next structure in line, followed by the next, etc. until the structure that is connected to the parent structure is named. For example, a substituent group having a structure such as: may be referred to generally as a"haloarylalkylaminocarboxylalkyl". An example of one such group would be fluorophenylmethylcarbamylpentyl.

The bonds having wavy lines through them represent the parent structure to which the alkyl is attached.

[00036] Substituent groups may also be named by reference to one or more"R"groups. The structure shown above would be included in a description, such as,"-C1-C6-alkyl-COR", where Ru is defined to include- NH-Ci-C4-alkylaryl-Ry, and where RY is defined to include halo. In this scheme, atoms having an"R"group are shown with the"R"group being the terminal group (i. e., furthest from the parent). In a term such as "C (RX) 2", it should be understood that the two Rx groups can be the same, or they can be different if Rx is defined as having more than one possible identity.

[00037] The present invention also comprises MK-2 inhibiting compounds having the structure shown in formula l : Formula II.

wherein: Z2 and Z3 are nitrogen, Zt, Z4 and Z5 are carbon, and join with Z2 and Z3 to form a pyrazol ring, or optionally, Z4 and Z5 are nitrogen, Z1, Z2 and Z3 are carbon and join with Z4 and Z5 to form a pyrazol ring; Ra is selected from: 1)

2) where dashed lines indicate optional single or double bonds;

when Ra is ring M and ring M is aromatic, M1 is carbon and is substituted with (L)nR1, M5 is carbon, and each of M2, M3, M4 and M6 is independently selected from carbon and nitrogen and is unsubstituted or substituted with (L) nR' ; when ring M is partially saturated, M1 is carbon and is mono-or di- substituted with (L) nR1, M5is carbon, and each of M2, M3, M4 and M6 is independently selected from carbon, nitrogen, oxygen and sulfur, and when M2, M3, M4, or M6 is oxygen or sulfur, it is unsubstituted, and when M2, M3, M4 or M6 is carbon or nitrogen, it is optionally unsubstituted; or mono-or di-substituted with (L) nR1 ; when Ra is ring Q and ring Q is aromatic, Q1 is selected from carbon and nitrogen, and when Q1 is carbon, it is substituted with (L)nR1, and when Q1 is nitrogen, it is unsubstituted, Q4 is selected from nitrogen and carbon, and each of Q2, Q3 and Q5 is independently selected from nitrogen and carbon, and if carbon, it is substituted with (L)"R1 ; optionally when ring Q is aromatic, Ql is carbon and is substituted with (L)nR1, Q4 is carbon, and one of Q2, Q3 and Q5 is optionally oxygen or sulfur, and the remainder of Q2, Q3 and Q5 are independently selected from nitrogen and carbon, and if carbon, are substituted with (L)nR1 ; when ring Q is partially saturated, Q1 is selected from carbon and nitrogen, and if carbon, it is mono-or di-substituted with (L)nR1, and if nitrogen, it is unsubstituted or substituted with (L)nR1, Q4 is selected from carbon and nitrogen, but only one of Q1 and Q4 can be nitrogen, each of Q2, Q3 and Q5 is independently selected from carbon, nitrogen, oxygen and sulfur, and if oxygen or sulfur, it is unsubstituted, and if carbon, it is mono-or di-substituted with (L) nR', and if nitrogen, it is unsubstituted or substituted with (L) nR1 ; when Ra is structure 3, it is fully conjugated, X2 is selected from oxygen or nitrogen substituted with (L) nR1, X1 is carbon and is substituted with (L) nR1, and each of X5 and X6 is independently selected from nitrogen and carbon, and if carbon, it is substituted with (L)"R1 ;

R1 is selected from -H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, hydroxyl, C1-C6 alkoxy, C2-C6 alkenyl-R11, C1-C6 alkoxy-R11, COR, C02R7, CON', N (R8) 2, amino C1-C4 alkyl, hydroxy Ci-C4 alkyl, amino, amino C1-C4 alkyl-R7, C1-C6 alkyl-NHR7, carbonitrile, SR10, halo, NHR7, NR8R9, NHR7-C1-C6 alkyl, NR8R9-C1-C6 alkyl, nitro, cyano, O-R10, C1-C4 alkyl-OR10, C1-C6 alkyl-COR11, halo C1-C4 alkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, or C1-C10 mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R12 ; R7 and R8 are each independently selected from-H, C1-C6 alkyl, C1- C4 alkyl-R11, C1-C6 alkyl-N(R13) 2, C02R'6, COR17, aryl, and arylalkyl, wherein aryl and arylalkyl, are optionally substituted with one or more of the groups defined by R18; R9 and R10 are each independently selected from-H, hydroxyl, C1- C6 alkyl, C1-C6 alkyl-R17, C1-C6 alkyl-NH2R13, CO2R16, COR17, C1-C6 alkyl- CO2R16, C1-C6 alkyl-CONH-R16, C1-C6 alkyl-CON (R16) 2, hydroxy C1-C4 alkyl, halo C1-C4 alkoxy, halo C1-C4 alkyl, Si (R13)2R17, aryl, heteroaryl, heterocyclyl, arylalkyl, and C1-C10 mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, and arylalkyl, are optionally substituted with one or more of the groups defined by R'8 ; R11 is selected from-H, C1-C6 alkyl, C1-C6 alkoxy, hydroxyl, halo, amino, NHR13, N (R13) 2, COR13, CO2R17, halo C1-C4 alkyl, aryl, heteroaryl, heterocyclyl, heteroarylalkyl, and heterocyclylalkyl, wherein heterocyclyl, heteroarylalkyl, and heterocyclylalkyl, are optionally substituted with one or more of the groups defined by R18 ; R12 is selected from-H, hydroxyl, oxo, C1-C6 alkyl, hydroxyl C1-C6 alkyl-R11, C1-C10 alkoxy, amino, amino Ci-C4 alkyl-R7, NHR7, N (R7) 2, Ci- C6 alkyl-NHR7, C1-C6 alkyl-NHR8R9, C1-C6 alkyl-N(R8)2, C1-C6 alkyl-R11, C1-C6 alkyl-CO2R7R11, C1-C6 alkoxy-R11, nitro, O-R10, C=O, COR11, CO2R11, WR10, SOR11, SO2R11, NHSO2R11, C1-C6 alkyl-SR10, halo, halo C1- C4 alkyl, halo C1-C4 alkoxy, hydroxy C1-C4 alkyl, hydroxy C1-C4 alkoxy,

aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and Cl-calo mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and heterocyclylalkyl, and Ci-Cio mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R18 ; R"9 and R14 are each independently selected from-H, oxo, C1-C6 alkyl, COR23, and aryl ; R"5 and R16 are each independently selected from-H, aryl, arylalkyl, wherein aryl, arylalkyl, are optionally substituted with one or more of the groups defined by R24 ; R17 is selected from-H, C1-6 alkyl, C1-C6 alkyl-R19, NHR19, aryl, heteroarylalkyl, and heterocyclylalkyl, wherein aryl is optionally substituted with one or more of the groups defined by R24 ; R'8 is selected from-H, oxo, hydroxyl, Ci-Cio alkyl, Ci-Cio alkoxy, amino, amino Ci-Ce alkyl, N (R'9) 2, C1-C6 alkyl-N(R19) 2, CO2R23, SR21, halo, halo C1-C4 alkyl, aryl, heteroaryl, and heterocyclyl, wherein aryl, heteroaryl, and heterocyclyl, are optionally substituted with one or more of the groups defined by R24 ; R'9 and R 20 are each independently selected from-H, C1-C6 alkyl, heteroaryl, heterocyclyl, wherein aryl, heteroaryl, and heterocyclyl, are optionally substituted with one or more of the groups defined by R30 ; R21 and R22 are each independently selected from-H and Ci-Ce alkyl ; R23 is selected from-H and C1-C6 alkyl ; R24 is selected from-H, Ci-Ce alkyl, C1-C6 alkoxy, CO2R29, halo, and halo Ci-C4 alkyl ; R29 is selected from-H, and C1-C6 alkyl ; R30 is selected from-H, aryl, heteroaryl, heterocyclyl, alkylaryl, arylalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, and arylalkyl, are optionally substituted with one or more of the groups defined by R36 ; R36 is selected from-H and halo ;

R2, R3, R4, R37 and R38 are each independently selected from an group; n is 0 ; and R3 and R4 optionally join to form a ring of 5,6, 7, or 8 atoms, where the atoms in the ring are independently selected from Z3, Z4, O, S, C=O, C=S, S=O, SO2, C that is mono or di-substituted with an Ri group, and N that is unsubstituted or substituted with an R1 group.

[00038] Table I and Table II show examples of MK-2 inhibiting compounds of the present invention, and also shows the chemical name and, where available, the IC50 value of the compound for MK-2 inhibition.

It is believed that any of the compounds that are listed in Table I and Table II are MK-2 inhibiting compounds that can be used in the method of the present invention. However, neither the novel MK-2 inhibiting compounds, nor the uses of an MK-2 inhibiting compound that are described herein are intended to be limited to the compounds that are presented in the following Tables. Table l : MK-2 Inhibitin Compounds MK-2 Avg. No. Structurea Compound Names) b IC50 (uM) 1 NH2 1-(2-aminoethyl)-3-(2-qUinolin-3-ylpyridin-4-0. 0269 yl)-l H-pyrazole-5-carboxylic acid 9 vOH trifluoroacetate i N, O O 1. 25 HOJ'LCF3 2 No2 NH 1-(3-aminopropyl)-3-[2-(3-0. 0397 nitrophenyl) pyridin-4-yll-1 H-pyrazole-5- carboxylic acid dihydrochloride OH N | O HCl H-CI N 3 H2N 6-(aminomethyl)-2-(2-quinolin-3-ylpyridìn-4-0. 0477 yl)-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one Ozone \ \ I \ I. W1v0 NoH 4 1-(2-aminoethyl)-3-{2-[(E)-2-0. 050g HO'CL phenylethenyl] pyridin-4-yl}-1 H-pyrazole-5- AI NN carboxylic acid trifluoroacetate N- //OH N I o 5 H-Cl NH 1- (2-aminoethyl)-3- (2- [4- 0. 0533 HCl ~ 2 (hydroxymethyl) phenyl] pyridin-4-yl}-1 H- Ho 3AOH pyrazole-5-carboxylic acid dEhydrochloride ou N o 6 HO 6- (hydroxymethyl)-2- (2-quinolin-3-ylpyridin- 0. 0615 4-yl)-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one % N N-N NH _ NI T _ 0 N 7 NH 1-(3-aminopropyl)-3-(2-quinolin-3-ylpyridin-0. 0686 N_N 4-yl)-1 H-pyrazole-5-carboxylic acid OH dihydrochloride v/I v II N O N-CI H-C) 8 1- (3-aminopropyl)-3- [2- (4- 0. 102 HO r/'z hydroxyphenyl) pyridin-4-yl]-l H-pyrazole-5- carboxylic acid hydrochloride OH 2 HCI 9 NO2 NH i-(2-aminoethyl)-3-[2-(3-nitrophenyl) pyridin 0. 109 4-ylj-1 H-pyrazole-5-carboxylic acid dihydrochloride OH 9 0"" _ 10 O'I 1- (2-aminoethyl)-3- {2- [4- 0. 117 HC) OF (dimethylamino) phenyllpyridin-4-yll-l H- NH2 pyrazole-5-carboxylic acid trifluoroacetate N O OH N, lao oJ4c (trifluoromethoxy) phenyì] pyridin-4-yl}-1 H- cFz°n NN~ pyrazole-5-carboxylic acid trifluoroacetate Caf3 O OH N 12 0 1- (2-aminoethy))-3- [2- (4- 0. 168 ) t NH methoxyphenyl) pyridin-4-yl]-1 H-pyrazole-5- < carboxylic acid trifluoroacetate OH 0 13 o 2-[2-(3-nitrophenyl) pyridin-4-yl]-6, 7-0. 171 dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one HO CF3 trifluoroacetate NH N- NOz Y/yr w0 N 14/\ 2-(2-isoquinolin-7-ylpyridin-4-yl)-6, 7 0. 194 < NN NH dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one N i / N<O N 15-_,,,-NH 1- (3-aminopropyl)-3- [2- (4- 0-196 N-N'2 methoxyphenyl) pyridin-4-yl]-l H-pyrazole-5- OH carboxylic acid hydrochloride i nu 2 HCI 16 H 2- [2- (1 H-indazol-5-yl) pyridin-4-yl]-6, 7- 0. 199 dihydropyrazolo (1, 5-alpyrazin-4 (5H)-one Z NH trifluoroacetate 1. 5 TFA 17 1-(3-aminopropyl)-3-{2-t4-0. 20 ; zN NH2 (dimethylamino) phenyl] pyridin-4-yl)-1 H- OH pyrazole-5-carboxylic acid hydrochloride OH N N O 2 HCI 18 2-{2-[(E)-2-pyridin-3-yìethenyl] pyridin-4-yl}-0. 21 96N H 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one N 19 N/s\ 2-(2-quinolin-3-ylpyridin-4-yl)-6, 7-0. 21 E N-N H dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one ZU o N 20 ~o 1-(2-aminoethyl)-3-[2-(3 0. 217 N methoxyphenyl) pyridin-4-yl]-iH-pyrazole-5- OH HN o carboxylic acid trifluoroacetate OH N O N O 21 2- [2- (l H-pyrrolo [2, 3-b] pyridin-5-yl) pyridin-4- 0. 228 H yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one trifluoroacetate 1. 25 TFA 22 OH 6- (hydroxymethyl)-2- [2- (1 H-indol-5-0. 25 H/-- yI) pyridin-4-yl]-6, 7-dihydropyrazolo [1, 5- NH a] pyrazin-4 (5H)-one trifluoroacetate N v \Y v 1. 6 TFA 23/H 2- (2-quinolin-6-yipyridin-4-yl)-6, 7- 0. 298 ß tI N-N NH dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one I NI _ 0 24 Br 1- (3- { [2- (4- 0. 3 bromophenyl) ethyl] amino) propyl)-3-pyridin- 4-yl-1 H-pyrazo, e-5-carboxy, ic acid OH hydrochloride OH 0 0 W r 2 HCI 25 Br 1- (3- { [2- (4- 0. 315 < bromophenyl) ethyl] amino} propyì)-3-{2-[(E)- 2-phenylethenyl] pyridin-4-yl}-1 H-pyrazole-5 carboxylic acid trifluoroacetate X 90 HO CF3 N N" HOcF3 N I 26 o 2-[2-(4-methoxyphenyl) pyridin-4-yl]-6, 7-0. 318 Jt dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one trifluoroacetate N H N- Nez 27 2-[2-(1-methyl-1 H-indoì-5-yl) pyridin-4-yl]-0. 322 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- N one trifluoroacetate Ns, Pi O 2. 25 TFA 28 2-{2-[(E)-2-phenylvinyl] pyridin-4-y,}-6, 7-0. 371 dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one N trifluoroacetate v o0 HO CF3 N 29 2- [2- (5-chlorothien-2-yl) pyridin-4-yl]-6, 7- 0. 444 N N NH dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 0 N N r 30 2- [2- (3-fluoro-4-methoxyphenyl) pyridin-4- 0, 471 Oo H yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one nu N/ 31 O/\ 2-[2-(1-oxo-2, 3-dihydro-1 H-inden-5-0. 478 ) NN NH yì) pyridin-4-yì]-6, 7-dihydropyrazolo [1, 5- a) pyrazin-4 (5H)-one Nov 32 2- [2- (1-methyl-1 H-indol-5-yl) pyridin-4-yl]- 0. 479 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- \nu onze nez 33 2- [2- (3-fluorophenyl) pyridin-4-yl]-6, 7-0. 505 NH dihydropyrazo) o [1, 5-a] pyrazin-4 (5H)-one FOR N. /' 34 methyl 4- [4- (4-oxo-4, 5, 6, 7-0. 511 0 N-N/-\ NH tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyridin-2-yl] benzoate nez 35 OH 2- [2- (3-hydroxyphenyl) pyridin-4-yl]-6, 7- 0. 52 t < dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one i f o0 N 0 36 o 2- [2- (2, 3-dihydro-i-benzof uran-5-yl) pyridin- 0. 521 N-N NH 4-yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one N N J 37 2- [2- (l-benzof uran-5-yl) pyridin-4-yl]-6, 7- 0. 543 N-N NH dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one < trifluoroacetate 0S, OH NEZ 0 OH F+F F 38 H/>\ 2-[2-(2-oxo-2, 3-dihydro-1 H-indol-5-0. 554 N-N NH yl) pyridin-4-ylj-6, 7-dihydropyrazolo [1, 5- f/a] pyrazin-4 (5H)-one Nlvi N'J 39 2- (2-quinolin-3-ylpyridin-4-yl)-5, 6, 7, 8-0. 577 tetrahydro-4H-pyrazolo [1, 5-a] [1, 4] diazepin- NH 4-one v Y Y v \O N, l 40 2- {2- [4- (methylthio) phenyl] pyridin-4-yl}-6, 7- 0. 581 N-N/--\ NH dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 0 w. b 41 N 2- (2, 3'-bipyridin-4-yl)-6, 7- 0. 586 NH dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 42 HO \ 2-[2-(4-hydroxyphenyl) pyridin-4-yl]-6, 7-0. 611 \NH dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one N, 43/--\ 2- (2- [4- (2-morpholin-4- 0. 63 OUN ylethoxy) phenyl] pyridin-4-y,}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one Zon H 44 Cl 2-[2-(3-ch, orophenyl) pyridin-4-y,]-6, 7-0. 638 N-N/N H dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 0 NI 45 ~NH2 1-(2-aminoethyì)-3-pyridin-4-yl-lH-pyrazole o 73c sN 5-carboxylic acid trifluoroacetate OH 0- N, o HO CF3 46 \ 2-(2-{4-[2-0. 766 N X (dimethylamino) ethoxyJphenyl} pyridin-4-yl)- < N ~ N ~\ 6, 7-dihydropyrazoìo [1, 5-a] pyrazin-4 (5H)- NH one NoS 47 H/\ 2-[2-(1 H-indol-5-yl) pyridin-4-yì]-6, 7-0. 80E N (NH dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one I T ° N\/ 48 2- {2- [4- (methylsulfonyl) phenyl] pyridin-4-yll- 0. 821 ÓS9 oH 67-dihydropyrazolo [1 5-a] pyrazin-4 (5H)- 0 onze \ v 49H-. 2-t2- (1, 2, 3, 4-tetrahydroquinolin-6-yl) pyridin-0. 83 ; N-N NH 4-yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one v ! v y INI 50 2- (6'-methoxy-2, 3'-bipyridin-4-yl)-6, 7- 0. 866 dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one Ho Nok 51 ~ o 2-[2-(3-methoxyphenyl) pyridin-4-yl]-6, 7-0. 906 dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one EUH /I v y Nez 52. < 2-[2-(4-aminophenyl) pyridin-4-yl]-6, 7-0. 914 N-N NH dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one trifluoroacetate I O N/ O9, OH 1. 25 F T F F 53 H 5- [4- (4-oxo-4, 5, 6, 7-tetrahydropyrazolo [1, 5-0. 923 /--\ H a] pyrazin-2-yl) pyridin-2-yl]-1H-indole-3- N- carbaldehyde H O NIJ O 54 -- 2- {2- [4- (hydroxymethyl) phenyl] pyridin-4-yl}- 0. 929 Ho N-N NH 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one o N, J 55 2- [2- (l H-indol-6-yl) pyridin-4-yi]-6, 7- 0. 93 NH dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one NZ N 56 00 2- [2- (l-benzothien-5-yl) pyridin-4-yl]-6, 7- 0. 965 oSmn H dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one Ho I o N/ 57 0 4-oxo-2-(2-quinolin-3-ylpyridin-4-yl)-4, 5, 6, 7- 1. 01 NH2 tetrahydropyrazolo [1, 5-a] pyrazine-6- carboxamide Vj) NU NIT O 58 ~NH2 ethyl 1-(2-aminoethyì)-3-(2-quinolin-3-1. 03 N-N yipyridin-4-yl)-l H-pyrazole-5-carboxylate \ \ //p dihydrochloride 0 N H-Cl HHCl Cl 59 H --- 2- [2- (2, 3-dihydro-1 H-indol-5-yl) pyridin-4-yl]- 1. 07 N\ N-N NH 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 60 C ^ 2- [2- (4-methoxyphenyl) pyridin-4-yl]-5, 6, 7, 8-1. 09 4 NH 4etrahydro-4H-pyrazolo [1, 5-a] [1, 4] diazepin- N 4-one NU N 61 3-ehìoro-2-[2-(3-chlorophenyì) pyridin-4-yl]-1 13 NH 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- CI \ \ one i o ci 0 one 62 B4- [4- (4-oxo-4, 5, 6, 7-tetrahydropyrazoo [1, 5-1 15 N-N NH F F a] pyrazin-2-yl) pyridin-2-yl] benzaldehyde 1 0 OF trifluoroacetate OH 63 NHZ 1- (3-aminopropyl)-3-pyridin-4-yl-1 H-1. 16 pyrazole-5-carboxylic acid N N OH 0 N/ 64 Cl 13012 or 6- (chloromethyl)-2- (2-quinolin-3- 1. 17 11-C ylpyridin-4-yl)-6, 7-dihydropyrazolo [1, 5- \ j e a] pyrazin-4 (5H)-one nit O 65 2- [2- (2-furyl) pyridin-4-yll-6, 7- 1. 2 dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one non 0 N/ 66 N02 2- [2- (3-nitrophenyl) pyridin-4-yl]-5, 6, 7, 8- 1. 26 tetrahydro-4H-pyrazolo [1, 5-a] [1, 4] diazepin- NH 4-one hydrochloride w X 0 H-Cl 67 ~\ 2-[2-(1, 3-thiazol-2-yl) pyridin-4-yl]-6, 7-1. 29 -a] pyrazin-4 (5H)-one s I w nit 0 68 2- [2- (3-aminophenyl) pyridin-4-yl]-6, 7- 1. 3 NNH dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one hlzN v \ v vo N 69 No2 1- (3-aminopropyl)-3- [2- (3- 1. 32 A N H2 nitrophenyl) pyridin-4-yl]-1H-pyrazoìe-5- i v carboxamide trifluoroacetate N O HO) CF, O 70 N TFA NN 2-[2-(1 H-imidazol-1-yl) pyridin-4-yl]-6, 7-1. 36 /=\ N H dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one trifluoroacetate N Hi O N 71. 2-[2-(4-hydroxyphenyl) pyridin-4-yl]-5, 6, 7, 8- 1. 37 tetrahydro-4H-pyrazolo [1, 5-a] [1, 4] diazepin- NH 4-one trifluoroacetate F F N F O_°°°/ F OH 72/~\ 3-bromo-2-[2-(3-chlorophenyl) pyridin-4-yl]-1. 39 N-N NH 6, 7-dihydropyrazoto [1, 5-a] pyrazin-4 (5H)- cl one 0 N Br 73 2- [2- (3-f uryl) pyridin-4-yl]-6, 7- 1. 46 dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one / 74 I 2- {2- [4- (dimethylamino) phenyl] pyridin-4-yl}- 1. 53 zN ~\ 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- NH one trifluoroacetate ,- Ni 2. 25 TFA 75-H 2- (2-thien-3-ylpyridin-4-yl)-6, 7- 1. 55 dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one v y / 76 0 2- [2- (2, 3-dihydro-1, 4-benzodioxin-6- 1. 56 N-N NH yl) pyridin-4-yl]-6, 7-dihydropyrazolo [1, 5- I/o a] pyrazin-4 (5H)-one N 77 \ 2-(5'-methoxy-2, 3'-bipyridin-4-yl)-6, 7-1. 69 0 dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one N-N NH N i I/o N 0 78--2-(2-{4-1. 73 H N-N NH [ (isopropylamino) methyl] phenyl} pyridin-4- yl)-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) 0 one NI 799 2- {2- [4- (hydroxymethyl) phenyl] pyridin-4-yl}- 1. 75 N-5, 6, 7, 8-tetrahydro-4H-pyrazolo [1, 5- NH a] [1, 4] diazepin-4-one N 0 N 80 l 2-(2-{4-[2-1. 98 zN (dimethylamino) ethyl] phenyl} pyridin-4-yì)- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- N-N N H one N 81 2-(2-pyrimidin-5-ylpyridin-4-yl)-6, 7-1. 99 N-N N H dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one N trifluoroacetate F N11 0 OH OH oH 82 2- [2- (1, 2, 3, 4-tetrahydroisoquinolin-7- 2. 08 N-K NH yl) pyridin-4-yll-6, 7-dihydropyrazolo [1, 5- H a] pyrazin-4 (5H)-one po 833 2- {2- [3- (methylsulfonyl) phenyl] pyridin-4-yl}- 2. 1 o= =0 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one NU nu xi 84 HN 2- {2- [3- (2-piperazin-1- 2. 13 ylethoxy) phenyl] pyridin-4-yll-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one hydrobromide Nez NU H Br Nu 85/-\ N-f3- [4- (4-oxo-4, 5, 6, 7- 2. 29 "in/tetrahydropyrazolo [1, 5-a] pyrazin-2- , S N /yl) pyridin-2-yl] phenyl} methanesulfonamide N 0 N 86 N/---1 2- {2- [4- (dimethylamino) quinazolin-6- 2. 4 N-N NH yl] pyridin-4-yl}-6, 7-dihydropyrazolo [1, 5- -4 (5H)-one O zNs N'J 87 \ 2-(2-{3-[2-2. 4 (dimethylamino) ethoxy] phenyl} pyridin-4-yl)- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- 0 one one N-N- / N o 88 2-pyridin-4-yl-6, 7-dihydropyrazolo [1, 5- 2. 6 0 <"a] pyrazin-4 (5H)-one trifluoroacetate CF/OH 0 C 3 OH I O 3 N 89 F/F ^ 2- [2- (2, 4-difluorophenyl) pyridin-4-yl]-6, 7- 2. 62 N H dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one I N 90/2-[2-(4-methyl-1 H-imidazol-1-yl) pyridin-4-2. 76 Nt N-N l yl]-5, 6, 7, 8-tetrahydro-4H-pyrazolo [1, 5- //NH a] [1, 4] diazepin-4-one hydrochloride Nu N 91 2- [2- (l H-pyrrol-2-yl) pyridin-4-yi]-6, 7- 2. 79 --N NH dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one N N/ 92 H/\ 2-[2-(2-methyl-1 H-indol-5-yl) pyridin-4-yl]-2. 8 N N-N NH 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one N\ N 93 . F 2- [2- (2-fluorophenyl) pyridin-4-yl]-6, 7- 2. 95 f NH dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one N O N o 94 2- {2- [4- (morpholin-4- 2. 99 C Nv N-N NH ylmethyl) phenyì] pyridin-4-yl}-6, 7- zu eo dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one N\/ N 95 ethyl ethyl4- (2- {3- [4- (4-oxo-4, 5, 6, 7- 3. 02 t Nk tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyridin-2-yl] phenoxy} ethyl) piperazine-1- carboxylate N-N---'N _ 96 H-Cl NH ethyl 1- (2-aminoethyl)-3- {2- [4- 3. 25 H-Cl 2 (hydroxymethyl) phenyl] pyridin-4-yl)-l H- pyrazole-5-carboxylate dihydrochloride zu o N, 97 2- {2- [3- (aminomethyl) phenyi] pyridin-4-yll- 3. 25 w N-N NH 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- H2N v one N 98 2- {2- [3- (2-pyrrolidin-1-3. 27 ylethoxy) phenyl] pyridin dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one o HNH H N 0 O 99 O N- {3- [4- (4-oxo-4, 5, 6, 7- 3. 31 H tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyridin-2-yl] phenyl} acetamide N N H v s N 100 2- {2- [4- (dimethylamino) phenyl] pyridin-4-yl}- 3. 44 -tetrahydro-4H-pyrazolo [1, 5- I NH a] [1, 4] diazepin-4-one trifluoroacetate F F F Oqk F OH ioi 2- {2- [4- (morpholin-4- 3. 65 N N_N NH ylcarbonyl) phenyl] pyridin-4-yl}-6, 7- o J S dihydropyrazo, o [1, 5-a] pyrazin-4 (5H)-one ,. O N 10203- {4- [4- (4-oxo-4, 5, 6, 7- 4. 19 HO N-NH tetrahydropyrazolo [1, 5-a] pyrazin-2- Ho 'N/yl) pyridin-2-yl] phenyl} propanoic acid w,. o N 103 2- [2- (1 N-pyrazol-1-y !) pyridin-4-yl]-6 7-4. 2 H dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one N O N 0 104 2-[2-(1, 3-benzothiazol-2-yl) pyridin-4-yl]-6, 7 4. 27 % dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one s 0 0 N 105 N/\ 2-[2-(4-phenyl-1 H-imidazo,-1-yl) pyridin-4-4. 31 N"' NH yl]-5, 6, 7, 8-tetrahydro-4H-pyrazolo [1, 5- < t D Jt cv, a] [1, 4] diazepin-4-one trifluoroacetate Nu 106 HO 2- {2- [3- (hydroxymethyl) phenyl] pyridin-4-yl}- 4. 54 5, 6, 7, 8-tetrahydro-4H-pyrazolo [1, 5- H a] [1, 4] diazepin-4-one trifluoroacetate F O < F OH OH 107 rOH 6-(hydroxymethyl)-2-[2-(1, 2, 3, 4- 4. 9 tetrahydroquinolin-3-yl) pyridin-4-yl]-6, 7- ß H dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one N 108 OH NH ethyl 1-(2-aminoethyl)-3-[2 (3-4. 98 i 2 hydroxyphenyl) pyridin-4-yl]-iH-pyrazole-5- N-N H-CI carboxylate dihydrochloride <, QN/Ost H-CI NJ 109 2- [2- (2H-1, 2, 3-triazol-2-yl) pyridin-4-yl]-6, 7-5. 21 NH dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one N compound with 2- [2- (l H-1, 2, 3-triazol-1- N 1 0 yl) pyridin-4-yl]-6, 7-dihydropyrazololl, 5- N\ NN ~ 0 a] pyrazin-4 (5H)-one (1 : 1) ,, C--',, I N'nu 110 ~O NH ethyl 1-(2-aminoethyl)-3-[2-(3-5. 23 !/- ~ 2 methoxyphenyl) pyridin-4-yl]-1 H-pyrazoìe-5- N-N H-CI carboxylate dihydrochloride H-Cl I o N v O 111 2-(2, 2'-bipyridin*4-yl)-6, 7-5. 34 N N H dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one / N O 112 s z 2-(2-{4-5. 35 jN Å [(dimethylamino) methyl] phenyl} pyridin-4-yl) 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- oyk F one trifluoroacetate OH 113 2- [2- (1 H-imidazol-1-yl) pyridin-4-yl]-5, 6, 7, 8- 5. 66 N N-N tetrahydro-4H-pyrazolo [1, 5-a] [1, 4] diazepin- NH 4-one hydrochloride CI NO H-CI 114 2- [2- (3- { [ (2- 5. 78 /N-N NH hydroxyethyl) amino] methyl} phenyl) pyridin- Ho''N I w ! 4-yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin- nui 4 (5H)-one 115'-\2- (2- {3-M7 N-N NH [ (isopropylamino) methyl] phenyl) pyridin-4- /yl)-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) 0 one N 116 2-t2- [3- (2-morpholin-4- 6. 73 ylethoxy) phenyl] pyridin-4-yl}-6, 7- N dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one N-N- N O . 0 O 117 2-[2-(4-phenyl-1 H-imidazol-1-yl) pyridin-4-7. 04 / NH yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one neo 118 NH2 1- (2-aminoethyl)-N-hydroxy-3- {2- [4- 7. 91 HO4 NN (hydroxymethy,) phenyì] pyridin-4-yl}-1 H- WJ/NOH pyrazoìe-5-carboxamide trifluoroacetate N OH nu HO CF3 119 1-(3-aminopropyl)-3-(4-hydroxyphenyl)-1 H-8. 11 N N 2 pyrazole-5-carboxylic acid dihydrochloride OH H-cl 0 H-Cl / 120 2- [2- (1 H-benzimidazol-2-yl) pyridin-4-yl]-6, 7 8. 92 N-N-' dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one N NI 0 121 _ 2-[2-(1 H-1, 2, 3-triazol-1-yl) pyridin-4-yl]- 9. 05 NaN N-N 5, 6, 7, 8-tetrahydro-4H-pyrazolo [1, 5- iN) < f H-CI a] [1, 4] diazepin-4-one hydrochloride N li o N 122 2-pyridin-4-yl-5, 6, 7, 8-tetrahydro-4H-10. 1 N Nir-)-al [1, 4] diazepin-4-one H X i j O 1 23 ^ 2-[2-(1 H-pyrrol-1-yì) pyridin-4-yl]-5, 6, 7, 8-1 0. 6 /+ N-N ; tetrahydro-4H-pyrazolo [1, 5-a] [1, 4] diazepin- \ON NH 0 4-one trifluoroacetate 'Ir I X/li HO CF, N'Di 0 124/NH2 1-(3-aminopropyl)-3-(2-quinolin-3-ylpyridin-10. 7 i,. N_N 4-yl)-1 H-pyrazole-5-carboxamide NH2 dihydrochloride i N @ H-CI H-cul 125 2-12- [3- (morpholin-4- 11. 4 N-N NH yimethyl) phenyl] pyridin-4-yl}-6, 7- N dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 0 N 126 4-(4-oxo-4, 5, 6, 7-tetrahydropyrazolot1, 5-1 3. E N-N NH a] pyrazin-2-yl) pyridine-2-carbonitrile N. "O N 127 3- [2- (l H-imidazol-I-yl) pyridin-4-yi]-l-propyl. 14. 3 1 H-pyrazole-5-carboxylic acid N N-N OH \ON 0 NEZ 128 0 2- (2- {3- 15. 4 _NH'I [ (dimethylamino) methyl] phenyl} pyridin-4-yl) 0 F 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one trifluoroacetate 129 p 2- {2- [3- (benzyloxy) phenyl] pyridin-4-yl}-6, 7- 15. 5 dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one rI NH N O 130 2- [2- (l H-pyrazol-1-yl) pyridin-4-yl]-5, 6, 7, 8- 16. 2 />N N-N l tetrahydro-4H-pyrazoìo [1, 5-a] [1, 4] diazepin- \, I NH 4-one hydrochloride N H-Cl N J ° 131 ethyl 1- (2-aminoethyl)-3-12- [3- 20 N-N (benzyloxy) phenyl] pyridin-4-yll-i H- H-a pyrazole-5-carboxylate dihydrochloride N N I 132-2- {3- [4- (4-oxo-4, 5, 6, 7- 20 N N-N H tetrahydropyrazolo [, 5-a] pyrazin-2- N I/yl) pyridin-2-yl] benzyl}-iH-isoindole-1, 3 (2H)- dione N 133 ~NH2 ethyl 1-(2-aminoethyl)-3-pyridin-4-yl-1H-24.' N-N H-CI pyrazole-5-carboxylate dihydrochloride 0 H-Cl Nu 134 1- (2-f (3- (5-methyl-2-f uryl) buty)] aminolethyl) 27. 2 3-pyridin-4-yl-1 H-pyrazole-5-carboxylic N~ acid trifluoroacetate N-N OH 0 M ° HOCF, 1352- [2- (1 H-1, 2, 4-triazol-1-yl) pyridin-4-yl]- 28. 2 /--N N-N 5, 6, 7, 8-tetrahydro-4H-pyrazolo [1, 5- N N H a] [1, 4] diazepin-4-one hydrochloride H-CI N O 136 ethyl 1- (2-aminoethyl)-3- [2- (4- { [tert- 28. 3 NHZ butyl (dimethyl) silyl] oxy) phenyl) pyridin-4-yl]- 1 H-pyrazole-5-carboxylate dihydrochloride I i O HCI 0 NI HCI 137 N02 NH ethyll- (3-aminopropyl)-3- [2- (3- 31. 6 S \ N nitrophenyl) pyridin-4-yl]-1 H-pyrazole-5- carboxylate dihydrochloride H-CI H-ci 138 CH TFA N, N 2- [2- (dimethylamino) pyridin-4-yl]-6, 7- 37. 2 dihydropyrazofo [1, 5-a] pyrazin-4 (5H)-one CH3/< ~ (trifluoroacetate N @ O 139 NH2 ethyl 1- (3-aminopropyl)-3- (2-quinolin-3- 38. 6 / N-N ylpyridin-4-yl)-1 H-pyrazole-5-carboxylate dihydrochloride v/I v N li o HCl H-Cl 140 NN ~ 2-(2-chloropyridin-4-yl)-6, 7-44. E CI i/ H dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one v N O 141 ethyl 1- (3-aminopropyl)-3- [2- (4- 47. 5 HOz N-N 2 hydroxyphenyl) pyridin-4-yì]-1 H-pyrazole-5- 4, +oEt carboxylatehydrochloride N li o N O 2 HCI 1 4Z 2-[2-(4-methyl-1 H-pyrazol-1-yl) pyridin-4-yl]-53. 4 N-Ni 0 5, 6, 7, 8-tetrahydro-4H-pyrazolo [1, 5- HOI, CF, a) [1, 4] diazepin-4-one trif I uoroacetate N li O 143 NH2 ethyl 1- (3-aminopropyl)-3-pyridin-4-yl-lH- 60. 8 pyrazole-5-carboxylate hydrochloride N 0 N. J HCI 144 ci 2- [2- (3, 4-dichlorophenyl) pyridin-4-yl]-6, 7- 65. 5 ci o dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one N-N NN trifluoroacetate Nez O N 145 2- (2-chloropyridin-4-yl)-5, 6, 7, 8-tetrahydro-80. 4 N N 4H-pyrazolo [1, 5-a] [1, 4] diazepin-4-one nu N li N N 146 F 2- [2- (3, 4-difluorophenyl) pyridin-4-yl]-6, 7- 88. 9 F i N-N H o dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one trifluoroacetate N O N 147 2- (4-hydroxyphenyl)-5, 6, 7, 8-tetrahydro-4H- 118 NJ-NI NH pyrazolo [1, 5-a] [1, 4] diazepin-4-one razz O HO 148 F O ^ 2- {2- [4- (trifluoromethoxy) phenyl] pyridin-4- 124 N-INI Yl}-5, 6, 7, 8-tetrahydro-4H-pyrazo, o [1, 5- F'F \ /NH a] [1, 4] diazepin-4-one 'ou 0 NEZ 149 O --, 2- {2- [4- (trifluoromethoxy) phenyl] pyridin-4- 131 CF < N-N NH yl}-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (6H)' one trifluoroacetate O N 0 0 U HO CF3 150 1- (3-aminopropyl)-3- (3-hydroxyphenyl)-1 H-153 NN\ 2 pyrazole-5-carboxylic acid trifluoroacetate HO//OH O HA F HOOF F 151 O t 1- {3- [ (tert-butoxycarbonyl) amino} propyl}-3- 155 / (4-methoxyphenyl)-1 H-pyrazole-5- N-N N carboxylic acid H s02 o 152 H ethyl 3-(1-oxidopyridin-4-yl)-1H-pyrazole-5-20C HAN0 Yr No li 0 0 153 N H, ethyl i- (3-aminopropyl)-3- (4- 200 methoxyphenyl)-1 H-pyrazole-5-carboxylate hydrochloride 0 H-ci 154 o ì 1-{3-[(tert-butoxyearbonyl) amino] propyl}-3-200 J''1/ (3-methoxyphenyl)-1 H-pyrazole-5- N-N H ° carboxylic acid OH O 155 ethyl 3-(2-chìoropyridin-4-yl)-1 H-pyrazole-5 20C carboxylate N o N O 156 ethy, 1-{3-[(tert-20C butoxycarbonyl) amino] propyl}-3- [2- (3- NO2, ho nitrophenyl) pyridin-4-yì]-l H-pyrazole-5- N-N carboxylate o_/ N O 0 157 2- [2- (1 H-1, 2, 4-triazol-1-yl) pyridin-4-yl]-6, 7- 200 dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one XN, N <NH N N O 158 o/ethyl 1-{2-[(tert-200 , HNo butoxycarbonyl) amino] ethyl}-3- [2- (4- { [tert- sl butyl (dimethyl) silyi] oxy} phenyl) pyridin-4-yl]- N 1 H-pyrazole-5-carboxylate Nsoi O o i 159 H o/ethyl 1-{2-[(tert-200 butoxycarbonyl) amino] ethyl}-3- {2- [4- Ho i N-N o (hydroxymethyl) phenyl] pyridin-4-yl}-1 H- + (o pyrazole-5-carboxyìate N v O 160- 2- [2- (4-methyl-1 H-pyrazol-1-yl) pyridin-4-yl]- 200 F N\ NjN 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- CH NY, N H one N, i O NJ 0 161 ° 2- {2- [4- (trifluoromethoxy) phenyl] pyridin-4- 200 yl}-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one trifluoroacetate N N U v v N 162 ethyl 1-{3-[(tert-20 ( \\) t butoxycarbonyì) amino] propyl}-3-(2- N ° chioropyridin-4-yl)-1 H-pyrazole-5- N-N H carboxylate cl"//' N 0 163 2- (3-methoxyphenyl)-5, 6, 7, 8-tetrahydro-4H 200 N _N pyrazolo [1, 5-a] [1, 4] diazepin-4-one zu 0 L JJ o 164 2- (3-hydroxyphenyl)-5, 6, 7, 8-tetrahydro-4H- 200 N-N pyrazolo [1, 5-a] [1, 4] diazepin-4-one HO L Jj ° 165 o I ethyl 1-{3-[(tert-20C 0- butoxycarbonyl) amino] propyl}-3- (3- N-N H methoxyphenyl)-1 H-pyrazole-5-carboxylate o 166 2- (4-methoxyphenyl)-5, 6, 7, 8-tetrahydro-4H 200 N N pyrazolo [1, 5-a] [1, 4] diazepin-4-one NH so 167 0 po H 0 Nv °Ct butoxycarbonyì) amino] ethyl}-3-(2- N-N IOI chloropyridin-4-yl)-iH-pyrazole-5- C, carboxylate CI// 0 168 ; ethyl 1-{2-[(tert- ° butoxycarbonyl) amino] ethyl}-3- (2-quinolin- eo 3-ylpyridin-4-yl}-1 H-pyrazole-5-carboxylate N O o 169 ethyl 1- (2-aminoethyO-3- [2- (3- N ~ N H2 nitrophenyl) pyridin-4-y,]-1 H-pyrazo, e-5- , N^N z carboxylate dihydrochloride HCl 0 Nu H-CRI H-Cl 170 N H2 ethyl 1-(2-aminoethyl)-3-[2-(4- /N N methoxyphenyl) pyridin-4-yl]-iH-pyrazole-5- / o . carboxylate dihydrochloride N zu H-C) __ _ 171 NH2 ethyl 1- (2-aminoethyl)-3- {2- [4- CF3 O N-N_N (trifluoromethoxy) phenyl] pyridin-4-yl}-1H- i 0, , pyrazole-5-carboxylate dihydrochloride N O H-c H-Ci H-CI 172 ethyì 1-(2-aminoethyl}-3-{2-[(E)-2- NH2 phenyletheny)] pyridin-4-yl}-1 H-pyrazole-5- N-carboxylate dihydrochloride 1 I/ N 0 N O H-CI HCl H-CI 173 (NH ethyl i- (2-aminoethyl)-3- {2- [4- , N/N-NO 2 (dimethylamino) phenyl] pyridin-4-yl}-1H- pyrazole-5-carboxylate trifluoroacetate ' A 1 0 HO CF3 174 O I ethyl 1-{3-[(tert- butoxycarbonyl) amino] propyl}-3- (4- N-NH o methoxyphenyl)-iFH-pyrazole-5-carboxylate 0 0 o 175 HO 1- (3-aminopropyl)-3- {2- [3- /__/-NH, (hydroxymethyf) phenyl] pyridin-4-yl}-1H- N % pyrazole-5-carboxyiic acid hydrochloride OH N 0 N O 2 HO 176 Fo NH2 1- (3-aminopropyl)-3- {2- [4- i N_N (trifluoromethoxy) phenyl] pyridin-4-yll-1H- F OH pyrazole-5-carboxylic acid hydrochloride F N 2 HCI 2 I- ! CI 177 r 2- (2-pyrimidin-5-ylpyridin-4-yl)-6, 7- N r NH dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one N o R-_ N O 178 ì 2-[2-(2, 4-dimethoxypyrimidin-5-yl) pyridin-4- oYN O N. N NH oine 7 dihydropyrazolo [1, 5-ajpyrazin-4 (5H) onze 0 N 179 0 4- [4- (4-oxo-4, 5, 6, 7-tetrahydropyrazolo [1, 5- HO vH a] pyrazin-2-yi) pyridin-2-y,] benzoic acid NEZ J- _o 180 °çx 2-t [4-oxo-2-(2-quinolin-3-y, pyridin-4-yl)- 4, 5, 6, 7-tetrahydropyrazolo [1, 5-a] pyrazin-6- yl] methyl}-1 H-isoindole-1, 3 (2H)-dione N-N NH O 0 Nit Table II : Additional MK-2 Inhibiting Compounds _ MK-2 Avg. No. Structurea Compound Name (s) b io (uM) 181 F NH F I i at 2- {2- [3, 5- bis (trifluoromethyì) phenyl] pyrimidin-4-yì}- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 182 NNOH /NN M-I 2-(2-phenylpyrimidin-4-yl)-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 183 0 2- [2- (2-bromophenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 184 /F N-N NH 0 N/ 2- [2- (2-fluorophenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 185 F F-N NH N F \ I i v i O F N\ 2- [2- (pentafluorophenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 186 N ! \ \ l O N/ 2-[2-(2, 5-difluorophenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 187 /F N NH 0 F N/ 2- [2- (2, 6-difluorophenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolofl, 5-a] pyrazin-4 (5H)-one 188 a N-N NH I 0 N 2-[2-(2-chlorophenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 189 /a N. NH 0 F N/ 2- [2- (2-chloro-6-fluorophenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 190 /a N rw o a N/ 2-[2-(2, 6-dichlorophenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 191 ./a , - NH . \ I I I r° o N 2- [2- (2-chloro-6-methylphenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 192 /° N NH N/ 2- [2- (2-methoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 193 o I X+ N-N NH N [2- (2, 3-dimethoxyphenyl) pyrimidin-4-yl]- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 194 P t /O/O NH O 2-[2-(2, 3, 4-trimethoxyphenyl) pyrimidin-4-yl] 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 195 //° NN -NH \ \ I O 2-[2-(2, 4-dimethoxyphenyl) pyrimidin-4-yl]- 196 6, 7-dihydropyrazoìo [1, 5-a] pyrazin-4 (5H)- one 196 /°/° r, r- NN N\ I/ neo zO N 2- [2- (2, 4, 6-trimethoxyphenyl) pyrimidin-4-yl] 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 197 / NN NH \ \ f A O /O N/ 2- [2- (2, 6-dimethoxyphenyl) pyrimidin-4-yl]- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 198 N-N NH kNA- 2-[2-(2-ethoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 199 F F \F j NH N 2-{2-[2-(trifluoromethyl) phenyl] pyrimidin-4- Y) P Y] PY yl}-6, 7-dihydropyrazolo zip 5-a] pyrazin-4 (5H) one 200 SC i O 2- [2- (2-methylphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 201 M.-N NH N il 2- [2- (2, 5-dimethylphenyl) pyrimidin-4-yl]-6, 7 dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 202 N /I , -NNH zozo 2- [2- (3-bromophenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 203 F 0 i O 2- [2- (3-fluorophenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [i, 5-a] pyrazin-4 (5H)-one 204 cri zone /-N NH O 2- [2- (3-chlorophenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 205 ci /NN NH N 2-[2-(3-chloro-4-methylphenyl) pyrimidin-4- YP Y) PY yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 206 ce /N NH . CI \ I i w r O 2- [2- (3, 5-dichlorophenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 207 o /N_N NH \ I i/o 2- [2- (3-methoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 208 N ANX I v i O 2- [2- (3, 4-dimethoxyphenyl) pyrimidin-4-yl]- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 209 /o<1H ia O N [2- (3, 4, 5-trimethoxyphenyl) pyrimidin-4-yl] 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 210 0 n N NH i/o 2- [2- (3, 5-dimethoxyphenyl) pyrimidin-4-ylj- (YP Y) PY Y 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 211 to NH by, N 0 N i i s 2- [2- (3-ethoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 212 F F F .. NH i f o U-<0 2- {2- [3- (trifluoromethyl) phenyl] pyrimidin-4- yell-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 213 zu N I v N/ 2-[2-(3-methylpheny,) pyrimidin-4-y,]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 214 N-/N NII \ 2- [2- (4-bromophenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 215 F zon NH po 2- [2- (4-f I uoroph enyl) pyrim idi n-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 216 a aN-N NH I d ) o N 2- [2- (4-chlorophenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 217 O N/N. NH 0y N NH N/ N- {4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenyl} acetamide 218 t'-N NH 0 2-t2- [4- (dimethylamino) phenyl] pyrimidin-4- yl}-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 219 //N-N NH if O N 2- [2- (4-methoxyphenyl) pyrimidin-4-y)]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 220 /N--N NH \ f O N 2- [2- (4-ethoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 221 221 NH \ f v i O 2- [2- (4-hydroxy-3-methoxyphenyl) pyrimidin I (Y Y YP Y) pY 4-yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 222 222 O-oye 0 2- [2- (1, 1'-biphenyl-4-yl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 223 o NH N methyl 4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] benzoate 224 a N-N NH \ I i O N ethyl 4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] benzoate 225 F F N-N NH b N/2- {2- [4- (trifluoromethyl) pheny ] pyrimidin-4- yl}-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 226 /N-N M-I v (, O N/ 2- [2- (4-methylphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 227 N-N NH zozo CHU 2-[2-(2-hydroxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 228 Br '6N-N, INH I N I/ N 2- [2- (3, 5-dibromo-4- hydroxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazoìo [1, 5-a] pyrazin-4 (5H)-one 229 ce HQ NNNH CI I/ ! v p 2- [2- (3, 5-dichloro-4- hydroxyphenyl) pyrimidin-4-y)]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 230 /rJ-N fG-I !/o I 2- [2- (3-hydroxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 231 '\ r, t-N NN I J o I 2- [2- (4-hydroxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 232 /N NH o w N. (J o Nu 3- [4- (4-oxo-4, 5, 6, 7-tetrahydropyrazo) o [1, 5- a] pyrazin-2-yl) pyrimidin-2-yI] benzoic acid 233 o / H N.-N NH v iso Ns 4- [4- (4-oxo-4, 5, 6, 7-tetrahydropyrazolo [1, 5- a] pyrazin-2-y)) pyrimidin-2-yl] benzoic acid 234 /N--N NH ow \ !/ 3- [4- (4-oxo-4, 5, 6, 7-tetrahydropyrazolo [1, 5- a] pyrazin-2-yl) pyrimidin-2-yl] benzaldehyde 235 p/\ , --N NH !/O 4- [4- (4-oxo-4, 5, 6, 7-tetrahydropyrazolo [1, 5- a] pyrazin-2-yl) pyrimidin-2-y,] benzaldehyde 236 , I \ N NN o N 2- [2- (1, 3-benzodioxol-5-yl) pyrimidin-4-yl]- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 237 /% I N-N NH \ \ 2- (2-quinolin-3-ylpyrimidin-4-yl)-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 238 \ N--N NH /i' i O M-h N/ 2- [2- (2-aminophenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 239 F H, N F N--N/--\ NH N i F 2- [2- (4-amino-2, 3, 5, 6- tetrafluorophenyl) pyrimidin-4-yl]-6, 7- dihydropyrazo) o [1, 5-a] pyrazin-4 (5H)-one 240 /N-N NH I-lz \ I i O Nu 2- [2- (3-aminophenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 241 N- N f 0 N/ 2- [2- (4-aminophenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 242 °V1 j" -. N KM |+H 2- [2- (6-methoxy-2-naphthyl) pyrimidin-4-yl]- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 243 F F i ii O 2- [2- (2, 4-difluoropheny)) pyrimidin-4-yl]-6, 7- 244 dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 244 F /F N_. NH N\ 2- [2- (2, 3-difluorophenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 245 F F N,/ 2-[2-(3, 5-difluorophenyl) pyrimidin-4-yì]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 246 2- {2- [4- (methylthio) phenyi] pyrimidin-4-yl}- 6, 7-dihydropyrazolojl, 5-a] pyrazin-4 (5H)- one 247 tNo+NoH F/NN NH f \ f N 2-[2-(3, 4-difíuorophenyl) pyrimidin-4-yí]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 248 r /F , NNH F \ I f \ f 2- [2- (2, 3, 5, 6-tetrafluorophenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 249 zon NI1 0 F N 2- [2- (2, 3, 6-triffuorophenyl) pyrimidin-4-yfj- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 250 ,,-N NH po I F N/ 2- [2- (2, 3, 4-trifluorophenyl) pyrimidin-4-yl]- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 251 F /NN NH \ \ i O F N-rif r'' 2- [2- (2, 4, 5-trifluorophenyl) pyrìmidin-4-yl]- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 252 \ N--N NH N\ i 'O O NHzN/ 2- [4- (4-oxo-4, 5, 6, 7-tetrahydropyrazolo [i, 5- a] pyrazin-2-yl) pyrimidin-2-yl] benzamide 253 ci Fb N-I (NH 2- [2- (3-chloro-4-f I uorophenyl) pyrim idi n-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 254 AN S ß \ iso 2- [2- (pentamethylphenyl) pyrimidin-4-yl]-6, 7 dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 255 fN Mi /N e i o N 2- [2- (2-amino-6-fluorophenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 256 256 N-\, /ruz I o NU N 2- [2- (2-amino-6-chlorophenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 257 X< NH \ \ i e O 2- {2- [2- (methylthio) phenyl] pyrimidin-4-yl}- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 258 cri /CI -NH i v i. O N/ 2- [2- (2, 3-dichlorophenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 259 /a N NH 0 N/ 2-[2-(2, 4-dichlorophenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 260 0 N-N NH 0 N 2-[2-(2, 5-dimethoxyphenyl) pyrimidin-4-yl]- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 261 0 261 N-NEZ H o N methyl 2- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] benzoate 262 1 N-N NII 0 o 2- [2- (2, 4-dimethylphenyl) pyrimidin-4-yl]-6, 7 dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 263 A S I/ - o ri 2-(2-mesitylpyrimidin-4-yl)-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 264 ci CI/N NH O 2- [2- (3, 4-dichlorophenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 265 N-N NH t.-N NH N\ 2- [2- (3, 4-dimethylphenyl) pyrimidin-4-yl]-6, 7 dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 266 H N-N NH N I N 2- (2- [4- (methylamino) phenyl] pyrimidin-4-yl} 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 267 NH I , i I j-NNH O 2- [2- (4-benzoylphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 268 I, N-N \ N 2- [2- (4-ethylphenyl) pyrimidin-4-yi]-6, 7- dihydropyrazolo (1, 5-a] pyrazin-4 (5H)-one 269 N-N NH 0 2- [2- (3, 4-dihydroxyphenyl) pyrimidin-4-yl]- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 270 OH /J N.-N NH ft N-/" 2- [2- (3, 5-dihydroxyphenyl) pyrimidin-4-yl]- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 271 //N-N NH \ \ I o 2- [2- (2-naphthyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 272 ANRA Ct/ NH UyY-<, N 2- [2- (3-amino-4-chlorophenyi) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 273 ci 73 Çl'H 1, O NHZ N[2-2-2-amino-5-chlorophenyl) pyrimidin-4- [ (P Y) PY yl]-6, 7-dihydropyrazolo [1, 5-ajpyrazin-4 (5H)- one 274 0 o HZ N NH N 4- [4- (4-oxo-4, 5, 6, 7-tetrahydropyrazolo [1, 5- a] pyrazin-2-yl) pyrimidin-2-yl] benzamide 275 & n 275 tN 0 \ I \ i O 2- [2- (3, 5-dibromo-4- methoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolofl, 5-alpyrazin-4 (5H)-one 276 cl Clt 1f X CI I i O 2-[2-(4-amino-3, 5-dichlorophenyl) pyrimidin- 4-yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 277 N / / NH \ I /o 2- [2- (4-phenoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 278 N-N NH /\ 1 O i/ 2- [4- (4-oxo-4, 5, 6, 7-tetrahydropyrazolo [1, 5- a] pvrazin-2-v,) pvrimidin-2-y,] benza, dehyde 279 cr zOs, oh I ! s o 2- [2- (2, 4, 5-trimethoxypheny,) pyrimidin-4-yl] [ ( YP Y) pY Y l 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 280 0 280 I i 3- [4- (4-oxo-4, 5, 6, 7-tetrahydropyrazolo [1, 5- a] pyrazin-2-yl) pyrimidin-2-yI] benzamide 281 N NH Hz \ I y N 2- [2- (5-amino-2-methylphenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 282 N NN a I ( o I 2- [2- (2, 5-dichlorophenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 283 N-N N-i o I F N 2-{2-[2-chloro-5- (trifluoromethyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolotl, 5-alpyrazin-4 (5H)-one 284 N-NOW n J 0 N 2-[2-(2-chloro-6-methoxyphenyl) pyrimidin-4 yì ;-6, 7-dihydropyrazolo [1 5-a] pyrazin-4 (5H) one 285 po \ s I/o I 2- [2- (2, 3-dimethylphenyl) pyrimidin-4-yl]-6, 7 dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 286 N N-N NH \ I r o 0 2- (2- [4- (diethylamino) phenyIyrimidin-4-I ( [ (Y) P Y 1pY Y l 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 287 one one v o O N 2- [2- (4-bromo-3-methylphenyl) pyrimidin-4- y [I-6, 7-dihydropyrazolo [1, 5-alpyrazin-4 (5H)- one 288 f-LzN N-- NN 0 O C7 N/ 2- [2- (4-amino-2-chlorophenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 289 N_ NN 289 M-N/--\ NH - o N 2- [2- (2-amino-4-chlorophenyl) pyrimidin-4- yl g-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 290 NH 2- [2- (4'-pentyl-1, 1'-biphenyl-4-yl) pyrimidin- 4-y,]-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 291 T N 3 0 N/ 2- [2- (2, 6-dimethylphenyl) pyrimidin-4-yl]-6, 7 dihydropyrazolofl, 5-a] pyrazin-4 (5H)-one 292 F F /, r-1JNH r 2- [2- [4- (trifluoromethoxy) phenyl] pyrimidin-4 yl}-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 293 F F N-N NH \ I \ 1 O F N\, 2- [2- (2, 3, 4, 5-tetrafluorophenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 294 my N N !)) 2- [2- (2-piperazin-1-ylphenyl) pyrimidin-4-yl]- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 295 a N-N NH N 'O a N 2- [2- (4-bromo-2-chlorophenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 296 /NN NH rot, F + F N S F 2- {2- [3- (trifluoromethoxy) phenyl] pyrimidin-4 yl}-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H). one 297 H, N N-N/--\ NH 1, e O 0 N 2- [2- (4-amino-3-ethylphenyl) pyrimidin-4-y)]- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 298 /N-N NH \ N 2- [2- (4-bromo-2-methylphenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 299 1-, N-N NH CI I/ ° O N 2-[2-(4-amino-3-chloro-5- methylphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 300 H, N F W-N NH N 2- {2- [4-amino-2- (trifluoromethyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 301 J N N-I a w I /o F/ 2- [2- (3-chloro-2-fluorophenyl) pyrimidin-4- yl -6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 302 r NH F N 2- [2- (2-fluoro-6-methoxyphenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 303 N--N NI-1 - O 2- [2- (5-fluoro-2-methylphenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 304 N-N NH F s F N--N NI-I w v I 6 0 I F 2- [2- (2, 4, 6-trifluorophenyl) pyrimidin-4-yl]- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 305 i I d o f F" jazz oN F 2- {2- [2- (trifluoromethoxy) phenyl] pyrimidin-4 yl}-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 306 1 0 I''L vo a N 2- [2- (2-chloro-4-fluorophenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 307 one w I y 2- [2- (4-butoxyphenyl) pyrimidin-4-yl]-6, 7- 308 dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one zu N N NH N 2- {2- [4- (octyloxy) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one /-A 309 pl-N/-\ iso I N 2- [2- (2-chloro-5-methylphenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 310 XNoq NH o 0 N/ 2- [2- (2-ethylphenyl) pyrimidin-4-yl]-6, 7- 311 dihydropyrazolo [l, 5-a] pyrazin-4 (5H)-one 311 N-N Nu 0 I N 2- [2- (3-chloro-2-methylphenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 312 ci /NH N 2- [2- (5-chloro-2-methylphenyl) pyrimidin-4- yell-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 313 N-N NH N NU \ I \ i i O 2- [2- (3-ethylphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazoto [1, 5-a] pyrazin-4 (5H)-one 314 /NN NH \ ( O N I N 2- [2- (4-chloro-2-methylphenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 315 N-N NH AN f ohm O q- N/ 2- [4- (4-oxo-4, 5, 6, 7-tetrahydropyrazolo [l, 5- a] pyrazin-2-yl) pyrimidin-2-yl] benzoic acid 316 I y, N.-N NH O 2- [2- (2-piperidin-1-ylphenyl) pyrimidin-4-yl]- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 317 oxo N-nN, 2- [2- (4-amino-2, 5- dimethoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one hydrochloride 318 cqzO 2- [2- (2-chloro-6-phenoxyphenyl) pyrimidin-4 yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 319 N NH N 2- [2- (4-tert-butyl-2, 6- dimethylphenyl) pyrimidin-4-yì]-6, 7- dihydropyrazolo [1, 5-alpyrazin-4 (5H)-one 320 No 0 2- [2- (2-chloro-4-hydroxyphenyl) pyrimidin-4- yl j-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 321 321 NH X g i tH F N 2-{2-[2-(dimethylamino)-6- fluorophenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolofl, 5-alpyrazin-4 (5H)-one 322 XN+H N I / 2- [2- (4-butylphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 323 Y yN N-N NH NH F N N- [4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl]-3- (trifluoromethyl) phenyl] acetamide 324 I i ; 2-{2-[2-(2, 4- dichlorophenoxy) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-415H)-one 325 M-N 2-f2- [4- (2-hydroxyethyl) pheny) lpyrimidin-4- y1}-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) a < C NRN NH one 326 row f'r o a N 2- [2- (2, 4, 6-trich, orophenyì) pyrimidin-4-yl j- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 327 F H F NH N- [4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-alpyrazin-2- yl) pyrimidin-2-yl]-2- (trifluoromethyl) phenyl] acetamide 328 N-N NH r O 2- [2- (2-ethyl-6-methylphenyl) pyrimidin-4-y ] 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 329 / N-NH N, a 2-[2-(2, 4-dichloro-6-methylphenyl) pyrimidin 4-y)]-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 330 ci XX NH N I zO N 2-[2-(5-chloro-2-methoxyphenyl) pyrimidin-4 I (Yp Y) PY yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 33i a 0 a I d o I N 2- [2- (4-amino-3-chlorophenyl) pyrimidin-4- y)]-6, 7-dihydropyrazololl, 5-a) pyraz) n-4 (SH)- one 332 By0 i rr- e o methyl 4-methoxy-3- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- _ yl) pyrimidin-2-yllbenzoate 333 -N NII nu 2- [2- (4-isopropylphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 334 N-N NH /\ I O N/ N 2- [2- (4-methoxy-2, 5- dimethylphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 335 335 B. \ \ s/O 2- [2- (3-bromo-4-fluorophenyl) pyrimidin-4- yì]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 336 336 one - O N 2- [2- (4-amino-3-fluorophenyl) pyrimidin-4- P Y) PY yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 337 /NHZ N-N NH zizi 'O 2- [2- (2-amino-4, 5- dimethoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 338 \ n,- N 2- [2- (2-amino-6-methylphenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 339 i N-N NH /i ! O N 2- [2- (4'-hydroxy-1, 1'-biphenyl-4-yl) pyrimidin 4-yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 340 /N Mi N ! o n) 2- [2- (1, 1'-bipheny !-2-yl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 341 N-N NH. I 1 i O zizi 2- [2- (3, 5-dimethylphenyl) pyrimidin-4-yl]-6, 7 dibydroDyrazolo [1 5-a] pyrazin-4 (5H)-one 342 F CI F NH I/, Fv i O N 2- {2- [4-chloro-2- (trifluoromethyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolol1, 5-a] pyrazin-4 (5H)-one 343 < X NH F \ F F N 2-{2-t2-fluoro-3- (trifluoromethyl) phenyl] pyrimidin-4-yl}-6, 7- dih dropyrazolo [1, 5-a] pyrazin-4 (5H)-one 344 FYF N i A O F F N\^ F 2-{2-[2-fluoro-6- (trifluoromethyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazo (o [1, 5-ajpyrazin-4 (5H)-one 345 F /N--N Ni F+F U 2-{2-[2, 4- F bis (trifluoromethyl) phenyl] pyrimidin-4-yl}- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 346 one F /PYN . F 1/ F 2-{2-12, 6- F bis (trifluoromethyl) phenyl] pyrimidin-4-yl}- 6, 7-dihydropyrazolo [1 >5-alpyrazin-4 (5H)- one 347 F F one NH F N I 0 F 2- {2- [2-f (uoro-4- (trifluoromethyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 348 F F/' N NN 2-{2-[2-fluoro-5- (trifluoromethyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazo) o [i, 5-a] pyrazin-4 (5H)-one 349 F _N NH F i \ i O F N 2-2-3-fil { [uoro-5- (trifluoromethyl) phenyl] pyrimidin-4-y)}-6, 7- dihydropyrazolofl, 5-alpyrazin-4 (5H)-one 350 N-N IIH \ i O F N F 2- {2- [4-fluoro-2- (trifluoromethyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazoiofl, 5-alpyrazin-4 (5H)-one 351 F N NH F \ I \ 2- {2- [4-fluoro-3- (trifluoromethyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 352 Nu NH 2- [2- (2-fluoro-6-phenoxyphenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 353 N /w is O rr 2- {2- [2-fluoro-6- (4- fluorophenoxy) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 354 - \ F N NH \ i O O N\ Ja {2- [2-fluoro-6- (4- methylphenoxy) phenyl] pyrimidin-4-yì}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 355 nu I/ 0 N 2- (2- {2-fluoro-6- [ (4- methylbenzyl) oxy] phenyl} pyrimidin-4-yl)- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 356 W OuH ( 0 N 9 2- (2- {2- [ (4-chlorobenzyl) oxy]-6- fluorophenyl} pyrimidin-4-yl)-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 357 N'rei 2- (2- {2-fluoro-6- [ (4- methylphenyl) thio] phenyl} pyrimidin-4-yl)- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 358 NH /\)/O Cl 2-(2-{2-[(4-chlorophenyl) thio]-6- fluorophenyl} pyrimidin-4-yl)-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 359 \ F N NH VY-c 0 F-r-I F-4-F 2- {2- [2-fluoro-6- (2, 2, 2- trifluoroethoxy) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazoìo [1, 5-a] pyrazin-4 (5H)-one 360 /\ N-Nnri \ ! I \ i a/ 2- {2- [2- (benzyloxy)-6- methoxyphenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 361 n I/T Ti \ 0 ° rr° U 2-(2-{2-[(2-chìorobenzy,) oxy]-6- methoxyphenyl} pyrimidin-4-yl)-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 362 362 \ \ N NH % 96NH F4F N 2- {2- [2-methoxy-6- (2, 2, 2- trifluoroethoxy) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo dz 5-a] pyrazin-4 (5H)-one 363 iXN+NH ! i I J o WF 0 N 2- {2- [2-ethoxy-6- (2, 2, 2- trifluoroethoxy) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazoìo [1 5-a] pyrazin-4 (5H)-one 364 H F ; 0 N F 2-{2-[2-isopropoxy-6-(2, 2, 2- trifluoroethoxy) phenyl] pyrimidin-4-yl}-6, 7- dih drop razolo [1, 5-a] pyrazin-4 (5H)-one 365 N IRE INS I/ 2- {2- [2- (phenylthio)-5- (trifluoromethyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [i, 5-a] pyrazin-4 (5H)-one 366 I \ I N N-. IJ NH 2- 2-{2-[4'-(pentyloxy)-1, 1'-biphenyl-4- yl] pyrimidin-4-yl}-6, 7-dihydropyrazo1O [1, 5- a] pyrazin-4 (5H)-one 367 I W"1 H I U 2- [2- (4'-heptyl-1, 1'-biphenyi-4-yl) pyrimidin- 4-yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 368 F 368 _ _ = X ; N <oH 2- [2- (3, 4, 5-trifluorophenyl) pyrimidin-4-yl]- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 369 369 N I Ui 2-[2-(4'-hexyl-1, 1'-biphenyl-4-yl) pyrimidin-4- yell-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 370 NH U ' i 2- (2- [4'- (octy (oxy)-1, f'-bfphenyf-4- yl] pyrimidin-4-yl)-6, 7-dihydropyrazololi, 5- a] pyrazin-4 (5H)-one 371 < 371 2- [2- (4-octyl- 1, 1 -b) phenyl-4-y)) pyrim) din-4- yl -6, 7-dihydropyrazolot1, 5-a] pyrazin-4 (5H) one 372 F F \ N. . NNH N F F N 2- [2- (4-bromo-2, 3, 5, 6- tetrafluorophenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a) p razin-4 (5H)-one 373 Oh 0 ; : 2- ( (2- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenyl} thio) benzoic acid 374 0 n --N NH \ i N I/ 2- [2- (10, 10-dioxido-9-oxo-9H-thioxanthen-3 yl) pyrimidin-4-yl]-6, 7-dihydropyrazolo [1, 5- a] pyrazin-4 (5H)-one 375 ,-tk PH y pentylcyclohexyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 376 /"Y.. NH EUH N 2- [2- (4-tert-butylphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 377 ri 0-0y, 6 2- {2- [4- (benzyloxy) phenyl] pyrimidin-4-yl}- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 378 F N NH F \ I \ f/O F N 2-[2-(2, 3, 5-trifluorophenyl) pyrimidin-4-yi]- 6, 7-dihydropyrazolo [l, 5-a] pyrazin-4 (5H)- one 379 p F N-N NH NOS 2-{2-[2-chloro-4- (trifluoromethyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazofo [1, 5-a] pyrazin-4 (5H)-one 380 N C NN NH Ilv) O 2- {2- [4- (1, 3-oxazol-5-yl) phenyllpyrimidin-4- yl}-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 381 F N-N M I \ ! O N 2- {2- [4- (difluoromethoxy) phenyl] pyrimidin-4 yl)-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 382 N-N NO zu I'O oH 2-[2-(4-hydroxy-7-methyl-2, 3-dihydro-1 H- inden-5-yl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 383 F N J, F ? 0 \ I Ij/o F 2-{2-[2, 6-bis (2, 2, 2- trifluoroethoxy) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 384 N-N NH i v I/o NU H 0 5-methoxy-2- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] benzoic acid 385 S n \ I W F 1 2-[2-(2-{[3-(dimethyìamino) propyllamino}-6- fluorophenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 386 N , NNH N 2-[2-(2-fluoro-6-piperidin-1- ylphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 387 F N NH I \ I O 2- (2- [3-bromo-2, 6-bis (2, 2, 2- trifluoroethoxy) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 388 \ , rN NH J 2- {2- [4'- (hexyloxy)-1, 1'-biphenyl-4- yl] pyrimidin-4-yl}-6, 7-dihydropyrazolo [1, 5- a] pyrazin-4 (5H)-one 389 H 2- {2- [4'- (heptyloxy)-1, 1'-biphenyl-4- yl] pyrimidin-4-yl}-6, 7-dihydropyrazolo [i, 5- a] pyrazin-4 (5H)-one 390 N-N NH NN NH / f/O F N/ 2- [2- (2-fluoro-5-methylphenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 391 F N-N NH rsr 2-[2-(2-bromo-5-fluorophenyl) pyrimidin-4- [ (P Y) PY yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 392 cr po 2- [2- (2-fluoro-5-methoxyphenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 393 /N--N M-I N f/ g o N 2- [2- (3-bromo-4-hydroxyphenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 394 / N-N NH ber 2- [2- (3-bromo-4-methoxyphenyl) pyrimidin- 4-yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 395 N-H \ O F 2-[2-(2-fluoro-4, 5- dimethoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolofl, 5-a] pyrazin-4 (5H)-one 396 N-N NH Iso I 2- [2- (4-bromo-2-fl uorophenyl) pyri mid in-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 397 N NH 0 N N 2- [2- (4-chloro-2-fluorophenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 398 NN NH 0 2- [2- (4-chloro-3-fluorophenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 399 0 _ N N NH N 2- [2- (9-oxo-9H-fluoren-4-yl) pyrimidin-4-yl]- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 400 /I N N NH one 400" N 2- [2- (9H-fluoren-4-yl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 401 N nu N, into 0 2- {2- [4- (heptyloxy) phenyl] pyrimidin-4-yl}- 6, 7-dihydropyrazolo [i, 5-a] pyrazin-4 (5H)- one 402 NN NH 402 N-N/-\ NH N 2- {2- [4- (hexyloxy) phenyl] pyrimidin-4-yl}-6, 7 dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 403 <H ' 2- [2- (4-heptylphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazo (o [i, 5-a] pyrazin-4 (5H)-one 404 N-N NH IOYI'o /0 N,, 2- {2- [4- (pentyloxy) phenyl] pyrimidin-4-yl}- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 405 z NV" N NH F/2- [2- (5-bromo-2-fluorophenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 406 zu f) NH 0, OH N\J 2-2--br hen I r''din- OH 2-[2-(5-bromo-2-hydroxyphenyl) pyrimidin-4 yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 407 Br NN NH /\ S O i 2- [2- (5-bromo-2-methoxyphenyl) pyrimidin- 4-yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 408 /N N 2- [2- (4'-methyl-1, 1'-biphenyl-2-yl) pyrimidin- 4-yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 409 F /N NH \ iB I \ O 2- [2- (3-fl uoro-4-m ethyl phenyl) pyri m ! din-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 410 410 0', ci /\ i O N 2-[2-(2-chloro-4-methoxyphenyl) pyrimidin-4 yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 411 \ p-N Ni i e i o 2- [2- (3, 5-di-tert-butyl-4- hydroxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 412 cri /NN NH N ci---\/\0 C, N 2- [2- (2-amino-3, 5-dichlorophenyl) pyrimidin- 4-yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 413 /N NH 0 9 N/ 2- [2- (2-bromo-4-methylphenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 414 n O \ INl"N NH 1- (4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenyl}-2-phenylethane- 1, 2-dione 415 un NH \I \ lo O 2- {2- [2- (phenylthio) phenyl] pyrimidin-4-yl}- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 416 M-N tM /N-NNi 0 o N-butyl-N'- {4-methyl-3- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenyl} urea 417 CON NH N H v i i O 2-morpholin-4-yl-N- {2- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenyl} acetamide 418 ex \ I \ N-NIdi v iso 2- [2- (4- { [ (4-bromo-3- methyíphenyl) amino] methyí} phenyl) pyrimid in-4-yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 419 N- /o w o I/ 2- (2- {2-fluoro-6- [3- F (trifluoromethyl) phenoxy] phenyl} pyrimidin-4 yl)-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 420/' N NH S\"Y u 4-tert-butyl-N- {2- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2- y)] phenyl} benzenesu) fonamide 421 xi L'YU I 2- {2- [2- (4-chloro-2-methylphenoxy)-6- fluorophenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 422 ce Cl< t Hn cri 0 cri N 2-[2-(pentachlorophenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 423 \ N.. N NH N 2- [2- (4-methoxy-7-methyl-2, 3-dihydro-iH- inden-5-yl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 424 N-N NH N\ I/ - o 2-[2-(2-amino-4-methylphenyl) pyrimidin-4- YP Y) PY yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 425 -N IIH w ir O my 2- [2- (4-propoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 426 ou O \ CI N_NNH / i S O N 2- [2- (2-chloro-3, 4- dimethoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 427 NsX N. N NH , i ! N 4- [4- (4-oxo-4, 5, 6, 7-tetrahydropyrazolo [1, 5- a] pyrazin-2-yl) pyrimidin-2- yl] benzenesulfonamide 428 er / & \ I i \ i O N 2- [2- (3, 5-dibromophenyl) pyrimidin-4-yl]-6, 7 dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 429 Br /NNx NNH N N 2- [2- (2-amino-3, 5-dibromophenyl) pyrimidin 4-yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 430 F H2N) SNH /v 1 O F N 2-[2-(4-amino-2, 5-difluorophenyl) pyrimidin- [ ( P Y) PY 4-yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 431 wu F F F NH I 2- {2- [4-chloro-3- (trifluoromethyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 432 H2 0 CH NH L-<, N 3- [4- (4-oxo-4, 5, 6, 7-tetrahydropyrazolo [1, 5- a] pyrazin-2-yl) pyrimidin-2-yl] phenylalanine 433 \ aJZ W i O 2- [2- (4'-amino-1, 1'-biphenyl-4-yl) pyrimidin- 4-yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 434 \ N NH /riz F N 2-[2-(2-fluoro-4-hydroxyphenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 435 BRAL Ao 435 su O 2- [2- (4'- { [ (2S)-2-methylbutyl] oxy}-1, 1'- biphenyl-4-yl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 436 \, i, \ N Ni N- [4- [4- (4-oxo-4, 5, 6, 7- F tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl]-2- (trifiuoromethoxy) phenyl] acetamide 437 han F HZN \ N-NH \ r _ N/ 2-t2- [4-amino-3- (trifì uoromethoxy) phenyl] pyrimidin-4-yi}-6, 7 dihydropyrazolo l, 5-a] pyrazin-4 (5H)-one 438 N. 0 2- (2-f3- [ (2-oxo-1, 3-benzoxazo)-3 (2H)- yl) methyl] phenyl} pyrimidin-4-yl)-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 439 0 " "'T 'C N-14- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2- yfjphenyfjmethanesutfonamide 440 Ho HO 2- (2-f2-amino-S- [l-hydroxy-2- (isopropylamino) ethyl] phenyl} pyrimidin-4- yl)-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 441 441 o //N Nti I "J 2- {2- [4- (4- mercaptobenzoyl) phenyl] pyrimidin-4-yl}- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 442 iS ° 2- (2- {10- 3- (4-hydroxypiperidin-1-yl) propyl]- I OH-phenothiazin-2-yl) pyrimidin-4-yl)-6, 7- dihydropyrazotof [1, 5-aXpyrazin-4 (5H)-one 443 F H N 0 N 2-[2-(3-fluoro-4-hydroxyphenyl) pyrimidin-4- yl]-6, 7-dihydropyrazoio [1, 5-a7pyrazin-4 (5H) one 444 \ N-N NH 1 S O 2- [2- (3-fluoro-4-methoxyphenyl) pyrimidin-4 yl]-6, 7-dihydropyrazolo [i, 5-a] pyrazin-4 (5H) one 445 0 zon N NH iv i 0 2- {2- [4- (methylsulfonyl) phenyl] pyrimidin-4- yl}-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 446 nu N :) /i" r O 2- [2- (4-penty (phenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 447 NN NH a I 'I v f d o N 2- [2- (5-chloro-2-hydroxyphenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 448 N-N NH cri N NN I o O N 2-{2-[2, 6-dichloro-4- (trifluoromethy)) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 449 "f° Y%, M-N NH o N- {2-ethyl-4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimìdin-2-yl] phenyl} acetamide 450 A So i'i o N 2- [2- (2, 3-dihydro-1, 4-benzodioxin-6- yl) pyrimidin-4-yl]-6, 7-dihydropyrazolo [1, 5- a] pyrazin-4 (5H)-one 451 /r,-rw I F O/ 2- {2- [2- (difluoromethoxy) phenyl] pyrimidin-4 yl}-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 452 HO N NH O N 2- [2- (4-hydroxy-3, 5- dimethylphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 453 0 V y o N- {2- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenyl} acetamide 454 454 NH o 2- [2- (4-chloro-2-hydroxyphenyl) pyrimidin-4-1 yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 455 N-N NH Hz \ I i, O N 2- [2- (3-amino-4-hydroxyphenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 456 zon NH N _o, roy, 2- {2- [3- (difluoromethoxy) phenyl] pyrimidin-4 yl}-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 457 one F t NNNH F I/ \ i i 0 F N 2-{2-[2, 3-difluoro-4- (trifluoromethyl) phenyl3pyrimidin-4-yl}-ô, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 458 F F/-NNH N__ I \ I \ i O F N. =% 2-2-3 4-difluoro-5- (trifluoromethyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 459 F \ N-N NH zozo 2-12- [3-fluoro-4- (trifluoromethyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 460 F \ F NN -NH If F I/ I s o N 2- {2- [5-fluoro-2- (trifluoromethyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 461 roc NN \NH \I i/O ki 2-[2-(2X2S3X3-tetrafluoro-2s3-dihydro-1, 4- benzodioxin-6-yl) pyrimidin-4-yl]-6, 7- 462 dihydropyrazolofl, 5-alpyrazin-4 (5H)-one ply F who F 9 F [(trifluoromethyl) thio] phenyl} pyrimidin-4-yl)- 6, 7-dihydropyrazolo [i, 5-a] pyrazin-4 (5H)- one 463 F NU \ y-NH [(trifluoromethyl) thio] phenyl} pyrimidin-4-yl)- 6, 7-dihydropyrazolo [1, 5-a3pyrazin-4 (5H)- one 464 -ou NI 2- [2- (1, 1'-biphenyl-3-yl) pyrimidin-4-yl]-6, 7- 465 dihydropyrazolofl, 5-a] pyrazin-4 (5H)-one 465 t, t-N NH / N 2- [2- (4-hydroxy-2, 6- dimethylphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazololi, 5-a] pyrazin-4 (5H)-one 466 N N \ I N\ i A O N 2- [2- (2, 3-difluoro-4- hydroxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [i, 5-a] pyrazin-4 (5H)-one 467 467 APH i w i o 2-[2-(2-propoxyphenyl) pyrimidin-4-yl]-6, 7- 468 razolo [1, 5-a] pyrazin-4 (5H)-one 468 CHORAL H2N <t N_N NH , N, zou nez 4- [4- (4-oxo-4, 5, 6, 7-tetrahydropyrazolo [1, 5- a] pyrazin-2-yl) pyrimidin-2-yi]-L- phenylalanine 469 CHIRAL H2N,,../N-N NH O. OH \ I i \ i O N 4- [4- (4-oxo-4, 5, 6, 7-tetrahydropyrazolo [1, 5- a] pyrazin-2-yl) pyrimidin-2-yl]-D- phenylaianine 470 H/\ N N--N NH /v l 0 2- [2- (4-mercaptophenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 471 F H, N- ; HzN/NNH v i/O 2- {2- [4-amino-3- (trifluoromethyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 472 i \ I', NNH ° -N NH Dot 2- {2- [3- (cyclopentyloxy)-4- methoxyphenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 473 NON NH /i \ is O N/ 2- [2- (4-butyl-2-methylphenyl) pyrimidin-4-yl] 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 474 NH2 N-N NH N F N 2- [2- (5-amino-2-fluorophenyl) pyrimidin-4- [ (P Y) PY yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 475 475 CL 4'- [4- (4-oxo-4, 5, 6, 7-tetrahydropyrazolo [1, 5- a] pyrazin-2-yl) pyrimidin-2-yl]-1, 1'-biphenyl- 4-carboxylic acid 476 476 /N N NH \ I N J/O N 2- [2- (4'-propyl-1, 1'-biphenyl-4-yl) pyrimidin- 4-yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 477 wr I a N NH 2- [2- (4'-butyl-1, 1'-biphenyl-4-yl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 478 ru Hi . o HAN NH 2-1 (14- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2- ypheny)) am) no) carbonyt] benzoicacid 479 479 Br Br NH N & I/ ! \ 1 i O 2- [2- (3, 5-dibromo-2- hydroxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolof i, 5-alpyrazin-4 (5H)-one 480 CHIRAL /N Mi . f i o 2- (2- {3- [ (3S)-1-propylpiperidin-3- yl] phenyl} pyrimidin-4-yl)-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one hydrochloride 481 BrJQ Br o/N NH NI 2- (2- (4- (2-bromobenzoyl) phenyllpyrimidin- 4-yl}-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 482 Br 1 Mi 2- {2- [4- (3-bromobenzoyl) phenyl] pyrimidin- 4-yl}-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 483 9 0 N-Nn 2- {2- [4- (4-bromobenzoyl) phenyl] pyrimidin- 4-yin-6, 7-dihydropyrazolo [1, 5-alpyrazin- 4 (5H)-one 484 'ON H f f O r I o ' Br 2-{2-f2-(2-bromobenzoyl) phenyl] pyrimidin- 4-yl}-6, 7-dihydropyrazolo [1, 5-a] pyrazin- Air ; 485 /N-Nrrtf \I if o I 2- {2- [2- (3-bromobenzoyl) phenyl] pyrimidin- 4-yl}-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 486 486 NH \ I I s'o B 2-{2-[2-(4-bromobenzoyl) phenyl] pyrimidin- 4-yl}-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 487 t<NH \I v i O / o ii/ 2- [2- (2-benzoylphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 488 H S H vN"A ANNE OH y-Pdi N-acetyl-4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [i, 5-a] pyrazin-2- yl) pyrimidin-2-yl]-L-phenylalanine 489 \ , -N NH /\ I B O a N 2- [2- (2-bromo-4-fluorophenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 490 Br \ NN NN /\ i O 2- [2- (5-bromo-2-chlorophenyl) pyrimidin-4- f (m r P Y) PY yl]-6, 7-dihydropyrazolol1, 5-a] pyrazin-4 (5H) one 491 er \ NN NH nez I o 2-[2-(2, 5-dibromophenyl) pyrimidin-4-yl]-6, 7 dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 492 & I N is &' I O 2- [2- (3, 5-dibromo-4- methylphenyl) pyrimidin-4-yl]-6, 7- with 493. 0 rV° M-M NH Uw° Nu 2-{2-[2-(octyloxy) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 494 F 0 N-N"4 N i zero 2- (2- {4- [3, 5- F bis (trifluoromethyl) phenoxy] phenyl} pyrimidi n-4-yl)-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 495 /N-N I i, 0 o 2- {4-bromo-2- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- y)) pyr)'midin-2-y)] phenoxy} acetamide 496 F zu J\/ NNFt \I is O 2- [2- (2, 2-difluoro-1, 3-benzodioxol-5- yl) pyrimidin-4-yl]-6, 7-dihydropyrazolo [1, 5- a] pyrazin-4 (5H)-one 497 N /N \ NN NH \ I/ \ 1 A O l, b 2- [2- (1 OH-phenothiazin-3-yl) pyrimidin-4-yl]- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 498 OH n \ N.-N NH OH OCH [2- (2, 5-dihydroxyphenyl) pyrimidin-4-yl]- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 499 /NNNH '" N I 2- [2- (4-propylphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 500 NN NH I i' ii o 2- [2- (4-hexylphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 501 /I N.-N NH O 2- [2- (4-octylphenyl) pyrimidin-4-yl]-6, 7- djhydropyrazolofl, 5-alpyrazin-4 (5H)-one 502 rf'Ni o 2- [2- (4'-ethyl-1, 1'-biphenyl-4-yi) pyrimidin-4- y !]-6, 7-dihydropyrazo ! o [1, 5-a] pyrazin-4 (5H) one 503. tu/-. one O 2-{2-f4-(4-butylcyclohexyl) phenyl] pyrimidin- 4-yl}-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 504 0 0 HO NH /w I f o methyl 2-hydroxy-5- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] benzoate 505 0 / N M-I N 2-[2-(2, 3-dihydro-1-benzofuran-5- yl) pyrimidin-4-yl]-6, 7-dihydropyrazolo [1, 5- a] pyrazin-4 (5H)-one 506 i N-N NH Nw I \ I B O 2-j2- (2-chloro-4-methylquinolin-3- yl) pyrimidin-4-yl]-6, 7-dihydropyrazolo [1, 5- a] pyrazin-4 (5H)-one 507 OH /N NH i' O 2- {2- [4- (hydroxymethy)) phenyllpyrimidin-4- yl}-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 508 ! ZO H 0 2- [ (t3- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2- yl] phenyl} amino) carbonyl] benzoic acid 509 /LhNNi \ i O / ( {4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl} benzyl} thio) acetic acid 510 . -N NH A Nit --' o N- {3- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) yrimidin-2-yl] phenyl} acetamide 511 « nH zero N [2- (1-oxo-1, 3-dihydro-2-benzofuran-5- yl) pyrimidin-4-yl]-6, 7-dihydropyrazolo [1, 5- a] pyrazin-4 (5H)-one 512 ° °H/N NH HN \ I i O N N-acetyl-3- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenylalanine 513 HzN/N.. N NH o > OH < R< o OH 6 4- [4- (4-oxo-4, 5, 6, 7-tetrahydropyrazolo [1, 5- a] pyrazin-2-yl) pyrimidin-2-yl]-L- phenylalanine 514 \I N-N, NH \ I NW I/O N11 2- {2- [4- (benzyloxy)-3- methoxyphenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 515 '/N--N NH O I i O N 2- [2- (3-ethoxy-4-hydroxyphenyl) pyrimidin-4 yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 516 516 NH 2- (2- [4- (benzyloxy)-3- ethoxyphenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 517 N-N NH N NH O F N 2- [2- (4-bromo-2, 6-difluorophenyl) pyrimidin- 4-yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 518 40/ 41 on0 v ii O MJ 2- {2- [2- (2- methoxybenzoyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one % 0 vNH \,,-rw i /o methoxybenzoyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 520 o o n N-/ (H \ I \ I i O i N 2- {2- [4- (2- methoxybenzoyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 521 0-N"i \ n O rflN Mi methoxybenzoyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 522 0 zu r,.-N NH ii / 2- {2- [3- (3- methoxybenzoyl) phenyl] pyrimidin-4-yl)-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 523 o riNa o 2- {2- [4- (3- methoxybenzoyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 524 NI NH i 0 2_ {2- [2_ (4_ methoxybenzoyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 525 o I U-N I% yl i 2- {2- [3- (4- methoxybenzoyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 526 rH o I 2- {2- [4- (4- methoxybenzoyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 527 N-N NH i _ 0 zNX 2-{2-[2-(dimethylamino) phenyl] pyrimidin-4- yl}-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 528 \ NNNH ii O 2- [2- (2-morpholin-4-ylphenyl) pyrimidin-4-yl] 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 529 /N NN NH ich N 2-[2-(2-azepan-1-yiphenyl) pyrimidin-4-yl]- [ (P YP Y) PY Y] 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 530 N-N NH N, \ 0 2_ {2_ [2_ N (cyclopropylmethoxy) phenyl] pyrimidin-4-yl} 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 531 one $ 1I I 2- [2- (4'-bromo-1, 1'-biphenyl-2-yl) pyrimidin- 4-yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 532 lu o 2- [2- (4'-bromo-1, 1'-biphenyl-3-yl) pyrimidin- 4-yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 533 N ) 1 \ NN NN Uy-<, 2- {2- [4- (1, 3-benzothiazol-2- yl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 534 0 or /N'NH ethyl 4-14- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo (1, 5-alpyrazin-2- yl) pyrimidin-2-yl]-1, 1 I-biphenyl-4- carboxylate 535 /N hH O I f iii ethyl 4'- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidìn-2-yl]-1, 1 -biphenyi-3- carboxylate 536 0 0 i ethyl 2'- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-ylj-1, 1'-biphenyl-3- carboxylate 537 o y) \ r-rH '\ I o I/o 1- {3- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yi) pyrimidin-2-yl] phenyl}-2-phenylethane- 1, 2-dione 538, y NN 0 o G 0 I-f2- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenyl}-2-phenylethane- 1, 2-dione 539 N NH f o o o N r ethy) oxo (2- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazofo [1, 5-a] pyrazin-2- yl) Dyrimidin~2-ylejphenyl} acetate 540 S 0 n NH i i 0 ethyl oxo {3- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- y) pyrimidin-2-yl] phenyl) acetate 541 °T° O/FyIJ NH \ I v /o ethyl oxo {4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenyi} acetate vf PH t N i/O \ F 2- {2- [2-filuoro-6- (2- fluorobenzoyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 543 zon NH i \ ii O 0 O F 2-{2-[2-(trifluoroacetyl) phenyl] pyrimidin-4- yl}-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 544 F O F -b \ \ i/o 2- {2- [3- (trifluoroacetyl) phenyl] pyrimidin-4- yl}-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 545 F F F Y N NH I/i O 2- {2- [4- (trifluoroacetyl) phenyl] pyrimidin-4- yl}-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 546 /-. N N-N/--\ NH in O N 2-[2-(4-piperazin-1-ylphenyl) pyrimidin-4-yl]- [ (PP YP Y) PY Y] 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 547 4< NH \ r I d /2- {2- [3- (hydroxymethyl) phenyl] pyrimidin-4- yl}-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 548 2- {2- [2- (benzyloxy)-5- bromophenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 549 \ N IvH G I/I I os 0 N 2- [2- (3-chloro-4-hydroxyphenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 550 COR i \ N 2- [2- (4-fluoro-3-methoxyphenyl) pyrimidin-4 yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 551 HAN -NNH O N 2- {2- [4- (1 H-pyrazol-3-yl) phenyl] pyrimidin-4- yl}-6, 7-dihydropyrazolotl, 5-a] pyrazin-4 (5H) one 552 a t+-N NH F N 2- [2- (5-chloro-2-fluorophenyl) pyrimidin-4- [ (P Y) PY yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 553 F , F -Nl-\NH 2-{2-[2-methyl-4- (trifluoromethoxy) phenyl] pyrimidin-4-yl}-6, 7 dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 554 F F-IY Ni irez CI ! O 2- {2- [3-chloro-4- (trifluoromethoxy) phenyl] pyrimidin-4-yl}-6, 7 dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 555 N-N NH N I F N\J F 2- {2- [3-fluoro-2- (trifluoromethyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 556 F NH \ 2- {2- [4-methoxy-3- (trifluoromethyl) phenyl] pyrimidin-4-yi}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 557 Fuzz F O F N 2-f2-[2-methyl-3- (trifluoromethyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 558 F F We0 o 2-{2-[2-methyl-5- (trifluoromethyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, S-a] pyrazin-4 (5H)-one 559 F F N-N/-\ NH 2- {2- [3-methyl-5- (trifluoromethyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 560 N-N NH I N I 560 < F 2- {2- [4-methyl-2- (trifluoromethyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 561 F N-N w \ N Mi i O 2- {2- [4-methyl-3- (trifluoromethyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1 ; 5-a] pyrazin-4 (5H)-one 562 F Zu F , rNNH IF W i O F N 2-{2-[2, 4-difluoro-5- (trifluoromethyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 563 F F FUN NH \ i v i O F 2- {2- [2, 5-difluoro-4- (trifluoromethyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 564 F F F NNH \ I ,/i O N 2- {2- [3, 5-difluoro-4- (trifluoromethyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 565 F F 1+-N/-\ f e F F/ F F 2- {2- [4, 5-difluoro-2- (trifluoromethyl) phenyl] pyrimidin-4-yi}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 566 F O FA N NH 0 1 yi 2- (2- [4- [(trifluoromethyl) sulfonyl] phenyl} pyrimidin-4 yl)-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) 5 67 CH FL one 567 iXen HJ O H NFi 3- [4- (4-oxo-4, 5, 6, 7-tetrahydropyrazolo [1, 5- a] pyrazin-2-yl) pyrimidin-2-yl]-D- phenylalanine 568 2- [2- (5-amino-2-fluorophenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one hydrochloride 569 ci At--N NH O N 2- [2- (3-chloro-4-hydroxy-5- methoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 570 H N NH N i "O 2- (2- 3- [ (dimethylamino) methyl]-1 H-indol-5- yl} pyrimidin-4-yl)-6, 7-dihydropyrazolo [1, 5- a] pyrazin-4 (5H)-one 571 po a I/I/ f o 2- {2- [4- (4-chloro-3- fluorophenoxy) phenyl] pyrimidin-4-yl}-6, 7- 572 dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one N-N m y \ N-nH 2- {2- [4- (2, 4- dimethylphenoxy) phenyl] pyrimidin-4-yl}-6, 7 dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 573 CHPAL 0 flan 'oh Pa1 2- [4- (4-oxo-4, 5, 6, 7-tetrahydropyrazolo [1, 5- a] pyrazin-2-yl) pyrimidin-2-yl]-D- phenylalanine 574 0 % nui 2- [4- (4-oxo-4, 5, 6, 7-tetrahydropyrazolo [1, 5- a] pyrazin-2-yl) pyrimidin-2-yl]-L- phenylalanine 575 \ N NH Uj HZ CN/ o 3- [4- (4-oxo-4, 5, 6, 7-tetrahydropyrazolo [1, 5- a] pyrazin-2-yl) pyrimidin-2-yl]-L- phenylalanine 576 W g N--NH 0 2- [2- (2-bromo-5-methoxyphenyl) pyrimidin- 4-ylj-6, 7-dihydropyrazolo [l, 5-a] pyrazin- 4 (5H)-one 577 W A I'i 6. I \ ie Q 2- [2- (4-amino-3-bromophenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 578 578 o a N-N NH I/s I, o _Y_-1 N- {2-chloro-5- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenyl} acetamide 579 a zea N +H N- {2-chloro-4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenyl} acetamide 580 TI 2-f2- [4- (aminomethyl) phenyl] pyrimidin-4-ylll 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one hydrochloride 581 d ? ° ruz 1 /° u 2- {2- [3, 4-bis (benzyloxy) phenyl] pyrimidin-4- yì}-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 582 mm. x'I NH O N NH N-acetyl-3- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl]-L-phenyìalanine 583 HzN/N NH O OH \ I i i ! O N N 4- [4- (4-oxo-4, 5, 6, 7-tetrahydropyrazolo [1, 5- a] pyrazin-2-yl) pyrimidin-2-yl] phenylalanine 584 W-N mi , r- Ni if 2-[2-(6-hydroxy-2-naphthyl) pyrimidin-4-yl]- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one MS O iN NH Y v/O F N 2- (2- {4- [3- F F (trifluoromethyl) phenoxy] phenyl} pyrimidin-4 yl)-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 586 xi r / I/o 2- (2-f4- [ (4- chlorobenzyl) oxy] phenyl} pyrimidin-4-yl)-6, 7 dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 587 \ N-NNH /i \ i/O 2- {2- [2- (4- methoxyphenoxy) phenyl] pyrimidin-4-yl}-6, 7 dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 588 <,, pNH in UY-<o 2- [2- (4-piperazin-1-ylphenyl) pyrimidin-4-yl]- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one hydrochloride 589 -N NH N 2- [2- (4-am ino-3-m ethyl phenyl) pyrim idin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 590 y " i n N- (4-methylphenyl)-2- {2- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxylacetamide ? YPH , Y",, HH < n NJJJ"777/'/ 2- {2- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxy}-N- phenylacetamide 592 Ha 4 NH N NH 2- {2- [4'- (aminomethyl)-1, 1'-biphenyl-2- yl] pyrimidin-4-yl}-6, 7-dihydropyrazolo [1, 5- a] pyrazin-4 (5H)-one hydrochloride 593 N w I 2-{2-[2-(2-phenylethyl) phenyl] pyrimidin-4- yl}-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 594 ci H N-N NH ici I N 2- [2- (3-chloro-5-ethoxy-4- hydroxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 595 zu '°' Tir, i 2-{2-[2-(benzyloxy)-3- methoxyphenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 596 nu2 22 N--NH i" ii O N 2- {4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxy} acetamide 597 nez -NH iv ie O N 2- [2- (4-ethoxy-3-methoxyphenyl) pyrimidin- (Y YP Y) PY 4-yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 598 /\/ \ N NH i O DGNX N 2- [2- (3-methoxy-4-propoxyphenyl) pyrimidin 4-yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 599 \/\ \ r, t- Na / i o 2- [2- (4-butoxy-3-methoxyphenyl) pyrimidin- 4-yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 600 Ho--o N-N NH \ lo/r i O 2- {2- [4- (2-hydroxyethoxy)-3- methoxyphenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 601 \ i o o NH 'dz N 2-methoxy-4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenyl benzoate 602 \/ N-N NH v i o 2- [2- (4-isopropoxy-3- [ (P P Y methoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 603 ti n po 0 2-(2-{4-[(2, 4-dichlorobenzyl) oxy]-3- methoxyphenyl} pyrimidin-4-yi)-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 604 ci 0 CI \ I i N^NH INH 2-(2-{4-[(2-chlorobenzyl) oxy]-3- methoxyphenyl} pyrimidin-4-yl)-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 605 H 4- (f2-methoxy-4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxy} methyl) benzoic acid 606 N-N -NH \ i O 2- [2- (3-ethoxy-4-methoxyphenyl) pyrimidin- 4-yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 607 607 NH 4+H 2- [2- (3, 4-diethoxyphenyl) pyrimidin-4-yl]-6, 7 dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 608 608 NN NH 1, : N N/ 2- [2- (3-ethoxy-4-propoxyphenyl) pyrimidin-4 yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 609 609 --N W o 2- [2- (4-butoxy-3-ethoxyphenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 610 nu 610 D t.,' O 2- {2- [3-ethoxy-4- (2- hydroxyethoxy) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 61 W n 611 OY. N NH 2-ethoxy-4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenyl benzoate 612 N NH \ Ne I N*-, I/ 2- [2- (3-ethoxy-4- isopropoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 613 ---- a o u Si4+ l 2- (2-f4- [ (2, 4-dichlorobenzyl) oxy]-3- ethoxyphenyl} pyrimidin-4-yl)-6, 7- dihydropyrazolo [1, 5-a) pyrazin-4 (5H)-one i A 614 ci c fuzz O'y Y ° O N 2- (2- (4- ( (2-chlorobenzyl) oxyl-3- ethoxyphenyl} pyrimidin-4-yl)-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 615 0 jazz N-, N-Oxo-4, 5, 6, 7- 2-12-mothoxy-4- [4- (4 N tetrahydropyrazolo [1, 5-a] pyrazin-2- y)) pyrimidin-2-yl] phenoxy}-N- phenylacetamide 616 I W i-NH a " N-benzy)-2- {2-methoxy-4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxy} acetamide 617 0- i \ N-NH °0 2- {2-methoxy-4- [4- (4-oxo-4, 5, 6, 7- NJ tetrahydropyrazolof 1, 5-a3pyrazin-2- yl) pyrimidin-2-yl] phenoxy}-N-(2- phenylethyl) acetamide XH Y- R-N NN NH 2-i2-methoxy-4- [4- (4-oxo-4, 5, 6, 7- N tetrahydropyrazoto [l, 5-a] pyrazin-2- y)) pyrimidin-2-yl) phenoxy}-N-(2- methyfphenyfjacetamide 619 yj, \ \ NN, NH 2- (2-methoxy-4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazo) o [1, 5-a) pyrazin-2- yl) pyrimidin-2-yl] phenoxy}-N-(4- methylphenyl) acetamide 620 "TR) I 'NNH 2-12-methoxy-4-14- (4-oxo-4, 5, 6, 7- " tetrahydropyrazolo [1, 5-a] pyrazin-2- y)) pyrimidin-2-ylphenoxy}-N-(2- . methoxyphenyl) acetamide 621 [j ? T S kA ethyl 4- [ ( {2-methoxy-4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2- yl] phenoxy) acetyl) amino] benzoate 622 aN) l XO i \ t'NNH 2- {2-methoxy-4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxy}-N, N- diphenylacetamide 623 HA/^\ n WNo><o 2-{2-methoxy-4-[4-(4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxy}-N-1- naphthylacetamide 624 aA \ H \, y NH 2- {2-methoxy-4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-alpyrazin-2- yl) pyrimidin-2-yl] phenoxy}-N- [3- (trifluoromethyl) phenyl] acetamide 625 H o i i o \ N-N 4- [ ( {2-methoxy-4- [4- (4-oxo-4, 5, 6, 7- o tetrahydropyrazolo [1, 5-a] pyrazin-2- yi) pyrimidin-2- . yl] phenoxy} acetyl) amino] benzoic acid 626 0 Hz I W NH o N 2- {2-methoxy-4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-alpyrazin-2- yl) pyrimidin-2-yl] phenoxy} acetamide 627 N NH p'1 \ NN NH 2- [2-ethoxy-4- [4- (4-oxo-4, 5, 6, 7- N) tetrahydropyrazolo [l, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxy}-N- phenylacetamide 628 0 INH "°Y) N-\, N Ns N-benzyl-2-{2-ethoxy-4-(4-(4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxy} acetamide 629 \ /i A I NNNH 0 2- [2-ethoxy-4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yi] phenoxy}-N-(2- phenylethyì) acetamide 630 N-N H -10- [2-ethoxy-4- [4- (4-oxo-4, 5, 6, 7- N tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxy}-N-(2- meth Iphen I) acetamide 631 niti rq NH o 2- {2-ethoxy-A- [4- (4-oxo-4, 5, 6, 7- Ni-tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxy}-N- (4- methylphenyl) acetamide 632 N NH 2- {2-ethoxy-4- [4- (4-oxo-4, 5, 6, 7- N tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-y)] phenoxy}-N- (2- methoxyphenyl) acetamide 633 /I l \ o ynr oH ethyl4- [ ( {2-ethoxy-4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2- y)] phenoxy} acetyi) am ! no] benzoate @At N N I r 2- [2-ethoxy-4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxy}-N-1- naphthylacetamide 635 H o yH 2- {2-ethoxy-4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxyl-N- [3- (trifluoromethyl) phenyl] acetamide 636 0 Nu X ENH \ N-\ MH 2- {2-ethoxy-4- [4- (4-oxo-4, 5, 6, 7- etrabydropyrazolol i, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxy} acetamide 637 ) N I 2- [2- (3-chloro-4, 5- dimethoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 638 i c* cl 0 2- [2- (3-chloro-4-ethoxy-5- methoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 639 % o Cltf +o NNNH CI I/v 2- [2- (3-chloro-5-methoxy-4- propoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 640 NH °A>f 6NH CI I N 2- [2- (4-butoxy-3-chloro-5- methoxyphenyl) pyrimidin-4-yl]-6, 7- 641 dihydropyrazoio [1, 5-a] pyrazin-4 (5H)-one iXocl °S, by, NH oSAS o>0 o N 2-chloro-6-methoxy-4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenyl benzoate 642 y cl N-N NH \ I/ \ i e O Ni [2- (3-chloro-4-isopropoxy-5- methoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 643 H C \ NNNH \0 I/v i i O 2- {2- [4- (benzyloxy)-3-chloro-5- methoxyphenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 644 inj cl a CL O \ N NH 2-(2-{3-chloro-4-[(2-chlorobenzyl) oxy]-5- methoxyphenyl} pyrimidin-4-yl)-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 645 0 ° \ N NH G I' w i 2- [2- (3-chloro-5-ethoxy-4- methoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazoto [1, 5-a] pyrazfn-4 (5H)-one 646 o NH CI /O Ni [2- (3-chloro-4, 5-diethoxyphenyl) pyrimidin 4-yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 647, 0 ° I y.,-rNH cy ° o 2- [2- (3-chloro-5-ethoxy-4- propoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one to 648 NH ci I N 2- [2- (4-butoxy-3-chloro-5- ethoxyphenyl) pyrimidin-4-yl]-6, 7- Wiihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 649 nu ° \ N-NNH O 2- {2- [3-chloro-5-ethoxy-4- (2- hydroxyethoxy) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 650 N H nu 0 N 2-chloro-6-ethoxy-4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenyl benzoate 651 yet N-N NH tj+H / I/v im O 2- [2- (3-chloro-5-ethoxy-4- isopropoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 652 CI n \ NN NH 0 2- {2- [4- (benzyfoxy)-3-chloro-5- ethoxyphenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 653 cl \ NNN 0 2-(2-{3-chloro-4-[(2, 4-dichiorobenzyl) oxy]-5 ethoxyphenyl} pyrimidin-4-yl)-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 654 NH O N 2-(2-{3-chloro-4-[(2-chlorobenzyl) oxy]-5- ethoxyphenyl} pyrimidin-4-yl)-6, 7- dih drop razolo [1, 5-a] pyrazin-4 (5H)-one 655 °1 "1 N-r-y 4- (f2-chloro-6-ethoxy-4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxy} methyi) benzoic acid 656 Br I NH N N 2- [2- (3-bromo-4, 5- dimethoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 657 1 er N-N NH 657 : Ber/\ 2- [2- (3-bromo-4-ethoxy-5- methoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 658 er // \ NN NH /i \ i O N 2- [2- (3-bromo-5-methoxy-4- propoxyphenyi) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 659 Br 0 \,/\i I N'Ni a 2- [2- (3-bromo-4-butoxy-5- methoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 660 Ou nit -6 0 2-bromo-6-methoxy-4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenyl benzoate 661 y Br - 661 N 0 N 2- [2- (3-bromo-4-isopropoxy-5- methoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 662 Br n" xi \ N Ni 2- (2- {3-bromo-4- [ (2, 4-dichlorobenzyl) oxy]-5 methoxyphenyl} pyrimidin-4-yl)-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one Q. ce o \ NN NH Fizz N 2-(2-{3-bromo-4-[(2-chlorobenzyi) oxy]-5- methoxyphenyl} pyrimidin-4-yl)-6, 7- dihydropyrazoto [1, 5-a] pyrazin-4 (5H)-one 664 C) n ci \ I prNNH 2- [2-chloro-6-methoxy-4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxy}-N- phenylacetamide 665 0 0 i HN CI 16---H O 2- {2-chforo-6-methoxy-4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxy} acetamide 666 0 HMI CI H2 D H zozo 2- {2-chloro-6-ethoxy-4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxylacetamide 667 N-N NH ou N 2- [2- (3-bromo-5-ethoxy-4- methoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 668 Br N-N, NH /\ i O 2- [2- (3-bromo-4, 5-diethoxyphenyl) pyrimidin 4-yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 669 Br 669 NH :) 6il 2- [2- (3-bromo-5-ethoxy-4- propoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 670 w t NN - / \ o 2- [2- (3-bromo-4-butoxy-5- ethoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 4 Br \ ! o Br NH / I/i" i O 2-bromo-6-ethoxy-4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- I) p rimidin-2-yl] phen I benzoate 672 y Br 0 N-N NH / I/iv r O N 2-j 2-(3-bromo-5-ethoxy-4- isopropoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolofl, 5-a] pyrazin-4 (5H)-one 673 ej, a og H °) °YS rC"' 2- (2- {3-bromo-4- [ (2, 4-dichlorobenzyl) oxy]-5 ethoxyphenyl} pyrimidin-4-yl)-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 674 er Cl NH NI 2-(2-{3-bromo-4-[(2-chiorobelizyl) oxyl-5- ethoxyphenyl} pyrimidin-4-yl)-6, 7- dihydropyrazoio [1, 5-a] pyrazin-4 (5H)-one ". p'je \ NNH 0 2- {2-bromo-6-methoxy-4- [4- (4-oxo-4, 5, 6, 7- N tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxy}-N- phenylacetamide 676 i o N-benzyl-2- {2-bromo-6-methoxy-4- [4- (4- oxo-4, 5, 6, 7-tetrahydropyrazolo [1, 5- a] pyrazin-2-yl) pyrimidin-2- yl] phenoxy} acetamide 677 A n zon 677 2- {2-bromo-6-methoxy-4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxy}-N-(2- phenylethyl) acetamide 678 N \ Ff 1 Br I \ N H \o'' e o 2- {2-bromo-6-methoxy-4- [4- (4-oxo-4, 5, 6, 7- N tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxy}-N-(2- methylphenyl) acetamide H i Br NH O \ N H yi, 2- [2-bromo-6-methoxy-4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxyl-N- (4- methylphenyl) acetamide 680 I I. \ F (1 6r /aß NN NH L o 0 2- {2-bromo-6-methoxy-4- [4- (4-oxo-4, 5, 6, 7- N tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxy}-N-(2- methoxyphenyl) acetamide 681 0 o I PH o ethyl 4- [ (12-bromo-6-methoxy-4- [4- (4-oxo- 4, 5, 6, 7-tetrahydropyrazolo [1, 5-a jpyrazin-2- yl) pyrimidin-2- yllphenoxy} acetyl) amino] benzoate 682 n 682 a jA A \ N-NH 2- {2-bromo-6-methoxy-4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxy}-N-1- naphthylacetamide 683 0 Br N-N NH 683 O i 2- {2-bromo-6-methoxy-4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxy} acetamide 684 \ bar \ NN NH 0 2- {2-bromo-6-ethoxy-4- [4- (4-oxo-4, 5, 6, 7- NJ tetrahydropyrazolo [l, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxy}-N- phenylacetamide 685 I/ QH N-benzyl-2- {2-bromo-6-ethoxy-4- [4- (4-oxo- 4, 5, 6, 7-tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxy} acetamide 686 I ar 2-12-bromo-6-ethoxy-4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxy}-N- (2- phenylethyl) acetamide 687 n1 °2 tH>i Br A 2-2-bromo-6-ethoxy-4- [4- (4-oxo-4, 5, 6, 7- N tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxy}-N-(2- methylphenyl) acetamide 688 0 nY l Br Fl'\ N NN 0 2- {2-bromo-6-ethoxy-4- [4- (4-oxo-4, 5, 6, 7- N tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxy}-N- (4- methylphenyl) acetamide r 689 Bu O \ NNNH 0 2- {2-bromo-6-ethoxy-4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxy}-N- (2- methoxyphenyl) acetamide 690 'I bu o T,- [ ( [2-bromo-6-ethoxy-4- [4- (4-oxo- 4, 5, 6, 7-tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2- yl] phenoxy} acetyl) amino] benzoate 691 /I I 2-i2-bromo-6-ethoxy-4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxy}-N-1- naphthylacetamide 692 0 JL N'NH l. ry l o 0 N 2- [2-bromo-6-ethoxy-4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yi) pyrimidin-2-yl] phenoxy} acetamide 693 N-N NH 0 2- [2- (2-bromo-4, 5- dimethoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 694 0 Br N-N NH 2- 2-2-2-bromo-4-ethoxy-5- methoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 695 ° M-\/" N I o Nu 2- [2- (2-butoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 696 \I -N +H 2- {2- [2- (benzyloxy) phenyl] pyrimidin-4-yl}- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 697 a fr i /w I f o 2-(2-{2-[(2- chlorobenzyl) oxy] phenyl} pyrimidin-4-yl)-6, 7 dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 698 a a 2 ° rn i%, + 2-(2-{2-[(2, 4- dichlorobenzyl) oxy] phenyl} pyrimidin-4-yl)- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one !/-\ \ NN NH zozo 2- [2- (2-isopropoxyphenyl) pyrimidin-4-yl]- P 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 700 0 N-N/NH -7, N 2-[2-(5-bromo-2-ethoxyphenyl) pyrimidin-4- [ (Yp Y) pY yi]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 701 XdeNH N m Br o 2- [2- (5-bromo-2-propoxyphenyl) pyrimidin-4 P Y yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 702 one fV° N-MMH N\< i i / 2-[2-(5-bromo-2-butoxyphenyl) pyrimidin-4- yi]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 703 cri I i er i I w I l o 2-(2-{5-bromo-2-[(2- chlorobenzyl) oxy] phenyl} pyrimidin-4-yl)-6, 7 dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 704 xi ,, rNrH 2- (2- (5-bromo-2- [ (2, 4- dichlorobenzyl) oxy] phenyl} pyrimidin-4-yl)- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 0 705 y 0 N-N m I I/, 6 2- [2- (5-bromo-2- isopropoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 706 Br & I/i i r O N 2-2--dibrom-2- methoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 707. Bu rk N-MNH ANisX 2- [2- (3, 5-dibromo-2- propoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazololl, 5-alpyrazin-4 (5H)-one 708 & ber y Are0 2- [2- (3, 5-dibromo-2- isopropoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 709 N Bu \ N NH Br I/ I/o 2-{2-[2-(benzyloxy)-3, 5- dibromophenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 710 /I \ Br \ pYNNi 2-(2-{3, 5-dibromo-2-[(2- chlorobenzyl) oxy] phenyl} pyrimidin-4-yl)-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 711 o c @ SH c/-<. N- (2-methoxyphenyl)-2- {2- [4- (4-oxo-4, 5, 6, 7 tetrahydropyrazolo [1, 5-a] pyrazin-2- y)) pyrimidin-2-yl] phenoxy} acetamide 712 N_N NH _ ethyl 4- [ (f2- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2- yl] phenoxy} acetyl) amino] benzoate 713 0 0 N /i ie O N-benzyl-2-f2- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxy} acetamide 714 OVi awl N-N, INH N- (2-methylphenyl)-2- {2- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxy} acetamide (Yi 715 aiti 0 frT°''""" 0 2- [4-bromo-2- [4- (4-oxo-4, 5, 6, 7- N tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxy}-N- phenylacetamide 716 N tj \ p \ N-N H 2- {4-bromo-2- [4- (4-oxo-4, 5, 6, 7- N tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxy}-N- (4- methylphenyl) acetamide 717, an ° , - 1 p,-NnH 2-f4-bromo-2- [4- (4-oxo tetrahydropyrazolo [1, 5-a] pyrazin-2- yi) pyrimidin-2-yl] phenoxy}-N- (2- methoxyphenyl) acetamide 7-f8 718 0 0 AY-, Br I o N N-benzyl-2- {4-bromo-2- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- y) pyrimidin-2-yl] phenoxy} acetamide 719 0 N \ ° N--NH o 2- {4-bromo-2- [4- (4-oxo-4, 5, 6, 7- N tetrahydropyrazolo [1, 5-a] pyrazin-2- y)) pyrimidin-2-yl] phenoxy}-N- (2- phenylethyl) acetamide 720 Osa \ °, -N , V° M-N m Br 0 ethyl 4- [ ( [4-bromo-2- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2- yllphenoxy) acetyl) aminolbenzoate 721 ? 1 N N INH - {4-bromo-2- [4- (4-oxo-4, 5, 6, 7- N tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenoxy}-N-(2- methylphenyl) acetamide 722 NH N-N/NH CIAO CI I "O N 2- {2- [5-chloro-2- (methylamino) phenyl] pyrimidin-4-yl)-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 723 ou 0 N-N NH N I i O N 2- [2- (3-hydroxy-4-methoxyphenyl) pyrimidin 4-yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 724 n rY N-M 1 \ 1 o N- {3-methyl-4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yi] phenyl} acetamide 725 OH OH N-N/--\ NH 2- [2- (2, 3-dihydroxyphenyl) pyrimidin-4-yl]- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 726 NH N/ N 2- [2- (2, 4-dihydroxyphenyl) pyrimidin-4-yl]- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 727 CH N-N/-\ NH / I O N 2- [2- (2, 6-dihydroxyphenyl) pyrimidin-4-yl]- 6, 7-dihydropyrazolo [l, 5-a] pyrazin-4 (5H)- one 728 OH H NN NH N I N 2- [2- (2, 3, 4-trihydroxyphenyl) pyrimidin-4-yl]- 6, 7-dihydropyrazolo [l 5-a] pyrazin-4 (5H)- one 729 I/\ I CH N 2-[2-(2, 4, 6-trihydroxyphenyl) pyrimidin-4-yl]- [ (y yp y) pyrimidin-4-yl]- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 730 o N 2- [2- (2-hydroxy-5-methoxyphenyl) pyrimidin 4-yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 731 vH I/\ i s, 0 2-[2-(2-hydroxy-3-methoxyphenyl) pyrimidin 4-yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 732 o 0- tj+H 2- [2- (5-bromo-2-hydroxy-3- methoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 733 ci °"j-N NH Ci I/I v ! o N 2- [2- (3, 5-dichloro-2- hydroxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazo) o [1, 5-a] pyrazin-4 (5H)-one 734 N I \ i N NH v O N 2-{2-[4-(diethylamino)-2- hydroxyphenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 735 735 (< NH 0 2- [2- (2-hydroxy-6-methylphenyl) pyrimidin-4 yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 736 1 N.-N t9-I N-0 2- [2- (2-hydroxy-4-methylphenyl) pyrimidin-4 y)]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 737 NH 1 ou/--\ \ i O i N 2- [2- (3-amino-2-hydroxyphenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 738 /-o N-N NH ZON NU v ! i O / 2- [2- (6-bromo-1, 3-benzodioxol-5- yl) pyrimidin-4-yl]-6, 7-dihydropyrazolo [l, 5- a] pyrazin-4 (5H)-one 739 0 T 2-f2- [3- (2-aminoethyl)-2-methyl-I H-indol-5- yl] pyrimidin-4-yl}-6, 7-dihydropyrazolo [1, 5- a] pyrazin-4 (5H)-one 740 iYi Y Z Ce (4-benzylpiperazin-1-yl)-N- {2- [4- (4-oxo- 4, 5, 6, 7-tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenyl} acetamide 741 2- [4- (4-fluorophenyl) piperazin-1-yl]-N- (2- [4- (4-oxo-4, 5, 6, 7-tetrahydropyrazolo [1, 5- a] pyrazin-2-yl) pyrimidin-2- yl] phenyl} acetamide 742 N- {2- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-ajpyrazin-2- yl) pyrimidin-2-yl] phenyl}-2- (4-pyridin-2- ylpiperazin-1-yl) acetamide 743 F O I i NNH O N 2- (2- {4- [ (2- fluorobenzyl) oxy] phenyl} pyrimidin-4-yl)-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 744 4, NH O 2-j 2-(3-hydroxy-2-methylphenyl) pyrimidin-4 y)]-6, 7-dihydropyrazoto [1, 5-a] pyrazin-4 (5H)' one 745 F NN NH i/O i o N/2- [2- (5-fluoro-2-methoxypheny)) pyrimidin-4 yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 746 N-N NH \ ii O 2- [2- (2, 4, 5-trimethylphenyl) pyrimidin-4-yl]- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 747 F 747 N I tN+H 2- [2- (2-amino-5-fluorophen Imidin-4- [ (op y) pynm 4 yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 748 0 L \ I N\ I/O HZN 2- {2- [3- (2-aminoethyl)-1 H-indol-5- yl] pyrimidin-4-yl}-6, 7-dihydropyrazolo [1, 5- a] pyrazin-4 (5H)-one 749 N N NH OH\ \I \ ! o 0 NI HZN 5- [4- (4-oxo-4, 5, 6, 7-tetrahydropyrazolo [1, 5- a] pyrazin-2-yl) pyrimidin-2-yl] tryptophan 750 N-11 nu 0. han H o 2- [4- (4-oxo-4, 5, 6, 7-tetrahydropyrazolo [1, 5- a] pyrazin-2-yl) pyrimidin-2-yl]-L- phenylalanine 751 NHZ/N-N NH Ha 0 3- [4- (4-oxo-4, 5, 6, 7-tetrahydropyrazolo [1, 5- a] pyrazin-2-yl) pyrimidin-2-yl]-L- phenylalanine 752 0 /N--NNH i o 2- {2- [4- (5-propyl-1, 3-dioxan-2- yl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 753 Cul 0 N-N NH N I N 2- [2- (3-chloro-4-methoxyphenyl) pyrimidin-4 YP Y) PY yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 754 C'N CI NN NH Nw I I \ ! s O N 2- [2- (4-chloroquinolin-3-yl) pyrimidin-4-yl]- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 755 F NN NH N ! r 0 2- [2- (2-chloro-5-fluorophenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 756 N-NI NH \ 2- [2- (2-fluoro-4-methylphenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 757 F NN NH i 2- [2- (3-fluoro-5-methylphenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 758 one _ I, r o 5-fluoro-2- (4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] benzoic acid 759 F <gH F/N.-N Ni N-N NH 0 2-fluoro-5- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- y) pyrimidin-2-yl] benzoic acid 760 CL (\ 1/O F N 3-fluoro-4-[4-(4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- y)) pyrimidin-2-yl] benzoic acid 761 N ich 1 e O 4-f) 4-fluoro-3- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] benzoic acid 762 F N NH /e N N (2- [2-f) uoro-5- (hydroxymethyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 763 F \ wNNH /v l O t'2-{2-[2, 5- F N bis (trifluoromethyì) phenyl] pyrimidin-4-yì}- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 764 ou n ANí, nu w I \ 1 e o N 2-ffuoro-4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yì] benzoic acid 765 N-N NH I I F N 2- [2- (2, 6-difluoro-4- methoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 766 F rt-N/--\w 0 F N 2- [2- (2, 6-difluoro-4- hydroxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 767 s\S, NH2/\ \\0'N-N NH N 2- [4- (4-oxo-4, 5, 6, 7-tetrahydropyrazolo [1, 5- a] pyrazin-2-yl) pyrimidin-2- yllbenzenesuffonamide 768 \Az) NH I/o a N 2- [2- (2-chloro-4-methylphenyl) pyrimidin-4- y ]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 769 \/o ber N N-I 1-6y, N- {2-bromo-4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenyl} acetamide 770 zoo tebH N Ni N- {2, 6-dibromo-4- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] pheny)} acetamide 771 Br H2Nt, <NH Br \ I I v ! O N 2-2-4-amino-3, 5-dibromo Imidi [ (pheny) pynm n 4-yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 772 lez N NH NyO 2- [2- (1, 2, 3, 4-tetrahydroisoquinolin-7- yl) pyrimidin-4-yl]-6, 7-dihydropyrazolo [1, 5- a] pyrazin-4 (5H)-one 773 /NH ZON NH N I F N\G- d0-I (-4-i- 2- [2- (5-fluoro-1 H ind l-6-yl) pyrimidin-4-y] 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 774 OH NH /N H N 5-fluoro-6- [4- (4-oxo-4, 5, 6, 7- F N tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl]-1 H-indole-2-carboxylic acid 775 ni \ e o F \y 2- {2- [3- (2-aminoethyl)-5-fluoro-1 H-indol-6- yl] pyrimidin-4-yl}-6, 7-dihydropyrazolo [1, 5- a] pyrazin-4 (5H)-one 776 /NU F N 2- N i I uoro-3-m ethyl-1 H-indol-6- F N 2-2-5-flu ro-3-h- [ (o met yl 1 H-mdol-6- yl) pyrimidin-4-yl]-6, 7-dihydropyrazolo [1, 5- 777 pyrazin-4 (5H)-one -H y NH /N NH I N i ethyl 5-fluoro-6- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl]-1 H-indole-2-carboxylate 778 NN NH 0 N [2- (4-bromo-3-ethoxyphenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [i, 5-a] pyrazin-4 (5H) one 779 Nit F, 2- [2- (4-fluoro-2-methylphenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 780 F F Br \ i A O 2- {2- [4-bromo-3- (trifluoromethyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 781 H 781'J nu HzN \ I v I. d O N/2- {2- [3-amino-4- (methylamino) phenyl] pyrimidin-4-y }-6, 7- dihydropyrazoio [1, 5-a] pyraz ! n-4 (5H)-one 782 N \ \ N N NH /i \ N (2- (4- (2-aminopyrimidin-4- yl) pheny lpyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 783 +H h ! NH kY 2- {2- [2-amino-5- (trifluoromethyl) phenyl] pyrimidin-4-yi}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 784 1-4zN \ F O F N 2- [2- (4-amino-2, 6-difluorophenyl) pyrimidin- 4-yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 785 F H2N NH F \ I i 1 i O N 2- [2- (4-amino-3, 5-difluorophenyl) pyrimidin- 4-yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 786 NN N NH \ I v i O 2-f2- [4- (2-methylpyrimidin-4- yl) phenyl] pyrimidin-4-yl)-6, 7- dihydropyrazo) o [1, 5-a] pyrazin-4 (5H)-one 9 Nr non a4W 2- {2- [4- (2-phenylpyrimidin-4- yl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 788 Y f f 788 v 2- {2- [4- (2-pyridin-2-yipyrimidin-4- yl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 789 w-N NH 789 :-Pyl 0 2- [2- (2-chloro-3-fluorophenyl) pyrimidin-4- yl]-6, 7-dihydropyrazoto [1, 5-a] pyrazin-4 (5H)- one 790 ci F = F I/ v ! O 2- [2- (3-chloro-5-fluorophenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 791 NU a ! I/i i O N H 2- {2- [3- (1 H-pyrazol-3-yl) phenyl] pyrimidin-4- yl}-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 792 At N--N NH O F N 2- [2- (2, 3, 6-trifluoro-4- methylphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 793 F F G/, YNtH F 0 2- {2- [4-chloro-3, 5- F bis (trifluoromethyl) phenyl] pyrimidin-4-yi}- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 794 F F S-rY i \ i Er 2-f2- [2-bromo-5- (trifluoromethyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 795 F ç NoH FI ci N 2- {2- [2-chloro-6- (trifluoromethyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 796 if F N NH 2- (2- {q- [chloro (difluoro) methoxy] phenyl} pyrimidin- 4-yl)-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 797 F F Ruz \/NNH I/ : is o 2- {2- [4'- (trifluoromethyl)-1, 1'-biphenyl-2- yl] pyrimidin-4-yl}-6, 7-dihydropyrazolo [1, 5- a] pyrazin-4 (5H)-one 798 N2 gB H N-N N _ I/v i O /2- {2- [4- (1-amino-3- hydroxypropyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 799 ,,-NNH , \I ie s w 2- {2- [3- (1-amino-3- hydroxypropyl) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 800 or. f o 800 1- {4-methyl-3- [4- (4-oxo-4, 5, 6, 7- N tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] phenyl} pyrrolidine-2, 5- dione 801 t, t-N NH /\ i O N/ ethyl 2- [4- (4-oxo-4, 5, 6, 7- tetrahydropyrazolo [1, 5-a] pyrazin-2- yl) pyrimidin-2-yl] benzoate 802 iX ra tf<NH 2-{2-[4- N (cyclohexylmethoxy) phenyl] pyrimidin-4-yl}- 6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 803 w I i, 2- (2- {4- [ (I- methylheptyl) oxy] phenyl} pyrimidin-4-yl)-6, 7 dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 804 /N-N NH i i O N 2- [2- (7-methyl-2, 3-dihydro-1 H-inden-4- yl) pyrimidin-4-yl]-6, 7-dihydropyrazolo [1, 5- a] pyrazin-4 (5H)-one ao5 ° \ NN NH 2- [2- (4-m ethoxy-2-m ethyl phenyl) pyri midi n- 4-yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 806 \ N-N NH N I o\ N/2- [2- (2-methoxy-5-methylphenyl) pyrimidin- 4-yl]-6, 7-dihydropyrazolo of 1, 5-a] pyrazin- 4 (5H)-one 807 ce \ NHz NN 1NH 2- [2- (2-amino-3-chlorophenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one 808 one N I \ N Ni NH I i i A p 2- [2- (3-benzyl-2, 3, 4, 5-tetrahydro-1 H-1, 4- benzodiazepin-7-yl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 809 N \ , r-N NH /iv le O 2- [2- (4-piperidin-4-ylphenyl) pyrimidin-4-yl]- 6, 7-dihydropyrazo) o [1, 5-a] pyrazin-4 (5H)- one silo N-N NH I/ - o N 2- [2- (4-methoxy-3, 5- dimethylphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 811 N-N NH ° / /No N 2- [2- (3-oxo-1, 3-dihydro-2-benzofuran-5- yl) pyrimidin-4-yl]-6, 7-dihydropyrazolo [1, 5- a] pyrazin-4 (5H)-one 812 | so po NN NH \ Is O 2- [2- (3, 4-dimethoxy-2- methylphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 813 o \ NNH i O 2- [2- (3-methoxy-4-methylphenyl) pyrimidin- 4-yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one 814 0 F N 2- [2- (2-fluoro-6-hydroxyphenyi) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 815 F_, F Nu 2-[2-(3, 4-difluoro-2- methoxyphenyl) pyrimidin-4-yl]-6, 7- 816 dihydropyrazoìo [1, 5-a] pyrazin-4 (5H)-one 816 F F \ NN \NH / i Q 2- [2- (3, 4-difluoro-2- hydroxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 817 a N-N NH \ F NN NN /\ j O N N 2- [2- (2, 3-difluoro-4- methoxyphenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 818 CI N-N/--\ NH ie o N 2- [2- (4-chloro-3-methylphenyl) pyrimidin-4- yi]-6, 7-dihydropyrazolo [i, 5-a] pyrazin-4 (5H)- one 819 F F 0 2- [2- (4-f [2-oxo-5- (trifl uorom ethyl) pyridin-' 1 (2H)-yl] methyl} phenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 820 n Y 2- [2- (4- { [5- (4-methylphenyl) pyrimidin-2- yl] oxy} phenyl) pyrimidin-4-yl]-6, 7- dihydropyrazoìo [ls5-a] pyrazin-4 (5H)-one 821 2- [2- (4- { [5- (4-methoxyphenyl) pyrimidin-2- yl] oxy} phenyl) pyrimidin-4-yl]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 822 n a R TY 1" 2- [2- (4- [ [5- (4-fluorophenyl) pyrimidin-2- yl] oxy} phenyl) pyrimidin-4-yì]-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 823 zozo 0 N-N NH 823 8 NH, N 2- [2- (6-amino-1, 3-benzodioxol-5- yl) pyrimidin-4-yl]-6, 7-dihydropyrazolo [1, 5- a] pyrazin-4 (5H)-one 824 ber N-N N I"1 0H 824 2- {2- [5-bromo-2- (2- hydroxyethoxy) phenyl] pyrimidin-4-yl}-6, 7- dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one 825 , NI- nit - o 2- [2- (4-f I uo ro-3-m ethyl phenyl) pyri mi din-4- yl]-6, 7-dihydropyrazolo [i, 5-a] pyrazin-4 (5H) one 826 826 NN NH O 2- [2- (3-fluoro-2-methylphenyl) pyrimidin-4- yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) one 827 0 °T" !) I/, methyl 4'- [4- (4-oxo-4, 5, 6, 7- NNNH tetrahydropyrazolo [1, 5-a] pyrazin-2- N yl) pyrimidin-2-yl]-1, 1'-biphenyl-4- carboxylate 828 0/-- 0 i I f o 2- [2- (2-amino-4, 5-diethoxypheny)) pyrimidin 4-yl]-6, 7-dihydropyrazolo [1, 5-a] pyrazin- 4 (5H)-one Notes: a) Chemical names were generated by ACD/Name software. b) The MK-2 inhibiting compound may be shown with a solvent, such as, for example, trifluoroacetate, with which it can form a salt. Both the salt and base forms of each compound are included in the present invention.

[00039] In one embodiment of the present invention, the MK-2 inhibiting compound is one that is listed in Table I.

[00040] In another embodiment of the present invention, the MK-2 inhibiting compound is one that is listed in Table 1 or in Table 2.

[00041] in yet another embodiment of the present invention, the MK-2 inhibiting compound is one that is listed in Table 2.

[00042] It is preferred that the MK-2 inhibiting compound is one that has an IC50 value for the inhibition of MK-2 that is lower than 1. By way of example, this would include the compounds in Table I numbered 1-56.

An MK-2 IC5o value that is lower than 0.5 is still more preferred (examples of these compounds include the compounds in Table I numbered 1-32), lower than 0.1 is even more preferred yet (examples of these compound include the compounds in Table I numbered 1-7).

[00043] In one embodiment of the present invention, the MK-2 inhibiting compound is one having the structure of formula 1, except when Z2 and Z3 are both nitrogen, R4 is other than pyrrole, or optionally when Z4 and Z5 are both nitrogen and Ra is ring Q, Q2 is other than nitrogen.

[00044] In another embodiment of the present invention, the MK-2 inhibiting compound is one having the structure of formula 1, except that Ra is selected from an M-ring or a Q-ring.

[00045] In another embodiment of the present invention, the MK-2 inhibiting compound is one having the structure of formula 1, except that Ra is an M-ring.

[00046] In another embodiment of the present invention, the MK-2 inhibiting compound is one having the structure of formula 1, except that Ra is an M-ring wherein ring M is an aromatic pyridine or pyrimidine ring, wherein M1, M3 and M4 are carbon and are substituted with (L)"R', M5 is carbon, M2 and M6 are independently selected from carbon and nitrogen and if M2 and/or M6 is carbon, the carbon is substituted with (L) nR'.

[00047] In another embodiment of the present invention, the MK-2 inhibiting compound is one having the structure of formula 1, except that Ra is an M-ring wherein ring M is an aromatic pyridine or pyrimidine ring,

wherein M1, M3 and M4 are carbon and are substituted with (L)nR1, M5 is carbon, M2 and M6 are independently selected from carbon and nitrogen and if M2 and/or M6 is carbon, the carbon is substituted with (L) nR1 ; and [00048] R3 and R4 optionally join to form a ring of 5,6, 7, or 8 atoms, where the atoms in the ring are independently selected from Z3, Z4, O, S, C=O, C=S, S=O, SO2, C that is mono or di-substituted with an R1 group, and N that is unsubstituted or substituted with an R1 group.

[00049] In another embodiment of the present invention, the MK-2 inhibiting compound is one having the structure of formula 1, except that Ra is an M-ring wherein ring M is an aromatic pyridine or pyrimidine ring, wherein M1, M3 and M4 are carbon and are substituted with (L)nR1, M5 is carbon, M2 and M6 are independently selected from carbon and nitrogen and if carbon, the carbon is substituted with (L)nR1 ; and [00050] R3 and R4 optionally join to form a ring of 6 or 7 atoms, where the atoms in the ring are independently selected from Z3, Z4, C=O, C that is mono or di-substituted with an R1 group, and N that is unsubstituted or substituted with an R'group.

[00051] In another embodiment of the present invention, the MK-2 inhibiting compound is one having the structure of formula 1, except that Ra is an M-ring, wherein ring M is an aromatic pyridine or pyrimidine ring, wherein M1, M3 and M4 are carbon and are substituted with (L)nR1, M5 is carbon, M2 and M6 are independently selected from carbon and nitrogen and if carbon, the carbon is substituted with (L) nR1 ; and [00052] R3 and R4 optionally join to form a ring of 6 atoms, where the atoms in the ring are independently selected from Z3, Z4, C=O, C that is mono or di-substituted with an Ri group, and N that is unsubstituted or substituted with an R1 group.

[00053] In another embodiment of the present invention, the MK-2 inhibiting compound is one having the structure of formula 1, except that Ra is an M-ring wherein ring M is an aromatic pyridine or pyrimidine ring, wherein M1, M3 and M4 are carbon and are substituted with (L) nS1, M5 is

carbon, M2 and M6 are independently selected from carbon and nitrogen and if carbon, the carbon is substituted with (L)nR1 ; and R3 and R4 optionally join to form a ring that is selected from: [00054] In another embodiment of the present invention, the MK-2 inhibiting compound is one having the structure of formula 1, except that Ra is an M-ring, wherein ring M is an aromatic pyridine ring, wherein M', M3, M4 and M6 are carbon and are substituted with (L)nR1, M5 is carbon, M2 is nitrogen.

[00055] In another embodiment of the present invention, the MK-2 inhibiting compound is one having the structure of formula 1, except that Ra is an M-ring, wherein ring M is an aromatic pyrimidine ring, wherein M1, M3 and M4 are carbon and are substituted with (L)nR1, M5 is carbon, M2 and M6 are nitrogen.

[00056] In another embodiment of the present invention, the MK-2 inhibiting compound is one having the structure of formula 1, except that Ra is an M-ring wherein ring M is an aromatic pyridine ring, wherein: M1, M3, M4 and M6 are carbon and are substituted with (L)nR1 ; M5 is carbon ; M2 is nitrogen; R1 is selected from-H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, hydroxyl, C1-C6 alkoxy, C2-C6 alkenyl-R11, C1-C6 alkoxy-R11, COR17, COR6, CO2R6, CONHR6, N (R8) 2, amino Ci-C4 alkyl, hydroxy C1-C4 alkyl, amino, amino C1-C4 alkyl-R7, C1-C6 alkyl-NHR7, carbonitrile, SR10, halo, NHR7, NR8R9, NHR'-C1-C6 alkyl, NR8R9-C1-C6 alkyl, nitro, cyano, O-R10, C1-C4 alkyl-OR10, Ci-Ce alkyl-COR11, halo C1-C4 alkyl, aryl, heteroaryl,

heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, or Ci-Cio mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R12 ; R', R8, are each independently selected from-H, C1-C6 alkyl, C1-C4 alkyl-R11 C1-C6 alkyl-N (R13) 2, C02R16, COR17, aryl, and arylalkyl, wherein aryl and arylalkyl, are optionally substituted with one or more of the groups defined by R18; R9, R1° are each independently selected from-H, hydroxyl, Cl-C6 alkyl, C1-C6 alkyl-R17, C1-C6 alkyl-NH2R13, CO2R16, COR17, C1-C6 alkyl- CO2R16, C1-C6 alkyl-CONH-R16, C1-C6 alkyl-CON(R16) 2, hydroxy C1-C4 alkyl, halo C1-C4 alkoxy, halo C1-C4 alkyl, Si (R13) 2R17, aryl, heteroaryl, heterocyclyl, arylalkyl, and C1-C10 mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, and arylalkyl, are optionally substituted with one or more of the groups defined by R18 ; R'1 is selected from-H, C1-C6 alkyl, C1-C6 alkoxy, hydroxyl, halo, amino, NHR13, N (R13) 2, COR13, CO2R17, halo C1-C4 alkyl, aryl, heteroaryl, heterocyclyl, heteroarylalkyl, and heterocyclylalkyl, wherein heterocyclyl, heteroarylalkyl, and heterocyclylalkyl, are optionally substituted with one or more of the groups defined by R18; R12 is selected from-H, hydroxyl, oxo, C1-C6 alkyl, hydroxyl C1-C6 alkyl-R11, Ci-Cio alkoxy, amino, amino C1-C4 alkyl-R7, NHR7, N (R7) 2, C1- C6 alkyl-NHR7, Cl-C6 alkyl-NHR8R9, C1-C6 alkyl-N (R8) 2, C1-C6 alkyl-R11, C1-C6 alkyl-CO2R7R11, C1-C6 alkoxy-R11, nitro, O-R10, C=O, COR11, CO2R11, SR10, SOR11, SO2R11, NHSO2R11, C1-C6 alkyl-SR10, halo, halo C1- C4 alkyl, halo C1-C4 alkoxy, hydroxy C1-C4 alkyl, hydroxy C1-C4 alkoxy, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-C10 mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and heterocyclylalkyl, and Ci-Cio mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R18 ;

R13 and R14 are each independently selected from-H, oxo, C1-C6 alkyl, COR23, and aryl ; R15, R16 are each independently selected from-H, aryl, arylalkyl, wherein aryl, arylalkyl, are optionally substituted with one or more of the groups defined by R24 ; R17 is selected from-H, C1-C6 alkyl, C1-C6 alkyl-R19, NHR19, aryl, heteroarylalkyl, and heterocyclylalkyl, wherein aryl is optionally substituted with one or more of the groups defined by R24 ; R18 is selected from-H, oxo, hydroxyl, C1-C10 alkyl, C1-C10 alkoxy, amino, amino C1-C6 alkyl, N (R19) 2, C1-C6 alkyl-N (R19) 2, CO2R23, SR21, halo, halo C1-C4 alkyl, aryl, heteroaryl, and heterocyclyl, wherein aryl, heteroaryl, and heterocyclyl, are optionally substituted with one or more of the groups defined by R24 ; R19 and R20 are each independently selected from-H, C1-C6 alkyl, heteroaryl, heterocyclyl, wherein aryl, heteroaryl, and heterocyclyl, are optionally substituted with one or more of the groups defined by R30 ; R21 and R22 are each independently selected from-H and Ci-Ce alkyl ; R23 is selected from-H and C1-C6 alkyl ; R24 is selected from-H, C1-C6 alkyl, Ci-C6 alkoxy, C02R29, halo, and halo C1-C4 alkyl ; R29 is selected from-H, and C1-C6 alkyl ; R30 is selected from-H, aryl, heteroaryl, heterocyclyl, alkylaryl, arylalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, and arylalkyl, are optionally substituted with one or more of the groups defined by R36 ; R36 is selected from-H and halo ; and R2, R3, R4, R37 and R38 are each independently selected from an R group.

[00057] In an embodiment of the present invention, the MK-2 inhibiting compound is one having the structure of formula 1, except that Ra is an M- ring wherein ring M is an aromatic pyrimidine ring, wherein: M1, M3 and M4 are carbon and are substituted with (L)nR1 ;

M5 is carbon; M2 and M6 are nitrogen; R1 is selected from-H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, hydroxyl, C1-C6 alkoxy, C2-C6 alkenyl-R11, C1-C6 alkoxy-R11, COR17, COR6, CO2R6, CONHR6, N (R8) 2, amino Ci-C4 alkyl, hydroxy Ci-C4 alkyl, amino, amino C1-C4 alkyl-R7, halo C1-C4 alkyl, C1-C6 alkyl-NHR7, carbonitrile, SR10, halo, NHR7, NR8R9, NHR7-C1-C6 alkyl, NR8R9-C1-C6 alkyl, nitro, cyano, O-R10, C1-C4 alkyl-OR10, C1-C6 alkyl-COR11, halo C1-C4 alkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, or Ci-Cio mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R12; R7, R8, are each independently selected from-H, Ci-C6 alkyl, C1-C4 alkyl-R11, C1-C6 alkyl-N(R13) 2, CO2R16, COR, aryl, and arylalkyl, wherein aryl and arylalkyl, are optionally substituted with one or more of the groups defined by R18; R9, Rio are each independently selected from-H, hydroxyl, C1-C6 alkyl, C1-C6 alkyl-R17, C1-C6 alkyl-NH2R13, CO2R16, COR17, C1-C6 alkyl- CO2R16, C1-C6 alkyl-CONH-R16, C1-C6 alkyl-CON(R16) 2, hydroxy Cl alkyl, halo C1-C4 alkoxy, halo C1-C4 alkyl, Si(R13)2R17, aryl, heteroaryl, heterocyclyl, arylalkyl, and Ci-C1o mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, and arylalkyl, are optionally substituted with one or more of the groups defined by Ris ; Ri'is selected from-H, C1-C6 alkyl, C1-C6 alkoxy, hydroxyl, halo, amino, NHR13, N (R13) 2, COR13, CO2R17, halo C1-C4 alkyl, aryl, heteroaryl, heterocyclyl, heteroarylalkyl, and heterocyclylalkyl, wherein heterocyclyl, heteroarylalkyl, and heterocyclylalkyl, are optionally substituted with one or more of the groups defined by R18 ; R12 is selected from-H, hydroxyl, oxo, C1-C6 alkyl, hydroxyl C1-C6 alkyl-R11, C1-Cio alkoxy, amino, amino C1-C4 alkyl-R7, NHR7, N (R7) 2, Ci- C6 alkyl-NHR7, C1-C6 alkyl-NHR8R9, C1-C6 alkyl-N(R8)2, C1-C6 alkyl-R11,

C1-C6 alkyl-CO2R7R11, C1-C6 alkyl-R11, nitro, O-R10, C=0, COR11, CO2R11, SR10, SOR11, SO2R11, NHSO2R11, C1-C6 alkyl-SR10, halo, halo C1- C4 alkyl, halo C1-C4 alkoxy, hydroxy C1-C4 alkyl, hydroxy C1-C4 alkoxy, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and C1-C10 mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and heterocyclylalkyl, and C1-C10 mono-and bicyclic cycloalkyl are optionally substituted with one or mo, re of the groups defined by R18 ; R13 and R14 are each independently selected from-H, oxo, C1-C6 alkyl, COR23, and aryl ; R15, R16 are each independently selected from-H, aryl, arylalkyl, wherein aryl, arylalkyl, are optionally substituted with one or more of the groups defined by R24 ; R7 is selected from-H, C1-C6 alkyl, C1-C6 alkyl-R19, NHR19, aryl, heteroarylalkyl, and heterocyclylalkyl, wherein aryl is optionally substituted with one or more of the groups defined by R24 ; R18 is selected from-H, oxo, hydroxyl, C1-C10 alkyl, C1-C10 alkoxy, amino, amino C1-C6 alkyl, N (R19) 2, C1-C6 alkyl-N(R19) 2, CO2R23, SR21, halo, halo C1-C4 alkyl, aryl, heteroaryl, and heterocyclyl, wherein aryl, heteroaryl, and heterocyclyl, are optionally substituted with one or more of the groups defined by R24 ; Ri9 and R20 are each independently selected from-H, Ci-Ce alkyl, heteroaryl, heterocyclyl, wherein aryl, heteroaryl, and heterocyclyl, are optionally substituted with one or more of the groups defined by R30 ; R21 and R22 are each independently selected from-H and Ci-Ce alkyl ; R23 is selected from-H and C1-C6 alkyl ; R24 is selected from-H, C1-C6 alkyl, C1-C6 alkoxy, CO2R29, halo, and halo C1-C4 alkyl ; R29 is selected from-H, and Ci-C6 alkyl ;

R30 is selected from-H, aryl, heteroaryl, heterocyclyl, alkylaryl, arylalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, and arylalkyl, are optionally substituted with one or more of the groups defined by R36 ; R36 is selected from-H and halo ; and R2, R3, R4, R37 and R38 are each independently selected from an group.

[00058] In another embodiment, the present MK-2 inhibiting compound has the structure shown in formula III : Formula III : wherein: dashed lines indicate optional single or double bonds; Z2 and Z3 are nitrogen, Z1, Z4 and Z5 are carbon, and join with Z2 and Z3 to form a pyrazol ring; where dashed lines indicate optional single or double bonds; M1, M3 and M4 is carbon and is substituted with (L)nR1, M5 is carbon, and each of M2 and M6 is independently selected from nitrogen and carbon, and if carbon, it is unsubstituted or substituted with (L)nR1 ; R'is selected from-H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, hydroxyl, C1-C6 alkoxy, C2-C6 alkenyl-R11, C1-C6 alkoxy-R11, COR17, CO2R7, CONHR7, N (R8) 2, amino C1-C4 alkyl, hydroxy Ci-C4 alkyl, amino, amino C1-C4 alkyl-R7, halo C1-C4 alkyl, C1-C6 alkyl-NHR7, C1-C6 alkyl- N (R7) 2, carbonitrile, SR10, halo, NHR7, NR8R9, NHR7-C1-C6 alkyl, NR8R9- C1-C6 alkyl, nitro, cyano, O-R10, C1-C4 alkyl-OR10, C1-C6 alkyl-COR11, aryl,

heteroaryl, heterocyclyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, or Ci-Clo mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R12 ; R7 and R8 are each independently selected from-H, Ci-Ce alkyl, C1- C4 alkyl-R11, C1-C6 alkyl-N (R13) 2, COgR, COR, aryl, and arylalkyl, wherein aryl and arylalkyl, are optionally substituted with one or more of the groups defined by R18; R9 and Rlo are each independently selected from-H, hydroxyl, C1- C6 alkyl, C1-C6 alkyl-R17, C1-C6 alkyl-NH2R13, CO2R16, COR17, C1-C6 alkyl- CO2R16, C1-C6 alkyl-CONH-R16, C1-C6 alkyl-CON(R16) 2, hydroxy Ci-C4 alkyl, halo C1-C4 alkoxy, halo C1-C4 alkyl, Si(R13)2R17, aryl, heteroaryl, heterocyclyl, arylalkyl, and Ci-Cio mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, and arylalkyl, are optionally substituted with one or more of the groups defined by R18 ; R11 is selected from-H, Ci-Ce alkyl, C1-C6 alkoxy, hydroxyl, halo, amino, NHR13, N (R13) 2, COR13, CO2R17, halo C1-C4 alkyl, aryl, heteroaryl, heterocyclyl, heteroarylalkyl, and heterocyclylalkyl, wherein heterocyclyl, heteroarylalkyl, and heterocyclylalkyl, are optionally substituted with one or more of the groups defined by R18 ; R12 is selected from-H, hydroxyl, oxo, Ci-Ce alkyl, hydroxyl C1-C6 alkyl-R11, C1-Cio alkoxy, amino, amino C1-C4 alkyl-R7, NHR7, N (R7) 2, C1-C6 alkyl-NHR7, C1-C6 alkyl-NHR8R9, C1-C6 alkyl-N(R8)2, C1-C6 alkyl-R11, C1-C6 alkyl-CO2R7R", C1-C6 alkoxy-R11, nitro, O-R10, C=O, COR11, CO2R11, SR10, SOR11, SO2R11, NHSO2R11, C1-C6 alkyl-SR10, halo, halo C1-C4 alkyl, halo C1-C4 alkoxy, hydroxy C1-C4 alkyl, hydroxy C1-C4 alkoxy, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, and Ci-Cio mono-and bicyclic cycloalkyl, wherein aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and heterocyclylalkyl, and Ci-Cio mono-and bicyclic cycloalkyl are optionally substituted with one or more of the groups defined by R18 ;

R13 and R14 are each independently selected from-H, oxo, C1-C6 alkyl, COR23, and aryl ; R15 and R16 are each independently selected from-H, aryl, arylalkyl, wherein aryl, arylalkyl, are optionally substituted with one or more of the groups defined by R24 ; R17 is selected from-H, C1-C6 alkyl, C1-C6 alkyl-R19, NHR19, aryl, heteroarylalkyl, and heterocyclylalkyl, wherein aryl is optionally substituted with one or more of the groups defined by R24 ; Ri$ is selected from-H, oxo, hydroxyl, C1-C10 alkyl, C1-C10 alkoxy, amino, amino C1-C6 alkyl, N (R19) 2, C1-C6 alkyl-N (R'9) 2, CO2R23, SR21, halo, halo C1-C4 alkyl, aryl, heteroaryl, and heterocyclyl, wherein aryl, heteroaryl, and heterocyclyl, are optionally substituted with one or more of the groups defined by R24 ; Ri9 and R20 are each independently selected from-H, C1-C6 alkyl, heteroaryl, heterocyclyl, wherein aryl, heteroaryl, and heterocyclyl, are optionally substituted with one or more of the groups defined by R30 ; R21 and R22 are each independently selected from-H and C1-C6 alkyl ; R23 is selected from-H and Cl-C6 alkyl ; R24 is selected from-H, C1-C6 alkyl, C1-C6 alkoxy, CO2R29, halo, and halo C1-C4 alkyl ; R29 is selected from-H, and C1-C6 alkyl ; R30 is selected from-H, aryl, heteroaryl, heterocyclyl, alkylaryl, arylalkyl, wherein aryl, heteroaryl, heterocyclyl, alkylaryl, and arylalkyl, are optionally substituted with one or more of the groups defined by R36 ; R36 is selected from-H and halo ; R2, R3, R4, R37 and R38 are each independently selected from an group; n is 0; and R3 and R4 optionally join to form a ring structure that is selected from :

[00059] The MK-2 inhibiting compounds that are described in formulas Hit, and in Tables I and 11 can be made by the methods that are described in the Examples below. Compounds that are not described specifically in the Examples can be made by reference to the methods used in the Examples, but with the substitution of starting compounds that are suitable for the compound that is desired.

[00060] The present invention also includes a method of inhibiting mitogen activated protein kinase-activated protein kinase-2, the method comprising contacting a mitogen activated protein kinase-activated protein kinase-2 with one or more of any of the MK-2 inhibiting compounds described herein. In one embodiment, the contacting of MK-2 with an MK- 2 inhibitory compound takes place inside a cell. The cell can be one of any type of organism, but is preferably an animal cell. Contacting can occur in vitro or in vivo, and the cell can be a living cell, or it can be non- living. When the contacting is carried out in vitro, the cell can be attached to other cells, or it can be a single cell, or clump of cells in suspension or on a solid medium. When the contacting is carried out in vivo, the MK-2 inhibitory compound can be administered as described below.

[00061] In one embodiment, the present invention provides a method for treating or preventing an MK-2 modulated disease or disorder in a subject, the method comprises contacting a mitogen activated protein kinase-activated protein kinase-2 in a subject with one or more of the MK- 2 inhibiting compounds that are described herein. A preferred MK-2 inhibiting compound for the present method is one having the structure

described by formula 1. In another perferred embodiment, the MK-2 inhibiting compound is one having the structure described by formula li.

[00062] The present invention also includes a method of inhibiting mitogen activated protein kinase-activated protein kinase-2 in a subject in need of such inhibition, the method comprising administering to the subject one or more of the MK-2 inhibiting compounds described herein.

[00063] The present invention also includes a method of preventing or treating a TNFa mediated disease or disorder in a subject, the method comprising administering to the subject an effective amount of one or more of the MK-2 inhibiting compounds described herein. In a preferred embodiment, the subject is one that is in need of such prevention or treatment.

[00064] The present methods can be practiced by the administration of any one or more of the present MK-2 inhibiting compounds. It is preferred tht the MK-2 inhibiting compound is one having an MK-2 tCso of less than about 10 uM, in an in vitro assay of MK-2 inhibitory activity, more preferred is a compound having an MK-2 ICso of less than about 1. 0 iM, yet more preferred is a compound having an MK-2 I of less than about 0.5 I1M.

[00065] It should be understood that the base forms, salts, pharmaceutical acceptable salts, and prodrugs of the compounds that are described herein, as well as isomeric forms, tautomers, racemic mixtures of the compounds, and the like, which have the same or similar activity as the compounds that are described, are to be considered to be included within the description of the compound.

[00066] The MK-2 inhibiting activity of any of the compounds described herein can be determined by any one of several methods that are well known to those having skill in the art of enzyme activity testing. One such method is described in detail in the general methods section of the examples. In addition, the efficacy of any one of the present MK-2 inhibiting compounds in therapeutic applications can be determined by

testing for inhibition of TNFa production in cell culture and in animal model assays. In general, it is preferred that the MK-2 inhibiting compounds of the present invention be capable of inhibiting the production and/or the release of TNFa in cell cultures and in animal models.

[00067] In the present method, the MK-2 inhibiting compounds that are described herein can be used as inhibitors of MAPKAP kinase-2. When this inhibition is for a therapeutic purpose, one or more of the present MK- 2 inhibitory compounds can be administered to a subject that is in need of MK-2 inhibition. As used herein, a"subject in need of MK-2 inhibition"is a subject who has, or who is at risk of contracting a TNFa mediated disease or disorder. TNFa mediated diseases and disorders are described in more detail below.

[00068] As described above, in an embodiment of the present method, a subject in need of prevention or treatment of a TNFa mediated disease or disorder is treated with one or more of the present MK-2 inhibiting compounds In one embodiment, the subject is treated with an effective amount of the MK-2 inhibiting compound. The effective amount can be an amount that is sufficient for preventing or treating the TNFa mediated disease or disorder.

[00069] The MK-2 inhibiting compound that is used in the subject method can be any MK-2 inhibiting compound that is described herein.

[00070] In the subject method, the MK-2 inhibiting compound can be used in any amount that is an effective amount. It is preferred, however, that the amount of the MK-2 inhibiting compound that is administered is within a range of about 0.1 mg/day per kilogram (kg) of the subject to about 1500 mg/day/kg. It is more preferred that the amount of the compound is within a range of about 1 mg/day/kg to about 500 mg/day/kg.

An amount that is within a range of about 10 mg/day/kg to about 400 mg/day/kg, is even more preferred.

[00071] When the term"about"is used herein in relation to a dosage amount of the MK-2 inhibiting compound, it is to be understood to mean an

amount that is within 10% by weight of the amount or range that is described. By way of example, "about 0.1-10 mg/day"includes all dosages within 0.9 to 11 mg/day.

[00072] In an embodiment of the present invention, a therapeutic composition is provided that contains at least one of the MK-2 inhibiting compounds that are described herein. A preferred therapeutic composition contains a therapeutically effective amount of a compound that is described by formula 1. In another embodiment, a preferred therapeutic composition is one having an MK-2 inhibiting compound that is described by formula 11.

[00073] In another embodiment of the present invention, a pharmaceutical composition that contains one or more of the present MK-2 inhibitors can be administered to a subject for the prevention or treatment of a TNFa mediated disease or disorder. The pharmaceutical composition includes an MK-2 inhibitor of the present invention and a pharmaceutical acceptable carrier. A preferred MK-2 inhibitor for use in the pharmaceutical composition is described by formula 1. In another embodiment, a preferred pharmaceutical composition is one having an MK-2 inhibiting compound that is described by formula 11.

[00074] In another embodiment, a kit can be produced that is suitable for use in the prevention or treatment of a TNFa mediated disease or disorder. The kit comprises a dosage form comprising at least one of the MK-2 inhibitors that is described herein in an amount which comprises a therapeutical effective amount.

[00075] As used herein, an"effective amount"means the dose or effective amount to be administered to a patient and the frequency of administration to the subject which is readily determined by one or ordinary skill in the art, by the use of known techniques and by observing results obtained under analogous circumstances. The dose or effective amount to be administered to a patient and the frequency of administration to the subject can be readily determined by one of ordinary skill in the art by the use of known techniques and by observing results obtained under

analogous circumstances. In determining the effective amount or dose, a number of factors are considered by the attending diagnostician, including but not limited to, the potency and duration of action of the compounds used, the nature and severity of the illness to be treated, as well as the sex, age, weight, general health and individual responsiveness of the patient to be treated, and other relevant circumstances.

[00076] The phrase"therapeutically-effective"indicates the capability of an agent to prevent, or improve the severity of, the disorder, while avoiding adverse side effects typically associated with alternative therapies. The phrase"therapeutically-effective"is to be understood to be equivalent to the phrase"effective for the treatment, prevention, or inhibition", and both are intended to qualify the amount of the MK-2 inhibitory compound for use in therapy which will achieve the goal of improvement in the severity of pain and inflammation and the frequency of incidence over treatment, while avoiding adverse side effects typically associated with alternative therapies.

[00077] Those skilled in the art will appreciate that dosages may also be determined with guidance from Goodman & Goldman's The Pharmacoloaical Basis of Therapeutics, Ninth Edition (1996), Appendix 11, pp. 1707-1711.

[00078] The frequency of dose will depend upon the half-life of the active components of the composition. If the active molecules have a short half life (e. g. from about 2 to 10 hours) it may be necessary to give one or more doses per day. Alternatively, if the active molecules have a long half-life (e. g. from about 2 to about 15 days) it may only be necessary to give a dosage once per day, per week, or even once every 1 or 2 months. A preferred dosage rate is to administer the dosage amounts described above to a subject once per day.

[00079] Daily dosages can vary within wide limits and will be adjusted to the individual requirements in each particular case. In general, for administration to adults, an appropriate daily dosage has been described above, although the limits that were identified as being preferred may be

exceeded if expedient. The daily dosage can be administered as a single dosage or in divided dosages.

[00080] For the purposes of calculating and expressing a dosage rate, all dosages that are expressed herein are calculated on an average amount-per-day basis irrespective of the dosage rate. For example, one 100 mg dosage of an MK-2 inhibitor taken once every two days would be expressed as a dosage rate of 50 mg/day. Similarly, the dosage rate of an ingredient where 50 mg is taken twice per day would be expressed as a dosage rate of 100 mg/day.

[00081] For purposes of calculation of dosage amounts, the weight of a normal adult human will be assumed to be 70 kg.

[00082] When the MK-2 inhibitor is supplied along with a pharmaceutical acceptable carrier, the pharmaceutical compositions that are described above can be formed. Pharmaceutical acceptable carriers include, but are not limited to, physiological saline, Ringer's, phosphate solution or buffer, buffered saline, and other carriers known in the art.

Pharmaceutical compositions may also include stabilizers, anti-oxidants, colorants, and diluents. Pharmaceutical acceptable carriers and additives are chosen such that side effects from the pharmaceutical compound are minimized and the performance of the compound is not canceled or inhibited to such an extent that treatment is ineffective.

[00083] The term"pharmacologically effective amount"shall mean that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by a researcher or clinician. This amount can be a therapeutical effective amount.

[00084] The term"pharmaceutically acceptable"is used herein to mean that the modified noun is appropriate for use in a pharmaceutical product.

Pharmaceutical acceptable cations include metallic ions and organic ions. More preferred metallic ions include, but are not limited to, appropriate alkali metal salts, alkaline earth metal salts and other physiological acceptable metal ions. Exemplary ions include aluminum,

calcium, lithium, magnesium, potassium, sodium and zinc in their usual valences. Preferred organic ions include protonated tertiary amines and quaternary ammonium cations, including in part, trimethylamine, diethylamine, N, V-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. Exemplary pharmaceutical acceptable acids include, without limitation, hydrochloric acid, hydroiodic acid, hydrobromic acid, phosphoric acid, sulfuric acid, methanesulfonic acid, acetic acid, formic acid, tartaric acid, maleic acid, malic acid, citric acid, isocitric acid, succinic acid, lactic acid, gluconic acid, glucuronic acid, pyruvic acid oxalacetic acid, fumaric acid, propionic acid, aspartic acid, glutamic acid, benzoic acid, and the like.

[00085] Also included in the compounds and compositions of the invention are the isomeric forms and tautomers and the pharmaceutically- acceptable salts of the present MK-2 inhibitors. Illustrative pharmaceutically acceptable salts are prepared from formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, stearic, salicylic, p-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, toluenesulfonic, 2-hydroxyethanesulfonic, sulfanilic, cyclohexylaminosulfonic, algenic, ß-hydroxybutyric, galactaric and galacturonic acids.

[00086] Suitable pharmaceutically-acceptable base addition salts of compounds of the present invention include metallic ion salts and organic ion salts. More preferred metallic ion salts include, but are not limited to, appropriate alkali metal (Group IA) salts, alkaline earth metal (Group IIA) salts and other physiological acceptable metal ions. Such salts can be made from the ions of aluminum, calcium, lithium, magnesium, potassium, sodium and zinc. Preferred organic salts can be made from tertiary amines and quaternary ammonium salts, including in part, trifluoroacetate, trimethylamine, diethylamine, N, N'-dibenzylethylenediamine,

chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N- methylglucamine) and procaine. All of the above salts can be prepared by those skilled in the art by conventional means from the corresponding compound of the present invention.

[00087] The method of the present invention is useful for, but not limited to, the prevention and/or treatment of diseases and disorders that are mediated by TNFa and/or mediated by MK-2, including pain, inflammation and/or arthritis. For example, the compounds described herein would be useful for the treatment of any inflammation-related disorder described below, such. as an analgesic in the treatment of pain and headaches, or as an antipyretic for the treatment of fever. The compounds described herein would also be useful for the treatment of an inflammation-related disorder in a subject suffering from such an inflammation-associated disorder.

[00088] As used herein, the terms"treating", "treatment","treated", or "to treat, "mean to alleviate symptoms, eliminate the causation either on a temporary or permanent basis. The term"treatment"includes alleviation, elimination of causation of pain and/or inflammation associated with, but not limited to, any of the diseases or disorders described herein. The terms"prevent", "prevention", "prevented", or"to prevent, "mean to prevent or to slow the appearance of symptoms associated with, but not limited to, any of the diseases or disorders described herein.

[00089] In preferred embodiments, the methods and compositions of the present invention encompass the prevention and/or treatment of pain, inflammation and inflammation-related disorders.

[00090] In other preferred embodiments, the methods and compositions of the present invention encompass the treatment of any one or more of the disorders selected from the group consisting of connective tissue and joint disorders, neoplasia disorders, cardiovascular disorders, otic disorders, ophthalmic disorders, respiratory disorders, gastrointestinal disorders, angiogenesis-related disorders, immunological disorders, allergic disorders, nutritional disorders, infectious diseases and disorders, endocrine disorders, metabolic disorders, neurological and

neurodegenerative disorders, psychiatric disorders, hepatic and biliary disorders, musculoskeletal disorders, genitourinary disorders, gynecologic and obstetric disorders, injury and trauma disorders, surgical disorders, dental and oral disorders, sexual dysfunction disorders, dermatologic disorders, hematological disorders, and poisoning disorders.

[00091] As used herein, the terms"neoplasia"and"neoplasia disorder", used interchangeably herein, refer to new cell growth that results from a loss of responsiveness to normal growth controls, e. g. to"neoplastic"cell growth. Neoplasia is also used interchangeably herein with the term "cancer"and for purposes of the present invention; cancer is one subtype of neoplasia. As used herein, the term"neoplasia disorder"also encompasses other cellular abnormalities, such as hyperplasia, metaplasia and dysplasia. The terms neoplasia, metaplasia, dysplasia and hyperplasia can be used interchangeably herein and refer generally to cells experiencing abnormal cell growth.

[00092] Both of the terms,"neoplasia"and"neoplasia disorder", refer to a"neoplasm"or tumor, which may be benign, premalignant, metastatic, or malignant. Also encompassed by the present invention are benign, premalignant, metastatic, or malignant neoplasias. Also encompassed by the present invention are benign, premalignant, metastatic, or malignant tumors. Thus, all of benign, premalignant, metastatic, or malignant neoplasia or tumors are encompassed by the present invention and may be referred to interchangeably, as neoplasia, neoplasms or neoplasia- related disorders. Tumors are generally known in the art to be a mass of neoplasia or"neoplastic"cells. Although, it is to be understood that even one neoplastic cell is considered, for purposes of the present invention to be a neoplasm or alternatively, neoplasia.

[00093] In still other preferred embodiments, the methods and compositions of the present invention encompass the prevention and treatment of the connective tissue and joint disorders selected from the group consisting of arthritis, rheumatoid arthritis, spondyloarthopathies, gouty arthritis, lumbar spondylarthrosis, carpal tunnel syndrome, canine

hip dysplasia, systemic lupus erythematosus, juvenile arthritis, osteoarthritis, tendonitis and bursitis.

[00094] In other preferred embodiments, the methods and compositions of the present invention encompass the prevention and treatment of the neoplasia disorders selected from the group consisting of acral lentiginous melanoma, actinic keratoses, adenocarcinoma, adenoid cycstic carcinoma, adenomas, familial adenomatous polyposis, familial polyps, colon polyps, polyps, adenosarcoma, adenosquamous carcinoma, adrenocortical carcinoma, AIDS-related lymphoma, anal cancer, astrocytic tumors, bartholin gland carcinoma, basal cell carcinoma, bile duct cancer, bladder cancer, brain stem glioma, brain tumors, breast cancer, bronchial gland carcinomas, capillary carcinoma, carcinoids, carcinoma, carcinosarcoma, cavernous, central nervous system lymphom, cerebral astrocytoma, cholangiocarcinoma, chondosarcoma, choriod plexus papilloma/carcinoma, clear cell carcinoma, skin cancer, brain cancer, colon cancer, colorectal cancer, cutaneous T-cell lymphoma, cystadenoma, endodermal sinus tumor, endometrial hyperplasia, endometrial stromal sarcoma, endometrioid adenocarcinoma, ependymal, epitheloid, esophageal cancer, Ewing's sarcoma, extragonadal germ cell tumor, fibrolamellar, focal nodular hyperplasia, gallbladder cancer, gastrinoma, germ cell tumors, gestational trophoblastic tumor, glioblastoma, glioma, glucagonoma, hemangiblastomas, hemangioendothelioma, hemangiomas, hepatic adenoma, hepatic adenomatosis, hepatocellular carcinoma, Hodgkin's lymphom, hypopharyngeal cancer, hypothalamic and visual pathway glioma, insulinoma, intaepithelial neoplasia, interepithelial squamous cell neoplasia, intraocular melanoma, invasive squamous cell carcinoma, large cell carcinoma, islet cell carcinoma, Kaposi's sarcoma, kidney cancer, laryngeal cancer, leiomyosarcoma, lentigo maligna melanomas, leukemia- related disorders, lip and oral cavity cancer, liver cancer, lung cancer, lymphom, malignant mesothelial tumors, malignant thymoma, medulloblastoma, medulloepithelioma, melanoma, meningeal, merkel cell

carcinoma, mesothelial, metastatic carcinoma, mucoepidermoid carcinoma, multiple myeloma/plasma cell neoplasm, mycosis fungoides, myelodysplastic syndrome, myeloproliferative disorders, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, neuroepithelial adenocarcinoma nodular melanoma, non-Hodgkin's lymphom, oat cell carcinoma, oligodendroglial, oral cancer, oropharyngeal cancer, osteosarcoma, pancreatic polypeptide, ovarian cancer, ovarian germ cell tumor, pancreatic cancer, papillary serous adenocarcinoma, pineal cell, pituitary tumors, plasmacytoma, pseudosarcoma, pulmonary blastoma, parathyroid cancer, penile cancer, pheochromocytoma, pineal and supratentorial primitive neuroectodermal tumors, pituitary tumor, plasma cell neoplasm, pleuropulmonary blastoma, prostate cancer, rectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, serous carcinoma, small cell carcinoma, small intestine cancer, soft tissue carcinomas, somatostatin-secreting tumor, squamous carcinoma, squamous cell carcinoma, submesothelial, superficial spreading melanoma, supratentorial primitive neuroectodermal tumors, thyroid cancer, undifferentiatied carcinoma, urethra cancer, uterine sarcoma, uveal melanoma, verrucous carcinoma, vaginal cancer, vipoma, vulvar cancer, Waldenstrom's macroglobulinemia, well differentiated carcinoma, and Wilm's tumor.

[00095] In other preferred embodiments, the methods and compositions of the present invention encompass the prevention and treatment of the cardiovascular disorders selected from the group consisting of myocardial ischemia, hypertension, hypotension, heart arrhythmias, pulmonary hypertension, hypokalemia, cardiac ischemia, myocardial infarction, cardiac remodeling, cardiac fibrosis, myocardial necrosis, aneurysm, arterial fibrosis, embolism, vascular plaque inflammation, vascular plaque rupture, bacterial-induced inflammation and viral induced inflammation, edema, swelling, fluid accumulation, cirrhosis of the liver, Bartter's syndrome, myocarditis, arteriosclerosis, atherosclerosis, calcification (such as vascular calcification and valvar calcification), coronary artery disease,

heart failure, congestive heart failure, shock, arrhythmia, left ventricular hypertrophy, angina, diabetic nephropathy, kidney failure, eye damage, vascular diseases, migraine headaches, plastic anemia, cardiac damage, diabetic cardiac myopathy, renal insufficiency, renal injury, renal arteriopathy, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, stroke, and headache.

[00096] In other preferred embodiments, the methods and compositions of the present invention encompass the prevention and treatment of the metabolic disorders selected from the group consisting of obesity, overweight, type I and type II diabetes, hypothyroidism, and hyperthyroidism.

[00097] In other preferred embodiments, the methods and compositions of the present invention encompass the prevention and treatment of the respiratory disorders selected from the group consisting of asthma, bronchitis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, pulmonary edema, pulmonary embolism, pneumonia, pulmonary sarcoisosis, silicosis, pulmonary fibrosis, respiratory failure, acute respiratory distress syndrome and emphysema.

[00098] In other preferred embodiments, the methods and compositions of the present invention encompass the prevention and treatment of the angiogenesis-related disorders selected from the group consisting of angiofibroma, neovascular glaucoma, arteriovenous malformations, arthritis, osler-weber syndrome, atherosclerotic plaques, psoriasis, corneal graft neovascularization, pyogenic granuloma, delayed wound healing, retrolental fibroplasias, diabetic retinopathy, scleroderma, granulations, solid tumors, hemangioma, trachoma, hemophilic joints, vascular adhesions, hypertrophic scars, age-related macular degeneration, coronary artery disease, stroke, cancer, AIDS complications, ulcers and infertility.

[00099] In other preferred embodiments, the methods and compositions of the present invention encompass the prevention and treatment of the infectious diseases and disorders selected from the group consisting of

viral infections, bacterial infections, prion infections, spirochetes infections, mycobacterial infections, rickettsial infections, chlamydial infections, parasitic infections and fungal infections.

[000100] In still further embodiments, the methods and compositions of the present invention encompass the prevention and treatment of the infectious diseases and disorders selected from the group consisting of hepatitis, HIV (AIDS), small pox, chicken pox, common cold, bacterial influenza, viral influenza, warts, oral herpes, genital herpes, herpes simplex infections, herpes zoster, bovine spongiform encephalopathy, septicemia, streptococcus infections, staphylococcus infections, anthrax, severe acquired respiratory syndrome (SARS), malaria, African sleeping sickness, yellow fever, chlamydia, botulism, canine heartworm, rocky mountain spotted fever, lyme disease, cholera, syphilis, gonorrhea, encephalitis, pneumonia, conjunctivitis, yeast infections, rabies, dengue fever, Ebola, measles, mumps, rubella, West Nile virus, meningitis, gastroenteritis, tuberculosis, hepatitis, and scarlet fever.

[000101] In other preferred embodiments, the methods and compositions of the present invention encompass the prevention and treatment of the neurological and neurodegenerative disorders selected from the group consisting of headaches, migraine headaches, Alzheimer's disease, Parkinson's disease, dementia, memory loss, senility, amyotrophy, ALS, amnesia, seizures, multiple sclerosis, muscular dystrophies, epilepsy, schizophrenia, depression, anxiety, attention deficit disorder, hyperactivity, bulimia, anorexia nervosa, anxiety, autism, phobias, spongiform encephalopathies, Creutzfeldt-Jakob disease, Huntington's Chorea, ischemia, obsessive-compulsive disorder, manic depression, bipolar disorders, drug addiction, alcoholism and smoking addiction.

[000102] In other preferred embodiments, the methods and compositions of the present invention encompass the prevention and treatment of the dermatological disorders selected from the group consisting of acne, psoriasis, eczema, burns, poison ivy, poison oak and dermatitis.

[000103] In other preferred embodiments, the methods and compositions of the present invention encompass the prevention and treatment of the surgical disorders selected from the group consisting of pain and swelling following surgery, infection following surgery and inflammation following surgery.

[000104] In other preferred embodiments, the methods and compositions of the present invention encompass the prevention and treatment of the gastrointestinal disorders selected from the group consisting of inflammatory bowel disease, irritable bowel syndrome, Crohn's disease, gastritis, irritable bowel syndrome, diarrhea, constipation, dysentery, ulcerative colitis, gastric esophageal reflux, gastric ulcers, gastric varices, ulcers, and heartburn.

[000105] In other preferred embodiments, the methods and compositions of the present invention encompass the prevention and treatment of the otic disorders selected from the group consisting of otic pain, inflammation, otorrhea, otalgia, fever, otic bleeding, Lermoyez's syndrome, Meniere's disease, vestibular neuronitis, benign paroxysmal positional vertigo, herpes zoster oticus, Ramsay Hunt's syndrome, viral neuronitis, ganglionitis, geniculate herpes, labyrinthitis, purulent labyrinthitis, viral endolymphatic labyrinthitis, perilymph fistulas, noise-induced hearing loss, presbycusis, drug-induced ototoxicity, acoustic neuromas, aerotitis media, infectious myringitis, bullous myringitis, otitis media, otitis media with effusion, acute otitis media, secretory otitis media, serous otitis media, acute mastoiditis, chronic otitis media, otitis extema, otosclerosis, squamous cell carcinoma, basal cell carcinoma, nonchromaffin paragangliomas, chemodectomas, globus jugulare tumors, globus tympanicum tumors, external otitis, perichondritis, aural eczematoid dermatitis, malignant external otitis, subperichondrial hematoma, ceruminomas, impacted cerumen, sebaceous cysts, osteomas, keloids, otalgia, tinnitus, vertigo, tympanic membrane infection, typanitis, otic furuncles, otorrhea, acute mastoiditis, petrositis, conductive and sensorineural hearing loss, epidural abscess, lateral sinus thrombosis,

subdural empyema, otitic hydrocephalus, Dandy's syndrome, bullous myringitis, cerumen-impacted, diffuse external otitis, foreign bodies, keratosis obturans, otic neoplasm, otomycosis, trauma, acute barotitis media, acute eustachian tube obstruction, post-otic surgery, postsurgical otalgia, cholesteatoma, conductive and sensorineural hearing loss, epidural abscess, lateral sinus thrombosis, subdural empyema and otitic hydrocephalus.

[000106] In other preferred embodiments, the methods and compositions of the present invention encompass the prevention and treatment of the ophthalmic disorders selected from the group consisting of retinopathies, uveitis, ocular photophobia, acute injury to the eye tissue, conjunctivitis, age-related macular degeneration diabetic retinopathy, detached retina, glaucoma, vitelliform macular dystrophy type 2, gyrate atrophy of the choroid and retina, conjunctivitis, corneal infection, fuchs'dystrophy, iridocorneal endothelial syndrome, keratoconus, lattice dystrophy, map- dot-fingerprint dystrophy, ocular herpes, pterygium, myopia, hyperopia, and cataracts.

[000107] In other preferred embodiments, the methods and compositions of the present invention encompass the prevention and treatment of menstrual cramps, kidney stones, minor injuries, wound healing, vaginitis, candidiasis, sinus headaches, tension headaches, dental pain, periarteritis nodosa, thyroiditis, myasthenia gravis, multiple sclerosis, sarcoidosis, nephrotic syndrome, Bahcet's syndrome, polymyositis, gingivitis, hypersensitivity, swelling occurring after injury, closed head injury, liver disease, and endometriosis.

[000108] As used herein, the terms"TNFa mediated disease or disorder" are meant to include, without limitation, each of the symptoms or diseases that are mentioned above.

[000109] The term"subject"for purposes of treatment includes any human or animal subject who is in need of the prevention of or treatment of any one of the TNFa mediated diseases or disorders. The subject is typically a mammal."Mammal", as that term is used herein, refers to any

animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, cattle, etc. , Preferably, the mammal is a human.

[000110] For methods of prevention, the subject is any human or animal subject, and preferably is a subject that is in need of prevention and/or treatment of a TNFa mediated diseases or disorders. The subject may be a human subject who is at risk of obtaining a TNFa mediated disease or disorder, such as those described above. The subject may be at risk due to genetic predisposition, sedentary lifestyle, diet, exposure to disorder- causing agents, exposure to pathogenic agents and the like.

[000111] The subject pharmaceutical compositions may be administered enterally and parenterally. Parenteral administration includes subcutaneous, intramuscular, intradermal, intramammary, intravenous, and other administrative methods known in the art. Enteral administration includes solution, tablets, sustained release capsules, enteric coated capsules, and syrups. When administered, the pharmaceutical composition may be at or near body temperature.

[000112] In particular, the pharmaceutical compositions of the present invention can be administered orally, for example, as tablets, coated tablets, dragees, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutical acceptable excipients which are suitable for the manufacture of tablets. These excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, maize starch, or alginic

acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.

[000113] Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredients are mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredients are present as such, or mixed with water or an oil medium, for example, peanut oil, liquid paraffin, or olive oil.

[000114] Aqueous suspensions can be produced that contain the MK-2 inhibitors in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl-cellulose, sodium alginate, polyvinylpyrrolidone gum tragacanth and gum acacia; dispersing or wetting agents may be naturally- occurring phosphatides, for example lecithin, or condensation products of an alkylen oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyoxyethylene sorbitan monooleate.

[000115] The aqueous suspensions may also contain one or more preservatives, for example, ethyl or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, or one or more sweetening agents, such as sucrose or saccharin.

[000116] Oily suspensions may be formulated by suspending the active ingredients in an omega-3 fatty acid, a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol.

[000117] Sweetening agents, such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation.

These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.

[000118] Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above.

Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.

[000119] Syrups and elixirs containing the novel MK-2 inhibitory compounds may be formulated with sweetening agents, for example glycerol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.

[000120] The subject compositions can also be administered parenterally, either subcutaneously, or intravenously, or intramuscularly, or intrasternally, or by infusion techniques, in the form of sterile injectable aqueous or olagenous suspensions. Such suspensions may be formulated according to the known art using those suitable dispersing of wetting agents and suspending agents which have been mentioned above or other acceptable agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally- acceptable diluent or solvent, for example as a solution in 1, 3-butanediol.

Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending

medium. For this purpose, any bland fixed oil may be employed including synthetic mono-, or di-, glycerides. In addition, n-3 polyunsaturated fatty acids may find use in the preparation of injectables.

[000121] The subject compositions can also be administered by inhalation, in the form of aerosols or solutions for nebulizers, or rectally, in the form of suppositories prepared by mixing the drug with a suitable non- irritating excipient which is solid at ordinary temperature but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and poly-ethylene glycols.

[000122] The novel compositions can also be administered topically, in the form of creams, ointments, jellies, collyriums, solutions or suspensions.

[000123] Various delivery systems include capsules, tablets, and gelatin capsules, for example.

[000124] The following examples describe preferred embodiments of the invention. Other embodiments within the scope of the claims herein will be apparent to one skilled in the art from consideration of the specification or practice of the invention as disclosed herein. It is intended that the specification, together with the examples, be considered to be exemplary only, with the scope and spirit of the invention being indicated by the claims which follow the examples. In the examples all percentages are given on a weight basis unless otherwise indicated.

GENERAL INFORMATION FOR PREPARATION METHODS: [000125] Unless otherwise noted, reagents and solvents were used as received from commercial suppliers.

[000126] NMR analysis : [000127] Proton nuclear magnetic resonance spectra were obtained on a Varian Unity Innova 400, a Varian Unity Innova 300 a Varian Unity 300, a Bruker AMX 500 or a Bruker AV-300 spectrometer. Chemical shifts are given in ppm (8) and coupling constants, J, are reported in Hertz.

Tetramethylsilane was used as an internal standard for proton spectra and the solvent peak was used as the reference peak for carbon spectra.

Mass spectra were obtained on a Perkin Elmer Sciex 100 atmospheric

pressure ionization (APCI) mass spectrometer, a Finnigan LCQ Duo LCMS ion trap electrospray ionization (ESI) mass spectrometer, a PerSeptive Biosystems Mariner TOF HPLC-MS (ESI), or a Waters ZQ mass spectrometer (ESI).

[000128] Determination of MK-2 IC5o : [000129] Recombinant MAPKAPK2 was phosphorylated at a concentration of 42-78 tM by incubation with 0. 23 zip of active p38a in 50 mM HEPES, 0.1 mM EDTA, 10 mM magnesium acetate, and 0.25 mM ATP, pH 7.5 for one hour at 30°C.

[000130] The phosphorylation of HSP-peptide (KKKALSRQLSVAA) by MAPKAPK2 was measured using an anion exchange resin capture assay method. The reaction was carried out in 50 mM ß-glycerolphosphate, 0.04 % BSA, 10 mM magnesium acetate, 2% DMSO and 0.8 mM dithiotheritol, pH 7.5 in the presence of the HSP-peptide with 0.2 µCi [γ33P] ATP and 0.03mM ATP. The reaction was initiated by the addition of 15 nM MAPKAPK2 and was allowed to incubate at 30°C for 30 min. The reaction was terminated and [γ33P] ATP was removed from solution by the addition of 150 je of AG 1X8 ion exchange resin in 900 mM sodium formate pH 3.0.

A 50 J a) iquot of head volume was removed from the quenched reaction mixture and added to a 96-well plate, 1501l1 of Microscint-40 (Packard) was added and the amount of phosphorylated-peptide was determined.

Allow the Microscint to sit in the plates for 60 minutes prior to counting.

[000131] Compounds are evaluated as potential inhibitors of the MK2 kinase by measuring their effects on MK2 phosphorylation of the peptide substrate. Compounds may be screened initially at two concentrations prior to determination of IC50 values. Screening results are expressed as percent inhibition at the concentrations of compound tested. For IC50 value determinations, compounds are tested at six concentrations in ten- fold serial dilutions with each concentration tested in triplicate. Results are expressed as IC50 values in micromolar. The assay is performed at a final concentration of 2% DMSO.

[000132] U937 Cell TNFa release assay 000133] The human monocyte-like cell line, U937 (ATCC &num CRL-1593. 2), is cultured in RPM11640 media with 10% heat-inactivated fetal calf serum (GIBCO), glutamine and pen/strep at 37°C and 5% C02. Differentiation of U937 to monocytic/macrophage-like cells is induced by the addition of phorbol12-myristate 13-acetate (Sigma) at final concentration of 20 ng/ml to a culture of U937 cells at #0. 5 million cells/ml and incubated for 24 hrs.

The cells are centrifuged, washed with PBS and resuspended in fresh media without PMA and incubated for 24 hrs. Cells adherent to the culture flask are harvested by scraping, centrifugation, and resuspended in fresh media to 2 million cells/ml, and 0.2 ml is aliquote to each of 96 wells in flat-bottom plate. Cells are then incubated for an additional 24 hrs to allow for recovery. The media is removed from the cells, and 0.1 mi of fresh media is added per well. 0.05 mi of serially diluted compound or control vehicle (Media with DMSO) is added to the cells. The final DMSO concentration does not exceed 1 %. After 1 hr incubation, 0.05 ml of 400ng/ml LPS (E Coli serotype 0111 : B4, Sigma) in media is added for final concentration of 100 ng/ml. Cells are incubated at 37°C for 4 hrs. After 4hrs incubation, supernatants are harvest and assayed by ELISA for the presence of TNFa.

[000134] U937 cell TNFa ELISA [000135] ELISA plates (NUNC-ImmunoT"Plate MaxisorbTM Surface) were coated with purified mouse monoclonal IgG1 anti-human TNFa antibody (R&D Systems &num MAB610 ; 1.25 ug/ml in sodium bicarbonate pH 8.0, 0.1 ml/well) and incubated at 4°C. Coating solution was aspirated the following day and wells were blocked with 1 mg/ml gelatin in PBS (plus 1x thimerasol) for 2 days at 4°C. Prior to using, wells were washed 3x with wash buffer (PBS with 0.05% Tween). Cultured media samples were diluted in EIA buffer (5 mg/ml bovine-globulin, 1 mg/ml gelatin, 1 ml/l Tween-20,1 mg/ml thimerasol in PBS), added to wells (0.1 ml/well) in triplicate and allowed to incubate for 1.5 hr at 37°C in a humidified

chamber. Plates were again washed and 0.1 ml/well of a mixture of rabbit anti-human TNFa polyclonal antibodies in EIA buffer (1: 400 dilution of Sigma #T8300, and 1: 400 dilution of Calbiochem #654250) was added for 1 hr at 37°C. Plates were washed as before and peroxidase-conjugated goat anti-rabbit IgG (H+L) antibody (Jackson ImmunoResearch #111-035- 144,1 ug/ml in EIA buffer, 0.1 mUwell) was added for 45 min. After final washing, plates were developed with peroxidase-ABTS solution (Kirkegaard/Perry &num 50-66-01, 0.1 ml/well). Enzymatic conversion of ABTS to colored product was measured after 5-30 minutes using a SpectroMax 340 spectrophotometer (Molecular Devices) at 405 nm. TNF levels were quantitated from a recombinant human TNFa (R&D Systems &num 210-TA- 010) standard curve using a quadratic parameter fit generated by SoftMaxPRO software. ELISA sensitivity was approximately 30 pg TNF/ml. IC50 values for compounds were generated using BioAssay Solver.

[000136] Lipopolysaccharide (LPS)-induced TNFa Production.

[000137] Adult male 225-250 gram Lewis rats (Harlan Sprague-Dawley) were used. Rats were fasted 18 hr prior to oral dosing, and allowed free access to water throughout the experiment. Each treatment group consisted of 5 animals.

[000138] Compounds were prepared as a suspension in a vehicle consisting of 0.5% methylcellulose, 0.025% Tween-20 in PBS.

Compounds or vehicle were orally administered in a volume of 1 ml using an 18 gauge gavage needle. LPS (E. coli serotype 0111 : B4, Lot #39H4103, Cat. # L-2630, Sigma) was administered 1-4 hr later by injection into the penile vein at a dose of 1 mg/kg in 0.5 ml sterile saline.

Blood was collected in serum separator tubes via cardiac puncture 1.5 hr after LPS injection, a time point corresponding to maximal TNFa production. After clotting, serum was withdrawn and stored at-20°C until assay by ELISA (described below).

[000139] Rat LPS TNFa ELISA [000140] ELISA plates (NUNC-lmmuno Plate Maxisorb Surface) were coated with 0.1 ml per well of a Protein G purified fraction of a 2.5 ug/ml of hamster anti-mouse/rat TNFa monoclonal antibody TN19. 12 (2.5 ug/ml in PBS, 0.1 ml/well). The hybridoma cell line was kindly provided by Dr. Robert Schreiber, Washington University. Wells were blocked the following day with 1 mg/ml gelatin in PBS. Serum samples were diluted in a buffer consisting of 5 mg/ml bovine-globulin, 1 mg/ml gelatin, 1 ml/I Tween-20,1 mg/ml thimerasol in PBS, and 0.1 ml of diluted serum was added wells in duplicate and allowed to incubate for 2 hr at 37°C. Plates were washed with PBS-Tween, and 0.1 ml per well of a 1: 300 dilution of rabbit anti-mouse/rat TNFa antibody (BioSource International, Cat.

#AMC3012) was added for 1.5 hr at 37°C. Plates were washed, and a 1: 1000 fold dilution of peroxidase-conjugated donkey anti-rabbit IgG antibody (Jackson ImmunoResearch, Cat. #711-035-152) was added for 45 min. After washing, plates were developed with 0.1 ml of ABTS- peroxide solution (Kirkegaard/Perry, Cat. #50-66-01). Enzymatic conversion of ABTS to colored product was measured after-30 minutes using a SpectroMax 340 spectrophotometer (Molecular Devices Corp. ) at 405 nm. TNF levels in serum were quantitated from a recombinant rat TNFa (BioSource International, Cat. #PRC3014) standard curve using a quadratic parameter fit generated by SoftMaxPRO software. ELISA sensitivity was approximately 30 pg TNF/ml. Results are expressed in percent inhibition of the production of TNFa as compared to blood collected from control animals dosed only with vehicle.

[000141] NMR analysis : [000142] Proton nuclear magnetic resonance spectra were obtained on a Varian Unity Innova 400, a Varian Unity Innova 300 a Varian Unity 300, a Bruker AMX 500 or a Bruker AV-300 spectrometer. Chemical shifts are given in ppm (8) and coupling constants, J, are reported in Hertz.

Tetramethylsilane was used as an internal standard for proton spectra and

the solvent peak was used as the reference peak for carbon spectra.

Mass spectra were obtained on a Perkin Elmer Sciex 100 atmospheric pressure ionization (APCI) mass spectrometer, a Finnigan LCQ Duo LCMS ion trap electrospray ionization (ESI) mass spectrometer, a PerSeptive Biosystems Mariner TOF HPLC-MS (ESI), or a Waters ZQ mass spectrometer (ESI).

[000143] Determination of MK-2 Iso : [000144] Recombinant MAPKAPK2 was phosphorylated at a concentration of 42-781lM by incubation with 0.23 jiM of active p38a in 50 mM HEPES, 0.1 mM EDTA, 10 mM magnesium acetate, and 0.25 mM ATP, pH 7.5 for one hour at 30°C.

[000145] The phosphorylation of HSP-peptide (KKKALSRQLSVAA) by MAPKAPK2 was measured using an anion exchange resin capture assay method. The reaction was carried out in 50 mM p-gtyceroiphosphate, 0.04 % BSA, 10 mM magnesium acetate, 2% DMSO and 0.8 mM dithiotheritol, pH 7.5 in the presence of the HSP-peptide with 0. 21lCi [f3P] ATP and 0.03mM ATP. The reaction was initiated by the addition of 15 nM MAPKAPK2 and was allowed to incubate at 30°C for 30 min. The reaction was terminated and [f3P] ATP was removed from solution by the addition of 150 Ll of AG 1X8 ion exchange resin in 900 mM sodium formate pH 3.0.

A 501l1 aliquot of head volume was removed from the quenched reaction mixture and added to a 96-well plate, 150 ill of Microscint-40 (Packard) was added and the amount of phosphorylated-peptide was determined.

Allow the Microscint to sit in the plates for 60 minutes prior to counting.

[000146] Compounds are evaluated as potential inhibitors of the MK-2 kinase by measuring their effects on MK-2 phosphorylation of the peptide substrate. Compounds may be screened initially at two concentrations prior to determination of IC50 values. Screening results are expressed as percent inhibition at the concentrations of compound tested. For IC50 value determinations, compounds are tested at six concentrations in ten- fold serial dilutions with each concentration tested in triplicate. Results are

expressed as IC5o values in micromolar. The assay is performed at a final concentration of 2% DMSO.

[000147] U937 Cell TNFa release assay [000148] The human monocyte-like cell line, U937 (ATCC #CRL-1593. 2), is cultured in RPMI1640 media with 10% heat-inactivated fetal calf serum (GIBCO), glutamine and pen/strep at 37°C and 5% CO2. Differentiation of U937 to monocytic/macrophage-like cells is induced by the addition of phorbol12-myristate 13-acetate (Sigma) at final concentration of 20 ng/ml to a culture of U937 cells at-0. 5 million cells/ml and incubated for 24 hrs.

The cells are centrifuged, washed with PBS and resuspended in fresh media without PMA and incubated for 24 hrs. Cells adherent to the culture flask are harvested by scraping, centrifugation, and resuspended in fresh media to 2 million cells/ml, and 0.2 ml is aliquote to each of 96 wells in flat-bottom plate. Cells are then incubated for an additional 24 hrs to allow for recovery. The media is removed from the cells, and 0.1 ml of fresh media is added per well. 0.05 ml of serially diluted compound or control vehicle (Media with DMSO) is added to the cells. The final DMSO concentration does not exceed 1 %. After 1 hr incubation, 0.05 ml of 400ng/ml LPS (E Coli serotype 0111 : B4, Sigma) in media is added for final concentration of 100 ng/ml. Cells are incubated at 37°C for 4 hrs. After 4hrs incubation, supernatants are harvest and assayed by ELISA for the presence of TNFa.

[000149] U937 cell TNFa ELISA [000150] ELISA plates (NUNC-ImmunoTM Plate Maxisorb Surface) were coated with purified mouse monoclonal IgG1 anti-human TNFa antibody (R&D Systems &num MAB610 ; 1. 25 pg/ml in sodium bicarbonate pH 8.0, 0.1 ml/well) and incubated at 4°C. Coating solution was aspirated the following day and wells were blocked with 1 mg/ml gelatin in PBS (plus 1x thimerasol) for 2 days at 4°C. Prior to using, wells were washed 3x with wash buffer (PBS with 0.05% Tween). Cultured media samples were diluted in EIA buffer (5 mg/ml bovine gamma-globulin, 1 mg/ml gelatin, 1 mill Tween-20,1 mg/ml thimerasol in PBS), added to wells (0.1 ml/well) in

triplicate and allowed to incubate for 1.5 hr at 37°C in a humidified chamber. Plates were again washed and 0.1 ml/well of a mixture of rabbit anti-human TNFa polyclonal antibodies in EIA buffer (1: 400 dilution of Sigma #T8300, and 1: 400 dilution of Calbiochem #654250) was added for 1 hr at 37°C. Plates were washed as before and peroxidase-conjugated goat anti-rabbit IgG (H+L) antibody (Jackson ImmunoResearch #111-035- 144,1 ug/ml in EIA buffer, 0.1 ml/well) was added for 45 min. After final washing, plates were developed with peroxidase-ABTS solution (Kirkegaard/Perry #50-66-01, 0.1 ml/well). Enzymatic conversion of ABTS to colored product was measured after 5-30 minutes using a SpectroMax 340 spectrophotometer (Molecular Devices) at 405 nm. TNF levels were quantitated from a recombinant human TNFa (R&D Systems &num 210-TA- 010) standard curve using a quadratic parameter fit generated by SoftMaxPRO software. ELISA sensitivity was approximately 30 pg TNF/ml. IC50 values for compounds were generated using BioAssay Solver.

[000151] Lipopolysaccharide (LPS)-Induced TNFa Production.

[000152] Adult male 225-250 gram Lewis rats (Harlan Sprague-Dawley) were used. Rats were fasted 18 hr prior to oral dosing, and allowed free access to water throughout the experiment. Each treatment group consisted of 5 animals.

[000153] Compounds were prepared as a suspension in a vehicle consisting of 0.5% methylcellulose, 0.025% Tween-20 in PBS.

Compounds or vehicle were orally administered in a volume of 1 mi using an 18 gauge gavage needle. LPS (E. coXi serotype 0111 : B4, Lot #39H4103, Cat. # L-2630, Sigma) was administered 1-4 hr later by injection into the penile vein at a dose of 1 mg/kg in 0.5 ml sterile saline.

Blood was collected in serum separator tubes via cardiac puncture 1.5 hr after LPS injection, a time point corresponding to maximal TNFa production. After clotting, serum was withdrawn and stored at-20°C until assay by ELISA (described below).

[000154] Rat LPS TNFa ELISA [000155] ELISA plates (NUNC-ImmunoTM Plate MaxisorbT" Surface) were coated with 0.1 ml per well of a Protein G purified fraction of a 2.5 ug/ml of hamster anti-mouse/rat TNFa monoclonal antibody TN19.12 (2.5 ug/ml in PBS, 0.1 ml/well). The hybridoma cell line was provided by Dr.

Robert Schreiber, Washington University. Wells were blocked the following day with 1 mg/ml gelatin in PBS. Serum samples were diluted in a buffer consisting of 5 mg/ml bovine gamma-globulin, 1 mg/ml gelatin, 1 mt/t Tween-20, 1 mg/ml thimerasol in PBS, and 0.1 ml of diluted serum was added wells in duplicate and allowed to incubate for 2 hr at 37°C.

Plates were washed with PBS-Tween, and 0.1 ml per well of a 1: 300 dilution of rabbit anti-mouse/rat TNFa antibody (BioSource International, Cat. #AMC3012) was added for 1.5 hr at 37°C. Plates were washed, and a 1: 1000 fold dilution of peroxidase-conjugated donkey anti-rabbit IgG antibody (Jackson ImmunoResearch, Cat. #711-035-152) was added for 45 min. After washing, plates were developed with 0.1 mi of ABTS- peroxide solution (Kirkegaard/Perry, Cat. #50-66-01). Enzymatic conversion of ABTS to colored product was measured after-30 minutes using a SpectroMax 340 spectrophotometer (Molecular Devices Corp. ) at 405 nm. TNF levels in serum were quantitated from a recombinant rat TNFa (BioSource International, Cat. #PRC3014.) standard curve using a quadratic parameter fit generated by SoftMaxPRO software. ELISA sensitivity was approximately 30 pg TNF/ml. Results are expressed in percent inhibition of the production of TNFa as compared to blood collected from control animals dosed only with vehicle.

[000156] Synthesis of MK-2 inhibiting compounds of the present invention : [000157] Unless otherwise noted, reagents and solvents were used as received from commercial suppliers. Proton nuclear magnetic resonance spectra were obtained on a Varian-300, Bruker AMX 500 or a Bruker AV- 300 spectrometer. Spectra are given in ppm (5) and coupling constants, J,

are reported in Hertz. Tetramethylsilane was used as an internal standard for proton spectra and the solvent peak was used as the reference peak for carbon spectra. 3-Bromobenzotrifluoride was used as an internal standard in 19F nuclear magnetic resonance spectra to calibrate the amount of TFA for TFA salts. Mass spectra were obtained on a Mariner electrospray ionization (ESI), Perkin Elmer Sciex 100 atmospheric pressure ionization (APCI) mass spectrometer, Hewlett Packard G1947A LCMS ion trap ionization (ESI), or a Finnigan LCQ Duo LCMS ion trap electrospray ionization (ESI) mass spectrometer. Thin-layer chromatography (TLC) was performed using Analtech silica gel plates and visualized by ultraviolet (UV) light. HPLC analyses were obtained using a YMC CombiScreen ODS-A (50 x 4.6 mm) with UV with diode array detection, using aqueous TFA in acetonitrile as the eluent on a Hewlett Packard 1100, or a Phenomenex C18 Luna column (150 x 4.6 mm) with UV detection at 254 nm, using aqueous TFA in acetonitrile as the eluent on a Varian Prostar. Purification using preparative HPLC was performed using a Phenomenex C18 Luna column (250 x 22 mm) with UV detection at 254 nm, using aqueous TFA in acetonitrile as the eluent on a Varian Prostar, or using a Waters Deltapack C 18 column (47 x 300 mm) with UV detection at 254 nm, using aqueous TFA in acetonitrile as the eluent on a Gilson. All reactions were carried out under nitrogen unless specified.

EXAMPLE 1 [000158] This example illustrates the production of ethyl 1- (2- aminoethyl)-3-pyridin-4-yl-1 H-pyrazole-5-carboxylate dihydrochloride.

[000159] Step 1. The preparation of lithium (1 Z)-4-ethoxy-3, 4-dioxo-1- pyridin-4-yibut-1-en-1-olate.

[000160] 4-Acetylpyridine (960.4 g, 7.93 mole) and diethyl oxylate (1170.8 g, 8.08 mole) were dissolved in 8 L toluene in a 22 L reactor. The reaction was cooled to-78 °C under N2, and a 1 M solution of Lithium bis (trimetnylsilyl) amide in THF (8.08 L, 8.08 mole) was added in a medium stream over 45 minutes, keeping the temperature near 10°C.

When the addition was complete, the reaction was allowed to warm to

room temperature with stirring for 18 hours. The reaction mixture was filtered, and the solid washed with toluene followed by diethyl ether. The product was air dried and desiccated to afford 1562.5 g of the lithium salt of the diketoester (87% yield).

[000161] Step Lithium (lZ)-4-ethoxy-3, 4-dioxo-1-pyridin-4-ylbut-1-en- 1-olate (1562.5 g, 6.88 mole) was placed in a 22 L reactor and slurried in 7 L of ethanol. The slurry was heated to 63°C under N2 with mixing. The heating mantle was removed, and the temperature stabilized at about 63°C. To this mixture hydrazine monohydrochloride (476.3 g, 6.95) was added. After a few minutes a slow exotherm started. An ice/water bath was applied when the reaction reached 80°C. The ice bath was removed, and the temperature held steady at 80°C. The heating mantle was re- installed, and the reaction was maintained at 80. 5°C (reflux) for one hour.

The reaction was cooled and stirred at room temperature for 18 hours.

The mixture was filtered, and the solids washed with ethanol followed by diethyl ether. The product was air dried and desiccated to afford 1365.6 g (91 % yield) of the desired pyrazol as a tan solid. LCMS showed a single peak with m/z 218 (M+H). 1 H NMR (DMSO-d6/300 MHz) 8 8.61 (d, 2H), 7.83 (d, 2H), 7.44 (s, 1 H), 4.31 (q, 2H), 1.30 (t, 3H).

[000162] Step 3. To a cooled (0°C) solution of ethyl 3-pyridin-4-yl-1 H- pyrazole-5-carboxylate (5.57 g, 25.6 mmol) in anhydrous DMF (140 mL) was added lithium f-butoxide (1 M in THF, 38.5 mL) dropwise. The reaction stirred for 30 min, then a solution of tert-butyl 2- bromoethylcarbamate (8.62 g, 38.5 mmol) and sodium iodide (5.77 g, 38.5 mmol) in anhydrous DMF (25 mL) was added dropwise. The reaction was allowed to stir and warm to room temperature for 20 h. The reaction was poured into water and brine, extracted with ethyl acetate, dried over MgS04, and concentrated to an orange solid. The solid was rinsed with diethyl ether to afford an off-white solid (5.49 g, 59.5% yield) : 1H NMR (DMSO-d6/300 MHz) 6 8.59 (d, 2H), 7.82 (d, 2H), 7.51 (s, 1 H), 6.90 (t, 1 H), 4.58 (t, 2H), 4.33 (q, 2H), 3.38-3. 33 (m, 2H), 1.34 (t, 3H), 1.27 (s, 9H); HRMS calculated for (M + H) 361.1870, found 361.1890.

EXAMPLE 2 [000163] This example illustrates the production of ethyl 1- (2-amino- ethyl)-3-pyridin-4-yl-1 H-pyrazole-5-carboxylate dihydrochloride.

[000164] To a flask charged with ethyl 1-{2-[(tert-butoxycarbonyl) amino3 ethyl}-3-pyridin-4-yl-1 H-pyrazole-5-carboxylate (5.39 g, 15.0 mmol) was added 4N HCI/dioxane (20 mL). After 1 h the reaction mixture was filtered and rinsed with diethyl ether to afford an off-white solid (5.02 g, 100% yield) : 1 H NMR (DMSO-d6/300 MHz) 8 8.93 (d, 2H), 8. 48-8. 43 (m, 5H), 7.95 (s, 1 H), 4.89 (t, 2H), 4.37 (q, 2H), 3.41-. 3.38 (m, 2H), 1.35 (t, 3H); HRMS calculated for (M + H) 261.1346, found 261.1317.

EXAMPLE 3 [000165] This example illustrates the production of 2-pyridin-4-yl-6, 7- dihydro-pyrazolo [1,5-a] pyrazin-4 (5H)-one trifluoroacetate.

[000166] A flask was charged with ethyl 1-(2-aminoethyl)-3-pyridin-4-yl- 1 H-pyrazole-5-carboxylate dihydrochloride (1.13 g, 3. 39 mmol), NH40H (30 mL), and ethanol (15 mL). After stirring for 1 h, the reaction mixture was purified by Gilson RP HPLC (5-95% acetonitrile/water). The appropriate fractions were concentrated to a pale yellow solid (0.725 g, 65.4% yield) : 1H NMR (DMSO-d6/300 MHz) 8 8.81 (d, 2H), 8.40 (br s, 1 H), 8.22 (d, 2H), 7.67 (s, 1 H), 4.43 (t, 2H), 3.70-3. 64 (m, 2H); HRMS calculated for (M + H) 215.0927, found 215.0885.

EXAMPLE 4 [000167] This example illustrates the production of 1- (2-aminoethyl)-3- pyridin-4-yl-1 H-pyrazole-5-carboxylic acid trifluoroacetate.

[000168] A solution of ethyl 1-(2-aminoethyl)-3-pyridin-4-yl-1 H-pyrazole- 5-carboxylate dihydrochloride (0.794 g, 2.38 mmol) and LiOH. H2O (0.310 g, 7.40 mmol) in 30 mL of THF/H2O (1: 1) was heated to 80°C with stirring.

After 2 h the reaction mixture was purified by Gilson RP HPLC (5-95% acetonitrile/water). The appropriate fractions were concentrated to a white solid (0.442 g, 53. 7% yield) : 1H NMR (DMSO-d6/300 MHz) 8 8.96 (br s,

2H), 8.48 (br s, 2H), 8. 07-7. 91 (m, 4H), 4.87 (br s, 2H), 3.41 (br s, 2H); HRMS calculated for (M + H) 233.1033, found 233.1025.

EXAMPLE 5 [000169] This example illustrates the production of 1-(2-{[3-(5-methyl-2- furyl) butyl] amino} ethyl)-3-pyridin-4-yl-1 H-pyrazole-5-carboxylic acid trifluoroacetate.

[000170] Ethyl 1-(2-aminoethyl)-3-pyridin-4-yl-1 H-pyrazole-5-carboxylate dihydrochloride (0.806 g, 2.42 mmol) was neutralized by stirring with morpholino-methylpolystyrene resin (4.15 g,-3. 5 mmol base/g resin) in dichloromethane/methanol (20: 1) for 1 h. The resin was filtered, rinsed with methanol, and the filtrates concentrated. The resulting white residue was dissolved in dichloromethane/methanol (20: 1). Six drops of glacial acetic acid were added with stirring, followed by 3- (5-methyl-2- furyl) butyraldehyde (0.422 g, 6.60 mmol. After 5 min, sodium triacetoxyborohydride (1.04 g, 4.90 mmol) was added. The reaction stirred for 1 h, both the mono-and dialkylated products formed. The reaction was quenched with water and extracted with dichloromethane. The organic layers were concentrated to an oil, which was subjected to hydrolysis conditions [3 eq LiOH*H20, THF/H20 (1: 1) ] for 3 h. The resulting product mixture was purified by Gilson RP HPLC (5-95% acetonitrile/water) and the fractions corresponding to the monoalkylated product were concentrated to a mauve solid (0. 106 g, 9. 0% yield) : 1H NMR (DMSO-d6/ 300 MHz) 8 8.77-8. 75 (m, 4H), 8.08 (d, 2H), 7.72 (s, 1 H), 5.97-5. 93 (m, 2H), 4.87 (t, 2H), 3.51-3. 47 (m, 2H), 2.96 (brs, 2H), 2.82 (q, 1H), 2.19 (s, 3H), 1.92-1. 72 (m, 2H), 1.16 (d, 3H); HRMS calculated for (M + H) 233.1033, found 233.1025.

EXAMPLE 6 [000171] This example illustrates the production of ethyl 3- (1- oxidopyridin-4-yl)-1 H-pyrazole-5-carboxylate.

[000172] A flask was charged with ethyl 3-pyridin-4-yl-1 H-pyrazole-5- carboxylate (5.04 g, 23.2 mmol) and 3-chloroperoxybenzoic acid (7.06g, 27.8 mmol) in 70 mL of dichloromethane. After 2 h the reaction was

concentrated in vacuo to remove most of the dichloromethane. To the residue was added 5% ethyl acetate/hexanes and the suspension filtered.

The solid was slurried in NaHCO3 (sat. ), filtered, and rinsed with NaHCO3 (sat. ). The solid was then slurried in NaS2O3, filtered, and then rinsed with water. The solid was slurried up in ethanol and concentrated to afford an orange-tan solid (4.25 g, 78.0% yield) : 1H NMR (DMSO-d6/300 MHz) 8 8.24 (d, 2H), 7.86 (d, 2H), 7.42 (s, 1 H), 4.31 (q, 2H), 1.31 (t, 3H); HRMS calculated for (M + H) 234.0873, found 234.0877.

EXAMPLE 7 [000173] This example illustrates the production of ethyl 3- (2- chloropyridin-4-yl)-1 H-pyrazole-5-carboxylate.

[000174] A suspension of ethyl 3- (1-oxidopyridin-4-yl)-1 H-pyrazole-5- carboxylate (11.16 g, 14.9 mmol) and phosphorus oxychloride (110 mL, 1.2 mol) was heated to 106°C for 48 h. The reaction mixture was concentrated, and then dissolved in chloroform (300 mL) and ice water (300 mL). Solid NaHCO3 was added until foaming was no longer observed, then the heterogeneous solution was extracted multiple times with chloroform. The organic layers were dried over MgS04, filtered, and concentrated. The residue was triturated with dichloromethane. The solid was filtered and rinsed with ethyl acetate, and then with diethyl ether to afford a pale yellow solid (3.59 g, 29.8% yield) : 1H NMR (DMSO-d6/300 MHz) 8 14.41 (br s, 1 H), 8.44 (d, 1 H), 7.98 (s, 1 H), 7.88 (d, 1 H), 7.61 (s, 1 H), 4.33 (q, 2H), 1.32 (t, 3H); HRMS calculated for (M + H) 252.0534, found 252.0508.

EXAMPLE 8 [000175] This example illustrates the production of ethyl 1- {3- [ (tert- butoxycarbonyl)-amino] propyl}-3- (2-chloropyridin-4-yl)-1 H-pyrazole-5- carboxylate.

[000176] Synthesis conducted as in the preparation of ethyl 1-{2-[(tert- butoxycarbonyl) amino] ethyl}-3-pyridin-4-yl-1 H-pyrazole-5-carboxylate using ethyl 3-(2-chloropyridin-4-yl)-1 H-pyrazole-5-carboxylate (3.36 g, 13.3 mmol), lithium t-butoxide (1 M in THF, 17.0 mL), ter-butyl 3-

bromopropylcarbamate (3. 81 g, 16.0 mmol) and sodium iodide (2.39 g, 16.0 mmol). Chromatographic purification (25% ethyl acetate/hexane) afforded a white solid (3.29 g, 60.5% yield) : 1H NMR (DMSO-d6/300 MHz) 8 8. 42 (d, 1 H), 7.95 (s, 1 H), 7.86 (dd, 1 H), 7.67 (s, 1 H), 6.85 (dd, 1 H), 4.54 (t, 2H), 4.35 (q, 2H), 2.98-2. 92 (m, 2H), 1.98-1. 88 (m, 2H), 1.36- 1.31 (m, 12H); HRMS calculated for (M + H) 409.1637, found 409.1634.

EXAMPLE 9 [000177] This example illustrates the production ofethyl 1-{2-[(tert- butoxycarbonyl)-amino] ethyl)-3- (2-chloropyridin-4-yl)-1 H-pyrazole-5- carboxylate.

[000178] Synthesis was conducted as in the preparation of ethyl 1- {2- [(tert-butoxycarbonyl) amino] ethyl}-3-pyridin-4-yl-1 H-pyrazole-5- carboxylate, using ethyl 3-(2-chloropyridin-4-yl)-1 H-pyrazole-5-carboxylate (6.00 g, 23.8 mmol), lithium t-butoxide (1 M in THF, 31.0 mL), tert-butyl 2- bromoethylcarbamate (6.59 g, 29.4 mmol), and sodium iodide (4.41 g, 29.4 mmol). Flash chromatography (25% ethyl acetate/hexane) afforded a white solid (6.07 g, 64.6% yield) : 1H NMR (DMSO-d6/300 MHz) 8 8.43 (d, 1 H), 7.94 (s, 1 H), 7.85 (dd, 1 H), 7.66 (s, 1 H), 6.89 (t, 1 H), 4.59 (t, 2H), 4.33 (q, 2H), 3.39-3. 32 (m, 2H), 1.36-1. 23 (m, 12H); HRMS calculated for (M + H) 395.1481, found 395.1512.

EXAMPLE 10 [000179] This example illustrates the production of2- (2-chloropyridin-4- yl)-5, 6,7, 8-tetrahydro-4H-pyrazolo [1,5-a] [1,4] diazepin-4-one.

[000180] A flask was charged with ethyl 1- {3- [ (tert-butoxycarbonyi) amino] propyl}-3-(2-chloropyridin-4-yl)-1 H-pyrazole-5-carboxylate (6.50 g, 15.9 mmol) and 4N HCI/dioxane (45 mL). The reaction mixture stirred for 1 h, then the suspension was filtered and the solid rinsed with diethyl ether.

This solid was taken up in ethanol (20 mL) and NH40H (40 mL). After stirring for 20 h, the suspension was filtered and rinsed with ethanol and diethyl ether to afford a white solid (3.64 g, 87. 4% yield) : 1H NMR (DMSO- due/300 MHz) 8 8.41 (d, 1 H), 8.35 (t, 1 H), 7.90 (s, 1 H), 7.83 (d, 1 H), 7.48

(s, 1H), 4.49 (t, 2H), 3.24-3. 18 (m, 2H), 2.20-2. 14 (m, 2H), HRMS calculated for (M + H) 263.0694, found 263.0689.

EXAMPLE 11 [000181] This example illustrates the production of ethyl 1- {3- [ (tert- butoxycarbonyl) amino] propyl}-3- [2- (3-nitrophenyl) pyridin-4-yl]-1 H- pyrazole-5-carboxylate.

[000182] A flask was charged with ethyl 1- {3- [ (tert-butoxycarbonyl) amino] propyi}-3-(2-chloropyridin-4-yl)-1H-pyrazole-5-carboxylate (0.875 g, 2.14 mmol), 3-nitrophenylboronic acid (0.536 g, 3.21 mmol), 2M Na2CO3 (9 mL), toluene (25 mL), and [1, 1'bis (diphenylphosphino) ferrocene] dichloropalladium(II), 1: 1 complex with dichloromethane [Pd [dppf] CI2'CH2CI2 (0.140 g, 0.170 mmol)], then purged with N2 and heated at 90°C for 20 h. The reaction mixture was diluted with ethyl acetate and washed with water and brine. The organic layer was dried over MgS04, filtered, and concentrated. Chromatographic purification (30% ethyl acetate/hexane) afforded a white solid (0.767 g, 72. 4% yield): 'H NMR (DMSO-d6/300 MHz) 8 9. 00 (dd, 1 H), 8.75 (d, 1 H), 8.68 (d, 1 H), 8.54 (s, 1 H), 8.30 (m, 1 H), 7.91 (dd, 1 H), 7.84-7. 70 (m, 2H), 6.87 (dd, 1 H), 4.58 (t, 2H), 4.36 (q, 2H), 3.00-2. 95 (m, 2H), 1.98-1. 92 (m, 2H), 1.38-1. 31 (m, 12H); HRMS calculated for (M + H) 496.2191, found 496.2175.

EXAMPLE 12 [000183] This example illustrates the production of 1- (3-aminopropyl)-3- <BR> <BR> <BR> <BR> [2- (3 nitrophenyl) pyridin-4-yl]-l H-pyrazole-5-carboxamide trifluoroacetate.

[000184] Ammonia gas was bubbled into a pressure tube charged with ethyl 1- {3- [ (tert-butoxycarbonyl) amino] propyl}-3- [2- (3-nitrophenyl) pyridin-4- yl]-1 H-pyrazole-5-carboxylate (0.084 g, 0.17 mmol) in 10 mL ethanol and cooled to-78 °C. The tube was then sealed and heated to 70°C for 6 days. The reaction mixture was concentrate in vacuo. To this residue was added 4N HCI/dioxane (6 mL). After 1.5 h the solution was purified by Gilson RP HPLC (5-95% acetonitrile/water). The appropriate fractions were concentrated to a light tan solid (0.048 g, 60% yield) : 1H NMR

(DMSO-d6/300 MHz) b 8.94 (dd, 1 H), 8.81 (d, 1 H), 8.60 (d, 1 H), 8.43 (s, 1 H), 8.36 (dd, 1 H), 8.20-8. 09 (m, 4H), 7.87-7. 74 (m, 3H), 4.66 (t, 2H), 2.86-2. 79 (m, 2H), 2.20-2. 15 (m, 2H); HRMS calculated for (M + H) 367.1513, found 367.1529.

EXAMPLE 13 [000185] This example illustrates the production of 1- (3-aminopropyl)-3- <BR> <BR> <BR> <BR> (2-quinolin-3-ylpyridin-4-yl)-1 H-pyrazole-5-carboxamide dihydrochloride.

[000186] Synthesis was conducted as for the production of 1- (3- <BR> <BR> <BR> <BR> aminopropyl)-3- [2- (3-nitrophenyl) pyridin-4-yl]-1 H-pyrazole-5-carboxamide trifluoroacetate using ethyl 1-{3-[(tert-butoxywarbonyl) am ino] propyl}-3-(2- quinolin-3-ylpyridin-4-yl)-1H-pyrazole-5-carboxylate (0. 127 g, 0. 254 mmol).

The TFA salt residue was taken up in methanol and 4N HCI/dioxane. After 20 h the suspension was concentrated to an off-white solid (0.069 g, 0.16 mmol) : 1H NMR (DMSO-d6/300 MHz) 8 9.90 (d, 1 H), 9.78 (s, 1 H), 8.87 (d, 1H), 8.69 (s, 1H), 8.46-8. 39 (m, 2H), 8.22-8. 08 (m, 5H), 7.96-7. 89 (m, 2H), 7.82-7. 78 (m, 2H), 4.67 (t, 2H), 2.86-2. 77 (m, 2H), 2.25-2. 16 (m, 2H); HRMS calculated for (M + H) 373.1771, found 373.1769.

EXAMPLE 14 [000187] This example illustrates the production of ethyl 1-{2-[(tertbutoxy- carbonyl) amino] ethyl}-3-(2-quinolin-3-ylpyridin-4-yl)-1H-pyrazole-5- carboxylate.

[000188] Synthesis was conducted as in the preparation of ethyl 1- {3- [(tert-butoxyCarbonyl) amino] propyl}-3-[2-(3-nitrophenyl) pyridin-4-yl]-1 H- pyrazole-5-carboxylate using ethyl 1-{2-[(tert-butoxycarbonyl) amino] ethyl}- 3-(2-chloropyridin-4-yl)-1H-pyrazole-5-carboxylate (0.732 g, 1.85 mmol), 3- quinolinylboronic acid (0.481 g, 2. 78 mmol), 2M Na2CO3 (7 mL), toluene (20 mL), and Pd[dppf]Cl2#CH2Cl2 (0.121 g, 0.148 mmol). The black residue obtained from the aqueous work-up was triturated with dichloromethane to afford an off-white solid (0.615 g, 68.2% yield) : 1H NMR (DMSO-d6/300 MHz) # 9. 72 (s, 1H), 9.14 (s, 1H), 8.78 (d, 1H), 8.62 (s, 1H), 8.15-8. 08 (m,

2H), 7.90-7. 82 (m, 3H), 7.71-7. 66 (m, 1 H), 6.94 (t, 1 H), 4.64 (t, 2H), 4.37 (q, 2H), 3.39-3. 32 (m, 2H), 1.39-1. 28 (m, 12H); HRMS calculated for (M + H) 488.2292, found 488.2296.

EXAMPLE 15 [000189] This example illustrates the production of 2- {2- [4- (trifluoromethoxy)-phenyl] pyridin-4-yl}-6, 7-dihydropyrazolo [1,5-a] pyrazin- 4 (5H)-one trifluoroacetate.

[000190] Synthesis was conducted as in the preparation of ethyl 1-{3- [(tert-butoxyCarbonyl) amino] propyl}-3-[2-(3-nitrophenyl) pyridin-4-yl]-1 H- pyrazole-5-carboxylate using ethyl 1- {3- [ (tert- butoxycarbonyl) amino] propyl}-3-(2-chloropyridin-4-yl)-1 H-pyrazole-5- carboxylate (0.954 g, 2.33 mmol), 3-quinolinylboronic acid (0.520 g, 3.00 mmol), 2M Na2CO3 (10 mL), toluene (25 mL), and Pd [dppf] C12'CH2C12 (0.152 g, 0.186 mmol). Flash chromatography (25% ethyl acetate/hexane) afforded a beige solid (0.593g, 50.7% yield) : 1H NMR (DMSO-d6/300 MHz) 8 9.72 (d, 1H), 9.14 (d, 1 H), 8.77 (d, 1H), 8.63 (s, 1 H), 8.15-8. 07 (m, 2H), 7.85-7. 82 (m, 3H), 7.69 (dd, 1 H), 6.88 (t, 1 H), 4.60 (t, 2H), 4.37 (q, 2H), 3.02-2. 96 (m, 2H), 2.01-1. 93 (m, 2H), 1.39-1. 34 (m, 12H); HRMS calculated for (M + H) 502.2449, found 502. 2419.

EXAMPLE 16 [000191] This example illustrates the production of ethyl 1-{2-[(tert- butoxycarbonyl) amino] ethyl}-3- {2- [4- (hydroxymethyl) phenyl] pyridin-4-yl}- 1 H-pyrazole-5-carboxylate.

[000192] Synthesis was conducted as in the preparation of ethyl 1-{3- [(tert-butoxycarbonyl) amino] propyl}-3- [2- (3-nitrophenyl) pyridin-4-yl]-1 H- pyrazole-5-carboxylate using ethyl 1-{2-[(tert-butoxycarbonyl) am ino] ethyl}- 3-(2-chloropyridin-4-yl)-1H-pyrazole-5-carboxylate (1.100 g, 2.79 mmol), 4- hydroxymethyl-phenylboronic acid (0.550 g, 3.62 mmol), 2M Na2CO3 (12 mL), toluene (32 mL), and Pd [dppf] CI2CH2CI2 (0.182 g, 0.223 mmol). The black residue obtained from the aqueous work-up was triturated with dichloromethane to yield an off-white solid (0.567 g, 43.6% yield) : 1H NMR

(DMSO-d6/300 MHz) 8 8.67 (d, 1 H), 8.32 (s, 1 H), 8.15 (d, 2H), 7.78-7. 76 (m, 2H), 7.45 (d, 2H), 6.92 (t, 1 H), 5.26 (t, 1 H), 4.62-4. 56 (m, 4H), 4. 35 (q, 2H), 3.39-3. 35 (m, 2H), 1. 36-1. 27 (m, 12H); HRMS calculated for (M + H) 467.2289, found 467.2259.

EXAMPLE 17 [000193] This example illustrates the production ethyl 1- (3-aminopropyl)- <BR> <BR> <BR> 3- [2- (3-nitrophenyl) pyridin-4-yl]-1 H-pyrazole-5-carboxylate dihydrochloride.

[000194] Synthesis was conducted as in the preparation of ethyl 1- (2- aminoethyl)-3-pyridin-4-yl-1 H-pyrazole-5-carboxylate dihydrochloride using ethyl 1-{3-[(tert-butoxycarbonyl) amino] propyt}-3- [2- (3-nitropheny !) pyridin-4- yl]-1 H-pyrazole-5-carboxylate (0.763 g, 1.53 mmol) and 4N HCI/dioxane (10 mL). A light yellow solid was obtained (0.685 g, 95.4% yield) : 1H NMR (DMSO-d6/300 MHz) 8 9.00 (dd, 1 H), 8.80 (d, 1 H), 8.68 (d, 1 H), 8.63 (s, 1H), 8.35 (dd, 1H), 8.13 (br s, 3H), 8.02 (dd, 1H), 7.93 (s, 2H), 7.85 (dd, 1H), 4.68 (t, 2H), 4.37 (q, 2H), 2. 87-2. 80 (m, 2H), 2.21-2. 16 (m, 2H), 1.36 (t, 3H); HRMS calculated for (M + H) 396.1666, found 396.1660.

EXAMPLE 18 [000195] This example illustrates the production of ethyl 1- (2- aminoethyl)-3- (2-quinolin-3-ylpyridin-4-yl)-1 H-pyrazole-5-carboxylate dihydrochloride.

[000196] Synthesis was conducted as in the preparation of ethyl 1- (2- aminoethyl)-3-pyridin-4-yl-1 H-pyrazole-5-carboxylate dihydrochloride using ethyl 1-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(2-quinolin-3-ylpy ridin-4-yl)- 1 H-pyrazole-5-carboxylate (0.588 g, 1.21 mmol) and 4N HCI/dioxane (12 mL). A white solid was obtained (0.557 g, 100% yield) : 1H NMR (DMSO- d6/300 MHz) # 9. 97 (s, 1 H), 9.86 (s, 1 H), 8.87-8. 85 (m, 2H), 8. 62 (s, 1 H), 8.48-8. 41 (m, 5H), 8.15-8. 08 (m, 2H), 7.98-7. 90 (m, 2H), 4.89 (t, 2H), 4.39 (q, 2H), 3.43-3. 36 (m, 2H), 1.37 (t, 3H); HRMS calculated for (M + H) 388.1768, found 388.1754.

EXAMPLE 19 [000197] This example illustrates the production of ethyl 1- (3- aminopropyl)-3-(2-quinolin-3-ylpyridin-4-yl)-1H-pyrazole-5-c arboxylate dihydrochloride.

[000198] Synthesis was conducted as for the preparation of ethyl 1- (2- aminoethyl)-3-pyridin-4-yl-1 H-pyrazole-5-carboxylate dihydrochloride, using ethyl 1- {3- [ (tert-butoxycarbonyl) amino] propyl}-3-(2-quinolin-3- ylpyridin-4-yl)-1 H-pyrazole-5-carboxylate (0.404 g, 0.805 mmol) and 4N HCI/dioxane (10 mL). A yellow solid was obtained (0.357g, 93.5% yield) : 'H NMR (DMSO-d6/300 MHz) 5 9. 92 (d, 1 H), 9.72 (d, 1 H), 8.84 (d, 1 H), 8.79 (s, 1 H), 8.40-8. 36 (m, 2H), 8.16 (br s, 3H), 8.07-8. 00 (m, 2H), 7.93- 7.88 (m, 2H), 4.66 (t, 2H), 4.38 (q, 2H), 2.90-2. 82 (m, 2H), 2.25-2. 16 (m, 2H), 1.37 (t, 3H); HRMS calculated for (M + H) 402.1925, found 402.1937.

EXAMPLE 20 [000199] This example illustrates the production of ethyl 1- (2- <BR> <BR> <BR> <BR> aminoethyl)-3- {2- [4- (hydroxymethyl) phenyl] pyridin-4-yl}-1 H-pyrazole-5-<BR> <BR> <BR> <BR> <BR> <BR> carboxylate dihydrochloride.

[000200] Synthesis was conducted as for the preparation of ethyl 1- (2- aminoethyl)-3-pyridin-4-yl-1 H-pyrazole-5-carboxylate dihydrochloride, using ethyl 1- {2- [ (tert-butoxycarbonyl) amino] ethyll-3- {2- [4- (hydroxymethyl) phenyl] pyridin-4-yl}-1 H-pyrazole-5-carboxylate (0.498 g, 1.07 mmol) and 4N HCI/dioxane (10 mL). A white solid was obtained (0.474g, 100% yield) : 1 H NMR (DMSO-d6/300 MHz) 8 8.83 (d, 1 H), 8.74 (s, 1 H), 8.38 (br s, 3H), 8.29-8. 20 (m, 3H), 8.08 (s, 1 H), 7.57 (d, 2H), 4.90 (t, 2H), 4.62 (m, 2H), 4.39 (q, 2H), 3.40-3. 35 (m, 2H), 1.36 (t, 3H); HRMS calculated for (M + H) 367.1765, found 367.1751.

EXAMPLE 21 [000201] This example illustrates the production of ethyl 1- (2- <BR> <BR> <BR> <BR> aminoethyl)-3- [2- (3-nitro-phenyl) pyridin-4-yl]-1 H-pyrazole-5-carboxylate dihydrochloride.

[000202] A flask was charged with ethyl 1-{2-[(tert-butoxycarbonyl) amino] ethyl}-3-(2-chloropyridin-4-yl)-1 H-pyrazole-5-carboxylate (0.700 g, 1.78 mmol), 3-nitrophenylboronic acid (0.446 g, 2.67 mmol), 2M Na2CO3 (7 mL), toluene (20 mL), and [1, 1'bis (diphenylphosphino) ferrocene] dichloropalladium (II), 1: 1 complex with dichloromethane [Pd [dppf] Cl2#CH2Cl2 (0.116 g, 0.142 mmol)], then purged with N2 and heated at 90°C for 20 h. The reaction mixture was filtered through Celite and the organic layer was concentrated. To this residue was added 4N HCI/dioxane (10.0 mL). After 2 h the reaction mixture was purified by Gilson RP HPLC (5-95% acetonitrile/water). The appropriate fractions were concentrated to a tacky residue, which was converted to the HCI salt using 4N HCI/dioxane and methanol. After stirring 1 h the reaction was concentrated to a brown solid (0.688 g, 85. 1% yield) : 1H NMR (DMSO-d6/ 300 MHz) # 9. 01 (s, 1 H), 8.80 (dd, 1 H), 8.70-8. 64 (m, 2H), 8.35-8. 28 (m, 4H), 8.03 (d, 1 H), 7.93 (s, 1 H), 7.84 (dd, 1 H), 4.87 (t, 2H), 4.38 (q, 2H), 3.39-3. 33 (m, 2H), 1.36 (t, 3H); HRMS calculated for (M + H) 382.1510, found 382.1525.

EXAMPLE 22 [000203] This example illustrates the production of ethyl 1- (2- aminoethyl)-3- [2- (4-methoxyphenyl) pyridin-4-yl]-1 H-pyrazole-5-carboxylate dihydrochloride.

[000204] Synthesis was conducted as for the production of ethyl 1- (2- aminoethyl)-3- [2- (3-nitrophenyl) pyridin-4-yl]-1 H-pyrazole-5-carboxylate dihydrochloride using ethyl 1-{2-[(tert-butoxycarbonyl) amino] ethyl}-3-(2- chloropyridin-4-yl)-1 H-pyrazole-5-carboxylate (0.700 g, 1.78 mmol), 4- methoxyphenylboronic acid (0.406 g, 2.67 mmol), 2M Na2CO3 (7 mL), toluene (20 mL), Pd [dppf] CI2 CH2CI2 (0.116 g, 0. 142 mmol), and 4N HCI/dioxane (10.0 mL). The product was isolated as a yellow solid (0.709 g, 90.7% yield) : 1H NMR (DMSO-d6/300 MHz) 8 8.77 (d, 1 H), 8.65 (s, 1H), 8.35 (br s, 3H), 8.24 (d, 2H), 8.16 (d, 1H), 8.04 (s, 1H), 7.18 (d, 2H),

4.89 (t, 2H), 4.38 (q, 2H), 3.87 (s, 3H), 3.42-3. 38 (m, 2H), 1.36 (t, 3H), HRMS calculated for (M + H) 367.1765, found 367.1790.

EXAMPLE 23 [000205] This example illustrates the production of Ethyl 1- (2- aminoethyl)-3-{2-[4-(trifluoromethoxy)phenyl]pyridin-4-yl}-1 H-pyrazole-5- carboxylate dihydrochloride.

[000206] Synthesis was conducted as for the production of ethyl 1- (2- aminoethyl)-3- [2- (3-nitrophenyl) pyridin-4-yl]-1 H-pyrazole-5-carboxylate dihydrochloride using ethyl 1- {2- [ (tert-butoxycarbonyl) amino] ethyl}-3-(2- chloropyridin-4-yl)-1 H-pyrazole-5-carboxylate (0.700 g, 1.78 mmol), 4- trifluoromethoxyphenylboronic acid (0.550 g, 2.67 mmol), 2M Na2CO3 (7 mL), toluene (20 mL), Pd [dppf] CI2CH2CI2 (0. 116 g, 0.142 mmol), and 4N HCI/dioxane (10.0 mL). The product was isolated as a reddish-tan solid (0.821 g, 93.5% yield) : 1 H NMR (DMSO-d6/300 MHz) # 8. 79 (d, 1 H), 8.59 (s, 1 H), 8.36-8. 33 (m, 5H), 8.07 (d, 1 H), 7.94 (s, 1 H), 7.57 (d, 2H), 4.87 (t, 2H), 4.38 (q, 2H), 3.42-3. 38 (m, 2H), 1.36 (t, 3H); HRMS calculated for (M + H) 421.1482, found 421.1482.

EXAMPLE 24 [000207] This example illustrates the production of ethyl 1- (2- aminoethyl)-3-{2-[(E)-2-phenylethenyl]pyridin-4-yl}-1H-pyraz ole-5- carboxylate dihydrochloride.

[000208] Synthesis was conducted as for the production of ethyl 1- (2- aminoethyl)-3- [2- (3-nitrophenyl) pyridin-4-yl]-1 H-pyrazole-5-carboxylate dihydrochloride in using ethyl 1-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(2- chloropyridin-4-yl)-1 H-pyrazole-5-carboxylate (1.044 g, 2.64 mmol), trans- 2-phenylvinylboronic acid (0.587 g, 3.97 mmol), 2M Na2CO3 (10 mL), toluene (30 mL), Pd[dppf]Cl2#CH2Cl2 (0. 172 g, 0.211 mmol), and 4N HCI/dioxane (10.0 mL). The product was isolated as a yellow solid (1.213 g, >100% yield, 73.0% pure) : 1H NMR (DMSO-d6/300 MHz) 8 8.79-8. 72 (m, 2H), 8.36 (br s, 3H), 8.24-8. 19 (m, 2H), 7.96 (s, 1 H), 7.71 (d, 2H),

7.62-7. 45 (m, 5H), 4.89 (t, 2H), 4.39 (q, 2H), 3.41-3. 39 (m, 2H), 1.37 (t, 3H); HRMS calculated for (M + H) 363.1816, found 363.1807.

EXAMPLE 25 [000209] This example illustrates the production of ethyl 1- (2- aminoethyl)-3- {2- [4- (dimethylamino) phenyl] pyridin-4-yl}-1 H-pyrazole-5- carboxylate trifluoroacetate.

[000210] Synthesis was conducted as for the production of ethyl 1- (2- aminoethyl)-3- [2- (3-nitrophenyl) pyridin-4-yl]-1 H-pyrazole-5-carboxylate dihydrochloride in using ethyl 1-{2-[(tert-butoxycarbonyl) amino] ethyl}-3-(2- chloropyridin-4-yl)-1 H-pyrazole-5-carboxylate (0.758 g, 1.92 mmol), 4- dimethylaminophenylboronic acid (0.475 g, 2.88 mmol), 2M Na2CO3 (8 mL), toluene (23 mL), Pd [dppf] CI2CH2CI2 (0.126 g, 0.154 mmol), and 4N HCI/dioxane (10.0 mL). The TFA salt was isolated as a yellow solid (0.666 g, 70.3% yield) : 1H NMR (DMSO-d6/300 MHz) 8 8.64 (d, 1 H), 8.46 (s, 1 H), 8.07-8. 04 (m, 5H), 7.95 (s, 1 H), 7.88 (d, 1 H), 6.86 (d, 2H), 4.85 (t, 2H), 4.38 (q, 2H), 3.47-3. 37 (m, 2H), 3.03 (s, 6H), 1.36 (t, 3H); HRMS calculated for (M + H) 380.2081, found 380.2098.

EXAMPLE 26 [000211] This example illustrates the production of ethyl 1- (2- <BR> <BR> <BR> <BR> aminoethyl)-3- [2- (3-methoxyphenyl) pyridin-4-yl]-1 H-pyrazole-5-carboxylate<BR> <BR> <BR> <BR> <BR> <BR> dihydrochloride.

[000212] Synthesis was conducted as for the production of ethyl 1- (2- aminoethyl)-3- [2- (3-nitrophenyl) pyridin-4-yl]-1 H-pyrazole-5-carboxylate dihydrochloride, using ethyl 1-{2-[(tert-butoxycarbonyl) amino] ethyl}-3-(2- chloropyridin-4-yl)-1 H-pyrazole-5-carboxylate (0.752g, 1.90 mmol), 3- methoxyphenylboronic acid (0.434 g, 2.86 mmol), 2M Na2CO3 (7 mL), toluene (20 mL), Pd [dppf] C12'CH2CI2 (0.124 g, 0.152 mmol), and 4N HCI/dioxane (10.0 mL). The product was isolated as an off-white solid (0.500 g, 60.0% yield) 1 H NMR (DMSO-d6/300 MHz) 8 8.81 (d, 1 H), 8.67 (s, 1 H), 8.37 (br s, 3H), 8.22 (d, 1 H), 8.04 (s, 1H), 7.82-7. 79 (m, 2H), 7.53 (dd, 1H), 7.18 (d, 1H), 4.89 (t, 2H), 4.38 (q, 2H), 3.89 (s, 3H), 3.42-3. 36

(m, 2H), 1.36 (t, 3H); HRMS calculated for (M + H) 367.1765, found 367.1755.

EXAMPLE 27 [000213] This example illustrates the production of ethyl 1- (2- <BR> <BR> <BR> <BR> aminoethyl)-3- [2- (3-hydroxyphenyl) pyridin-4-yl]-1 H-pyrazole-5-carboxylate dihydrochloride.

[000214] Synthesis was conducted as for the production of ethyl 1- (2- aminoethyl)-3-[2-(3-nitrophenyl)pyridin-4-yl]-1H-pyrazole-5- carboxylate dihydrochloride using ethyl 1-{2-[(tert-butoxycarbonyl) amino] ethyl}-3-(2- chloropyridin-4-yl)-1 H-pyrazole-5-carboxylate (0.752g, 1.90 mmol), 3- hydroxyphenylboronic acid (0. 629 g, 2.86 mmol), 2M Na2CO3 (7 mL), toluene (20 mL), Pd [dppf] CI2 CH2CI2 (0.124 g, 0.152 mmol), and 4N HCI/dioxane (10.0 mL). The product was isolated as an off-white solid (0.381 g, 46.8% yield) : H NMR (DMSO-d6/300 MHz) 6 8.80 (d, 1 H), 8.62 (s, 1 H), 8.37 (br s, 3H), 8.22 (d, 1 H), 8.04 (s, 1 H), 7.62-7. 58 (m, 2H), 7.41 (dd, 1 H), 7.05 (dd, 1 H), 4.89 (t, 2H), 4.38 (q, 2H), 3.89 (s, 3H), 3.42-3. 36 (m, 2H), 1.36 (t, 3H); HRMS calculated for (M + H) 353.1608, found 353.1630.

EXAMPLE 28 [000215] This example illustrates the production of 2- (2-quinolin-3- ylpyridin-4-yl)-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) -one.

[000216] A flask was charged with ethyl 1- (2-aminoethyl)-3- (2-quinolin-3- ylpyridin-4-yl)-1 H-pyrazole-5-carboxylate dihydrochloride (0.303 g, 0.659 mmol), NH40H (6 mL) and ethanol (3 mL). After stirring for 20 h, the reaction was filtered, and the solid rinsed with water, ethanol, and diethyl ether to obtain a white solid (0.178 g, 76.8% yield) : 1H NMR (DMSO-d6/ 300 MHz) # 9. 73 (s, 1 H), 9.16 (s, 1 H), 8.79 (s, 1 H), 8.64 (s, 1 H), 8.35 (s, 1 H), 8.16-8. 08 (m, 2H), 7.90-7. 69 (m, 4H), 4.45 (br s, 2H), 3.69 (br s, 2H); HRMS calculated for (M + H) 342.1349, found 342.1365.

EXAMPLE 29 [000217] This example illustrates the production of 2- (2-quinolin-3- ylpyridin-4-yl)-5, 6,7, 8-tetrahydro-4H-pyrazolo [1,5-a] [1,4] diazepin-4-one.

[000218] Synthesis was conducted as it was for the production of 2- (2- quinolin-3-ylpyridin-4-yl)-6, 7-dihydropyrazolo [1,5-a] pyrazin-4 (5H)-one using ethyl 1- (3-aminopropyl)-3- (2-quinolin-3-ylpyridin-4-yl)-1 H-pyrazole-5- carboxylate dihydrochloride (0.144 g, 0.303 mmol), NH40H (6mL), and ethanol (3 mL). A white solid was obtained (0.046 g, 43% yield) : 1H NMR (DMSO-d6/300 MHz) 8 9. 72 (d, 1H), 9.16 (d, 1 H), 8.77 (d, 1H), 8.61 (s, 1H), 8.35 (brs, 1H), 8.15-8. 07 (m, 2H), 7.88-7. 79 (m, 2H), 7.71-7. 66 (m, 2H), 4.55 (t, 2H), 3.29-3. 23 (m, 2H), 2.22-2. 18 (m, 2H); HRMS calculated for (M + H) 356.1506, found 356.1525.

EXAMPLE 30 [000219] This example illustrates the production of 2- {2- [4- (hydroxymethyl) phenyl] pyridin-4-yl}-6, 7-dihydropyrazolo [1,5-a] pyrazin- 4 (5H)-one.

[000220] Synthesis was conducted as it was for the production of 2- (2- quinolin-3-ylpyridin-4-yl)-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one using ethyl 1- (2-aminoethyl)-3- {2- [4- (hydroxymethyl) phenyl] pyridin-4-yl}- 1 H-pyrazole-5-carboxylate dihydrochloride (0.202 g, 0.459 mmol), NH40H (8 mL), and ethanol (4 mL). A white solid was obtained (0.098 g, 66% yield) : 1 H NMR (DMSO-d6/300 MHz) 8 8.67 (d, 1 H), 8.36-8. 32 (m, 2H), 8.15 (d, 2H), 7.78 (d, 1H), 7.64 (s, 1H), 7.45 (d, 2H), 5.27 (t, 1H), 4.57 (d, 2H), 4.42 (t, 2H), 3.70-3. 66 (m, 2H); HRMS calculated for (M + H) 321. 1346, found 321. 1333.

EXAMPLE 31 [000221] This example illustrates the production of 2- [2- (3- methoxyphenyl) pyridin-4-yl]-6, 7-dihydropyrazolo [1,5-a] pyrazin-4 (5H)-one.

[000222] Synthesis was conducted as it was for the production of 2- (2- quinolin-3-ylpyridin-4-yl)-6, 7-dihydropyrazolo [1,5-a] pyrazin-4 (5H)-one using ethyl 1- (2-aminoethyl)-3- [2- (3-methoxyphenyl) pyridin-4-yl]-1 H-

pyrazole-5-carboxylate dihydrochloride (0.253 g, 0.575 mmol), NH40H (8 mL), and ethanol (4 mL). An off-white solid was obtained (0.160 g, 86.8% yield): 1H NMR (DMSO-d6 / 300 MHz) # 8.69 (s, 1H), 8.37-8.32 (m, 2H), 7.80-7.68 (m, 4H), 7.42 (dd, 1H) 7.03 (d, 1H), 4.42 (t, 2H), 3.86 (s, 3H), 3.69-3. 65 (m, 2H); HRMS calculated for (M + H) 321.1346, found 321.1344.

EXAMPLE 32 [000223] This example illustrates the production of 2- [2- (3- hydroxyphenyl) pyridin-4-yl]-6, 7-dihydropyrazolo [1,5-a] pyrazin-4 (5H)-one.

[000224] Synthesis was conducted as it was for the production of 2- (2- quinolin-3-ylpyridin-4-yl)-6, 7-dihydropyrazolo [1,5-a] pyrazin-4 (5H) -one using ethyl 1-(2-aminoethyl)-3-[2-(3-hyd roxyphenyl) pyridin-4-yl]-1 H- pyrazole-5-carboxylate dihydrochloride (0.304 g, 0.715 mmol), NH40H (10 mL), and ethanol (5 mL). An off-white solid was obtained (0.178 g, 81. 1% yield) : 1 H NMR (DMSO-d6/300 MHz) 8 9.56 (br s, 1 H), 8.66 (d, 1 H), 8.32- 8.28 (m, 2H), 7.79 (s, 1 H), 7.63-7. 59 (m, 3H), 7.30 (dd, 1 H), 6.85 (d, 1 H), 4.42 (t, 2H), 3.69-3. 64 (m, 2H); HRMS calculated for (M + H) 307.1190, found 307.1214.

EXAMPLE 33 [000225] This example illustrates the production of 2- [2- (3- nitrophenyl) pyridin-4-yl]-5, 6,7, 8-tetrahydro-4H-pyrazolo [1,5- a] [1,4] diazepin-4-one hydrochloride.

[000226] Synthesis was conducted as it was for the production of 2- pyridin-4-yl-6, 7-dihydropyrazolo [1,5-a] pyrazin-4 (5H)-one trifluoroacetate using ethyl 1- (3-aminopropyl)-3- [2- (3-nitrophenyl) pyridin-4-yl]-l H-pyrazole- 5-carboxylate dihydrochloride (0.253 g, 0.540 mmol), NH40H (8 mL), and ethanol (4 mL). The isolated TFA salt was converted to the HCI salt using methanol and 4N HCI/dioxane. After 0.5 h, the suspension was concentrated and the solid rinsed with diethyl ether to afford a white solid (0.140 g, 65.2% yield) : 1H NMR (DMSO-d6/300 MHz) 6 9. 00 (dd, 1 H), 8.78 (d, 1 H), 8.65 (d, 1 H), 8.60 (s, 1 H), 8.39-8. 33 (m, 2H), 8.00 (dd, 1 H),

7.84 (dd, 1H), 7.74 (s, 1H), 4.54 (t, 2H), 3.27-3. 21 (m, 2H), 2.20-2. 15 (m, 2H); HRMS calculated for (M + H) 342.1349, found 342.1365.

EXAMPLE 34 [000227] This example illustrates the production of 2- {2- [4- (trifluoromethoxy)-phenyl] pyridin-4-yl}-6, 7-dihydropyrazolo [1,5-a] pyrazin- 4 (5H)-one trifluoroacetate.

[000228] Synthesis was conducted as it was for the production of 2- pyridin-4-yl-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)-one trifluoroacetate using ethyl 1- (2-aminoethyl)-3- {2- [4- (trifluoromethoxy) phenyl] pyridin-4-yl}- 1 H-pyrazole-5-carboxylate dihydrochloride (0.439 g, 0.889 mmol), NH40H (8 mL), and ethanol (4 mL). An off-white solid was obtained (0.181 g, 43.0% yield) : 1H NMR (DMSO-d6/300 MHz) 8 8.72 (d, 1 H), 8.45 (s, 1 H), 8.33-8. 30 (m, 3H), 7.88 (d, 1 H), 7.69 (s, 1 H), 7.51 (d, 2H), 4.43 (q, 2H), 3.70-3. 64 (m, 2H); HRMS calculated for (M + H) 375.1063, found 375. 1068.

EXAMPLE 35 [000229] This example illustrates the production of 2- {2- [ (E)-2- phenylvinyl] pyridin-4-yl}-6, 7-dihydropyrazolo [1,5-a] pyrazin-4 (5H)-one trifluoroacetate.

[000230] Synthesis was conducted as it was for the production of 2- pyridin-4-yl-6, 7-dihydropyrazolo [1,5-a] pyrazin-4 (5H)-one trifluoroacetate using ethyl 1-(2-aminoethyl)-3-{2-[(E)-2-phenylvinyl] pyridin-4-yl}-1 H- pyrazole-5-carboxylate dihydrochloride (0.610 g, 1.40 mmol), NH40H (10 mL), and ethanol (5 mL). A yellow solid was obtained (0.352 g, 58.4% yield) : 1H NMR (DMSO-d6/300 MHz) 8 8.69 (d, 1 H), 8.40 (br s, 2H), 7.97- 7.92 (m, 2H), 7.71-7. 68 (m, 3H), 7.49-7. 37 (m, 4H), 4.45 (t, 2H), 3.70-3. 66 (m, 2H); HRMS calculated for (M + H) 317.1397, found 317.1405.

EXAMPLE 36 [000231] This example illustrates the production of 2- {2- [4- (dimethylamino) phenyl]-pyridin-4-yl}-6, 7-dihydropyrazolo [1,5-a] pyrazin- 4 (5H)-one trifluoroacetate.

[000232] Synthesis was conducted as it was for the production of 2- pyridin-4-yl-6, 7-dihydropyrazolo [1,5-a] pyrazin-4 (5H)-one trifluoroacetate using ethyl 1- (2-aminoethyl)-3- {2- [4- (dimethylamino) phenyl] pyridin-4-yl}- 1 H-pyrazole-5-carboxylate trifluoroacetate (0.350 g, 708 mmol), NH40H (8 mL), and ethanol (4 mL). A yellow solid was obtained (0.204 g, 64.5% yield) : 1H NMR (DMSO-d6/300 MHz) 8 8.61 (d, 1 H), 8.51 (s, 1 H), 8.40 (s, 1 H), 8.03 (d, 2H), 7.96 (d, 1 H), 7.86 (s, 1 H), 6.88 (d, 2H), 4.46 (t, 2H), 3.71-3. 66 (m, 2H), 3.05 (s, 6H); HRMS calculated for (M + H) 334.1662, found 334.1673.

EXAMPLE 37 [000233] This example illustrates the production of 2- [2- (4- methoxyphenyl)-pyridin-4-yl]-6, 7-dihydropyrazolo [1,5-a] pyrazin-4 (5H)-one trifluoroacetate.

[000234] Synthesis was conducted as it was for the production of 2- pyridin-4-yl-6, 7-dihydropyrazolo [1,5-a] pyrazin-4 (5H)-one trifluoroacetate using ethyl 1- (2-aminoethyl)-3- [2- (4-methoxyphenyl) pyridin-4-yl]-1 H- pyrazole-5-carboxyl ate dihydrochloride (0.368 g, 0.838 mmol), NH40H (8 mL), and ethanol (4 mL). A white solid was obtained (0.225 g, 61.8% yield) : 1H NMR (DMSO-d6/300 MHz) 8 8.69 (d, 1 H), 8.45 (s, 1 H), 8.36 (s, 1H), 8.13 (d, 2H), 7.93 (d, 1H), 7. 76 (s, 1H), 7.12 (d, 2H), 4.44 (t, 2H), 3.85 (s, 3H), 3.71-3. 66 (m, 2H); HRMS calculated for (M + H) 321.1346, found 321.1359.

EXAMPLE 38 [000235] This example illustrates the production of 2- [2- (3- nitrophenyl) pyridin-4-yl]-6, 7-dihydropyrazolo [1,5-a] pyrazin-4 (5H)-one trifluoroacetate.

[000236] Synthesis was conducted as it was for the production of 2- pyridin-4-yl-6, 7-dihydropyrazolo [1,5-a] pyrazin-4 (5H)-one trifluoroacetate using ethyl 1- (2-aminoethyl)-3- [2- (3-nitrophenyl) pyridin-4-yl]-1 H-pyrazole- 5-carboxylate dihydrochloride (0.350 g, 0.771 mmol), NH40H (8 mL), and ethanol (4 mL). A beige solid was obtained (0.152 g, 43.8% yield) : 1H

NMR (DMSO-d6/300 MHz) S 9.00 (s, 1 H), 8.75 (d, 1 H), 8.66 (d, 1 H), 8.32- 8.28 (m, 2H), 7.89 (d, 1 H), 7.81 (dd, 1 H), 7.73 (s, 1 H), 4.43 (t, 2H), 3.70- 3.65 (m, 2H); HRMS calculated for (M + H) 336. 1091, found 336.1068.

EXAMPLE 39 [000237] This example illustrates the production of 2- [2- (3, 4- difluorophenyl) pyridin-4-yl]-6, 7-dihydropyrazolo [1,5-a] pyrazin-4 (5H)-one trifluoroacetate.

[000238] Synthesis was conducted as for the production of ethyl 1- (2- aminoethyl)-3- [2- (3-nitrophenyl) pyridin-4-yl]-1 H-pyrazole-5-carboxylate dihydrochloride using 2-(2-chloropyridin-4-yl)-6, 7-dihydropyrazolo [1,5- a] pyrazin-4 (5H) -one (0.175 g, 0.702 mmol), 3, 4-difluorophenylboronic acid (0. 167 g, 1.05 mmol), 2M Na2CO3 (2 mL), toluene (7 mL), and Pd [dppf] Ct2'CH2Ct2 (0.046 g, 0.057 mmol). The TFA salt was isolated as a white solid (0.076 g, 25% yield) : 1H NMR (DMSO-d6/300 MHz) 8 8.68 (d, 1 H), 8.42 (s, 1 H), 8.32-8. 23 (m, 2H), 8.09 (d, 1 H), 7.82 (s, 1 H), 7.69 (s, 1 H), 7.55 (dd, 1 H), 4.41 (t, 2H), 3.69-3. 64 (m, 2H) ; HRMS calculated for (M + H) 327.1052, found 327.1078.

EXAMPLE 40 [000239] This example illustrates the production of 2- [2- (3, 4- dichlorophenyl) pyridin-4-yl]-6, 7-dihydropyrazolo [1,5-a] pyrazin-4 (5H)-one trifluoroacetate.

[000240] Synthesis was conducted as for the production of ethyl 1- (2- aminoethyl)-3- [2- (3-nitrophenyl) pyridin-4-yl]-1 H-pyrazole-5-carboxylate dihydrochloride using 2- (2-chloropyridin-4-yl)-6, 7-dihydropyrazolo [1,5- a] pyrazin-4 (5H) -one (0.175 g, 0.702 mmol), 3, 4-dichlorophenylboronic acid (0.200 g, 1.05 mmol), 2M Na2CO3 (2 mL), toluene (7 mL), and Pd [dppf] CI2 CH2CI2 (0.046 g, 0.057 mmol). The TFA salt was obtained as a gray solid (0. 016 g, 4.9% yield) : 1H NMR (DMSO-d6, TFA/300 MHz) 8 8.81 (d, 1H), 8.66 (s, 1H), 8.42-8. 34 (m, 2H), 8. 28-8. 18 (m, 2H), 7.87-7. 85 (m, 2H), 4.45 (t, 2H), 3.71-3. 64 (m, 2H), HRMS calculated for (M + H) 359.0461, found 359.0476.

EXAMPLE 41 [000241] This example illustrates the production of 1- (3-aminopropyl)-3- [2- (3-nitrophenyl) pyridin-4-yl]-1 H-pyrazole-5-carboxylic acid dihydrochloride.

[000242] Synthesis was conducted as for the preparation of 1- (2- aminoethyl)-3-pyridin-4-yl-1 H-pyrazole-5-carboxylic acid trifluoroacetate, using ethyl 1-{3-[(tert-butoxycarbonyl)amino]propyl}-3-[2-(3- nitrophenyl) pyridin-4-yl]-1 H-pyrazole-5-carboxylate (0.253 g, 0.539 mmol) and LiOH. H20 (0.0679 g, 1.62 mmol. The isolated TFA salt was a tacky solid, and thus converted to the HCI salt using methanol and 4N HCI/dioxane. After 0.5 h, the suspension was concentrated and the solid rinsed with diethyl ether to afford a white solid (0.223 g, 94.6% yield) : 1 H NMR (DMSO-d6/300 MHz) 8 9.00 (dd, 1 H), 8.79 (d, 1 H), 8.68 (d, 1 H), 8.60 (s, 1H), 8.34 (dd, 1H), 8.11 (brs, 3H), 7.99 (dd, 1H), 7.88-7. 81 (m, 2H), 4.68 (t, 2H), 2.86-2. 79 (m, 2H), 2.20-2. 15 (m, 2H); HRMS calculated for (M + H) 368.1353, found 368.1336.

EXAMPLE 42 [000243] This example illustrates the production of 1- (2-aminoethyl)-3- (2- quinolin-3-ylpyridin-4-yl)-1 H-pyrazole-5-carboxylic acid trifluoroacetate.

[000244] Synthesis was conducted as for the preparation of 1- (2- aminoethyl)-3-pyridin-4-yl-1 H-pyrazole-5-carboxylic acid trifluoroacetate, using ethyl 1-(2-aminoethyl)-3-(2-quinolin-3-ylpyridin-4-yl)-1 H-pyrazole-5- carboxylate dihydrochloride (0.211 g, 0.457 mmol) and LiOH'HgO (0.077 g, 1.8 mmol). A pink solid was obtained (0. 150 g, 69.4% yield) : 1H NMR (DMSO-d6/300 MHz) b 9.75 (s, 1 H), 9.23 (d, 1 H), 8.82 (d, 1 H), 8.69 (s, 1H), 8.17-8. 10 (m, 2H), 8.01-7. 94 (m, 3H), 7.89-7. 83 (m, 2H), 7.72 (dd, 1 H), 4.86 (t, 2H), 3.44-3. 38 (m, 2H); HRMS calculated for (M + H) 360.1455, found 360.1466.

EXAMPLE 43 [000245] This example illustrates the production of 1- (2-aminoethyl)-3- [2- (3-nitrophenyl) pyridin-4-yl]-1 H-pyrazole-5-carboxylic acid dihydrochloride.

[000246] Synthesis was conducted as for the preparation of 1- (2- aminoethyl)-3-pyridin-4-yl-1 H-pyrazole-5-carboxylic acid trifluoroacetate, using ethyl 1- (2-aminoethyl)-3- [2- (3-nitrophenyl) pyridin-4- yl]-1 H-pyrazole-5-carboxylate dihydrochloride (0.262 g, 0.516 mmol) and LiOH. H2O (0.097 g, 2.3 mmol). The isolated TFA salt converted to the HCI salt using methanol and 4N HCI/dioxane. After 0.5 h, the suspension was concentrated and the solid rinsed with diethyl ether to afford a yellow solid (0.102 g, 46.5% yield) : 1H NMR (DMSO-d6/300 MHz) 89. 01 (s, 1 H), 8.80 (d, 1 H), 8.70-8. 64 (m, 2H), 8.35-8. 28 (m, 4H), 8.02 (d, 1 H), 7.89-7. 82 (m, 2H), 3.39-3. 33 (m, 2H); HRMS calculated for (M + H) 354.1197, found 354.1176.

EXAMPLE 44 [000247] This example illustrates the production of 1- (2-aminoethyl)-3- [2- (4-methoxyphenyl) pyridin-4-yl]-1 H-pyrazole-5-carboxylic acid trifluoroacetate.

[000248] Synthesis was conducted as for the preparation of 1- (2- aminoethyl)-3-pyridin-4-yl-1 H-pyrazole-5-carboxylic acid trifluoroacetate, using ethyl 1-(2-aminoethyl)-3-[2-(4-methoxyphenyl) pyridin-4-yl]-1 H- pyrazole-5-carboxylate dihydrochloride (0.260 g, 0.591 mmol) and LiOH. H2O (0.099 g, 2.4 mol). A pale yellow solid was obtained (0.212 g, 79.4% yield) : 1H NMR (DMSO-d6/300 MHz) b 8.69 (d, 1 H), 8.42 (s, 2H), 8.15 (d, 1H), 8.00 (brs, 3H), 7.88-7. 84 (m, 2H), 7.09 (d, 2H), 4.84 (t, 2H), 3.84 (s, 3H), 3.38-3. 42 (m, 2H); HRMS calcd for (M + H) 339.1452, found 339.1472.

EXAMPLE 45 [000249] This example illustrates the production of 1- (2-aminoethyl)-3- {2- [4-(trifluoromethoxy) phenyl] pyridin-4-yl}-1 H-pyrazole-5-carboxylic acid trifluoroacetate.

[000250] Synthesis was conducted as for the preparation of 1- (2- aminoethyl)-3-pyridin-4-yl-1 H-pyrazole-5-carboxylic acid trifluoroacetate, using ethyl 1- (2-aminoethyl)-3- {2- [4- (trifluoromethoxy) phenyl] pyridin-4-yl}-

1 H-pyrazole-5-carboxylate dihydrochloride (0.257 g, 0.521 mmol) and LiOHH2O (0.097 g, 2.3 mmol). A beige solid was obtained (0. 088 g, 34% yield) : 1H NMR (DMSO-d6/300 MHz) 6 8. 73 (d, 1 H), 8.50 (s, 1 H), 8.32 (d, 2H), 8.01 (br s, 3H), 7.88 (d, 1 H), 7.81 (s, 1 H), 7.51 (d, 2H), 4.84 (t, 2H), 3.42-3. 38 (m, 2H); HRMS calculated for (M + H) 393.1169, found 393.1189.

EXAMPLE 46 [000251] This example illustrates the production of 1-(2-aminoethyl)-3-{2- [4-(dimethylamino) phenyl] pyridin-4-yl}-1 H-pyrazole-5-carboxylic acid trifluoroacetate.

[000252] Synthesis was conducted as for the preparation of 1- (2- aminoethyl)-3-pyridin-4-yl-1 H-pyrazole-5-carboxylic acid trifluoroacetateusing ethyl 1- (2-aminoethyl)-3- {2- [4- (dimethylamino) phenyl] pyridin-4-yl}-1 H-pyrazole-5-carboxylate trifluoroacetate (0.238 g, 0.482 mmol) and LiOH. H2O (0.088 g, 2.1 mmol).

A neon orange solid was obtained (0.150 g, 67.0% yield): 1H NMR (DMSO-d6/300 MHz) 8 8.64 (d, 1 H), 8.46 (s, 1 H), 8.07-8. 04 (m, 5H), 7.91- 7.88 (m, 2H), 6.86 (d, 2H), 4.86 (t, 2H), 3.43-3. 37 (m, 2H), 3.03 (s, 6H); HRMS calcd for (M + H) 352.1768, found 352.1770.

EXAMPLE 47 [000253] This example illustrates the production of 1-(2-aminoethyl)-3-{2- [(E)-2-phenylethenyl] pyridin-4-yl}-1 H-pyrazole-5-carboxylic acid trifluoroacetate.

[000254] Synthesis was conducted as in the preparation of 1- (2- aminoethyl)-3-pyridin-4-yl-1 H-pyrazole-5-carboxylic acid trifluoroacetate, using ethyl 1- inoethyl)-3-{2-[(E)-2-phenylvinyl] pyridin-4-yl}-1 H- pyrazole-5-carboxylate dihydrochloride (0.311 g, 0.714 mmol) and LiOHH20 (0. 120 g, 2.86 mmol). The TFA salt was isolated as a light yellow solid (0.220 g, 68.7% yield) : 1H NMR (DMSO-d6/300 MHz) 8 8.68 (d, 1 H), 8.26 (s, 1 H), 8.03 (br s, 3H), 7.89-7. 84 (m, 2H), 7.73-7. 68 (m, 3H),

7.45-7. 36 (m, 4H), 4.89 (t, 2H), 3.41-3. 39 (m, 2H); HRMS calculated for (M + H) 335.1503, found 335.1496.

EXAMPLE 48 [000255] This example illustrates the production of 1- (3-aminopropyl)-3- (2-quinolin-3-ylpyridin-4-yl)-1 H-pyrazole-5-carboxylic acid dihydrochloride.

[000256] Synthesis was conducted as for the preparation of 1- (2- aminoethyl)-3-pyridin-4-yl-1 H-pyrazole-5-carboxylic acid trifluoroacetate, using ethyl 1-(3-aminopropyl)-3-(2-quinolin-3-ylpyridin-4-yl)-1 H-pyrazole-5- carboxylate dihydrochloride (0.134 g, 0.282 mmol) and LiOH. H2O (0.047 g, 1.1 mmol). The TFA salt was converted to the HCI salt using methanol and 4N HCI/dioxane. After 0.5 h, the suspension was concentrated and the solid rinsed with diethyl ether to afford a yellow solid (0.086 g, 68% yield) :'H NMR (DMSO-d6/300 MHz) b 9.92 (d, 1 H), 9.95 (s, 1 H), 9.83 (s, 1H), 8.44-8. 41 (m, 2H), 8.17-8. 09 (m, 4H), 8.03 (d, 1H), 7.94 (dd, 1H), 7.86 (s, 1H), # 4. 69 (t, 2H), 2.90-2. 82 (m, 2H), 2.25-2. 16 (m, 2H); HRMS calculated for (M + H) 374.1612, found 374.1622.

EXAMPLE 49 [000257] This example illustrates the production of 1- (2-aminoethyl)-3- {2- [4-(hydroxymethyl)phenyl]pyridin-4-yl)-1H-pyrazole-5-carboxy lic acid dihydrochloride.

[000258] Synthesis was conducted as for the preparation of 1- (2- aminoethyl)-3-pyridin-4-yl-1 H-pyrazole-5-carboxylic acid trifluoroacetate, using ethyl 1- (2-aminoethyl)-3- {2- [4- (hydroxymethyl) phenyl] pyridin-4-yl}- 1 H-pyrazole-5-carboxylate dihydrochloride (0.167 g, 0.379 mmol) and LiOH*H2O (0.064 g, 1. 5 mmol). The TFA salt was converted to the HCI salt using methanol and 4N HCI/dioxane. After 0.5 h, the suspension was concentrated and the solid rinsed with diethyl ether to afford a pale pink solid (0.069 g, 70% yield) : 1H NMR (DMSO-d6/300 MHz) 8 8.80 (d, 1 H), 8.67 (s, 1H), 8.33 (br s, 3H), 8.22-8. 19 (m, 3H), 8.00 (s, 1H), 7.55 (d, 2H), 4.89 (t, 2H), 4.62 (m, 2H), 3.40-3. 35 (m, 2H); HRMS calculated for (M + H) 339. 1452, found 339. 1435.

EXAMPLE 50 [000259] This example illustrates the production of 1- (2-aminoethyl)-3- [2- (3-methoxyphenyl) pyridin-4-yl]-1 H-pyrazole-5-carboxylic acid trifluoroacetate.

[000260] Synthesis was conducted as for the preparation of 1- (2- aminoethyl)-3-pyridin-4-yl-1 H-pyrazole-5-carboxylic acid trifluoroacetate, using ethyl 1- (2-aminoethyl)-3- [2- (3-methoxyphenyl) pyridin-4-yl]-1 H- pyrazole-5-carboxylate dihydrochloride (0.179 g, 0.407 mmol) and LiOH'HsO (0.105 g, 2.50 mmol). An off-white solid was obtained (0.168 g, 91.2% yield) : 1H NMR (DMSO-d6/300 MHz) 8 8.72 (d, 1 H), 8.43 (s, 1 H), 8.00 (br s, 3H), 7.88 (d, 1 H), 7.83 (s, 1 H), 7.78-7. 74 (m, 2H), 7.44 (dd, 1 H), 7.06 (dd, 1H), 4.84 (t, 2H), 3.85 (s, 3H), 3.44-3. 38 (m, 2H); HRMS calculated for (M + H) 339.1452, found 339.1469.

EXAMPLE 51 [000261] This example illustrates the production of 1- (2-aminoethyl)-N- hydroxy-3- {2- [4- (hydroxymethyl) phenyl] pyridin-4-yl}-1 H-pyrazole-5- carboxamide trifluoroacetate.

[000262] Freshly made sodium methoxide (3.48 M, 0.27 mL) was added dropwise to a stirring solution of hydroxylamine hydrochloride (0.039 mL, 0.94 mmol) in methanol (1 mL) maintained at 40°C. The white slurry was cooled to room temperature, and then a solution of ethyl 1-{2-[(tert- <BR> <BR> <BR> butoxycarbonyl) amino] ethyl}-3- {2- [4- (hydroxymethyl) phenyl] pyridin-4-yl}- 1 H-pyrazole-5-carboxylate (0.400 g, 0.857 mmol) in methanol (5 mL) was added. After stirring for 48 h, 7 mL of 4N HCI (aq) was added and the reaction stirred for 20 h. Purification by Gilson RP HPLC (5-95% acetonitrile/water) afforded a pink solid (0.129 g, 32. 1% yield): 1H NMR (DMSO-d6/300 MHz) 8 11. 53 (br s, 1 H), 8.73 (d, 1 H), 8.31 (s, 1 H), 8.11- 8.01 (m, 5H), 7.75 (d, 1 H), 7.52-7. 46 (m, 3H), 4.77 (t, 2H), 4.58 (s, 2H), 3 42-3.35 (m, 2H); HRMS calculated for (M + H) 354. 1561, found 354.1538.

EXAMPLE 52 [000263] This example illustrates the production of 2- [2- (1 H-pyrazol-1- yl) pyridin-4-yl]-5, 6,7, 8-tetrahydro-4H-pyrazolo [1,5-a] [1,4] diazepin-4-one hydrochloride.

[000264] A flask was charged with 1. 2- (2-chloropyridin-4-yl)-5, 6,7, 8- tetrahydro-4H-pyrazolo [1,5-a] [1,4] diazepin-4-one (0.251 g, 0.960 mmol), pyrazol (0.325 g, 4.78 mmol), and sodium hydride (0.229 g, 5.73 mmol) in 6 mL anhydrous DMF and stirred under N2 for 60 h at 138°C. The reaction was then quenched with 1 N HCI (aq) and purified by Gilson RP HPLC (5-95% acetonitrile/water). The appropriate fractions were concentrated and converted to the HCI salt using methanol and 4N HCI/dioxane. The mixture was concentrated to a light yellow solid (0.028 g, 8.2% yield) : 1 H NMR (DMSO-d6/300 MHz) 8 8.64 (d, 1 H), 8.48 (d, 1 H), 8.35 (br s, 2H), 7.85 (s, 1 H), 7.77 (d, 1 H), 7.45 (s, 1 H), 6.59 (s, 1 H), 4.53 (t, 2H), 3.26-3. 20 (m, 2H), 2.22-2. 16 (m, 2H); HRMS calculated for (M + H) 295. 1302, found 295. 1285.

EXAMPLE 53 [000265] This example illustrates the production of 2- [2- (1 H-imidazol-1- yl) pyridin-4-yl]-5, 6,7, 8-tetrahydro-4H-pyrazolo [1,5-a] [1,4] diazepin-4-one hydrochloride.

[000266] Synthesis was conducted as for the production of 2- [2- (1 H- pyrazol-1-yl) pyridin-4-yl]-5, 6,7, 8-tetrahydro-4H-pyrazolo [1,5- a] [1,4] diazepin-4-one hydrochloride using 2- (2-chloropyridin-4-yl)-5, 6,7, 8- tetrahydro-4H-pyrazolo [1,5-a] [1,4] diazepin-4-one (0.251 g, 0.960 mmol) and imidazole, sodium derivative (0.431 g, 4.78 mmol). A white solid was obtained (0.074 g, 23% yield) : 1H NMR (DMSO-d6/300 MHz) 8 10.0 (s, 1 H), 8.62 (d, 1 H), 8.55 (s, 1 H), 8.48 (s, 1 H), 8.41 (br s, 1 H), 7.99 (d, 1 H), 7.90 (s, 1H), 7.65 (s, 1H), 4.53 (t, 2H), 3.28-3. 22 (m, 2H), 2.22-2. 16 (m, 2H); HRMS calculated for (M + H) 295.1302, found 295.1290.

EXAMPLE 54 [000267] This example illustrates the production of 2- [2- (1 H-pyrrol-1- yl) pyridin-4-yl]-5, 6,7, 8-tetrahydro-4H-pyrazolo [1,5-a] [1,4] diazepin-4-one trifluoroacetate.

[000268] Synthesis was conducted as for the production of 2- [2- (1 H- pyrazol-1-yl) pyridin-4-yl]-5, 6,7, 8-tetrahydro-4H-pyrazolo [1,5- a] [1,4] diazepin-4-one hydrochloride, using 2-(2-chloropyridin-4-yl)-5, 6,7, 8- tetrahydro-4H-pyrazolo [1,5-a] [1,4] diazepin-4-one (0.251 g, 0.960 mmol), pyrrole (0.334 mL, 4.78 mmol), and sodium hydride (0.229 g, 5.73 mmol).

The TFA salt was isolated as a black solid (0.128 g, 32.7% yield) : 1H NMR (DMSO-d6/300 MHz) 8 8.42 (d, 1 H), 8.34 (br s, 1 H), 8.05 (s, 1 H), 7.79 (br s, 2H), 7.67-7. 64 (m, 2H), 6.30 (br s, 2H), 4.52 (t, 2H), 3.28-3. 22 (m, 2H), 2. 22-2. 16 (m, 2H); HRMS calculated for (M, + H) 294.1349, found 294.1348.

EXAMPLE 55 [000269] This example illustrates the production of 2- [2- (4-methyl-1 H- imidazol-1-yl) pyridin-4-yl]-5, 6,7, 8-tetrahydro-4H-pyrazolo [1,5-a] [1, 4] diazepin-4-one hydrochloride.

[000270]-Synthesis was conducted as for the production of 2- [2- (1 H- pyrazol-1-yl) pyridin-4-yl]-5, 6,7, 8-tetrahydro-4H-pyrazolo [1,5- a] [1,4] diazepin-4-one hydrochloride, using 2-(2-chloropyridin-4-yl)-5, 6,7, 8- tetrahydro-4H-pyrazolo [1,5-a] [1,4] diazepin-4-one (0.251 g, 0.960 mmol), 4-methylimidazole (0.393 g, 4.78 mmol), and sodium hydride (0.229 g, 5.73 mmol). A brown solid was obtained (0.053 g, 16% yield) : 1H NMR (DMSO-d6/300 MHz) 8 9.88 (s, 1 H), 8.60 (d, 1 H), 8.40 (br s, 2H), 8.28 (s, 1 H), 7.97 (d, 1 H), 7.63 (s, 1 H), 4.53 (t, 2H), 3.29-3. 22 (m, 2H), 2.36 (s, 3H), 2.22-2. 16 (m, 2H); HRMS calculated for (M + H) 309.1458, found 309. 1462.

EXAMPLE 56 [000271] This example illustrates the production of 2- [2- (4-phenyl-1 H- imidazol-1-yl) pyridin-4-yl]-5, 6,7, 8-tetrahydro-4H-pyrazolo [1, 5-a] [1,4] diazepin-4-one trifluoroacetate.

[000272] Synthesis was conducted as for the production of 2- [2- (1 H- pyrazol-1-yl) pyridin-4-yl]-5, 6,7, 8-tetrahydro-4H-pyrazolo [1,5- a] [1,4] diazepin-4-one hydrochloride, using 2- (2-chloropyridin-4-yl)-5, 6, 7, 8- tetrahydro-4H-pyrazolo [1,5-a] [1,4] diazepin-4-one (0.251 g, 0.960 mmol), 4-phenylimidazole (0.690 g, 4.78 mmol), and sodium hydride (0.229 g, 5.73 mmol). The TFA salt was isolated as a white solid (0. 060 g, 13% yield) : 1H NMR (DMSO-d6/300 MHz) 8 9. 17 (s, 1H), 8.76 (s, 1H), 8.57 (d, 1 H), 8.37-8. 32 (m, 2H), 7.93-7. 88 (m, 3H), 7.65 (s, 1 H), 7.47 (dd, 2H), 7.36-7. 34 (m, 1H), 4.54 (t, 2H), 3.29-3. 22 (m, 2H), 2.22-2. 16 (m, 2H); HRMS calculated for (M + H) 371.1615, found 371.1626.

EXAMPLE 57 [000273] This example illustrates the production of 2- [2- (4-methyl-1 H- pyrazol-1-yl) pyridin-4-yl]-5, 6,7, 8-tetrahydro-4H-pyrazolo [1,5-a] [1,4] diazepin-4-one trifluoroacetate.

[000274] Synthesis was conducted as it was for the production of 2- [2- (1 H-pyrazol-1-yl) pyridin-4-yl]-5, 6,7, 8-tetrahydro-4H-pyrazolo [1,5- a] [1, 4] diazepin-4-one hydrochloride, using 2- (2-chloropyridin-4-yl)-5, 6,7, 8- tetrahydro-4H-pyrazolo [1,5-a] [1,4] diazepin-4-one (0.251 g, 0. 960 mmol), 4-methylpyrazole (0.40 mL, 4.8 mmol), and sodium hydride (0.229 g, 5.73 mmol). The TFA salt was isolated as a white solid (0.068 g, 16% yield) : 1H NMR (DMSO-d6 I 300 MHz) # 8. 45-8.29 (m, 4H), 7.72 (m, 1 H), 7.66 (s, 1 H), 7.42 (s, 1 H), 4.54 (t, 2H), 3.25-3. 20 (m, 2H), 2.20-2. 11 (m, 5H); HRMS calculated for (M + H) 309.1458, found 309.1448.

EXAMPLE 58 [000275] This example illustrates the production of 2- [2- (1 H-1,2, 4-triazol- 1-yl) pyridin-4-yl]-5, 6,7, 8-tetrahydro-4H-pyrazolo [1,5-a] [1,4] diazepin-4-one hydrochloride.

[000276] Synthesis was conducted as it was for the production of 2- [2- (1 H-pyrazol-1-yl) pyridin-4-yl]-5, 6,7, 8-tetrahydro-4H-pyrazolo [1,5- a] [1,4] diazepin-4-one hydrochloride, using 2- (2-chloropyridin-4-yl)-5, 6,7, 8- tetrahydro-4H-pyrazolo [1,5-a] [1,4] diazepin-4-one (0.251 g, 0.960 mmol) and 1,2, 4-triazole, sodium derivative (0.435 g, 4.78 mmol). A white solid was obtained (0.157 g, 48.4% yield) : 1H NMR (DMSO-d6/300 MHz) 8 9.40 (s, 1 H), 8.55 (d, 1 H), 8.37-8. 33 (m, 2H), 8.27 (s, 1 H), 7.90 (dd, 1 H), 7.50 (s, 1H), 4.53 (t, 2H), 3.25-3. 20 (m, 2H), 2.22-2. 14 (m, 2H); HRMS calcd for (M + H) 296.1254, found 296.1244.

EXAMPLE 59 [000277] This example illustrates the production of 2- [2- (1 H-1,2, 3-triazol- 1-yl) pyridin-4-yl]-5, 6, 7, 8-tetrahydro-4H-pyrazolo [1,5-a] [1,4] diazepin-4-one hydrochloride.

[000278] Synthesis was conducted as it was for the production of 2- [2- (1 H-pyrazol-1-yl) pyridin-4-yi]-5, 6,7, 8-tetrahydro-4H-pyrazolo [1,5- a] [1,4] diazepin-4-one hydrochloride, using 2-(2-chloropyridin-4-yl)-5, 6,7, 8- tetrahydro-4H-pyrazolo [1,5-a] [1,4] diazepin-4-one (0.251 g, 0.960 mmol), 1,2, 3-triazole (0.28 mL, 4.8 mmol), and sodium hydride (0.229 g, 5.73 mmol). A white solid was obtained (0. 118 g, 36.0% yield) : 1H NMR (DMSO-d6/300 MHz) 8 8.89 (s, 1 H), 8.61 (d, 1 H), 8.52 (s, 1 H), 8.37 (br s, 1 H), 8.01-7. 96 (m, 2H), 7.55 (s, 1 H), 4.54 (t, 2H), 3.29-3. 22 (m, 2H), 2.22- 2.16 (m, 2H); HRMS calcd for (M + H) 296.1254, found 296.1243.

EXAMPLE 60 [000279] This example illustrates the production of ethyl 1- {3- [ (tert- butoxycarbonyl)-amino] propyl}-3- (4-methoxyphenyl)-1 H-pyrazole-5- carboxylate.

[000280] To a cooled (0°C) solution of ethyl 3-(4-methoxyphenyl)-1 H- pyrazole-5-carboxylatein anhydrous DMF (35 mL) was added lithium t- butoxide (1 M in THF, 6.6 mL) dropwise. The reaction stirred for 30 min, and then a solution of tert-butyl 3-bromopropylcarbamate (1.57 g, 6.60 mmol) and sodium iodide (0.989 g, 6. 60 mol) in anhydrous DMF (10 mL) was added dropwise. The reaction was allowed to stir and warm to room temperature for 4 h. The reaction was then poured into water and brine and extracted with ethyl acetate. The organic layers were combined, dried over MgS04, filtered, and concentrated. Chromatographic purification (15% ethyl acetate/hexane) afforded a yellow oil (1.13 g, 63.7% yield) : 1 H NMR (DMSO-d6/300 MHz) 8 7.81 (d, 2H), 7.27 (s, 1 H), 6.87 (t, 1 H), 6.79 (d, 2H), 4.52 (t, 2H), 4.37 (q, 2H), 3.80 (s, 3H), 3.30-2. 94 (m, 2H), 1.96- 1.91 (m, 2H), 1.39-1. 33 (m, 12H); HRMS calculated for (M + H) 404.2180, found 404.2190.

EXAMPLE 61 [000281] This example illustrates the production of 1- {3- [ (tert- butoxycarbonyl)-amino] propyl}-3-(4-methoxyphenyl)-1 H-pyrazole-5- carboxylic acid.

[000282] A solution of ethyl 1-{3-[(tert-butoxycarbonyl) amino] propyl}-3-(4- methoxyphenyl)-1H-pyrazole-5-carboxylate (0.467 g, 1.16 mmol) and UOH. H20 (0.097 g, 2.32 mmol) in 12 mL of THF/H20 (1: 1) stirred at room temperature for 3 h. The reaction mixture was concentrated to the aqueous phase, then diluted with 0. 1 N HCI and extracted three times with ethyl acetate. The organic layers were combined, dried over MgS04, filtered, and concentrated to a pale yellow solid (0.359 g, 82.3% yield) : 1H NMR (DMSO-d6/300 MHz) 8 7. 71 (d, 2H), 7.01-6. 94 (m, 3H), 6.88 (s, 1 H), 4.62 (t, 2H), 3.80 (s, 3H), 2.94-2. 90 (m, 2H), 1.91-1. 84 (m, 2H), 1.39 (s, 9H); HRMS calculated for (M + H) 376.1867, found 376.1906.

EXAMPLE 61 [000283] This example illustrates the production of 1- (3-aminopropyl)-3- (4-hydroxyphenyl)-1 H-pyrazole-5-carboxylic acid dihydrochloride.

[000284] To a cooled (-78 °C) solution of 1- {3- [ (tert- butoxycarbonyl) amino] propyl}-3- (4-methoxyphenyl)-1 H-pyrazole-5- carboxylic acid (0.262 g, 0.70 mmol) in anhydrous dichloromethane (7 mL) was added boron tribromide (1. OM in CH2CI2, 7.0 mL) dropwise. After 1 h the reaction was carefully quenched with water, then concentrated to the aqueous layer and purified by Gilson RP HPLC (5-95% acetonitrile/water).

The appropriate fractions were concentrated. The residue was converted to the HCI salt using 4N HCI/dioxane and methanol. After stirring 1 h, the mixture was concentrated to a white solid (0.238 g, 100% yield) : 1 H NMR (DMSO-d6/300 MHz) 8 8.07 (br s, 3H), 7.67 (d, 2H), 7.18 (s, 1 H), 6.83 (d, 2H), 4.59 (t, 2H), 2.84-2. 78 (m, 2H), 2.18-2. 08 (m, 2H); HRMS calculated for (M + H) 262. 1186, found 262. 1195.

EXAMPLE 62 [000285] This example illustrates the production of ethyl 1- (3- aminopropyl)-3- (4-methoxyphenyl)-1 H-pyrazole-5-carboxylate hydrochloride.

[000286] To a flask charged with ethyl 1- {3- [ (tert- butoxycarbonyl) amino] propyl}-3- (4-methoxyphenyl)-1 H-pyrazole-5- carboxylate (0.588 g, 1.46 mmol) was added 4N HCI/dioxane (5 mL).

After 1 h the reaction mixture was filtered and rinsed with diethyl ether to yield a white solid (0.443 g, 89.4% yield) : 1H NMR (DMSO-d6/300 MHz) 8 8.06 (br s, 3H), 7.81 (d, 2H), 7.32 (s, 1 H), 7.00 (d, 2H), 4.61 (t, 2H), 4.37 (q, 2H), 3.80 (s, 3H), 2.87-2. 80 (m, 2H), 2.20-2. 11 (m, 2H), 1.36 (t, 3H), HRMS calcd for (M + H) 304.1656, found 304.1665.

EXAMPLE 63 [000287] This example illustrates the production of 2- (4-methoxyphenyl)- 5,6, 7, 8-tetrahydro-4H-pyrazolo [1, 5-a] [1, 4] diazepin-4-one.

[000288] To a flask charged with ethyl 1- (3-aminopropyl)-3- (4- methoxyphenyl)-l H-pyrazole-5-carboxylate hydrochloride (0.418 g, 1.23 mmol) was added NH40H (20 mL) and ethanol (10 mL). After stirring for 18h, the reaction was filtered, and the white solid rinsed with diethyl ether to afford a white solid (0.243 g, 76.8% yield) : 1H NMR (DMSO-d6/300

MHz) 6 8.28 (br s, 1 H), 7.77 (d, 2H), 7.10 (s, 1 H), 6. 98 (d, 2H), 4.45 (t, 2H), 3.80 (s, 3H), 3.26-3. 21 (m, 2H), 2.20-2. 13 (m, 2H); HRMS calculated for (M + H) 258.1242, found 258.1237.

EXAMPLE 64 [000289] This example illustrates the production of 2- (4-hydroxyphenyl)- 5,6, 7, 8-tetrahydro-4H-pyrazolo [1,5-a] [1,4] diazepin-4-one.

[000290] Synthesis was conducted as it was for the preparation of 1- (3- amino-propyl)-3- (4-hydroxyphenyl)-1 H-pyrazole-5-carboxylic acid dihydrochloride using ethyl 1- (3-aminopropyl)-3- (4-methoxyphenyl)-1 H- pyrazole-5-carboxylate hydrochloride (0.182 g, 0.70 mmol) and boron tribromide (7.0 mL). Purification by Gilson RP HPLC (5-95% acetonitrile/ water) afforded a white solid (0.078 g, 46% yield) : 1H NMR (DMSO-d6/ 300 MHz) 5 9. 55 (br s, 1 H), 8.25 (br s, 1 H), 7.65 (d, 2H), 7.03 (s, 1 H), 6.80 (d, 2H), 4.44 (t, 2H), 3.26-3. 21 (m, 2H), 2.18-2. 13 (m, 2H); HRMS calculated for (M + H) 244.1081, found 244.1049.

EXAMPLE 65 [000291] This example illustrates the production of ethyl 1- {3- [ (tert- butoxy-carbonyl) amino] propyl}-3- (3-methoxyphenyl)-1 H-pyrazole-5- carboxylate.

[000292] Synthesis was conducted as it was for the preparation of ethyl 1- {3- [ (tert-butoxycarbonyl) amino] propyl}-3- (4-methoxyphenyl)-1 H- pyrazole-5-carboxylate, using ethyl 3- (3-methoxyphenyl)-1 H-pyrazole-5- carboxylate (2.01 g, 8.17 mmol), lithium t-butoxid (12.3 mL), tert-butyl 3- bromopropylcarbamate (2.92 g, 12.3 mmol) and sodium iodide (1.84 g, 12.3 mmol). Flash chromatography (12% ethyl acetate/hexane) afforded a yellow oil, which was triturated with diethyl ether to yield a pale yellow solid (1.47 g, 45.0% yield) : HRMS calculated for (M + H) 404.2180, found 404.2206.

EXAMPLE 66 [000293] This example illustrates the production of 1- {3- [ (tert- butoxycarbonyl)-amino] propyl}-3- (3-methoxyphenyl)-1 H-pyrazole-5- carboxylic acid.

[000294] Synthesis was conducted as it was for the preparation of 1- {3- [(tert-butoxycarbonyl) amino] propyl}-3- (4-methoxyphenyl)-1 H-pyrazole-5- carboxylic acid using ethyl 1-f3- [ (tert-butoxycarbonyl) amino] propyl}-3-(3- methoxyphenyl)-1 H-pyrazole-5-carboxylate (0. 610 g, 1.51 mmol) and LiOHH2O (0.127 g, 3.02 mmol). An off-white solid was obtained (0.565g, 100% yield) : 1H NMR (DMSO-d6/300 MHz) 8 13.47 (br s, 1 H), 7.46-7. 32 (m, 4H), 6.93-6. 86 (m, 2H), 4.56 (t, 2H), 3.83 (s, 3H), 3.01-2. 95 (m, 2H), 1.96-1. 90 (m, 2H), 1.39 (s, 9H); HRMS calculated for (M + H) 376.1873, found 376.1896.

EXAMPLE 67 [000295] This example illustrates the production of 1- (3-aminopropyl)-3- (3-hydroxyphenyl)-1 H-pyrazole-5-carboxylic acid trifluoroacetate.

[000296] Synthesis was conducted as it was for the preparation of 1- (3- amino-propyl)-3- (4-hydroxyphenyl)-l H-pyrazole-5-carboxylic acid dihydrochloride, using 1-{3-[(tert-butoxycarbonyl) amino] propyl}-3-(3- methoxyphenyl)-1 H-pyrazole-5-carboxylic acid (0.496 g, 1.32 mmol) and boron tribromide (1. OM in CH2CI2, 13.0 mL). The TFA salt was isolated as an off-white solid (0.353 g, 71.3% yield) :'H NMR (DMSO-d6/300 MHz) 8 13.62 (br s, 1 H), 9.56 (br s, 1 H), 7.80 (br s, 3H), 7.27-7. 23 (m, 4H), 6.77 (d, 1H), 4.63 (t, 2H), 2.89-2. 81 (m, 2H), 2.17-2. 07 (m, 2H); HRMS calculated for (M + H) 262.1192, found 262.1223.

EXAMPLE 68 [000297] This example illustrates the production of 2- (3-methoxyphenyl)- 5,6, 7, 8-tetrahydro-4H-pyrazolo [1,5-a] [1,4] diazepin-4-one.

[000298] Synthesis was conducted as it was for the preparation of ethyl 1- (3-aminopropyl)-3- (4-methoxyphenyl)-1 H-pyrazole-5-carboxylate hydrochloride, using ethyl 1-{3-[(tert-butoxycarbonyl) amino] propyl}-3-(3- methoxyphenyl)-1 H-pyrazole-5-carboxylate (0.737 g, 1.83 mmol) and 4N HCI/dioxane (10 mL). The resulting colorless oil was subjected to conditions described for the production of 2-(4-methoxyphenyl)-5, 6,7, 8- tetrahydro-4H-pyrazolo [1,5-a] [1, 4] diazepin-4-one, sing NH40H (12 mL) and ethanol (6 mL). An off-white solid was obtained : H NMR (DMSO-d6/

300 MHz) 8.29 (br s, 1 H), 7.34-7. 45 (m, 3H), 7.23 (s, 1 H), 6.90 (dd, 1 H), 4.48 (t, 2H), 3.83 (s, 3H), 3. 26-3. 21 (m, 2H), 2.22-2. 14 (m, 2H); HRMS calculated for (M + H) 258.1242, found 258.1232.

EXAMPLE 69 [000299] This example illustrates the production of 2- (3-hydroxyphenyl)- 5,6, 7, 8-tetrahydro-4H-pyrazolo [1,5-a] [1,4] diazepin-4-one.

[000300] Synthesis was conducted as it was for the preparation of 1- (3- amino-propyl)-3- (4-hydroxyphenyl)-1 H-pyrazole-5-carboxylic acid dihydrochloride, using 2- (3-methoxyphenyl)-5, 6,7, 8-tetrahydro-4H- pyrazol [1,5-a] [1,4] diazepin-4-one (0.325 g 1.26 mmol) and boron tribromide (13.0 mL). Purification by Gilson RP HPLC (5-95% acetonitrile/ water) afforded a white solid (0.194 g, 63.3% yield) : 1H NMR (DMSO-d6/ 300 MHz) 6 9. 45 (br s, 1 H), 8.28 (br s, 1 H), 7.28-7. 19 (m, 3H), 7.08 (s, 1 H), 6.75-6. 72 (m, 1H), 4.47 (t, 2H), 3.26-3. 21 (m, 2H), 2. 20-2. 16 (m, 2H); HRMS calculated for (M + H) 244.1086, found 244.1115.

EXAMPLE 70 [000301] This example illustrates the production of 1- (3- { [2- (4- bromophenyl) ethyl]-amino} propyl)-3-pyridin-4-yl-1 H-pyrazole-5-carboxylic acid hydrochloride.

[000302] A single neck round bottom flask was charged with ethyl 3- pyridin-4-yl-1 H-pyrazole-5-carboxylate (1.0 g, 4.6 mmol) and 30 mL DMF.

The solution was cooled to-40°C in a dry ice/CH3CN bath. A 1 M solution of lithium t-butoxid in THF (6.9 mL, 6.9 mmol) was added dropwise over 5 minutes. After stirring at-40 °C for 30 minutes, a solution of 3- [ [2- (4- bromophenyl) ethyl] (tert-butoxycarbonyl) amino] propyl methanesulfonate (3.0 g, 6.9 mmol) in 10 mL DMF was added dropwise over 5 minutes.

After 1 hour the reaction was allowed to warmed to ambient temperature and stirred for 18 hours. The reaction mixture was concentrated in vacuo, and the residue taken up in ethyl acetate. This was washed 3 times with brine, dried over magnesium sulfate, and concentrated to a brown oil. The oil was treated with 20 mL of a 4 N Hui in dioxane solution, and stirred for 30 minutes to remove the protecting group. After concentrating in vacuo

the crude mixture was treated with 20 mL of a 2.5 N sodium hydroxide solution. The mixture was heated to 100 °C for 1 hour to hydrolyze the ester. The resulting product mixture was concentrated in vacuo to half the volume, and then chromatographed on a Gilson reverse phase HPLC eluting with an acetonitrile/water gradient (5-70% CH3CN over 15 minutes) to provide the desired product as a TFA salt. The salt was taken up in methanol, and treated with 10 mL of a 4 N solution of HCI in dioxane to convert to the HCI salt. Crystallization from diethyl ether afforded 1.30g (56%) of the title compound as a tan solid. LCMS showed a single peak with m/z 429 (M+H). iH nmr (DMSO-d6/300 MHz) 5 9.48 (broad s, 2H), 8.94 (d, 2H), 8.46 (d, 2H), 7.90 (s, 1 H), 7.50 (d, 2H), 7.22 (d, 2H), 4.71 (t, 2H), 3.20-2. 88 (m, 6H), 2.30 (m, 2H), ES+ HRMS calculated for M+H 429.0921, observed 429.0934.

EXAMPLE 71 [000303] This example illustrates the production of 1- (3-aminopropyl)-3- [2- (4-methoxyphenyl) pyridin-4-yl]-1 H-pyrazole-5-carboxylic acid hydrochloride.

[000304] Step 1. Preparation of ethyl 1- (3-aminopropyl)-3- [2- (4- methoxyphenyl) pyridin-4-yl]-1 H-pyrazole-5-carboxylate hydrochloride.

[000305] This compound was prepared as part of a parallel library. A reaction tube was charged with ethyl 1- {3- [ (tert- butoxycarbonyl) amino] propyl}-3-(2-chloropyridin-4-yl)-1 H-pyrazole-5- carboxylate (550 mg, 1.35 mmol) and 4-methoxybenzene boronic acid (307 mg, 2.02 mmol). The mixture was purged with N2, and then 16 mL toluene and 6 mL of a 2M sodium carbonate solution were added. The reaction mixture was again purged with N2. To this stirring mixture [1,1'- bis (diphenyl phosphino) ferrocene] dichloropalladium II CH2CI2 (88 mg, 0. 11 mmol) was added, and the reaction heated to 80°C for 18 hours. The water layer was decanted, and the organic layer filtered through celite, and washed with CH2CI2. The filtrate was concentrated in vacuo, and the residue treated with 10 mL of a 4 N HCI in dioxane solution for 1 hour.

The product was concentrated in vacuo, washed with diethyl ether, and air

dried to afford 673 mg (quantitative) of the desired ester. LCMS showed one major peak with m/z 381 (M+H).

[000306] Step2. Preparation of 1- (3-aminopropyl)-3- [2- (4- methoxyphenyl) pyridin-4-yl]-1 H-pyrazole-5-carboxylic acid hydrochloride.

[000307] This compound was prepared as part of a parallel library. A reaction tube was charged with ethyl 1- (3-aminopropyl)-3- [2- (4- methoxyphenyl) pyridin-4-yl]-1 H-pyrazole-5-carboxylate hydrochloride (200 mg, 0.44 mmol) and 10 mL of a 2.5 N NaOH solution. The mixture was heated to 100°C for 30 minutes, and concentrated in vacuo. The product mixture was chromatographed on a Gilson reverse phase HPLC eluting with an acetonitrile/water gradient (5-70% CH3CN over 15 minutes). The fractions containing the desired product were combined and concentrated.

The oil was taken up in methanol and treated with 5 mL of a 4 N HCI in dioxane solution to obtain the HCI salt. The solution was concentrated to dryness, washed with diethyl ether, and air dried to afford 196 mg (quantitative) of the title carboxylic acid. LCMS showed a single peak with m/z 353 (M+H). ES+ HR MS calculated for M+H 353.1608, observed 353.1640.

EXAMPLE 72 [000308] This example illustrates the production of 1- (3-aminopropyl)-3- {2- [4- (dimethylamino) phenyl] pyridin-4-yl}-1 H-pyrazole-5-carboxylic acid hydrochloride.

[000309] The preparation of 1- (3-aminopropyl)-3- {2- [4- (dimethylamino) phenyl]-pyridin-4-yl}-1 H-pyrazole-5-carboxylic acid hydrochloride was carried out in the same manner as that described for the production of 1-(3-aminopropyl)-3-l2-(4-methoxyphenyl) pyridin-4-yl]- 1 H-pyrazole-5-carboxylic acid hydrochloride, using 4- dimethyl (amino) phenyl boronic acid. Purification afforded the title carboxylic acid as an orange solid. 6% yield over 2 steps. LCMS showed a single peak with m/z 366 (M+H). ES+ HR MS calculated for M+H 366.1925, observed 366. 1918.

EXAMPLE 73 [000310] This example illustrates the production of 1- (3-aminopropyl)-3- {2- [3- (hydroxymethyl) phenyl] pyridin-4-yl}-1 H-pyrazole-5-carboxylic acid hydrochloride.

[000311] The preparation of 1- (3-aminopropyl)-3- {2- [3- (hydroxymethyl) phenyl]-pyridin-4-yl}-1 H-pyrazole-5-carboxylic acid hydrochloride was carried out in the same manner as that described for the production of 1- (3-aminopropyl)-3- [2- (4-methoxyphenyl) pyridin-4-yl]- 1 H-pyrazole-5-carboxylic acid hydrochloride, using 3-hydroxymethylphenyl boronic acid. Purification afforded the title carboxylic acid as a brown solid.

5% yield over 2 steps. LCMS showed a single peak with m/z 353 (M+H).

ES+ HR MS calculated for M+H 353.1608, observed 353.1608.

EXAMPLE 74 [000312] This example illustrates the production of 1- (3-aminopropyl)-3- {2- [4- (trifluoromethoxy) phenyl] pyridin-4-yll-l H-pyrazole-5-carboxylic acid hydrochloride.

[000313] The preparation of 1- (3-aminopropyl)-3- {2- [4- (trifluoromethoxy)- phenyl] pyridin-4-yl}-1 H-pyrazole-5-carboxylic acid hydrochloride was carried out in the same manner as that described for the production of 1- (3-aminopropyl)-3- [2- (4-methoxyphenyl) pyridin-4-yl]-1 H-pyrazole-5- carboxylic acid hydrochloride using 4-trifluoromethoxy-benzene boronic acid. Purification afforded the title carboxylic acid as a brown solid. 3% yield over 2 steps. LCMS showed a single peak with m/z 407 (M+H). ES+ HR MS calculated for M+H 407.1326, observed 407.1358.

EXAMPLE 75 [000314] This example illustrates the production of 2- [2- (4- methoxyphenyl)-pyridin-4-yl]-5, 6,7, 8-tetrahydro-4H-pyrazolo [1,5- a] [1,4] diazepin-4-one.

[000315] This compound was prepared as part of a parallel library. A reaction tube was charged with ethyl 1- (3-aminopropyl)-3- [2- (4-

methoxyphenyl) pyridin-4-yl]-1 H-pyrazole-5-carboxylate hydrochloride (250 mg, 0.55 mmol), 20 mL ammonium hydroxide, and 10 mL ethanol. The reaction mixture was stirred at room temperature for 18 hours. The mixture was then concentrated in vacuo, washed with water, filtered, and vacuum dried to afford 150 mg (81 %) of the title lactam as a tan solid.

LCMS showed a single peak with m/z 335 (M+H). 1H nmr (DMSO-d6 + TFA/300 MHz) 8 8.78 (d, 1 H), 8.68 (s, 1 H), 8.43 (br s, 1 H), 8.26 (d, 1 H), 8.09 (d, 2H), 7.93 (s, 1 H), 7.23 (d, 2H), 4.59 (m, 2H), 3.89 (s, 3H), 3.26 (m, 2H), 2.21 (m, 2H). ES+ HR MS calculated for M+H 335.1503, observed 335.1490.

EXAMPLE 76 [000316] This example illustrates the production of 2- {2- [4- (dimethylamino)-phenyl] pyridin-4-yl}-5, 6,7, 8-tetrahydro-4H-pyrazolo [1,5- a] [1,4] diazepin-4-one trifluoroacetate.

[000317] The preparation of 2-12- [4- (dimethylamino) phenyl] pyridin-4-yll- 5,6, 7, 8-tetrahydro-4H-pyrazolo [1, 5-a] [1,4] diazepin-4-one trifluoroacetate was carried out in a manner similar to that described for the preparation of 2- [2- (4-methoxyphenyl) pyridin-4-yl]-5, 6,7, 8-tetrahydro-4H-pyrazolo [1,5- a] [1,4] diazepin-4-one, except that it was chromatographed on a Gilson reverse phase HPLC eluting with an acetonitrile/water gradient (5-70% CH3CN over 15 minutes). The pure fractions were combined and concentrated to afford the title lactam as a yellow solid (44% yield). LCMS showed a single peak with m/z 348 (M+H). 1H nmr (DMSO-d6/300 MHz) 8 8.61 (d, 1 H), 8. 52 (s, 1 H), 8.41 (br s, 1 H), 8.03 ( (d, 2H), 7.98 (d, 1H), 7.84 (s, 1 H), 6.89 (d, 2H), 4.57 (t, 2H), 3.25 (m, 2H), 3.05 (s, 6H), 2.21 (m, 2H). mp=223.0-226. 7°C ES+ HR MS calculated for M+H 348.1819, observed 348.1790.

EXAMPLE 77 [000318] This example illustrates the production of 2- {2- [3- (hydroxymethyl)-phenyl] pyridin-4-yl}-5, 6,7, 8-tetrahydro-4H-pyrazolo [1,5- a] [1,4] diazepin-4-one trifluoroacetate.

[000319] The preparation of 2- {2- [3- (hydroxymethyl) phenyl] pyridin-4-yl}- 5,6, 7, 8-tetrahydro-4H-pyrazolo [1, 5-a] [1,4] diazepin-4-one trifluoroacetate was carried out in a manner similar to that described for the preparation of 2- [2- (4-methoxyphenyl) pyridin-4-yl]-5, 6,7, 8-tetrahydro-4H-pyrazolo [1,5- a] [1, 4] diazepin-4-one, except that it was chromatographed on a Gilson reverse phase HPLC eluting with an acetonitrile/water gradient (5-70% CH3CN over 15 minutes). The pure fractions were combined and concentrated to afford the lactam as a white solid (26% yield). LCMS showed a single peak with m/z 335 (M+H).'H nmr (DMSO-d6/300 MHz) 8 8.71 (d, 1 H), 8.40 (s, 1 H), 8.35 (br s, 1 H), 8.11 (s, 1 H), 8.03 (d, 1 H), 7.86 (d, 1 H), 7.63 (s, 1 H), 7.53-7. 41 (m, 2H), 4.61 (s, 2H), 4.54 (t, 2H), 3.24 (m, 2H), 2.19 (m, 2H). ES+ HR MS calculated for M+H 335.1503, observed 335.1520.

EXAMPLE 78 [000320] This example illustrates the production of 2- {2- [4- (trifluoromethoxy)-phenyl] pyridin-4-yl}-5, 6,7, 8-tetrahydro-4H-pyrazolo [1, 5- a] [1,4] diazepin-4-one.

[000321] The preparation of 2- {2- [4- (trifluoromethoxy) phenyl] pyridin-4-yl}- 5,6, 7, 8-tetrahydro-4H-pyrazolo [1,5-a] [1,4] diazepin-4-one was carried out in a manner similar to that described for the preparation of 2- [2- (4- methoxyphenyl) pyridin-4-yl]-5, 6,7, 8-tetrahydro-4H-pyrazolo [1,5- a] [1,4] diazepin-4-one. The mixture was then concentrated in vacuo, washed with water, filtered, and vacuum dried to afford the title lactam as an off-white solid (65%). LCMS showed a single peak with m/z 389 (M+H).

1 H nmr (DMSO-d6/300 MHz) 8 8. 70 (d, 1 H), 8.40 (s, 1 H), 8.33 (m, 3H), 7.82 (d, 1 H), 7.62 (s, 1 H), 7.49 (d, 2H), 4.53 (m, 2H), 3.24 (m, 2H), 2. 19 (m, 2H). ES+ HR MS calculated for M+H 389.1220, observed 389.1225.

EXAMPLE 79 [000322] This example illustrates the production of 2- {2- [4- (hydroxymethyl) phenyl] pyridin-4-yl}-5, 6,7, 8-tetrahydro-4H-pyrazolo [1,5- a] [1,4] diazepin-4-one.

[000323] Step 1. The preparation of ethyl 1- (3-aminopropyl)-3- {2- [4- (hydroxymethyl) phenyl] pyridin-4-yl}-1 H-pyrazole-5-carboxylate hydrochloride was carried out in a manner similar to that described for the production of 1- (3-aminopropyl)-3- [2- (4-methoxyphenyl) pyridin-4-yl]-1 H- pyrazole-5-carboxylic acid hydrochloride, step 1 using 4- hydroxymethylphenyl boronic acid. Upon completion of the reaction, ethyl acetate and water were added. The layers were separated, and the organic layer was washed with water, dried over magnesium sulfate, filtered, and concentrated. The resulting residue was treated with excess 4 N HCI/dioxane for 15 minutes at room temperature. The reaction mixture was then chromatographed on a Gilson reverse phase HPLC eluting with an acetonitrile/water gradient (5-70% CH3CN over 15 minutes). The pure fractions were combined, taken up in MeOH, and treated with 4 N HCI/dioxane to afford the HCI salt of the amine ester as a red solid (19 % yield). LCMS showed one major peak with m/z381 (M+H).

[000324] Step 2. The preparation of 2- {2- [4- (hydroxymethyl) phenyl] pyridin-4-yl}-5, 6,7, 8-tetrahydro-4H-pyrazolo [1, 5- a] [1,4] diazepin-4-one was carried out in a manner similar to that described for the preparation of 2- [2- (4-methoxyphenyl) pyridin-4-yl]-5, 6,7, 8- tetrahydro-4H-pyrazolo [1,5-a] [1,4] diazepin-4-one. The product mixture was concentrated and filtered to afford the lactam as a tan solid (44% yield). LCMS showed a single peak with m/z 335 (M+H). ES+ HR MS calculated for M+H 335.1503, observed 335.1520.

EXAMPLE 80 [000325] This example illustrates the production of ethyl 1- (3- aminopropyl)-3- [2- (4 hydroxyphenyl) pyridin-4-yl]-1 H-pyrazole-5- carboxylate hydrochloride.

[000326] The preparation of ethyl 1- (3-aminopropyl)-3- [2- (4- hydroxyphenyl) pyridin-4-yl]-1 H-pyrazole-5-carboxylate hydrochloride was carried out in a manner similar to that described for the production of 1- (3- <BR> <BR> <BR> aminopropyl)-3- [2- (4-methoxyphenyl) pyridin-4-yl]-1 H-pyrazole-5-carboxylic

acid hydrochloride, step 1 using 4-hydroxyphenyl boronic acid THP ether.

Upon completion of the reaction in step 1, ethyl acetate and water were added. The layers were separated, and the organic layer was washed with water, dried over magnesium sulfate, filtered, and concentrated. The residue was treated with excess 4 N HCI/dioxane for 15 minutes. The mixture was concentrated, triturated with ether, and filtered to afford the title amine ester as a tan solid (95% yield). LCMS showed one major peak with m/z 367 (M+H). mp = 241.6-244. 4 °C.

EXAMPLE 81 [000327] This example illustrates the production of 1- (3-aminopropyl)-3- [2- (4-hydroxyphenyl) pyridin-4-yl]-1 H-pyrazole-5-carboxylic acid hydrochloride.

[000328] The preparation of 1- (3-aminopropyl)-3- [2- (4- hydroxyphenyl) pyridin-4-yl]-1 H-pyrazole-5-carboxylic acid hydrochloride was carried out in a manner similar to that described for the production of 1- (3-aminopropyl)-3- [2- (4-methoxyphenyl)-pyridin-4-yl]-1 H-pyrazole-5- carboxylic acid hydrochloride, step 2. The title carboxylic acid was obtained as an off-white solid (51 % yield).). LCMS showed a single peak with m/z 339 (M+H). ES+ HR MS calculated for M+H 339.1452, observed 339. 1455.

EXAMPLE 82 [000329] This example illustrates the production of 2- [2- (4- hydroxyphenyl) pyridin-4-yl]-5, 6,7, 8-tetrahydro-4H-pyrazolo [1,5- a] [1, 4] diazepin-4-one trifluoroacetate.

[000330] The preparation of 2- [2- (4-hydroxyphenyl) pyridin-4-yl]-5, 6,7, 8- tetrahydro-4H-pyrazolo [1,5-a] [1,4] diazepin-4-one trifluoroacetate was carried out in a manner similar to that described for the preparation of 2- [2- (4-methoxyphenyl) pyridin-4-yl]-5, 6,7, 8-tetrahydro-4H-pyrazolo [1,5- a] [1,4] diazepin-4-one. Upon completion of the reaction, the product mixture was concentrated, washed with water, and filtered. The mixture was then chromatographed on a Gilson reverse phase HPLC eluting with

an acetonitrile/water gradient (5-70% CH3CN over 15 minutes). The pure fractions were combined and concentrated to afford the title compound as an off-white solid (41 % yield). LCMS showed a single peak with m/z 321 (M+H). 1 H NMR (DMSO-d6/300 MHz) 8 8.72 (d, 1 H), 8.63 (s, 1 H), 8.42 (br s, 1 H), 8.22 (d, 1 H), 8.02 (d, 2H), 7.81 (s, 1 H), 7.03 (d, 2H), 4.57 (m, 2H), 3.25 (m, 2H), 2.20 (m, 2H). ES+ HR MS calculated for M+H 321.1346, observed 321.1368.

EXAMPLE 83 [000331] This examples illustrates the production of 1- (3- { [2- (4- bromophenyl) ethyl]-amino} propyl)-3-{2-[(E)-2-phenylvinyl] pyridin-4-yl}-1 H- pyrazole-5-carboxylic acid trifluoroacetate.

[000332] Step 1. Preparation of ethyl 1-{3-[[2-(4-bromophenyl) ethyl] (tert- butoxycarbonyl)-amino] propyl}-3- (2-chloropyridin-4-yl)-1 H-pyrazole-5- carboxylate. A single neck roundbottom flask was charged with ethyl 3- (2- chloropyridin-4-yl)-1 H-pyrazole-5-carboxylate (1.0 g, 4.0 mmol) and 30 mL dimethyl formamide under N2. The solution was cooled to-40 °C in a dry ice/acetonitrile bath. A 1 M solution of lithium t-butoxide in THF (4.8 mL, 4.8 mmol) was added dropwise over 5 minutes. The reaction was stirred for 1 hour at-40 °C. A solution of 3- [ [2- (4-bromophenyl) ethyl] (tert- butoxycarbonyl) amino] propyl methanesulfonate (2.1 g, 4.8 mmol) in 10 mL dimethylformamide was added dropwise over 5 minutes. The resulting reaction mixture was stirred for 1 hour at-40 °C, and then stirred for 18 hours at room temperature. The mixture was then concentrated, and the residue taken up in diethyl ether. The solid impurities were filtered off, and washed with diethyl ether. The filtrate was concentrated to a brown oil.

LCMS showed a mixture of the ethyl ester and hydrolyzed carboxylic acid.

This product mixture was taken on to the next step without further purification.

[000333] Step 2. The preparation of ethyl 1- (3- { [2- (4- bromophenyl) ethyl] amino}-propyl)-3-{2-[(E)-2-phenylvinyl] pyridin-4-yl}-1 H- pyrazole-5-carboxylate. hydrochloride was carried out in a manner similar

to that described in example 2, step 1, using 2-phenylvinyl boronic acid.

Upon completion of the reaction, ethyl acetate and water were added. The layers were separated, and the organic layer was washed with water, dried over magnesium sulfate, filtered and concentrated. The residue was treated with excess 4N HCI/dioxane for 30 minutes. The mixture was concentrated, washed with ether, and filtered to afford the ethyl ester as a brown solid (29% yield over 2 steps). LCMS showed one major peak with m/z 559 (M+H). ES+ HR MS calculated for M+H 559.1703, observed 559. 1679.

[000334] Step 3. The preparation of 1- (3- { [2- (4- <BR> <BR> <BR> <BR> bromophenyl) ethyl] amino} propyl)-3-{2-[(E)-2-phenylvinyl] pyridin-4-yl}-1 H- pyrazole-5-carboxylic acid trifluoroacetate was carried out in a manner similar to that described for the production of 1- (3-aminopropyl)-3- [2- (4- methoxyphenyl) pyridin-4-yl]-1 H-pyrazole-5-carboxylic acid hydrochloride, step 2. Upon completion of the reaction, the mixture was concentrated.

The residue was then chromatographed on a Gilson reverse phase HPLC eluting with an acetonitrile/water gradient (5-70% CH3CN over 15 minutes). The pure fractions were combined and concentrated to afford the title compound as an off-white solid (30% yield). LCMS showed a single peak with m/z 531 (M+H). ES+ HR MS calculated for M+H 531.1390, observed 531.1411.

EXAMPLE 84 [000335] This examples illustrates the production of ethyl 1- {2- [ (tert- <BR> <BR> <BR> <BR> butoxy-carbonyl) amino] ethyl}-3- [2- (4- { [tert-butyl (dimethyl) silyl] oxy} phenyl)-<BR> <BR> <BR> <BR> <BR> <BR> pyridin-4-yl]-1 H-pyrazole-5-carboxylate.

[000336] Ethyl 1- {2- [ (tert-butoxycarbonyl) amino] ethyl}-3-(2-chloropyridin- 4-yl)-1H-pyrazole-5-carboxylate (5. 0 g, 0. 013 mol), 4- (t- butyidimethylsilyloxy) phenyl boronic acid (6.4 g, 0.025 mol), sodium carbonate (2.7 g, 0.025 mol), water (12.5 mL), and [1, 1'- bis (diphenylphosphino) ferrocene] dichloro palladium (II) complex with dichloromethane (1: 1) (1.0 g, 0.0013 mol) in toluene (100 mL) were

refluxed for 4 hours. Contents were allowed to cool and partitioned between EtOAc and water. The EtOAc layer was washed with brine, dried over MgS04 and concentrated in vacuo. The residue was filtered through a pad of silica gel, eluting with 25% EtOAc/hexanes to give a light amber oil. The oil crystallized under hexanes and was filtered to give the desired product as a white solid, 3.77 g (51% yield). FABHRMS m/z 567.2983 (M+H, C3oH43N405Si requires 567. 2997). 1H NMR (CI3/300 MHz): 8.70 (s, 1H) ; 8.12 (s, 1H) ; 7.97 (d, 2H); 7.60 (s, 1H) ; 7.29 (d, 1H) ; 6.95 (d, 2H) ; 4.97 (br, 1 H) ; 4.77 (t, 2H); 4.40 (q, 2H); 3.63 (br, 2H); 1.40 (t, 3H); 1.38 (s, 9H); 1.00 (s, 9H); 0.25 (s, 6H).

[000337] Anal. Calculated for C3oH42N40sSi : C, 63.58 ; H, 7.47 ; N, 9.89.

Found: C, 63.51 ; H, 7.58 ; N, 9.73.

EXAMPLE 85 [000338] This example illustrates the preparation of ethyl 1- (2- <BR> <BR> <BR> <BR> aminoethyl)-3- [2- (4- { [tert-butyl (dimethyl) silyl] oxy} phenyl) pyridin-4-yl]-1 H- pyrazole-5-carboxylate dihydrochloride.

[000339] Ethyl 1-{2-[(tert-butoxycarbonyl) amino] ethyl}-3-[2-(4-{[tert- butyl (dimethyl)-silyl] oxy} phenyl) pyridin-4-yl]-1 H-pyrazole-5-carboxylate (1.0 g, 0.0018 mol) and 4N HCI in dioxane were mixed for 2 hours and filtered to give the desired product as a white solid, 875 mg (90% yield).

FABHRMS m/z 467.2450 (M+H, C25H35N403Si requires 467. 2473). 1H NMR (DMSO-d6 + TFA/300 MHz): 8.80 (d, 1 H) ; 8.75 (s, 1 H) ; 8.35 (d, 1 H) ; 8.22 (br, 3H); 8.20-8. 10 (m, 3H); 7.13 (d, 2H); 4.90 (t, 2H); 4.40 (q, 2H); 3.40 (q, 2H); 1.39 (t, 3H); 0.95 (s, 9H); 0.23 (s, 6H).

[000340] Anal. Calculated for C25H34N403Si (2 HCI, 1.1 H20) : C, 53.68 ; H, 6.88 ; N, 10.02. Found: C, 53.34 ; H, 6.98 ; N, 10. 18.

EXAMPLE 86 [000341] This example illustrates the production of 2- [2- (4- hydroxyphenyl) pyridin-4-yl]-6, 7-dihydropyrazolo [1,5-a] pyrazin-4 (5H)-one.

[000342] Ethyl 1-(2-aminoethyl)-3-[2-(4-{[tert- butyl (dimethyl) silyl] oxy} phenyl) pyridin-4-yi]-1 H-pyrazole-5-carboxylate dihydrochloride (770 mg, 0.0014 mol), conc ammonium hydroxide (2 mL)

and methanol (20 mL) were stirred overnight. Contents were concentrated in vacuo and the residue was slurried in water and filtered to give the desired product as a white solid, 373 mg, (87% yield). FABHRMS m/z 307.1222 (M+H, C17H15N402requires 307. 1190). 1 H NMR (DMSO-d6+ TFA/300 MHz): 8.75 (d, 1H) ; 8.63 (s, 1H) ; 8.40 (s, 1H) ; 8.21 (d, 1H) ; 8.00- 7.95 (m, 3H); 7.00 (d, 2H); 4.43 (t, 2H); 3.65 (br, 2H).

[000343] Anal. Calculated for C17H14N402 (1.3 H2O) : C, 61.92 ; H, 5.07 ; N, 16.99. Found: C, 61.79 ; H, 5.11 ; N, 16.85.

EXAMPLE 87 [000344] This example illustrates the production of 2- {2- [4- (2-morpholin- 4-ylethoxy) phenyl] pyridin-4-yl}-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H)- one.

[000345] 2- [2- (4-hydroxyphenyl) pyridin-4-yl]-6, 7-dihydropyrazolo [1,5- a] pyrazin-4 (5H) -one (500 mg, 0.0016 mol), 4-(2-chloroethyl)morpholine hydrochloride (372 mg (0.002 mol) and potassium carbonate (600 mg, 0.004 mol) were heated in DMF (20 mL) at 80°C for 3 hours. Contents were allowed to cool, diluted with water (50 mL), cooled to 0°C and filtered to give the desired product as a white solid, 515 rpg (77% yield).

FABHRMS m/z 420.2004 (M+H, C23H26N503 requires 420. 2030). 1H NMR (DMSO-d6 + TFA/300 MHz): 8.81 (d, 1 H) ; 8.66 (s, 1 H) ; 8.43 (s, 1 H) ; 8.23 (d, 1H) ; 8.15 (d, 2H); 7.94 (s, 1H) ; 7.28 (d, 2H); 4.55-4. 40 (m, 4H); 4.05- 3.95 (m, 2H); 3.80-3. 50 (m, 8H); 3.30-3. 18 (m, 2H).

[000346] Anal. Calculated for C23H25N503 (0. 8 H20) : C, 63.60 ; H, 5.96 ; N, 16.25. Found: C, 63.67 ; H, 6.18 ; N, 16.14.

EXAMPLE 88 [000347] This example illustrates the production of 2- (2- (4- [2- (dimethylamino) ethoxy]-phenyl} pyridin-4-yl)-6, 7-dihydropyrazolo [1,5- a] pyrazin-4 (5H)-one.

[000348] 2- (2- {4- [2- (dimethylamino) ethoxy] phenyl} pyridin-4-yl)-6, 7- dihydropyrazolo [1,5-a] pyrazin-4 (5H) -one was prepared according to the procedure of 2- {2- [4- (2-morpholin-4-ylethoxy) phenyl] pyridin-4-yl}-6, 7- dihydropyrazolo [1,5-a] pyrazin-4 (5H) -one to give the desired product as a

white solid (72% yield). FABHRMS mlz 378. 1901 (M+H, C2rH24N502 requires 378. 1925). 1H NMR (DMSO-d6+ TFA/300 MHz) : 9.80 (br, 1 H) ; 8.80 (d, 1H) ; 8.70 (s, 1H) ; 8.42 (s, 1H) ; 8.28 (d of d, 1H) ; 8.12 (d, 2H); 7.96 (s, 1 H) ; 7.28 (d, 2H); 4.50-4. 40 (m, 4H); 3.70 (br, 2H); 3.60 (br, 2H); 2.90 (s, 6H). Anal. Calculated for C2rH23N502 (0.6 H20) : C, 64.91 ; H, 6.15 ; N, 18.03. Found: C, 64.97 ; H, 6.28 ; N, 18.04.

EXAMPLE 89 [000349] This example illustrates the production of Ethyl 1- (2- aminoethyl)-3-{2-[3-(benzyloxy)phenyl]pyridin-4-yl}-1H-prazo le-5- carboxylate dihydrochloride.

[000350] Ethyl 1-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(2-chloropyridin- 4-yl)-1 H-pyrazole-5-carboxylate and 3-benzyloxyboronic acid were reacted according to the procedure described for the preparation of ethyl 1-{2- [(tert-butoxycarbonyl)-amino] ethyl}-3-[2-(4-{[tert- butyl (dimethyl) silyl] oxy} phenyl) pyridin-4-yl]-1 H-pyrazole-5-carboxylate, to give ethyl 1- (2-t-butoxycarbonylaminoethyl)-3- {2- [3- (benzyloxy- phenyl] pyridin-4-yl}-1 H-pyrazole-5-carboxylate as a light amber oil. Ethyl <BR> <BR> <BR> <BR> 1- (2-t-butoxycarbonytaminoethyi)-3- {2- [3- (benzytoxy) phenyt] pyridin-4-yt}- 1 H-pyrazole-5-carboxylate and 4N HCI in dioxane were stirred 3 hours and filtered to give the desired product as a pale yellow solid, 8.0 g (81% yield). FABHRMS m/z 443.2053 (M+H, C26H27N403 requires 443.2078).

1H NMR (DMSO-d6+ TFA/300 MHz) : 8.88 (d, 1H) ; 8.80 (s, 1H) ; 8.10 (s, 1 H) ; 8.05 (br, 3H); 7.78 (s, 1 H) ; 7.65 (d, 1 H) ; 7.55 (t, 1 H) ; 7.45 (d, 1 H) ; 7.40-7. 30 (m, 6H); 5.21 (s, 2H); 4.85 (t, 2H); 4.35 (q, 2H); 3.40 (q, 2H); 1.35 (t, 3H).

[000351] Anal. Calculated for C26H26N403 (3HCl, H20) : C, 54.80 ; H, 5.48 ; N, 9.83. Found: C, 55. 01; H, 5.84 ; N, 10.75.

EXAMPLE 90 [000352] This example illustrates the production of 2- {2- [3- (benzyloxy) phenyl]-pyridin-4-yl}-6, 7-dihydropyrazolo [1, 5-a] pyrazin-4 (5H) - one.

[000353] 2- {2- [3- (benzyloxy) phenyl] pyridin-4-yl]-6, 7-dihydropyrazolo [1,5- a] pyrazin-4 (5H)-one was prepared according to the procedure for the preparation of 2- [2- (4-hydroxyphenyl) pyridin-4-yl]-6, 7-dihydropyrazolo [1,5- a] pyrazin-4 (5H) -one, using ethyl 1- (2-aminoethyl)-3-12- [3- <BR> <BR> <BR> <BR> (benzyloxy) phenyl] pyridin-4-yl}-1 H-pyrazole-5-carboxylate dihydrochloride, to give the desired product as a white solid (63% yield). FABHRMS m/z 397.1634 (M+H, C24H21 N402 requires 397. 1659). 1H NMR (DMSO-d6+ TFA/300 MHz): 8.81 (d, 1 H) ; 8.62 (s, 1 H) ; 8.40 (s, 1 H) ; 8.21 (d, 1 H) ; 7.92 (s, 1 H); 7.80 (s, 1 H); 7.70 (d, 1 H); 7.63-7. 25 (m, 6H); 5. 23 (s, 2H); 4.51- 4.40 (m, 2H); 3.78-3. 60 (m, 2H). Anal. Calculated for C24H2oN402 (H20): C, 69.55 ; H, 5.35 ; N, 13.52. Found: C, 69.65 ; H, 5.11 ; N, 14.50.

EXAMPLE 91 [000354] This example illustrates the production of ethyl 1- (2- <BR> <BR> <BR> <BR> aminoethyl)-3- [2- (3-hydroxyphenyl) pyridin-4-yl]-1 H-pyrazole-5-carboxylate dihydrochloride.

[000355] Ethyl 1- (2-t-butoxycarbonylaminoethyl)-3- {2- [3- (benzyloxy)phenyl]pyridin-4-yl}-1H-pyrazole-5-carboxylate (9.1 g, 0.017 mol), prepared as for ethyl 1-(2-aminoethyl)-3-{2-[3- (benzyloxy)phenyl]pyridin-4-yl}-1H-pyrazole-5-carboxylate dihydrochloride and 10% palladium/carbon (2.0 g) in ethanol (150 mL) were shaken at 55 psi H2 on a Parr hydrogenator for three and a half days. Contents were filtered through clay and the filtrate was concentrated in vacuo leaving a pale yellow solid (6.4 g). The solid and 4N HCI in dioxane were stirred overnight and filtered to give the desired product as a white solid, 6.0 g (83% yield). HRMS calculated for (M + H) 353.1608, found 353.1630.

1H NMR (DMSO-d6 + TFA/300 MHz): 8.86 (d, 1H) ; 8.77 (s, 1H) ; 8.40 (d, 1 H) ; 8.20 (br s, 3H); 8.12 (s, 1 H) ; 7.59-7. 40 (m, 3H); 7.09 (d, 1 H) ; 4.90 (t, 2H), 4.39 (q, 2H); 3.40 (q, 2H); 1.35 (t, 3H).

EXAMPLE 92 [000356] This example illustrates the production of 2- {2- [3- (2-morpholin- 4-ylethoxy)-phenyl] pyridin-4-yl}-6, 7-dihydropyrazolo [1,5-a] pyrazin-4 (5H)- one.

[000357] 2- {2- [3- (2-morpholin-4-ylethoxy) phenyl] pyridin-4-yl}-6, 7- dihydropyrazolo- [1, 5-a] pyrazin-4 (5H) -one was prepared according to the procedure for 2- {2- [4- (2-morpholin-4-ylethoxy) phenyl] pyridin-4-yl}-6, 7- dihydropyrazolo [1,5-a] pyrazin-4 (5H) -one, using 2- [2- (3- hydroxyphenyl) pyridin-4-yl]-6, 7-dihydropyrazolo [1,5-a] pyrazin-4 (5H)-one and chloroethylmorpholine hydrochloride to give the desired as a white solid (55% yield). FABHRMS m/z 420.1996 (M+H, C23H26N503 requires 420. 2030). in NMR (DMSO-d6 + TFA/300 MHz): 8.85 (d, 1 H) ; 8.61 (s, 1 H); 8.40 (s, 1 H); 8.21 (d, 1 H); 7.89 (s, 1 H); 7.78 (s, 2H); 7.59 (t, 1 H); 7.28 (d, 1H) ; 4.58-4. 40 (m, 4H); 4.08-3. 91 (m 2H); 3.84-3. 48 (m, 8H); 3.45-3. 13 (m, 2H).

[000358] Anal. Calculated for C23H25N503 (0.7 H20) : C, 63.93 ; H, 6.16 ; N, 16.21. Found: C, 63.93 ; H, 5.96 ; N, 16.42.

EXAMPLE 93 [000359] This example illustrates the preparation of 2- (2-Chloropyridin-4- yl)-2, 5,6, 7-tetrahydro-4H-pyrazolo [4, 3-c] pyridin-4-one.

[000360] Step 1. Preparation of 2-Chloro-4-hydrazinopyridine hydrochloride. A solution of 4-amino-2-chloropyridine (1.0 g, 7.78 mmol) in 20% sulfuric acid (20 mL) was cooled to 0 °C and treated with a solution of sodium nitrite (564 mg, 8.17 mmol) in water (3 mL) at a rate such that the reaction temperature did not exceed 10 °C. After 15 minutes, the solution was added to a 0°C suspension of tin (li) chloride in 20% sulfuric acid (20 mL). The frothy suspension was stirred for 15 minutes at 0 °C and then warmed to room temperature over 15 minutes. The mixture was poured into 100 mL of ice water and made basic with concentrated ammonium hydroxide. The product was extracted with diethyl ether and ethyl acetate repeatedly. The organic layers were dried (sodium sulfate) and concentrated to give crude 2-chloro-4-hydrazinopyridine as a yellow solid (830 mg, 5.78 mmol). The solid was dissolved in tetrahydrofuran (5 mL) and diluted with diethyl ether (15 mL). The solution was treated with 1 N HCI in diethyl ether (5.8 mL, 5.8 mmol). The white precipitate was filtered and washed with ether to give 2-chloro-4-hydrazinopyridine

hydrochloride as a white solid (995 mg, 5.53 mmol, 71 % yield). LC-MS (ES+) MH+ = 144.'H NMR (300 MHz, DMSO-d6) b 10.0-9. 40 (br s, 4H), 8.07 (d, J = 6. 1, 1 H), 6.95 (d, J = 1.9, 1 H), 6.86 (dd, J = 5.8, 2.0, 1H).

[000361] Step 2. Preparation of Piperidine-2, 4-dione 4-[(2-chloropyridin- 4-yl) hydrazone]. A mixture of 2-chloro-4-hydrazinopyridine hydrochloride (961 mg, 5.33 mmol), piperdiene-2. 4-dione (Example 1, step 3) (604 mg, 5.33 mmol) and ethanol (20 mL) was refluxed overnight. The reaction mixture was cooled to room temperature, diluted with diethyl ether (20 mL), and filtered. The precipitate was washed with 50% ethanol/diethyl ether and dried to give piperidine-2,4-dione 4-[(2-chloropyridin-4- yl) hydrazone] as an off-white solid (940 mg, 3.94 mmol, 74% yield). LC- MS (ES+) MH+ = 239.

[000362] Step 3. Preparation of 2- (2-Chloropyridin-4-yl)-2, 5,6, 7- tetrahydro-4H-pyrazolo [4,3-c] pyridin-4-one.

[000363] A mixture of piperidine-2,4-dione 4- [ (2-chloropyridin-4- yl) hydrazone] (863 mg, 3.62 mmol) in dimethylformamide dimethyl acetal (16 mL) was refluxed for 1 hour. The solvent was removed under reduced pressure. The residue was suspended in ethanol/diethyl ether and filtered.

The precipitate was washed with 50% ethanol/diethyl ether to give 2- (2- chloropyridin-4-yl)-2, 5,6, 7-tetrahydro-4H-pyrazolo [4,3-c] pyridin-4-one as an off-white solid (378 mg, 1.52 mmol, 42% yield). The mother liquor was concentrated and purified by flash chromatography (0+10% methanol/ethyl acetate). The resultant oil was triturated with methanol/ether to give another 58 mg (0.23 mmol, 6%) of 2- (2- chloropyridin-4-yl)-2, 5,6, 7-tetrahydro-4H-pyrazolo [4,3-c] pyridin-4-one. 1 H NMR (300 MHz, DMSO-d6) 8 9.17 (s, 1 H), 8.47 (d, J = 5.7, 1 H), 8.04 (d, J = 1. 6,1 H), 7.94 (dd, J = 5.5, 1.8, 1 H), 7.71 (br s, 1 H), 3.44 (td, J = 6.5, 2.6, 2H), 2.89 (t, J = 6. 6,2H). HRMS calculated for C11H10 CIN4O (MH+) 249.0538, found 249.0545.

EXAMPLE 94 [000364] This example illustrates the preparation of 2-(2-quinolin-3- ylpyridin-4-yl)-2, 5,6, 7-tetrahydro-4H-pyrazolo [4,3-c] pyridin-4-one bis (trifluoroacetate).

[000365] The title compound was prepared from 2-(2-chloropyridin-4-yl)- 2,5, 6, 7-tetrahydro-4H-pyrazolo [4,3-c] pyridin-4-one (Example 508) and 3- quinolinylboronic acid by the procedure described for Example 2. 1H NMR (300 MHz, DMSO-d6) b 9.76 (d, J = 2.2, 1 H), 9.38 (s, 1 H), 9.26 (d, J = 2.0, 1 H), 8.82 (d, J = 5.4, 1 H), 8.71 (d, J = 1. 6,1 H), 8.16 (d, J = 7.7, 1 H), 8.12 (d, J = 8.3, 1 H), 7.96 (dd, J = 5.6, 2.0, 1 H), 7.87 (td, J = 7.7, 1.3, 1 H), 7.76- 7.68 (m, 2H), 3.48 (td, J = 6.6, 2.4, 2H), 2.95 (t, J = 6.6, 2H). HRMS calculated for C20H16N50 (MH+) 342.1349, found 342.1334.

[000366] The following examples were made by the same method. Calculated Example No. Compound Name (s) Found (m+H) (m+H) 2-[2-(2-fluorophenyl) pyridin-4-yl]-2, 5, 6, 7- 95 tetrahydro-4H-pyrazolo [4, 3-c] pyridin-4- 309. 1146 309. 119 one trifluoroacetate 2-(2-phenylpyridin-4-yl)-2, 5, 6, 7- 96 tetrahydro-4H-pyrazolo [4, 3-c] pyridin-4- 291. 124 291. 1252 one trifluoroacetate EXAMPLE 97 [000367] This example illustrates the preparation of 2- {2- [ (E)-2- (4- morpholin-4-ylphenyl) vinyl] pyridin-4-yl}-6, 7-dihydropyrazolo [1,5-a] pyrazin- 4 (5H)-one trifluoroacetate.

[000368] mp 290°C (decomposition) ; 1H NMR (300 MHz, DMSO-d6) 8 8.62 (d, J = 6.5 Hz, 1 H), 8.39 (2 x s, 2H), 7.97-7. 83 (m, 2H), 7.70 (s, 1 H), 7.57 (d, J= 8.6 Hz, 2H), 7.15 (d, J= 16.2 Hz, 1H), 7.03 (d, J= 16.2 Hz, 2H), 4.50-4. 38 (m, 2H), 3.80-3. 60 (m, 6H), 3.28-3. 19 (m, 4H); m/z402 [M+H] +.

EXAMPLE 98 [000369] This example illustrates that MK2 knock-out mice (MK2 (-/-)) are resistant to the formation of K/BN serum-induced arthritis and that compounds that inhibit MK-2 should be effective for the prevention and treatment of TNFa-mediated diseases or disorders.

A strain of mice has been reported that develops symptoms similar to human rheumatoid arthritis. The mice were designated K/BxN mice.

See, Wipke, B. T. and P. M. Allen, J. of Immunology, 167 : 1601-1608 (2001). Serum from the mice can be injected into host animals to provoke a typical RA response. The progression of the RA symptoms in the mice is measured by measuring paw thickness as a function of time.

[000370] In the present example, host mice having normal MK-2 production (MK2 (+/+) ) were genetically altered by disabling the gene encoding MK-2 to produce mice having no capability of endogenous synthesis of active MK-2 (MK2 (-/-)). Normal host mice (MK2 (+/+) ) and MK-2 knock-out mice (MK2 (-/-), were separated into four groups with each group containing both male and female mice. All groups of mice were treated similarly, except that one group (Normal), composed of MK2 (+/+) mice that served as the control group, was not injected with serum from K/BxN mice, while the other three groups were injected with K/BxN serum at day 0. The other three groups of mice were MK2 (+/+), MK2 (-/-), and Anti-TNF. The Anti-TNF group was composed of MK2 (+/+) mice which were also injected at day) with anti-TNF antibody. The paw thickness of all mice was measured immediately after the injections on day 0, and then on each successive day thereafter for 7 days.

[000371] Figure 1 is a graph that shows paw thickness as a function of time from day 0 to day 7 for MK2 (+/+) and MK2 (-/-) mice, which have received serum injection. It can be seen that paw thickness increased significantly for MK2 (+/+) mice, whereas there was substantially no increase in paw thickness for MK2 knock-out mice. This indicated the requirement for a functioning MK2 regulatory system to the inflammatory response caused by the serum challenge. When anti-TNF antibody was

administered to the MK2 (+/+) mice along with the serum injection, the swelling response was significantly reduced. This can be seen in Figure 2, which is a bar chart showing paw thickness at seven days after injection for normal mice, MK2 (+/+) mice receiving serum, MK2 (-/-) mice receiving serum, and MK2 (+/+) mice receiving serum and anti-TNF antibody.

[000372] This data shows that the MK2 knock-out mice show no arthritic response to a serum challenge, whereas MK2 (+/+) mice show a normal response. Treatment of MK2 (+/+) mice that receive a serum challenge with anti-TNF antibody reduces the response back to near-normal levels.

This illustrates the utility of the MK2 regulatory system as a potential control point for the modulation of TNF production, and indicates that such regulation could serve as a treatment for inflammation-such as that caused by arthritis, for example. It further shows that MK2 inhibition can have a beneficial effect on inflammation, and indicates that administration of an MK2 inhibitor can be an effective method of preventing or treating TNF modulated diseases or disorders.

[000373] All references cited in this specification, including without limitation all papers, publications, patents, patent applications, presentations, texts, reports, manuscripts, brochures, books, internet postings, journal articles, periodicals, and the like, are hereby incorporated by reference into this specification in their entireties. The discussion of the references herein is intended merely to summarize the assertions made by their authors and no admission is made that any reference constitutes prior art. Applicants reserve the right to challenge the accuracy and pertinency of the cited references.

[000374] In view of the above, it will be seen that the several advantages of the invention are achieved and other advantageous results obtained.

[000375] As various changes could be made in the above methods and compositions without departing from the scope of the invention, it is intended that all matter contained in the above description shall be interpreted as illustrative and not in a limiting sense.